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Abstract 
Histone deacetylases (HDACs) regulate the acetylation pattern of chromatin to control gene 
expression. Previous studies reported class I HDACs and specifically HDAC3 as a key 
regulator of MMP1/13 expression, the major collagenases in cartilage. Moreover, HDAC 
inhibitors were shown to have a chondroprotective role in in vivo models of osteoarthritis. The 
aim of this study was to examine the role of HDAC3 in catabolic gene expression in 
osteoarthritis and in chondrocyte differentiation in vivo and in vitro. 
Chemical inhibitors against all HDACs (e.g. TSA) and specifically against HDAC3 
(Apicidin) were used in conjunction with HDAC3 RNAi in human SW1353 chondrocytes, 
stimulated with IL-1 and in a mesenchymal stem cell (MSC) chondrogenic differentiation 
model. Gene expression was quantified using qRT- PCR and protein by western blotting, 
immunohistochemistry and biochemical methods. RNA microarray analysis was performed 
following RNAi or Apicidin treatment, across a time-course of IL-1 stimulation in 
chondrocytes to identify critical regulators of catabolic gene expression. Subsequently the role 
of E2F-1 transcription factor was studied with gain or loss of function experiments. E2F-1 
activity on MMP1/13 was assessed by luciferase reporter gene activation and interaction with 
HDAC3 determined by immunoprecipitation. The role of HDAC3 in murine development 
was determined by generating a cartilage specific conditional knockout mouse model. 
HDAC3 is essential for IL-1- induced MMP1/13 and FRA1 expression in chondrocytes. 
Microarray analysis suggests the E2F-1 transcription factor may mediate the effect of HDAC3 
on gene expression regulation. Accordingly, modulation of E2F1 levels alters IL-1 induced 
MMP1/13 expression and HDAC3 appears to interact with E2F1. Additionally, HDAC3 
regulates anabolic gene expression, including COL2A1 and ACAN, during MSC 
chondrogenesis and is required for normal endochondral ossification, since conditional 
deletion resulted in embryonic lethality. 
We propose a novel role for HDAC3 in the regulation of catabolic and anabolic gene 
expression. 
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Chapter 1. Introduction 
 
1.1 Articular Cartilage: Structure and Function. 
Articular cartilage is the connective tissue of the synovial joints that provide a smooth, 
lubricated surface for articulation and load-bearing, minimising at the same time the stress on 
the subchondral bone. (Fox et al. 2009) Unlike the majority of other tissues, articular cartilage 
lacks blood vessels and nerves and is subject to harsh mechanical stress. The unique and 
complex structure of articular cartilage, together with environmental factors, and also lifestyle 
usually lead to the initiation and progression of major human diseases, including rheumatoid 
arthritis (RA) and osteoarthritis (OA). (Goldring & Marcu 2009) Most importantly, articular 
cartilage has a limited ability of self-repair and healing and hence once the damage has 
initiated, it leads to a series of catabolic events that result in the degradation of the tissue. 
(Simkin 2008) This degradation of articular cartilage is mediated by the expression of specific 
matrix metalloproteinase enzymes, also called collagenases, produced at least in part by the 
sole cartilage cell type, the chondrocyte. (Drissi et al. 2005)   
Articular cartilage is composed of a dense extracellular matrix (ECM) that includes many sub-
components and some sparse (<10%) specialised chondrocytes. Articular cartilage can be 
divided into four distinct zones: 1) the superficial zone, 2) the middle zone, 3) the deep zone 
and 4) the calcified zone. In total articular cartilage in an adult human knee is approximately 
2-4mm thick with each zone being of variable depth (Fox et al. 2009) (see Figure 1.1). The 
superficial zone comprises 10-20% of articular cartilage and protects deeper layers from 
mechanical stresses. This zone contains mainly collagen type II and IX fibres that are packed 
tightly and aligned parallel to the cartilage surface. There is also a relatively high number of 
flattened chondrocytes and the integrity of this layer is imperative in the protection and 
maintenance of deeper layers. This zone is in contact with synovial fluid and is responsible 
for most of the tensile properties of cartilage, which enable it to resist the sheer, tensile and 
compressive forces imposed by articulation. Below to the superficial zone and before the deep 
and calcified zone, there is the middle zone that comprises 40-60% of articular cartilage and it 
contains proteoglycans and thicker collagen fibres. Here, there are less chondrocytes and the 
collagen fibrils are aligned in an angle rather than parallel to the cartilage surface. 
Functionally, the middle zone is the first line of resistance to compressive forces. The deep 
zone comprises approximately 30% of articular cartilage volume and provides the greatest 
resistance to mechanical stresses, since it contains the larger collagen fibres, the highest 
proteoglycan percentage and the lowest water concentration. The chondrocytes of this zone 
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are usually arranged in columns parallel to the collagen fibres. Between the deep zone and the 
last calcified zone there is also the tidemark that distinguishes the previous two zones. Last 
but not least, there is the calcified zone that plays an important role in maintaining the 
structural integrity of articular cartilage as it anchors the collagen fibres of the deep zone in 
the subchondral bone. The number of chondrocytes here is small and the chondrocytes are 
hypertrophic. (Fox et al. 2009) 
 
 
Figure 1.1. Healthy articular cartilage and articular zones. Adapted from (Fox et al. 2009). 
 
Preservation of articular cartilage homeostasis depends on maintaining cartilage unique 
structural composition and organisation of the matrix throughout development (Martel-
Pelletier et al. 2008). Cartilage strength and function depend on both the properties of the 
tissue and on their structural parameters (ECM and chondrocytes).  
 
 1.1.1   Extracellular Matrix (ECM) 
The ECM is a complex of macromolecules that is principally composed of collagen and 
proteoglycans with other glycosylated or non-glycosylated proteins present in a smaller 
amount. Together with water, these components are critical for the maintenance of the 
mechanical properties of ECM, with the collagenous network mainly responsible for the 
tensile strength of articular cartilage and the proteoglycans (mainly aggrecan) for the elastic 
properties of ECM. It also serves as a reservoir of growth factors and cytokines that in turn 
are responsible for cell activation and gene expression. (Chiara & Cancedda 2009) 
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The most abundant component of articular cartilage is water constituting approximately 60-
80% of the total weight. The rest is mainly accounted for by cartilage fibres and 
proteoglycans. The water content decreases from the superficial to deeper zones while the 
amount of collagen and proteoglycan is increased. Water flow also serves to distribute 
nutrients to chondrocytes in addition to providing lubrication. (Fox et al. 2009) 
Collagen is the most abundant structural macromolecule in ECM. Type II collagen represents 
90% to 95% of the collagen in ECM and forms fibres intertwined with proteoglycan 
aggregates. (Fox et al. 2009) In particular, it is composed of three identical α1 polypeptide 
chains that intertwine, like all collagens, to form a triple helix. This basic structure of any 
collagen is characterized by the presence of a glycine at every third amino acid of the 
polypeptide sequence that forms the triple helix. Other types of collagen, for example 
collagen type I, IV, V, VI, IX and XI represent only a smart part of the total volume in ECM 
and help to stabilise the collagen II fibres network that provides the shape and tensile stiffness 
of the tissue. Interestingly, although collagen is resistant to degradation by most proteases, it 
can be cleaved by the action of collagenases. In mammals there are three main collagenases, 
named matrix metalloproteinases (MMP-) MMP-1, MMP-8 and MMP-13, with MMP-13 
favouring the cleavage of type II collagen over other fibrillar collagens. Further collagen 
degradation can be processed by other MMPs, for example MMP-2 and MMP-9 (Fox et al., 
2009; Martel-Pelletier et al., 2008).  
The importance of type II collagen in cartilage formation and function is demonstrated by the 
consequence of type II collagen (COL2A1) gene mutations which give both growth plate and 
articular cartilage abnormalities. (Byers 2001) To date, over 100 different mutations have 
been detected, the most common being missense substitutions in a glycine codon in an exon 
encoding the helical region of the pro-α-chain. In this region there is an absolute requirement 
of glycine in every third amino acid and replacement by any other amino acid perturbs triple 
helix formation. This result in a dominant negative effect due to both intracellular degradation 
of the newly synthesised procollagen molecule and perturbation of fibres formation, thus 
weakening the cartilage. (Martel-Pelletier et al. 2008) The site of the mutation determines the 
severity of the disease. Stickler syndrome for example is characterised by nonsense mutations 
and the phenotype is a consequence of haploinsufficiency. (Ahmad et al. 1991) The mildest 
phenotype is caused by an arginine to cysteine substitution in the triple helical region. (Pun et 
al. 1994) 
Type XI collagen is another collagen that is less abundant than type II collagen in cartilage, 
and its abundance decreases from about 10% in fetal cartilage to 3% in adult articular 
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cartilage. (Eyre et al. 2006) Mutations in the gene also results in chondrodystrophic 
phenotypes, one of which is the Stickler syndrome, which can result from mutations either in 
type II or type XI collagen genes. Early onset of osteoarthritis is a common feature of these 
disorders. (Byers 2001) Type IX collagen is a member of the FACIT (Fibril associated 
collagen with interrupted triple helix) family and is also cartilage specific. It does not form a 
collagen fibril but is instead present at the surface of the type II/ XI fibril. Specific mutations 
have been described for type IX collagen giving rise to multiple epiphyseal dysplasia. Early 
onset of osteoarthritis is again a feature of this disorder. (Byers 2001) 
Articular collagen also contains other types of collagen including type VI, which accounts for 
about 1% of its total collagen content. (Eyre et al. 2006) However, its content is increased in 
OA cartilage. (Söder et al. 2002) Mutations in any of the type VI collagen results in 
congenital muscular dystrophy, although it is not clear how this may affect cartilage function. 
Type X collagen is also cartilage specific, which under normal conditions is present in the 
hypertrophic zone of growth plate cartilage where it participates in endochondral ossification, 
the process of long bone growth. Although type X collagen is not a component of normal 
articular cartilage, it is present in OA cartilage and can be cleaved by MMP1. Mutations to the 
gene result in the development of metaphyseal dysplasia. (Bateman 2001; Boos et al. 1999) 
Proteoglycans are the second most abundant component of ECM accounting for 5-10% of the 
tissue total weight. The proteoglycans in articular cartilage are complex macromolecules that 
consist of a central hyaluronic acid filament to which multiple monomers are noncovalently 
attached, with the most important one being aggrecan. Aggrecan itself is the largest in size 
and the most abundant by weight proteoglycan in cartilage and is made up of 3 core globular 
domains (G1-3). These domains are intersected by a glycosaminogycan (GAG) -rich region 
which is composed of a keratin sulphate region and two chondroitin sulphate regions. These 
regions are negatively charged which in turn creates a hydrophilic environment resulting in 
hydration of aggrecan. Thus, high concentrations of aggrecan are necessary in articular 
cartilage to resist compressive loads. A decrease in the GAG content can lead to 
overcompression and subsequent secretion of proteases by the chondrocytes that can lead to 
tissue degeneration (Martel-Pelletier et al., 2008). Other proteoglycans in cartilage include 
biglycan, decorin and fibromodulin and are characterized by their ability to interact with 
collagen. (Fox et al. 2009) 
 
5 
 
1.1.2 Chondrocytes 
Despite the hypoxic environment, 2% of the total volume of articular cartilage is constituted 
of a highly specialised and metabolically active type of cell, the chondrocyte. Chondrocytes of 
articular cartilage (AC) and of cartilage undergoing mineralization (Growth Plate, GF) are 
biochemically distinguishable although they originate from the same chondroprogenitor cell 
source. For example the AC chondrocytes (also termed as ‘maturationally arrested’) primarily 
act to maintain the ECM by expressing collagen types II, VI, IX, XI and aggrecan. AC 
chondrocytes do not proliferate significantly, yet respond to a variety of stimuli including 
growth factors and mechanical loads, although rarely do they create cell-to-cell contact 
interactions in order to promote signal transduction between the cells (Fox et al., 2009; Drissi 
et al., 2005). Comparatively, mineralizing cartilage is composed of chondrocytes (GF) that 
surpass this maturational stage, as evidenced by acceleration of proliferation, increased cell 
volume and expression of other markers such as type X collagen and alkaline phosphatase. 
(Böhme et al. 1995)  
Mineralizing chondrocytes are also responsible for the development of bone. In terms of 
endochondral ossification, mesenchymal tissue differentiates into cartilage which is then 
replaced by bone. Endochondral ossification can be divided into five distinct phases (Figure 
1.2). First, the mesenchymal stem cells (MSC) commit to becoming cartilage cells. This 
process is stimulated by sonic hedgehog (Shh) that induces expression of Pax1 transcription 
factor that will then induce a cascade of downstream transcription factors. During the second 
phase, the MSC condense and differentiate into chondrocytes. BMPs appear to be critical at 
this stage, because they will induce the expression of the adhesion molecules N-cadherin, N-
CAM and the transcription factor Sox9. N-cadherin seems to be important for the initiation of 
these condensations and N-CAM for the maintenance of them. Sox9 will activate the 
expression of type II collagen and aggrecan, both critical for cartilage function. During the 
third phase, the chondrocytes proliferate rapidly. In the fourth phase, the chondrocytes stop 
dividing and become hypertrophic. This step appears to be mediated by Runx2 transcription 
factor that is crucial both for the intramembranous and endochondral ossification. Runx2 is 
itself regulated by histone deacetylase 4 (HDAC4), a chromatin remodelling enzyme. These 
hypertrophic chondrocytes alter the matrix they produce (by adding collagen X and 
fibronectin), to enable it to become mineralised by calcium phosphate. They also produce 
VEGF, which can transform MSC into blood vessels and recruits bone cell progenitors from 
the bloodstream. In the fifth phase, the hypertrophic chondrocytes either die by apoptosis and 
the cells that surround the cartilage model differentiate into osteoblasts (Gilbert S, 2010) or 
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differentiate into osteobalsts (Zhou et al. 2014). The osteoblasts will then start producing bone 
matrix. (Gilbert S, 2010) 
In contrast to the chondrocytes undergoing endochondral ossification (e.g. growth plate), AC- 
chondrocytes (resting zone, Figure 1.1) do not fully mature and remain arrested before 
terminal hypertrophy occurs. These chondrocytes are also responsible for the maintenance 
and repair of ECM components via the production of a group of degradative enzymes such as 
matrix metalloproteinases. They can also encode and release many of the ECM components 
including glycoproteins, and this production can be affected by proinflammatory cytokines, 
such as interleukin 1 (IL-1) and tumor necrosis factor α (TNFα) and other growth factors, for 
instance insulin-like growth factors and transforming growth factor β (TGFβ). However, the 
molecular mechanisms and the pathways underlying this production of molecules by the 
chondrocytes are not yet completely clear. (Kevorkian et al. 2004; Davidson et al. 2006) 
 
 
Figure 1.2. Control of endochondral ossification. 
Active paracrine and transcription factors during the transition of cartilage to bone. Adapted from 
(Pitsillides and Beyer, 2011). 
 
AC chondrocytes maintain normal and healthy ECM by renewing the ECM components with 
new products, while at the same time are protected by the potentially damaging mechanical 
forces by the ECM components. It has been previously shown that inactivity of the joint leads 
to cartilage degradation and so a normal movement of the joint is considered to be crucial for 
maintaining a healthy articular cartilage. Nevertheless, in case of an imbalance between the 
anabolic synthesis and the catabolic degradation of cartilage products, human diseases such as 
osteoarthritis can develop (Drissi et al., 2005). 
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1.2 Arthritis 
According to Arthritis Research UK (http://www.arthritisresearchuk.org/), arthritis is the 
biggest cause of pain and mobility disability in UK, with one fifth of the population seeking 
consultation for a musculoskeletal condition in general practise each year. As previously 
mentioned, the destruction of key components of cartilage, such as collagen II and aggrecan 
lead to the progression of cartilage degeneration that characterise the disease endpoints of 
both rheumatoid arthritis and osteoarthritis. This loss of cartilage can lead to the development 
of many symptoms including pain and narrowing in the range of movements, increasing 
disability and decreasing patient’s morbidity and quality of life. 
 
1.2.1    Osteoarthritis 
Osteoarthritis (OA) is the most common form of arthritis affecting mainly people over the age 
of 45.  Data collected over a seven-year period revealed that a total of 8.75 million people in 
UK have sought treatment for OA, with women to be more likely to develop the disease. The 
most common skeletal site for OA to be developed is the knee, followed by the hip and then 
by the wrist, the ankle and other sites. The most common symptoms of OA include joint pain, 
stiffness, swelling and loss of mobility (http://www.arthritisresearchuk.org/system/search-
results.aspx?keywords=osteoarthritis). An increase in the numbers of those affected by OA is 
expected to occur together with the increasing prevalence of obesity and ageing of society. 
(Peach et al. 2005) 
OA is characterised by degradation and eventually loss of articular cartilage, remodelling of 
the subchondral bone with some inflammation of the synovial membrane. There are numerous 
alterations in the osteoarthritic cartilage, and these involve metabolic and morphologic 
changes of chondrocytes as well as biochemical and structural changes in ECM components 
(Martel-Pelletier et al. 2008). However OA is considered to be a disease of the whole joint 
and not just the cartilage. In an OA knee joint, articular cartilage becomes damaged so the 
joint does not move as smoothly (Figure 1.3). In particular articular cartilage roughens and 
becomes thin and the subchondral bone sclerosis. All the tissues within the joint become more 
active as they try to repair the damage. In particular, the bone at the end of the joint grows 
outwards, forming bony spurs, known as osteophytes. The synovium (the inner layer of the 
joint capsule that produces the synovial fluid) might thicken and produce extra fluid. This 
causes the joint to swell. The production of inflammatory cytokines is also induced in an OA 
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knee and this will cause more damage. The ligaments that hold the joint together slowly 
stiffen making movements even more difficult. (Little and Hunter, 2013) 
 
 
Figure 1.3. Normal and osteoarthritic knee (by http://www.arthritisresearchuk.org/) 
A. A normal joint in comparison to B. A joint that has been deformed by severe osteoarthritis. 
The cartilage covering the ends of the bones gradually roughens and becomes thin, and the bone 
underneath thickens. All the tissue within the joint becomes more active than normal. The bone at the 
end of the joint grows outwards, forming bony spurs called osteophytes. The synovium may thicken 
and produce extra fluid, which then causes the joint to swell. The capsule and ligaments slowly 
thicken and contract as they would try to stabilise the joint. 
 
With reference to the pathogenesis of the disease, increasing age, gender female, weight that 
can cause excess load-bearing and nutritional deficiencies, as well as a major genetic 
component and appear to be important for the vulnerability of the joint to develop OA. 
Moreover, the misalignment of the joint, muscle weakness, alterations of the structural 
integrity for example meniscus damage or a previous injury can facilitate the progression of 
the disease and define a group with high risk of developing OA (Hunter & Felson 2006) 
(Figure 1.4). OA is a complex disease in terms of genetic association of specific genetic loci 
in the initiation and the progression of the disease. 
Evidence for genetic component in OA comes from family and twin studies, which estimate 
the genetic component of OA to be between 40% and 80%, which is similar to many other 
complex traits (Van Meurs 2017).  Many genes or genetic loci are associated with the 
initiation and/or the progression of OA in different skeletal sites. Candidate gene studies were 
initially focused on ECM genes for example COL2α1 (12q13.11), COL11α1 (1p21.1) and 
COL11α2 (6p21.32) and non-collagenous genes including COMP and matrilin 3, mutations of 
which have been implicated in osteochondrodysplasia pseudochondrodysplasia (PSACH) 
(Peach et al. 2005) with early onset OA (van Meurs, 2017). Other studies were also focused 
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on genes influencing bone density, since subchondral sclerosis appears early in OA or genes 
encoding for inflammatory cytokines (Peach et al. 2005). However, most recent heritability 
studies in European populations based in twins, siblings and families revealed only three loci 
including GDF5, chromosome 7q22 and MCF2L that were associated with high risk of 
developing hip or knee osteoarthritis (Day-Williams et al. 2011; Evangelou et al. 2009; 
Miyamoto et al. 2007; Valdes et al. 2011). An unbiased large-scale genome wide association 
study in 7410 unrelated patients was recently completed and the data obtained were compared 
with  publicly available data from 11009 unrelated controls (from UK and other European 
countries). Most of the above cases (80%) had primary osteoarthritis requiring a hip or knee 
joint replacement. The most significant region to be associated with patients with primary 
osteoarthritis who were undergoing total joint replacement (TJR) was located on chromosome 
3; a missense polymorphism within exon 3 of GNL3 gene and a SNP situated in the 3’ prime 
untranslated region (UTR) of the GLT8D1 gene. The remaining significant signals were 
derived from patients who were undergoing total hip replacement (THP); a SNP located in 
intron 18 of the ASTN2 gene, a polymorphism found 38kb upstream of FILIP1 and 70kb 
upstream of SENP6, a SNP located 59kb downstream of KLHDC5 and 96kb downstream of 
PTHLH and finally a polymorphism located in intron 2 of CHST11 gene (Zeggini et al., 2012, 
arcOGEN Consortium). In conclusion, these eight novel loci including the three previously 
established OA susceptibility loci in European populations on chromosome 7q22, in the 
GDF5 and MCF2L genes make the current total of eleven OA susceptibility loci. 
Interestingly, a more recent study by (Lindner et al. 2015) suggested that three previously 
identified susceptibility loci including rs5009270 (near IFRD1 gene), rs6976 (near GLT8D1 
gene) and rs4836732 (within the ASTN2 gene) may contribute to hip OA susceptibility by 
altering proximal femur shape. 
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Figure 1.4. Risk factors for osteoarthritis. 
 
Cartilage homeostasis is usually maintained by a balanced turnover between the anabolic and 
catabolic processes. In OA patients an imbalance between anabolic and catabolic factors 
produced by the chondrocytes, (in normal cartilage the maintenance of balance would be 
responsible for maintaining structural integrity of the tissue), occurs, in favour of the latter. 
Interestingly, an increase of the anabolic factors also occurs but is not sufficient to reverse 
tissue damage. During the progression of OA, an increase in the pro-inflammatory cytokines 
IL-1β, Tumour Necrosis factor α (TNF-α), IL-6 and IL-17 maintain the catabolic phenotype. 
(Mueller & Tuan 2011) 
 
1.3 Matrix metalloproteinases and cartilage degradation. 
Physiological and pathophysiological turnover can coexist in articular cartilage. Although 
there are distinct molecular mechanisms that mediate cartilage turnover leading to self-repair 
and regeneration of the ECM components, there are also those mechanisms that can lead to 
cartilage degeneration and the development of arthritis. In particular, inappropriate articular 
cartilage destruction in OA patients is largely the result of elevated expression and activities 
of proteolytic enzymes. (Goldring & Marcu 2009) Disturbance of cartilage homeostasis can 
lead to an increasing metabolic activity of chondrocytes and activation of the irreversible 
pathological processes causing cartilage erosion. The irreversibility of these processes is due 
to a very low regeneration rate of the basic ECM components; for example collagen has an 
OsteoarthritisGenetic Factors
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Previous joint 
injury or disease 
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Obesity
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estimated half-life of over 100 years, and aggrecan with a more moderate regeneration rate 
has an estimated half-life of 3-24 years (Karsdal et al. 2008). Many proteases have been 
identified to play crucial roles in cartilage degradation, but serine proteinases and 
metalloproteinases are the only extracellular members and so are able to cleave cartilage 
components. In OA, these degradative enzymes are produced primarily by chondrocytes 
(Goldring & Marcu 2009) and also by synoviovytes (Wassilew wt al. 2010; Volk et al. 2003), 
due to inductive stimuli, joint injury with attendant destabilization, mechanical stress, 
oxidative stress, cell matrix interactions and changes in growth factor responses and matrix 
during aging. (Goldring & Marcu 2009)  
Of the proteinases that can cleave cartilage collagens and proteoglycans, matrix 
metalloproteinases and aggrecanases have been given the greatest attention because they can 
degrade cartilage collagens and proteoglycans. (Cawston & Wilson 2006; Sandy 2006; 
Rengel et al. 2007) These include the collagenases MMP1, MMP8 and MMP13, the 
gelatinases (MMP2 and MMP9), stomelysin-1 (MMP3), and membrane type-1 (MMP14). 
(Murphy & Nagase 2008) Hence, a better understanding of the enzymes involved in cartilage 
degradation, in terms of their regulation and specific function, is a prerequisite in order to 
achieve successful specific pharmacological targeting. 
 
1.3.1 Matrix metalloproteinases (MMPs). 
The matrix metalloproteinase family (MMP) consists of 23 zinc and calcium dependent 
enzymes (endopeptidases) that are involved in the degradation of ECM components. Low 
expression of MMPs in healthy cartilage can contribute to cartilage remodelling and turnover. 
(Fox et al. 2009) However, there is now significant evidence for the overexpression of MMPs 
in tissues derived from patients with arthritic disease. In the development of OA, 
inflammatory cytokines such as IL-1 successfully bind to their receptors in chondrocytes, 
activating downstream pathways, for instance NF-κB and activator protein 1 (AP-1) that will 
up-regulate the expression of MMPs. (Kevorkian et al. 2004; Davidson et al. 2006) 
MMPs can be classified into 5 distinct categories depending on their target-substrates, 
structure and cellular localisation (Figure 1.5): the matrilysins, collagenases, stromelysins, 
gelatinases and membrane type (MT)-MMPs. However, some MMPs for instance, MMP11, 
MMP12, MMP19, MMP20, MMP23 and MMP28 do not fall into any of these groups and 
some other, for example MMP14 belongs to more than one group. (Murphy & Nagase 2009) 
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Figure 1.5. Basic structure of various matrix metalloproteinases (MMPs).  
MMPs consist of a pro-peptide (red) that maintain the enzyme in a latent state, a catalytic domain 
(blue) with the active catalytic Zinc (Zn-orange), and with the exceptions of matrillysins a COOH-
terminal domain (yellow) with homology to the serum protein hemopexin. The latter two domains are 
connected by a linker peptide. Gelatinases also have an insert of three fibronectin type II repeats 
(green) in the catalytic domain, which is involved in substrate recognition. Membrane type MMPs 
contain a transmembrane domain (black) and a cytoplasmic domain (blue) at the COOH- terminus, 
that anchors these enzymes in the cell membrane. Adapted from (Murphy et al. 2002). 
 
There are three main collagenases; collagenase 1 (MMP1), collagenase 2, also called 
neutrophil collagenase (MMP8) and collagenase 3 (MMP13) (Table 1.1). (Murphy & Nagase 
2009) They consist of a pro-petide, calatytic and hemopexin domain (Figure 1.5). They play 
an important role in cleaving collagen type I, II and III into characteristic ¼ or ¾ fragments, 
but they also have activity against other ECM molecules and soluble proteins. (Murphy & 
Nagase 2009) The catalytic domains of collagenases can cleave non-collagenous substrates, 
but they are unable to cleave collagen in the absence of their hemopexin domains (Chung et 
al. 2004). 
In the context of pathological collagen degradation that characterise both rheumatoid arthritis 
(RA) and OA, collagenases are the most pertinent MMPs (Murphy et al. 2002). Kozaci et al. 
(1998) defined, in a tissue culture model system that MMP3, MMP8 and MMP13 are unlikely 
to be involved in proteoglycan degradation but play major roles in type II collagen 
degradation. MMP1 and MMP13 are both produced by the chondrocytes, but MMP1 is also 
produced by the synovial fibroblast which is one reason why it is thought that MMP1 is the 
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main collagenase in RA, whilst MMP13 is the main collagenase in OA. (Van Meurs 2017) 
However, other expression studies suggest that the amount of MMP1 produced by 
chondrocytes is 10 times more than the amount of MMP13 produced, and also these two 
collagenases co-localise peri-cellularly to chondrocytes, indicating that collagen proteolysis is 
driven by not only MMP13, but equally by MMP1 (Elliot et al. 2003). MMP13 also degrades 
aggrecan, giving it a dual role in cartilage degeneration. Moreover, MMP13 plays a key role 
in cartilage degeneration, since its expression can be induced by many pathways. 
Interestingly, MMP13 knockout mice have been found to be somewhat resistant to cartilage 
degradation (in the presence of aggrecan deletion), when compared with wild-type littermates, 
using an OA surgical-induced mouse model (Little et al. 2009). Furthermore, postnatal 
overexpression of MMP13 in hyaline cartilages of the mouse resulted in an OA-like similar 
phenotype, with loss of proteoglycan and type II collagen cleavage and synovial hyperplasia. 
These findings suggest that MMP13 overexpression might lead to the progression of OA 
(Neuhold et al. 2001).  
MMP8 and MMP14 can be collagenolytic and are expressed by cells within the synovial 
joints, but their contribution to cartilage degeneration has not yet been established. (Murphy 
& Nagase 2009) Other MMPs, such as MMP2, MMP3, MMP9, MMP10 and MMP19 are also 
elevated in arthritis and along with MMP13 these enzymes cleave non-collagen ECM 
components. (Cawston & Wilson 2006) Although, many MMPs have been associated with 
matrix turnover, other MMPs (MMP1, MMP2, MMP3, MMP9, MMP12, MMP13 and 
MMP19) are also linked to osteoclastic resorption and cleavage of non-collagenous proteins 
of the bone matrix and clearly play roles beyond ECM cleavage. (Andersen et al. 2004) 
 
MMPs- 
Collagenases 
Other names Substrate specificity 
MMP-1 
Interstitial collagenase 
(Collagenases-1) 
Collagen I, II, III, VII, VIII, X and aggrecan, 
gelatin, proteoglycan link protein 
MMP-8 
Neutrophil collagenases 
(Collagenase-2) 
Collagen I, II, III, V, VII, VIII, X and 
aggrecan, gelatine, fibronectin 
MMP-13 Collagenase-3 
Collagen I, II, III, IV and gelatine, 
plasminogen activator inhibitor 2, aggrecan 
Table 1.1. Collagenase activities and specific substrates. Αdapted from (Murphy et al. 2002). 
 
Gelatinases A (MMP2) and B (MMP9) share similar proteolytic activity and degrade ECM 
components such as type IV, V and XI collagens, laminin and aggrecan. MMP2 also has the 
ability to degrade collagens type I, II and III similar to collagenases, but MMP9 does not. 
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However, the collagenolytic activity of MMP2 is much weaker than MMP1 and any other 
collagenase in solution. (Murphy et al. 2002) Stromelysins (MMP3, MMP10 and MMP11) 
have the same structure as collagenases, though they are unable to cleave collagens. MMP3 
and MMP10 can cleave some ECM molecules and participate in pro-MMP activation, but 
MMP11 has very weak proteolytic activity towards ECM components. Finally, matrilysins 
MMP7 and MMP26 lack the hemopexin domain and are both able to degrade several ECM 
components. (Murphy et al. 2002) 
 
1.3.2. A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS). 
Other proteases that have been implicated in articular cartilage damage are the ADAMTS (a 
disintegrin and metalloproteinase with thrombospondin motifs) proteases for example, 
ADAMTS4, ADAMTS5 and ADAMTS9 that are able to cleave matrix components including 
aggrecan, versican and brevican (Porter et al. 2006). ADAMTS5 knockout mice showed 
significant reduction in the severity of cartilage destruction after surgically destabilising the 
joint in comparison with wild-type mice. This was the first report of a single gene deletion 
capable of abrogating the course of cartilage destruction in an animal model of osteoarthritis 
and demonstrated that ADAMTS5 is the main aggrecanase in cartilage. (Glasson et al. 2005) 
Mice lacking both ADAMTS4 and ADAMTS5 showed resistant in cartilage degradation 
following surgical destabilisation and cartilage explants stimulated with IL-1 and retinoic acid 
showed decreased aggrecanase degradation to a level comparable with that in the ADAMTS5 
knockout mice. (Majumdar et al. 2007) ADAMTS5 (-/-) joints also showed minor 
subchondral bone changes in contrast to wild-type mice where substantial changes were found 
(Botter et al. 2009) and were resistant to pain-related behaviour during the course of knee 
osteoarthritis (Malfait et al. 2010). 
 
1.4 Proinflammatory cytokines. 
Proinflammatory cytokines are potent regulators of numerous biological processes and are 
tightly regulated in the body. Chronic uncontrolled levels of such cytokines can initiate and 
derive many pathologies, including autoimmune diseases such as RA and cancer. (Rider et al. 
2016) In particular, during the progression of OA, the catabolic phenotype is maintained by a 
number of pro-inflammatory cytokines, including Interleukin-1β (IL-1β) and tumor necrosis 
factor α (TNF-α), IL-6 and IL-17. The best studied cytokines in degenerative cartilage disease 
are IL-1β and TNF-α. (Mueller & Tuan 2011) 
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1.4.1 Interleukin 1 (IL-1). 
The IL-1 family includes 7 ligands with agonist activity (IL-1α, IL-1β, IL-18, IL-33, IL36α 
and IL-36β), three receptor antagonists (IL-1Ra, IL-36Ra, IL-38) and an inflammatory 
cytokine IL-37. Members of the IL-1 receptor family include 6 receptor chains forming 4 
signalling receptor complexes, two decoy receptors (IL-1R2, IL-18BP) and two negative 
regulators (TIR8 or SIGIRR, IL-1RAcPb). A tight regulation via receptor antagonists, decoy 
receptors and signaling inhibitors ensures a balance between amplification of innate immunity 
and uncontrolled inflammation. IL-1 affects cells of the innate and adaptive immune system 
and exerts a wide variety of biological functions including promoting fever, vasolidation, 
haematopoiesis, lymphocyte activation, leucocyte attraction and extravasation, angiogenesis 
and antibody synthesis (Garlanda et al. 2013)  
Despite a low percentage homology (only 26%), IL-1α and IL-1β activate the same cell 
surface receptor and have a practically identical range of biological activities. (Afonina et al. 
2015) Interestingly, IL-1β but not IL-1α deficiency was shown to result in impaired febrile 
and acute-phase inflammatory responses in a turpentine-induced model of local inflammation 
and tissue injury. On the other hand IL-1α has been uniquely implicated in initiating sterile 
inflammation in response to dying cells by inducing neutrophil recruitment, whereas IL-1β 
has been shown to recruit macrophages only in a later phase. (Afonina et al. 2015)  
Both IL-1α and IL-1β are synthesized as precursor proteins that are post-translationally 
cleaved to the active forms (17kDa each) and can be produced by synovial cells, osteoblasts, 
endothelial cells and a number of other cells. Their production can be triggered by other 
cytokines, microorganisms, endotoxins and other antigens. In response to ligand binding of 
the receptor, a complex sequence of combinatorial phosphorylation and ubiquitination events 
results in activation of nuclear factor kappaB signaling and the JNK and p38 mitogen-
activated protein kinase pathways, which, cooperatively, induce the expression of canonical 
IL-1 target genes (such as IL-6, IL-8, MCP-1, COX-2, I kappa B alpha, IL-1 alpha, IL-1 beta, 
MKP-1) by transcriptional and posttranscriptional mechanisms. Of note, most intracellular 
components that participate in the cellular response to IL-1 also mediate responses to other 
cytokines (IL-18 and IL-33), Toll-like-receptors (TLRs), and many forms of cytotoxic 
stresses. (Weber et al. 2010) 
IL-1β is the most well studied cytokine in OA and is found in the synovial fluid of OA 
patients and is expressed by the synovial tissue and the chondrocytes (Mueller and Tuan, 
2011). The level of IL-1β is increased in the OA joint. IL-1β has been proven to be associated 
with an increase in the expression of matrix-degrading enzymes and also decrease the 
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synthesis of ECM components by the chondrocytes (Mueller and Tuan, 2011). Interestingly, 
intra-articular injection of IL-1β in rabbit knee joints induces proteoglycan loss. These effects 
of IL-1β are mediated by receptor IL-1RI, whose density is increased in OA cartilage, which 
in turn increases the sensitivity of chondrocytes to IL-1β. IL-1β and TNF-α alone or 
synergistically, can inhibit synthesis of collagen and proteoglycans by the chondrocytes and 
induce the production of degrading enzymes. (Cawston et al. 2003) 
 
1.4.2 Tumour Necrosis Factor α (TNF-α) 
TNF-α acts synergistically with IL-1β to suppress ECM synthesis and stimulate the 
expression of matrix-degrading enzymes. Both IL-1β and TNF-α, alone or in combination, 
inhibit synthesis of proteoglycan and collagen in chondrocytes.(Saklatvala 1986; Goldring et 
al. 1988) Blocking TNF-α and/or IL-1β decrease the degeneration of collagen II and aggrecan 
and also decrease the expression of MMPs. (Kobayashi et al. 2005) In response to stimulation 
by catabolic cytokines, chondrocytes produce more prostaglandin E2, and bone 
morphogenetic protein-2 (BMP-2), both of which increase type II collagen expression. This 
can be interpreted as an attempt by the chondrocytes to compensate for the increased loss of 
ECM. (Fukui et al. 2003) 
 
1.4.3 IL-1-mediated cell signalling pathways. 
There are many pathways that are directly regulated by cytokines such as IL-1, IL-17 or TNF-
α. These include the mitogen- activated protein kinases (MAPK), nuclear factor-κB (NF-κB), 
activator protein- 1 (AP-1), the Janus kinase/ signal transducers and activators of transcription 
(JAK/STAT) pathway and the phosphatidylinositol 3-kinase (PI3K) pathway. (Rowan & 
Young 2007) 
NF-κB family of transcription factors includes five members: p50, p52, p65, c-Rel and RelB 
that homo- or hetero-dimerize to provide differential biological effects. Of these only p65, c-
Rel and RelB have c-terminal transactivation domains, which contain binding sites for other 
co-regulators. (Panday et al. 2016) The key event in NF-κB activation is the phosphorylation 
and subsequent ubiquitination and degradation of IκΒ inhibitory protein. The classical NF-κΒ 
pathway is activated in response to cytokines including IL-1 and TNFα or bacterial products 
(lipopolysaccharides, LPS) which activate the inhibitory κB kinases (IKK). IKKβ 
phosphorylates IκBα at serine 32 and 36, resulting in poly-ubiquitination and degradation by 
the 26S proteasome. This release of NF-κB, classically p50:p65 heterodimers, from its 
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inhibitor IκBα, leads to NFκB nuclear translocation and subsequent gene target activation 
(Pereira and Oakley, 2007). More than 150 genes are regulated by NF-κΒ family of 
transcription factors and involved in inflammation, immunity, cell proliferation, 
differentaition and survival (Panday et al. 2016). Importantly, it has been proposed that NF-
κB has transcriptional regulation over MMP1 and MMP13 collagenases and blocking the NF-
κB pathway reduce MMP1 and MMP13 expression in synovial fibroblasts and human and 
bovine chondrocytes in response to IL-1 (Liacini et al. 2002). Interestingly, DNA-bound p50 
and p52 homodimers and heterodimers repress κB- mediated transcription by preventing the 
binding of transcriptionally active NF- κB dimers or through recruitment of deacetylases 
(Zhong et al. 2002). Indeed, Elshakrawy and colleagues (Elsharkawy et al. 2010) showed that 
the p50:p50:HDAC1 repressory complex inhibits multiple pro-inflammatory genes including 
CCL2, CXCL10, Gm-CSF and MMP13 and binding of both p50 and HDAC1 has been 
detected in their gene promoters in wild type normal cells, but not in nfkb1(-/-) cells.   
IL-1 can also trigger the phosphorylation of important kinases including mitogen activated 
protein kinase (MAPK) pathways. Activation of MAPK will result in a series of 
phosphorylation cascades that culminate in the activation of effector molecules such as 
transcription factors that induce transcription of target genes. There are three distinct 
pathways that are encompassed within MAPK activation: i) extracellular-signal regulated 
kinase (ERK), ii) Jun N-terminal kinase (JNK) and iii) p38 kinase. These specific pathways 
are involved in the transduction of the pro-inflammatory cytokine IL-1 signal that causes 
collagenase expression and cartilage degradation. JNK and p38 kinase, in addition to NF-κB 
signaling pathway, have been implicated in the regulation of MMP1 and MMP13 expression 
in human articular chondrocytes (HACs). (Mengshol et al. 2002) Mengshol and colleagues 
(2002) further demonstrated the importance of these three MAPK pathways in the regulation 
of MMP1 and MMP13 expression in the SW1353 chondrosarcoma cell line. For example 
inhibition of p38 kinase by SB 203580 blocked IL-1 mediated MMP13 expression in HACs 
and the SW1353 cell line, with similar effects on MMP1 in the SW1353 cells (Mengshol et al. 
2002). Furthermore, JNK inhibition led to a 60% decrease of MMP13 expression in SW1353 
cell, with no significant effect on MMP1 expression. Also pharmaceutical inhibition of JNK 
pathway decreased joint destruction in a rat arthritis model in part due to decreased MMP1 
expression (Han et al. 2000). The mechanism of action on MMPs expression by these three 
pathways is not yet clear. The JNK MAPK pathway activates c-Jun and NF-κB pathways, 
both of which can activate the expression of MMPs, while the ERK and p38 MAPK pathways 
can activate STAT (Rowan & Young 2007) 
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BMPs, members of TGF-β superfamily of proteins are directly affected by IL-1 cytokines. In 
particular, BMP-2, BMP-7 and BMP-4 are the most well studied BMPs in terms of their 
expression in articular cartilage. BMP-2 is up-regulated in OA patients by IL-1, resulting in 
an increase in the expression of type II collagen. In healthy articular cartilage, BMP-7 would 
promote biosynthesis of ECM molecules, but is down-regulated in OA chondrocytes (Fukui et 
al. 2003; Drissi et al. 2005).  Although the expression of BMPs is highly dependent on IL-1 
and TNF-α cytokines, there are also some BMPs antagonists, such as gremlin and follistatin, 
that regulate the levels of BMPS, by binding to BMPs receptors (Mueller & Tuan 2011). 
Fibroblast Growth factors (FGFs) act mainly through the NF-κB signalling pathway 
depending on the receptor they bind. In terms of OA, FGF-2 and FGF-18 have been 
extensively studied. FGF-2 binds the FGF receptor type 1 and act mainly as a catabolic factor 
for cartilage homeostasis by activating NF-κB downstream signalling pathways. Whereas, 
FGF-18 binds to FGF receptor type 3 and has clearly anabolic effects in matrix components 
biosynthesis (Mueller and Tuan, 2011). 
 
1.5 Immediate Early genes and the Activator-Protein 1 family of transcription 
factors. 
Immediate early genes (IEG) encode a plethora of transcription factors that control cell 
proliferation, differentiation and survival by altering specific transcriptional programs. Most 
of them share common characteristics; for example, they have an abundance of RNA 
polymerase II at their promoters, high affinity TATA boxes, small exon numbers and are 
rapidly induced usually after only 30min-1h of growth factor/cytokine/interferon stimulation 
without the requirement for protein synthesis. (Hargeaves et al. 2009) In addition, IEG are 
believed to have a characteristic chromatin structure. Several studies had shown that 
acetylation at histone H3 lysine 9 and 14 remain consistently present prior to and after gene 
expression stimulation, and thereby generating a constitutively permissive and open to 
transcription factors structure. (Healy et al. 2012)  
Many of the critical targets of the signalling cascades that are activated by cytokine or growth 
factor stimulation are transcription factors which then regulate secondary response genes. IEG 
induction is mediated by one of the two mitogen-activated protein kinase (MAPK) signalling 
pathways: either the RAS-MAPK pathway which is activated by growth factor stimulation 
and mitogens and results in activation of extracellular signal related kinase 1 and 2 (ERK1/2) 
or the p-38 MAPK pathway, which is activated by UV or stress (McCay and Morrison, 2007). 
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Both of these pathways results in the phosphorylation and activation of regulatory proteins 
involved in IEG expression, including members of the ETS- domain family (such as ELK1 
and ETS1/2, which bind to the IEG promoter and complex with lysine acetyltransferases), 
regulatory factors such as the SRF and mediator complex which are essential for IEG 
induction (Fowler et al. 2011) 
Two of the most well characterised IEG are the FOS (c-fos) and JUN (c-jun) that belong to 
the Activated-Protein 1 (AP1) family of transcription factors. These genes form a heterodimer 
c-jun/c-fos complex that is necessary for the induction of AP1-responsive target genes 
(Rowan and Young, 2007). It has been proposed that AP-1 DNA binding sites within the 
promoters of MMP1 and MMP13 are important for regulating expression of these genes in 
chondrocytes. The MMP1 promoter is activated by Jun complexes as well as the Fos/Jun 
heterodimer, whereas MMP13 induction by IL-1 requires c-Fos (Benderdour et al. 2002). 
MMP3 and MMP9 are also positively regulated by c-Fos containing AP-1. Interestingly, co-
transfection studies that were performed to reveal the transcriptional effect of c-jun showed 
that c-jun transcriptional activity can be amplified by c-fos and also that the c-jun/c-fos 
complex is more active as a transcriptional activator than c-jun alone. Litherland et al, (2010) 
also showed that silencing of c-fos and c-jun expression was sufficient to abrogate IL-1 and 
Oncostatin M (OSM) stimulated collagenase expression and over-expression of c-fos and c-
jun was sufficient to induce transcription of the MMP1 in the absence of stimulus. 
Interestingly, histone deacetylases (HDACs) which are involved in gene silencing are 
upregulated in FOS-transformed cells and are required for c-Fos dependent invasion. 
(McGarry et al. 2004) 
 
1.6 Epigenetic modification and gene expression regulation 
1.6.1 Chromatin remodelling 
Chromatin is the complex of DNA and proteins (mainly histones) that condense to form a 
chromosome during cell division. The compaction also helps to package DNA to fit into the 
cell nucleus. (Nishibuchi & Déjardin 2017) The basic repeating unit of chromatin is the 
nucleosomes. In each nucleosome, 146 base pairs of DNA is wrapped around an octamer of 
core histone proteins formed by four histone partners: an H3-H4 tetramer and two H2A- H2B 
dimers. Structural changes in chromatin control gene expression. Histones are basic proteins 
consisting of a globular domain and a charged NH2-terminus (histone tail) that protrudes from 
the nucleosome.(Jenuwein & Allis 2001) Epigenetics is the study of heritable changes in gene 
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activity that are not caused by changes in the DNA sequence. For example histone 
modifications, DNA methylation or phosphorylation alters chromatin structure to facilitate 
gene transcription (Kim & Kaang 2017). Chromatin remodelling that occurs during 
development will erase almost every epigenetic tag from the parents to the offspring, but a 
small minority of epigenetic marks will remain through to the next generation unchanged. A 
characteristic example is genomic imprinting during which some genes keep their epigenetic 
marks and will start the process of development with those epigenetic tags in place 
(Kouzarides 2007).  
At least eight different categories of epigenetic post-translational histone modifications have 
been identified and more than 60 different sites where modifications can take place have been 
found. Enzymes that are responsible for acetylation, methylation, phosphorylation, ADP- 
ribosylation, deimination, ubiquitination and proline isomerisation have been determined and 
the modifications they mediate function either by disrupting chromatin contacts or by 
remodelling chromatin structure making it more or less accessible to transcription factors and 
other non-histone proteins (Figure 1.6). (Kouzarides 2007) Thus, the nature of histone amino-
termini modifications revealed a ‘histone code’ hypothesis which predicts that the 
modification marks on the histone tails should provide binding sites for effector proteins 
which allow regulatable contacts with the underlying DNA. The enzymes mediating these 
histone tail modifications are highly specific for particular amino acid positions and 
modifications on the same or different histone tails may be independent and generate various 
combinations on any nucleosome. (Jenuwein & Allis 2001) However, under different 
conditions many modifications can determine expression or repression, adding complexity to 
the concept of a code. (Kouzarides 2007) 
The timing of the appearance of each chromatin modification depends on the signalling 
conditions within the cell. For example for actively transcribed genes, it has been found that 
acetylation of histone H3K9/K14 is enriched in the promoter and the 5’- UTR of the coding 
regions. Whereas, acetylation of H2BK16, H4K8 and K16 within and 3’-UTR of coding 
regions were not correlated with transcription. It is generally believed that a modification 
occurs in a genetic region under certain conditions (for example when a gene is transcribed) 
and this state is reversed when the gene is silent. (Liu et al. 2005) 
Histone methylation can either occur in a lysine or arginine and may be one of many different 
forms: mono-, di-, or tri- methyl for lysines and mono-, or di-methyl for arginines. It is 
mediated by enzymes called histone methyltransferases and histone demethylases. Three 
methylation sites are implicated with the activation of transcription: H3K4, H3K26 and 
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H3K79, and three are associated with transcriptional repression: H3K9, H3K27 and H4K20. 
(Kim & Kaang 2017) 
Little is known about histone phosphorylation and gene expression. MSK1/2 and RSK2 in 
mammals, and SNF1 in budding yeast, have been shown to target H3S10. A role for H3S10 
has been demonstrated in regulating NF-κB-regulated genes and also for immediate early 
genes such as c-fos and c-jun by allowing phospho-binding of 14-3-3 protein on chromatin. 
(Macdonald et al. 2005) 
Ubiquitination has been found on H2A (K119) and H2B (K120 in humans) and linked to both 
transcriptional activation (H2BK120) and repression (H2AK119). It is unclear how 
ubiquitination functions; it might recruit additional factors to chromatin or physically keep 
chromatin ‘open’, due to its large size. (Wang et al. 2006) 
 
 
Figure 1.6. Transcription process and its regulation by histone modifications.  
A. Schematic representation of a nucleosome (bue-purple). DNA (black) is wrapped around the 
nucleosome. Dark blue represents histone tails that can be post-translationally modified by 
HDAC/HAT complexes, methyltransferases/demethylases (Me) or phosphorylases (P). Red 
circles represent transcription factor binding. Transcriptional activation or repression in 
chromatin depends on a combination of histone modifications. B. Epigenetic modifications 
identified on histone N-tail domains. Adapted from (Bannister & Kouzarides 2011). 
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1.6.2 Acetylation of histones 
Acetylation of histones is probably the most well understood modification, with 
hyperacetylation to be associated with an increase in gene transcription and hypoacetylation 
to have the opposite effect. Alfrey et al. (Allfrey et al. 1964) first reported histone acetylation 
in 1964. Since then, it has been shown that the acetylation of lysines is a highly dynamic 
process and regulated by two families of enzymes, the histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). The HATs utilize acetyl CoA as a cofactor to catalyse the 
transfer of an acetyl group in the ε-amino group of lysines. (Bannister & Kouzarides 2011) 
Important acetylation sites are K9 and K14 on histone H3 and K5, K8, K12 and K16 on 
histone H4. (Nishibuchi & Déjardin 2017) Acetylation neutralizes the lysine’s positive 
charge. This action favors an open chromatin structure and releases the histone tails from the 
linker DNA, make it accessible by transcription factors. Chromatin regions that are marked by 
acetylated lysines catalysed by HATs are generally more actively transcribed, whereas 
genomic regions that are bound by HDACs are inactive (Figure 1.6 A). (Bannister & 
Kouzarides 2011) 
There are two major classes of HATs: type A and type B. The type B are mainly cytoplasmic 
acetylating free histones and not those already compacted into chromatin. This class of HATs 
are highly conserved and all type B HATs share homology with HAT1. The type A HATs are 
a more diverse group of enzymes than type B and can be further classified into three 
categories depending on amino-acid sequence homology and conformational structure: GNAt, 
MYST and CBP/p300 families. Type A HATs are structural components of multiprotein co-
activatory or co-repressory complexes. These complexes may act either in a site-specific 
manner, when they are recruited by specific binding activators on the DNA or in a broad 
manner whereby they function in larger genomic areas. (Kretsovali et al. 2012) For example, 
purified GCN5 acetyltransferase acetylates free histones, but not those present within a 
nucleosome. However, when it is part of the SAGA complex, it efficiently acetylates 
nucleosomal histones. (Grant et al. 1997) 
 
1.6.3 Histone Deacetylases (HDACs). 
The histone deacetylase (HDAC) family involve four classes. Class I HDACs include 
HDAC1, 2, 3 and 8 and these members are more closely related to the yeast transcriptional 
factor RPD3. Class II HDACs involve HDAC4, 5, 6, 7, 9 and 10 and these are more closely 
related to HDA1, another deacetylase found in yeast. Class III HDACs are also refered to as 
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sirtuins and are homologues to yeast Sir2. This class of HDACs, in contrast to the other three 
classes of HDACs, requires the co-factor NAD+ for their activity- importantly they are not 
inhibited by the broad-spectrum HDAC inhibitor TSA. Finally class IV HDAC contain only 
one member HDAC11, which has low sequence similarity with all the other HDACs. HDACs 
oppose the effect of HATs by removing acetyl-groups from histone tails, restoring their 
positive charge. This stabilizes the local chromatin architecture and is consistent with HDACs 
being predominantly transcriptional repressors. (Bannister & Kouzarides 2011) Contrary to 
their consideration as repressors, HDACs can also induce transcription as it was found for 
some selected interferon-stimulated early response genes (Sakamoto et al. 2004). 
Class I HDACs are expressed in most cell types whereas class II HDACs have a more 
restricted pattern of expression indicating a possible contribution to differentiation and 
developmental processes. Most class I HDACs have a nuclear localisation signal (NLS), thus 
they can be found in the nucleus where they exert their function. However some class I 
HDACs, for example HDAC3 have a nuclear export signal (NES) and can be also found in 
the cytoplasm. Class II HDACs on the other hand can be found either in the nucleus or out in 
the cytoplasm depending on certain cellular signals (De Ruizter et al. 2003). Despite their 
name, histone deacetylases, especially those that carry a nuclear export signal have non-
histone targets-substrates such as tubulin (Kretsovali et al. 2012), thus they are occasionally 
termed more generally as lysine deacetylases (KDACs). In general, HDACs have relatively 
low substrate specificity by themselves. Instead, HDAC recruitment and specificity is usually 
mediated by multi-protein complexes often with more than one HDAC members. For instance 
HDAC1 is found together with HDAC2 within the NuRD, Sin3A and co-REST complexes.  
(Bannister & Kouzarides 2011) 
Analysis of knockout (KO) mice lacking Hdac revealed their functions during mammalian 
development and differentiation (see Table 1.2 for class I Hdac KO). For example deletion of 
Hdac1 is embryonic lethal by embryonic day 9.5 (E9.5) due to cell proliferation and growth 
defects (Lagger et al. 2002). Although, cardiac- specific deletion of Hdac1 had no significant 
effect due to functional redundancy with Hdac2, conditional deletion of both Hdac1 and 
Hdac2 from the heart induced lethality due to cardiac arrhythmias, dilated cardiomyopathy 
and up-regulation of genes encoding encoding skeletal muscle-specific contractile proteins 
and calcium channels (Montgomery et al. 2007). Global Hdac3 deletion is also embryonic 
lethal due to deficient gastrulation that is potentially connected to failure of the DNA damage 
repair mechanisms (Bhaskara et al. 2011). Also conditional tissue-specific deletion of Hdac3 
has pointed to an involvement in liver (Knutson et al. 2008)and heart (Montgomery et al. 
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2008) function, as well as in bone formation (Razidlo et al. 2010) and very recently in 
endochondral ossification (Carpio et al. 2016). Finally, global and conditional deletion of 
Hdac8 in cranial neural crest cells leads to lethality due to skull instability (Haberland, 
Montgomery, et al. 2009). 
 
Class I Hdac 
KO 
Loss of function phenotype 
Time of lethality 
of knockouts 
Reference 
Hdac1 Growth retardation and proliferation defects E10.5 
Lagger et al. 
2002 
Hdac2 Cardiac malformation P1 
Montgomery 
et al. 2007 
cKO 
Hdac1/Hdac2- 
Heart 
Functional redundancy in the heart, brain, 
endothelial cells, smooth muscle and neural 
crest cells 
Viable, due to 
functional 
redundancy 
postnatally and in 
adulthood 
Montgomery 
et al. 2007 
Hdac3 Gastrulation and DNA repair defects E9.5 
Bhaskara et al. 
2010  
cKO Hdac3- 
Bone (skeleton) 
Impaired intramembranous and 
endochondral ossification, thinner calvarial 
bones, smaller size of long bones, shorter 
lifespan, more  adipocytes than osteoblasts 
Mostly before 
weaning 
Razidlo et al. 
2010 
icKO Hdac3- 
Liver 
Hepatomegaly-Lipid and cholesterol 
homeostasis disrupted 
Viable 
Knutson et al. 
2008 
icKO Hdac3- 
Heart 
Diet (high fat) induced- hypertrophic 
cardiomyopathy and heart failure 
Die within weeks 
(if high fat diet) 
Sun et al. 2011 
cKO Hdac3- 
Cartilage 
Embryonic lethal 
Between E12.5 
and E16.5 
Carpio et al. 
2016 
icKO Hdac3- 
Cartilage 
Delayed secondary ossification centre 
formation, altered maturation of growth 
plate chondrocytes and increased osteoclast 
activity in the primary spongiosa 
Viable 
Carpio et al. 
2016 
Hdac8 
Affects intramembranous ossification-
Craniofacial defects 
P1 
Haberland et 
al. 2009 
Table 1.2.Class I Hdac Knockout mouse models. cKO: conditional Knockout, icKO: inducible 
conditional Knockout. 
 
HDAC4 is found to regulate skeletogenesis and knockout mice die in the first weeks postnatal 
due to premature endochondral ossification of cartilage which interferes with breathing (Vega 
et al. 2004). HDAC5 and HDAC9 control cardiac development in a redundant manner, since 
single knockout mice are viable, though the double knockout mutant is lethal due to defects in 
cardiac development (Chang et al., 2004). HDAC7 is specifically expressed in the endothelial 
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cells of the cardiovascular system (Chang et al. 2006) and HDAC6 and HDAC10 regulate 
cytoskeletal dynamics by controlling the acetylation of cytoskeletal proteins such as tubulin 
(Q. Zhang et al. 2008).  
 
1.6.4 Histone Deacetylase 3 (HDAC3). 
HDAC3 belongs to class I HDACs, is a 428 amino acid (aa) protein with an estimated 
molecular mass of 49 kDa and shares 53% of aa sequence similarity with HDAC1 and 52% 
homology with HDAC2. HDAC3 is ubiquitiously expressed and shares common features with 
HDAC1 and HDAC2, such as deacetylation of histone substrates and transcriptional 
repression when targetted to promoters. (Yang et al. 1997; Karagianni & Wong 2007) Apart 
from the role of class I HDACs on deacetylating histone tails and playing a role in 
transcriptional repression when binding to a promoter, HDAC3 can also associate with YY1 
DNA- binding factor and increase its repression activity (Dangond et al., 1998; Yang et al., 
1997; Emiliani et al., 1998). However, HDAC3 has a unique C-terminus that shares no 
apparent similariy with other HDACs indicating it may not be completely redundant with 
other HDACs. This is also suggested by the differential localization of HDAC3, which 
through its nuclear export signal (NES) can be found apart from the nucleus, in the cytoplasm 
and plasma membrane. (Yang et al. 2002) 
Through its association with the silencing mediator for retinoic acid and thyroid hormone 
receptor (SMRT) and/or nuclear receptor co-repressor (N-CoR), HDAC3 is recruited to 
specific promoters where it deacetylates histones and mediates silencing of corresponding 
genes. Other components of this complex include the transducing β-like 1 (TBL1), the TBL1-
related protein (TBL1R1) and the G protein pathway suppressor 2 (GPS-2) (Figure 1.7). 
(Millard et al. 2017) Both TBL1 and TBLR1 interact directly with N-CoR and SMRT but not 
with HDAC3 and are not required for HDAC3 enzymatic activity. Histone deacetylation by 
HDAC3 and N-CoR/SMRT causes transcriptional repression in two ways. First, the removal 
of acetyl-groups increases the affinity of histone tails to the DNA backbone, which yields a 
closed chromatin conformation intractable to transcription and second by reducing the 
recruitment of bromo-domain co-activators, such as chromatin associated proteins and HATs 
that typically bind the acetyl lysine motifs and promote transcription. (McQuown & Wood 
2011)  
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Figure 1.7. HDAC3 interacts with the SMRT and/or N-CoR co-repressors (complex of SMRT 
and N-CoR shown in purple) to silence gene transcription. TBL1, TBLR1 and GPS2 interact 
directly with SMRT/NCoR but not with HDAC3. 
SMRT/ NCoR is unique among the class I HDAC complexes in terms of it also recruits the class II 
HDAC4/ 5/ 7 and 9. The role of the class II HDACs in this complex has yet to be established. Adapted 
from (Millard et al. 2017). 
 
The existence of different HDACs and HDAC complexes has raised the question of potential 
specificity in their target-substrates and functions. In particular, Johnson et al. showed that 
HDAC3 completely deacetylates H2AK5, H4K5 and H4K12, but only partially deacetylate 
H3, H2B, H4K8 and H4K16.Compared with HDAC1, HDAC3 also deacetylated H4K8, 
H4K16 and H2B at the same rate, but it deacetylated H4K5, H4K12 and H2AK5 much more 
rapidly. (Johnson et al. 2002) Interestingly, the enzymatic activity of HDAC3 has also been 
shown to be regulated by phosphorylation at Ser424 by CK2 (Casein kinase 2) and 
dephosphorylated by serine/threonine phosphatase 4. (Zhang et al. 2005) In addition to 
protein-protein interactions and phosphorylation, subcellular localization may serve as 
another regulatory mechanism for HDAC3. For example, export of N-CoR to the cytoplasm 
in response to IL-1β stimulation has been proposed as a mechanism of de-repression of a set 
of NF-κB regulated genes (Baek et al. 2002). The reverse process, nuclear translocation of 
HDAC3 has been described as a mechanism of inhibition of PPARγ by TNFα. Cytoplasmic 
HDAC3 was shown to associate with IκBα and TNFα-treatment induced degradation of the 
latter and HDAC3 release, allowing it to enter the nucleus and repress PPARγ (Gao et al. 
2006). 
Apart from histone tails substrates, HDAC3 also targets non-histone proteins indicating its 
role extends beyond direct transcriptional regulation. One such target is the NF-κB protein 
RelA. HDAC3 has been shown to inhibit NF-κB signaling by deacetylating RelA which 
triggers its nuclear export via interaction with inhibitory IκB (Chen et al. 2001). Other non-
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histone substrates include the myocyte enhancer factor 2 (MEF2) as well as the 
acetyltransferases PCAF and p300/CBP. (McQuown & Wood 2011) 
In vivo studies showed that HDAC3 is necessary for normal embryonic development since 
global knockout of Hdac3 was embryonic lethal by embryonic day E9.5 due to gastrulation 
defects. Also a conditional knockout mouse expressing Cre recombinase under the control of 
osterix promoter revealed the role of Hdac3 in bone formation. The resulted conditional 
knockout (cKO) mice had severe deficits in intramembranous and endochondral ossification. 
Moreover, calvarial bones were severely thinner and the trabecular volume of femurs was 
decreased by 75% in the Hdac3 cKO. Fewer osteoblasts and more bone marrow adipocytes 
were also detected in the cKO when compared with wild-type or heterozygous littermates. 
Microarray analysis also revealed that many developmental signaling pathways were affected 
by the Hdac3 deficiency, indicating in this way that Hdac3 is an important regulator of normal 
skeletal development. (Razidlo et al., 2010). More recently, Carpio et al. supported that 
HDAC3 is important for normal endochondral ossification and Hdac3 deficient chondrocytes 
exhibited reduced abundance of chondrogenic genes such as COL2α1, Ihh, ACAN and 
COL10α1. (Carpio et al. 2016) 
 
1.6.5 Histone deacetylase inhibitors (HDACi). 
As described above, the perceived mechanism of action of HDACs involve removing acetyl 
groups from histone tails resulting in the DNA wrapping tighter around the nucleosome, 
hence diminishing accessibility of transcription factors. HDAC inhibitors (HDACi) were 
discovered as various structurally diverse compounds that bind to the active site of HDACs, 
displacing the zinc and blocking substrate access, usually in reversible manner. (Bose et al. 
2014) Different classes of HDACi based on structure include the hydroxamates (ie. 
Trichostatin A), fatty acids, benzamides (ie. MS-275) and cyclic peptides (ie. Apicidin) 
(Figure 1.8). (New et al. 2012) 
Trichostatin A (TSA) is the most well-known reversible HDAC inhibitor (HDACi). Yoshida 
and his colleagues first reported (Yoshida et al. 1990) TSA as a Streptomyces product which 
could inhibit the cell cycle of rat fibroblasts in the G1 and G2 phases at very low 
concentrations. Like most other HDAC inhibitors, TSA has the optimal conformation to fit 
into the active site of HDACs and inhibit their function. All HDACs are thought to be equally 
sensitive to inhibition by TSA in low (nanomolar) concentration. The benzamide class of 
HDACi show more selectivity towards inhibiting the class I HDACs. Such an inhibitor is 
28 
 
Chidamide which has been recently licensed for treating T-cell lymphoma (Lu et al. 2016) 
Another HDACi that shows more selectivity is RGFP966, which selectively targets HDAC3 
over HDAC1 and HDAC2. (Millard et al. 2017) Apicidin is another class I selective HDACi 
which preferentially inhibits HDAC3 in in vitro experiments (in the nanomolar range) over 
HDAC2 and HDAC1. (Khan & Davie 2013) 
 
 
Figure 1.8. Representative structures of HDACi used in this study.  
 
The major clinical application of HDACi has been in the treatment of cancer where they cause 
terminal differentiation and apoptosis of cancer cells. HDACi have been approved for clinical 
use (Table 1.3), others are currently in clinical trials or in preclinical development. SAHA 
(vorinostat) and FK228 (romidepsin) for example were licensed for the treatment of advanced 
cutaneous T-cell lymphoma. (Bose et al. 2014) Belinostat and panbinostat have also been 
recently approved for the treatment of peripheral T-cell lymphoma and multiple myeloma 
respectively. (Poole 2014; VanderMolen et al. 2011) Givinostat is currently in clinical trial for 
haematologic malignancies, for example Hodgkin lymphoma and multiple myeloma and has 
also been shown to reduce the production of pro-inflammatory cytokines in vitro and systemic 
inflammation in vivo. (Losson et al. 2016) HDACi have been also used in neurology for many 
years as mood stabilisers and anti-epileptic cards, with valproic acid being the most prominent 
amongst them. (New et al. 2012) 
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Furthermore mocetinostat and entinostat are two examples of benzamides currently in clinical 
studies for the treatment of Hodgkin lymphoma. Valproic acid is a short chain fatty acid 
which has been used in the treatment of epilepsy for more than two decades and it was shown 
that it has beneficial effects in solid tumours including neuroblastomas, neuoroendocrine 
carcinomas, glioblastomas and in cervical cancer. Another 32 HDACi are currently in clinical 
trials in the USA (https://clinicaltrials.gov/), and UK (https://www.ukctg.nihr.ac.uk/). 
 
HDACi Indication  
Licencing 
body 
Year 
licensed 
Reference 
Vorinostat 
(Zolinza) 
Cutaneous T cell 
lymphoma 
FDA 2007 Mann et al. 2007 
Romidepsin 
(Isodax) 
Cutaneous T cell 
lymphoma 
FDA 2011 
VanderMolen et al. 
2011 
Belinostat 
(Beleodaq) 
Peripheral T cell 
lymphoma 
FDA 2014 Poole et al. 2014 
Panbinostat 
(Farydak) 
Multiple myeloma FDA/EMA 2016 Raedler et al. 2016 
Chidamide 
(Epidaza) 
Peripheral T cell 
lymphoma 
Chinese FDA 2016 Lu et al. 2016 
Table 1.3. HDACi licenced for clinical use. Adapted from (Millard et al. 2017). 
 
1.7 The Retinoblastoma protein and E2Fs regulate the cell cycle. 
1.7.1 The Retinoblastoma (Rb) protein 
The Retinoblastoma gene, Rb1 or Rb, was the first tumour suppressor gene to be identified in 
humans. Studies following the inheritance patterns of a pediatric tumor of the retina, showed 
that deletion or mutation of chromosome 13q14.1-13q14.2 could result in retinoblastoma and 
patients could also be victim of a secondary non-ocular tumor, such as osteosarcoma. 
(Cavenee et al. 1983; Friend et al. 1986) These studies also showed that mutation in the Rb 
gene could be hereditary and also occur during gametogenesis. The Rb gene encodes for a 
nuclear phosphoprotein with weak DNA binding activity. (White et al. 1983) It was found 
that the Rb can form stable protein-protein complexes with viral oncoproteins of adenovirus 
E1A and SV-40 T-antigen, both of which form tumour in rodents, in addition to the human 
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papilloma virus (HPV) E7, which causes cancers in humans. (Ludlow et al. 1989; Dyson et al. 
1989) 
Rb is one of three proteins of the pocket protein family made up of Rb (p105), p107, and 
p130. The common pocket domain is used to bind to viral oncoproteins, transcription factor 
and other proteins. The pocket domain is comprised of two pocket domains A and B which 
are separated by a spacer (as shown in Figure 1.9). The spacer region is utilised for cyclin 
binding, while other proteins including HDACs, E2Fs and viral oncoproteins bind to region 
B. (Classon et al. 2002) Studies have shown that Rb can bind to about 100 different proteins 
including HDACs, HATs, kinases, histone demethylases, phosphatases and transcription 
factors, serving as a conduit of cell cycle regulation and gene expression initiation or 
repression. These interactions assist Rb in the regulation of the G1 checkpoint, blocking S-
phase entry and cell growth, differentiation during embryogenesis and adult tissue 
development, regulation of apoptosis and chromosomal stability. (Giacinti & Giordano 2006) 
Aside from E2F-mediated cell cycle regulation, Rb can also regulate stability of cell cycle 
inhibitor p27 through an interaction with anaphase-promoting complex/ cyclosome (APC/C). 
(Ji et al. 2004; Binné et al. 2007)  
 
 
Figure 1.9. The retinoblastoma (pRb) protein. 
Region A and B are required for the interaction of the protein with E2Fs and many other transcription 
factors. Domain C within the carboxy-terminus of pRb is important for E2F binding. Phosphorylation 
and acetylation sites are also indicated. Adapted from (Classon & Harlow 2002). 
 
Rb can also regulate the transcriptional output of other transcription factors besides E2F. (Noé 
et al. 1998; Lee et al. 2006) For example, Rb can associate with HES1 to promote stronger 
binding of Runx2 to target gene promoters. Rb also associates with Sp1, HIF1α and MYOD 
transcription factors to modulate gene transcription. Aside from being a transcription co-
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factor, Rb is also an adaptor protein that can recruit a variety of co-activators/ co-repressors to 
target gene promoters. (Noé et al. 1998; Lee et al. 2006) 
 
1.7.2 Rb and cell cycle. 
Two of the most important proteins involved in the cell cycle machinery are cyclin-dependent 
kinases (cdk) and cyclins. Cyclin/cdk complexes are formed during distinct phases of the cell 
cycle and are involved in the phosphorylation of target proteins. (Giacinti & Giordano 2006) 
In particular, Cdk4/6 in association with D-type cyclins is exclusive for the phosphorylation 
and inactivation of Rb family proteins, initiating transition into the S phase. (Brewer et al. 
1999; Satyanarayana et al. 2009) When in its hypo-phosphorylated form, Rb associates with 
E2F factors and block their ability to activate expression of genes that are necessary for the S-
phase progression. Rb is thought to inhibit expression of E2F-regulated genes in two ways: by 
directly binding and blocking the activation domain of E2F proteins or by active repression 
through the recruitment of HDAC, SWI/SNF factors, polycomb group proteins or 
methyltransferase. (Dyson et al. 2002; Dahiya et al 2001; Vandel et al. 2001) Progression of 
the cells through the G1 and S phases requires phosphorylation and thus inactivation of Rb 
protein. 
The E2F family of transcription factors consists of eight E2F family members: E2F-1 to -8. 
Functional E2F co-exist with a DP transcription factor to act as heterodimers. Each of the 
E2Fs can heterodimerise with either DP1 or DP2, although the E2F-7 can bind DNA 
independently of DP. (Ormondroyd et al. 1995) There are functional and structural 
differences between the E2F family members. E2F-1, E2F-2 and E2F-3 are transcriptional 
activators, which interact with Rb. E2F-4 and E2F-5 are transcriptional repressors which 
mostly interact with p130 and p107. E2F-6 interacts with polycomb proteins and represses 
transcription. E2F-7 and E2F-8 are also believed to repress specific promoters. (Di Stefano et 
al. 2003; De Bruin et al. 2003; Christensen et al. 2005) 
The Rb protein together with E2Fs are the main regulator of the mammalian cell cycle. Rb 
physically interacts with E2F-1, -2 and -3 via their transcription activation domain repressing 
their transcriptional activity. However, in response to mitogenic signalling, Rb is inactivated 
in the G1 phase of the cell cycle via phosphorylation by cyclin dependent kinases 2, 4 and 6, 
leading to its dissociation from E2F1-3. This facilitates the expression of various genes that 
are necessary for DNA synthesis and cell cycle progression, including cyclin E, dihydrofolate 
reductase and DNA polymerase α. Not surprisingly, oncogenic mutations target the Rb- E2F 
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pathway to promote cell proliferation. The Rb gene itself is mutated in a variety of cancers, 
while mutations in signaling molecules like K-Ras, p16INK4 and PTEN that affect Rb function 
are prevalent in almost all cancers. (Johnson et al. 2012) 
 
1.7.3 Regulation of MMPs by E2Fs. 
Existing functional evidence provided by a high-density oligonucleotide array in HeLa cells 
identified E2F-1 target genes by examining the localisation of E2F-1 binding sites. This study 
demonstrated that the majority of E2F-1 binding sites are located in core promoters and that 
50% of the sites overlap with Transcription Start Sites (TSS). (Bieda et al. 2006) cDNA 
microarray also revealed novel E2F-1 target genes, including MMP16 and MMP2 which are 
involved in promoting tumour invasion and metastasis. (Stanelle et al. 2002) More recently, 
E2F-1 was found to regulate MMP9, MMP14 and MMP15 gene expression and most 
importantly E2F-1 binding sites were predicted in all 23 human MMP promoters. E2F-1 
siRNA depletion reduced the expression of these genes in two different cell lines with a 
corresponding reduction in collagen degradation activity. (Johnson et al. 2012) These results 
were partly confirmed by an independent study which indicated decreased MMP9 and 
MMP16 expression following E2F-1 depletion in a small cell lung cancer (SCLC) cell line. 
Further experiments demonstrated that E2F-1 trascriptionally controlled the expression of Sp1 
and p65, which in turn promoted MMP9 activity in the SCLC cells. (Li et al. 2014)
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1.8 Aims of this study 
As mentioned previously, collagen degradation is a key step in the initiation and progression 
of osteoarthritis that leads to articular cartilage loss and MMP1 and MMP13 enzymes play a 
key role in this process. The expression of these genes is induced by pro-inflammatory 
cytokine signalling via the chondrocyte and is regulated by a number of signalling pathways, 
as well as histone modifications and DNA methylation (Roach et al. 2005). Previous work 
within the lab has shown that broad-spectrum HDAC inhibitors including TSA and sodium 
butyrate can reduce cytokine-induced metalloproteinase expression at the mRNA and protein 
level, in the chondrosarcoma cell line SW1353 and also in primary human articular 
chondrocytes (HACs). In addition to that, in a bovine nasal cartilage (BNC) explants assay, 
the same compounds were shown to inhibit cytokine-induced cartilage degradation via the 
reduction of MMP expression (Young et al., 2005). Moreover, the chondroprotective role of 
HDAC inhibitors is also supported in in vivo models of osteoarthritis (Culley et al., 2013; 
Chen et al., 2010). With the use of selective HDAC inhibitors, class I HDACs were 
implicated in the regulation of MMP expression, and RNAi studies introduced HDAC3 as a 
potentially key regulator of their expression (Culley et al., 2013).  
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This study aims to investigate: 
1. The consequences of HDAC3 loss on gene expression programmes related to cartilage 
degeneration using a chondrosarcoma cell line (SW1353) and also determine whether 
HDAC3 is involved in cell signalling pathways associated with osteoarthritis 
(Chapter 3. HDAC3 regulates collagenases expression and NF-κB in 
chondrocytes.).  
2. To define the mechanism by which HDAC3 regulates gene expression in 
chondrocytes by performing RNA microarray analysis of global gene expression 
changes following RNAi of HDAC3 or HDAC3i (Chapter 4. Identification of 
differentially regulated genes by HDAC3 using RNA microarray analysis.). 
3. To investigate a possible interaction of E2F-1 and HDAC3 in chondrocytes and 
determine the mechanism by which E2F-1 and by interacting with HDAC3 controls 
MMP1 and MMP13 expression in chondrocytes (Chapter 5. Regulation of MMP1 
and MMP13 expression by HDAC3 involves the E2F-1 transcription 
factor.). 
4. To determine how HDAC inhibition, and particularly HDAC3 depletion or selective 
inhibition, affects chondrogenic differentiation in vitro, using human bone marrow-
derived mesenchymal stem cells (Chapter 6. The role of HDAC3 in 
chondrogenesis in a human mesenchymal stem cell model system.). 
5. To determine the effects of HDAC3 loss:  
- On the DMM-induced OA mouse model and through the delivery of class I 
specific HDACi (eg. TSA, Apicidin) via intra-articular injections. 
- In chondrocyte- specific Hdac3- null mice or wild- type littermates (by generating 
a cartilage specific HDAC3 conditional knockout mouse model. (Chapter 7. The 
effect of Hdac3 loss in cartilage murine development.)
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Chapter 2. Materials and Methods 
 
2.1 Materials  
2.1.1 Antibodies 
All antibodies used for immunoblotting, co-immunoprecipitation (co-IP) and Chromatin 
Immunoprecipitation (ChIP) experiments are listed in Table 2.1. Polyclonal secondary goat 
anti-mouse and anti-rabbit immunoglobulins/HRP conjugated antibodies were purchased from 
Dako (Cambridgeshire, UK). Mouse monoclonal anti-rabbit IgG Light chain specific HRP 
(ab99697, Abcam, Cambridge, UK) and Mouse TrueBlot ULTRA: Anti-Mouse Ig HRP (18-
8817-30, tebu-bio, Peterborough, UK) were used as the secondary antibodies for the co-IP 
experiments. 
 
Antibody Species 
Purchased 
from 
Catalogue 
Number 
Dilution for 
Immunoblotting 
Monoclonal/ 
Polyclonal 
Experiment 
HDAC3 Rabbit Abcam ab7030 1:2500 Polyclonal IB 
E2F1 (C- 20) Rabbit Santa Cruz sc-193 1:2500 Polyclonal IB 
Anti- FLAG-M2 Mouse 
SIGMA-
Aldrich 
F1804 1:2000 Monoclonal IP 
Anti- HA tag (HA 
C5) 
Mouse Abcam ab18181 1:1000 Monoclonal IP 
Acetylated histone 
H3 
Rabbit 
Cell 
signaling 
#9715 1:2500 Polyclonal IB 
Acetylated α-
tubulin 
Mouse Abcam ab24610 1:1000 Monoclonal IB 
Acetylated Lysine Rabbit Abcam ab80178 1:1000 Polyclonal IB 
Glyceraldehyde-3-
Phosphate 
Dehydrogenase 
(GAPDH) 
Mouse MILLIPORE MAB374 1:40000 Monoclonal IB 
β-catenin Rabbit 
Cell 
Signaling 
#9562 1:1000 Polyclonal IB 
E2F-1 Mouse MILLIPORE #17-10061 
1µg antibody/ 
106 cells  
Monoclonal ChIP 
HDAC3 Mouse MILLIPORE #17-10238 
4µg antibody/ 3 
x 106 cells 
Monoclonal ChIP 
Table 2.1. Antibodies used for immunoblotting (IB), immunoprecipitation (IP) and chromatin IP 
(ChIP) experiments. All antibodies were purchased from either Cell Signaling Technology 
(Beverly, MA, USA), Santa Cruz Biotechnology (CA, USA), Sigma-Aldrich (Poole, UK), 
Millipore (Watford, UK) or Abcam (Cambridge, UK) as stated. 
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2.1.2 Immunoblotting Reagents 
Ammonium persulphate (APS), β-mercaptoethanol, bovine serum albumin (BSA), 
polyoxyethylene sorbitan (Tween-20), N,N,N’,N’-Tetramethylethylenediamine (TEMED), 
Triton X-100 and Kodak high-speed X-ray film were all purchased from Sigma-Aldrich 
(Poole, UK). A standard stock solution of bovine serum albumin (BSA) Fraction V was 
purchased from Fischer Scientific UK Ltd (Leicestershire, UK). BradfordUltra reagent was 
purchased from Expedeon (Cambridge, UK). A 37.5:1 mix of acrylamide/bis-acrylamide was 
purchased from Severn Biotech Ltd. (Worcestershire, UK). PageRuler™ pre-stained protein 
ladder was purchased from Thermo Scientific (Leicestershire, UK). Immobilon-P 
polyvinylidene difluoride (PVDF) 0.45µM membrane and Immobilon western 
chemiluminescent HRP substrate were purchased from Millipore (Watford, UK). Enhanced 
chemiluminescence (ECL) and ECL-advanced western blotting detection reagents were 
purchased from GE Healthcare Life Sciences (Buckinghamshire, UK). Marvel non-fat dry 
milk powder was purchased from Premier Foods (St. Albans, UK). 
2.1.3 Cells 
2.1.3.1 Cell lines 
SW1353 
SW1353 cells were purchased from the American Type Culture Collection (ATCC) (HTB-94) 
and cultured in Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F-12 (DMEM/F-12) 
culture medium as described in section 2.2.1 Cell culture. This cell line initiated from a 
primary grade II chondrosarcoma of the right humerus of a 72 year old Caucasian female in 
1977. Full details for this cell line’s characteristics and culture method can be found at the 
ATCC website (www.atcc.org/).  
HEK 293T 
HEK 293T cells were purchased from the ATCC and cultured in DMEM as described in 
section 2.2.1 Cell culture. This cell line, originally referred to as 293tsA1609neo originated 
from a foetus, is a highly transfectable derivative of human embryonic kidney 293 cells and 
contains the SV40 T- antigen. Full details can be found at the ATCC website 
(www.atcc.org/). 
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2.1.3.2 Mesenchymal stem cells 
Mesenchymal stem cells (MSC) were obtained from LONZA and cultured in MSCBM™ 
(PT-3238 and PT-4105) growth medium. The phenotypes of all donors of MSCs were tested 
by Flow Cytometry on a FACSCantoII system (Becton Dickinson, Oxford, UK) using a 
human MSC phenotyping kit (Miltenyi, Biotec, Bisley, UK) with positive staining for CD73, 
CD90 and CD105 and negative staining for CD14, CD20, CD34 and CD45 (Zeybel et al. 
2012; Barter et al. 2015). Cells were also demonstrated to be capable of osteogenic and 
adipogenic differentiation (Barter et al. 2015). 
2.1.4 Cell culture reagents 
DMEM/F-12 (High glucose, 21331020) and DMEM culture media were both purchased from 
Gibco, Life Technologies Ltd. (Paisley, UK). Foetal bovine serum (FBS), Dulbecco’s 
phosphate buffered saline (PBS), trypsin-EDTA (derived from porcine pancreas), L-
glutamine, penicillin-streptomycin, and dimethyl sulphoxide (DMSO), were purchased from 
Sigma-Aldrich (Poole, UK). MSCBM™ Mesenchymal Stem Cell Growth BulletKit™ 
medium (PT-3001) and high glucose DMEM for chondrogenic differentiation were purchased 
form LONZA (LONZA Sales AG, Basel, Switzerland). 
2.1.5 Transfection reagents 
DharmaFECT Transfection Reagent 1 was used for transfection of cells with ON-
TARGETplus SMARTpool small interfering RNAs (siRNAs) or siGENOME Non-targeting 
Pool #2 (siControl), all purchased from Dharmacon (Leicestershire, UK). For transient 
transfections with plasmid DNA, FuGENE HD transfection reagent was used and purchased 
from Promega (Southampton, UK). 
2.1.6 Plasmids 
HA-E2F1 and HA-DP1 plasmids as well as a CDC6-luciferase reporter construct were a kind 
gift of Professor Nicholas La Thangue from the University of Oxford (Oxford, UK) and have 
been previously described (Milton et al., 2006). FLAG-HDAC3 (#13819) was obtained from 
Addgene and deposited by Eric Verdin (USCF School of Medicien, San Fransisco, USA). 
GFP plasmid, NF-κB firefly luciferase reporter and pRL-TK Renilla expression vectors were 
a gift from Dr Matt Barter (Newcastle University, Newcastle, UK). 3.2 kb MMP13 (enhancer 
+ proximal promoter), 1.6 kb MMP13 (proximal promoter only) have been previously 
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described (Schmucker et al., 2012) and MMP1 firefly luciferase expression vectors were 
provided by Professor David Young (Newcastle University, Newcastle, UK). 
  
2.1.7 Histone Deacetylase Inhibitors 
The Histone Deacetylase inhibitors (HDACi) used in this study are summarised in Table 2.2. 
Following serum starvation, SW1353 cells were treated with the appropriate concentration of 
HDACi (explained in each experiment separately) for 30min, before IL-1α stimulation was 
performed. Alternatively, MSC were treated either one day before chondrogenesis or on the 
day of chondrogenic differentiation induction and were left to differentiate for 7 days. 
Following 3 days of differentiation, the media was replaced and no HDACi was added. The 
cells were allowed to differentiate for a further four days. The HDACi was dissolved either in 
sterile DMSO or sterile filtered 100% ethanol as indicated in each experiment and according 
to manufacturer’s instructions. These diluents were used as vehicle controls and compared to 
the HDACi treated cells. 
 
Compound 
(HDACi) 
Source Code Inhibits IC50 (nM) Reference 
Trichostatin 
(1mg)  ≥98% 
(HPLC) from 
Streptomyces 
hygroscopicus 
SIGMA- 
Aldrich 
T8552 
All 
HDACs 
2 for HDAC1 
3 for HDAC2 
4  1 for HDAC3, 
HDAC6 
Khan et al., 2008 
MS-275 
(1mg) 
Santa 
Cruz 
SC279455 
HDAC1 
HDAC2 
HDAC3 
181  62 for HDAC1 
1155  134 for HDAC2 
2311  803 for HDAC3 
Khan et al., 2008 
Apicidin 
(1mg)  ≥98% 
(HPLC) from 
Streptomyces 
sp. 
SIGMA- 
Aldrich 
A8851 
HDAC2 
HDAC3 
120 ± 28 for HDAC2 
43  7 for HDAC3 
Khan et al., 2008 
Table 2.2. Histone Deacetylase inhibitors (HDACi) used during this study. Trichostatin (TSA) 
and Apicidin were bought from Sigma Aldrich (Poole, UK), while MS-275 was purchased from 
Santa Cruz Biotechnology (CA, USA). 
 
Cell death was quantified as an indicator of the cytotoxicity effects of the HDAC inhibitors 
used in this study, in the SW1353 and the MSC-treated cells. The GloMax® Discover System 
in combination with the CytoTox-Glo™ Cytotoxicity Assay (Promega, Southampton, UK) 
were used according to manufacturer’s instructions. Briefly, cells were cultured for the 
desired period and in the end media was collected. 50μl of the CytoTox-Glo™ Cytotoxicity 
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Assay was added to each sample and incubated at room temperature for 15 minutes. 
Luminescence was then measured using the GloMax® Discover System. The homogeneous 
CytoTox-Glo™ Cytotoxicity Assay is a single-reagent-addition luminescent assay that 
measures the number of dead cells in cell populations. The assay uses a luminogenic peptide 
substrate (alanyl-alanylphenylalanyl-aminoluciferin; AAF-Glo™ Substrate) to measure 
“dead-cell protease activity”, which is released from cells that have lost membrane integrity. 
The AAF-Glo™ Substrate cannot cross the intact membrane of live cells, does not generate 
any appreciable signal from the live-cell population and therefore selectively detects dead 
cells. Figure 2.1 shows the cytotoxicity of TSA and Apicidin in the SW1353 (Figure 2.1 A-
B) and MSC (Figure 2.1 C) - treated cells.  
 
 
Figure 2.1. Toxicity of different concentrations of TSA and Apicidin in SW1353 and MSC cells. 
A- B. SW1353 cells were incubated for 30min with increasing concentrations of TSA or Apicidin 
before IL-1α (0.5ng/ml) stimulation for 6h was performed. C. MSC were incubated with 
100ng/ml of HDACi before inducing chondrogenic differentiation (Day -1) or at the day of the 
induction (Day 0) and cultured thereafter for 7 days The media was then collected and a 
toxicity assay was performed using the CytoTox-Glo™ Cytotoxicity Assay according to 
manufacturer’s instructions. The luminescence for each sample was detected by GloMax® 
Discover System and the results were quantified using Microsoft Office Excel. For statistical 
analysis, one-way ANOVA with a Bonferroni multiple comparison test was performed.  
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2.1.8 General molecular biology reagents 
Ampicillin and Luria-Broth EZMixTM powder (LB) were purchased from Sigma-Aldrich 
(Poole, UK). Bacto Agar was purchased from Scientific Laboratory Supplies (Nottingham, 
UK). Molecular biology grade agarose was purchased from Severn Biotech Ltd. 
(Worcestershire, UK). Super Optimum Broth (SOB or SOC) medium and Subcloning 
Efficiency™ DH5α™ Competent Cells were bought from Invitrogen, Life Technologies Ltd. 
(Paisley, UK). GeneRulerTM 100bp and 1kb DNA ladders, Phire Reaction Buffer and Phire 
Hot Start II DNA Polymerase were purchased from Thermo Scientific (Leicestershire, UK). 
FastDigest® restriction enzymes were purchased from Thermo Fisher Scientific 
(Leicestershire, UK). Cells-to-cDNA II lysis buffer was purchased from Ambion, Ambion 
(Europe) Ltd. (Huntingdon, UK).  Random hexamers p(dN)6 were synthesised by Integrated 
DNA Technologies (IDT) (Leuven, Belgium).  Deoxyribonucleotide triphosphate (dNTP) mix 
was purchased from Bioline (London, UK). RNase-, DNase-free water and all real-time 
reverse transcriptase quantitiative polymerase chain reaction (real-time qRT-PCR) primers 
and probes and regular desalted oligonucleotides were purchased from Sigma-Aldrich (Poole, 
UK). Probe library probes were purchased from Roche, Roche Diagnostics Ltd. (West Sussex, 
UK). Moloney Murine Leukaemia Virus (M-MLV) reverse transcriptase, 5X First Strand 
Buffer and 100mM DTT were all purchased from Invitrogen, Life Technologies Ltd. (Paisley, 
UK) and TaqMan® gene expression master mix was purchased from Applied Biosystems, 
Life Technologies Ltd. (Paisley, UK). Protein G, A, or a mixture of G/A PLUS-Agarose 
beads for immunoprecipitation (IP) or chromatin immunoprecipitation experiments (ChIP) 
was purchased from Santa Cruz Biotechnology (CA, USA). Stellar Competent Cells were 
purchased from Takara Bio Europe/Clontech (Paris, France). Vectorshield® Mounting 
Medium with DAPI for Fluorescence was purchased from Vector Laboratories (Peterborough, 
UK). 
 
2.1.9 Commercially available kits 
PureYieldTM Plasmid Miniprep, Dual-Luciferase® Reporter Assay, Dual-Glo® Luciferase 
Reporter Assay Systems were purchased from Promega (Southampton, UK). ChIPAb+ E2F-1 
(#17-10061) and ChIPAb+ HDAC3 (#17-10238) kits were purchased from MILLIPORE 
(Watford, UK). 
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2.2 Methods  
2.2.1 Cell culture 
Reagents 
 HEK293T cells and DMEM culture media containing 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin and 10% (v/v) FBS 
 SW1353 cells and DMEM-F12 culture media containing 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin and 10% (v/v) FBS 
 MSC cells with MSCBM™ Mesenchymal Stem Cell Growth BulletKit™ medium 
 Chondrogenic differentiation media: 47.5ml DMEM (Dulbecco’s Modified Eagle’s 
Media; LONZA 12-614, 4.5 g/L Glucose) , 50µl 100µM Dexamethasone (SIGMA-
Aldrich, D4902-25mg) , 50µl 10µg/ml TGF-β3 (PeproTech INC., #100-36E-100UG), 
500µl 5mg/ml ascorbic-acid-2-phosphate (SIGMA-Aldrich, A8960-5G), 500µl 
4mg/ml proline (SIGMA-Aldrich,  P5607-25G), 500µl L-Glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin, 500µl 100x ITS+L premix (Insulin, transferrin, 
selenium+ Linoleic acid) (Corning- 354352) 
 Freezing medium: 90% (v/v) FBS and 10% (v/v) DMSO  
Method 
Cells were plated into vented T75cm2 flasks and incubated at 37°C with 5% CO2 (v/v) in a 
humidified incubator until they reached approximately 90% confluence. For passaging, cells 
were washed with sterile PBS and detached by incubation for 2-3min with trypsin-EDTA and 
then split into further T75cm2 flasks every 72 hours, or were plated onto the appropriate 
culture dishes for experimentation. For long-term storage in liquid nitrogen, cells were 
resuspended in freezing medium, transferred to cryovials, and frozen gradually at -80°C 
overnight before being transferred for storage in liquid nitrogen. 
SW1353/HEK293T cells were seeded overnight at a density of 10,000 cells/ cm2 in 96-well 
plates for mRNA quantification or at 150,000 cells/cm2 in 6-well plates for immunoblotting. 
Prior to cytokine stimulation, culture media was removed and the cells were washed with PBS 
and then cultured overnight with serum-free DMEM culture media at 37oC in 5% (v/v) 
CO2/humidified air.  
MSC were seeded at a density of 18,000 /cm2 cells in 10cm petri dishes and siRNA 
transfection was performed when the required confluency was achieved (as described in 
section 2.2.7 RNA interference (RNAi)). The cells were subsequently seeded in transwells 
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(Figure 6.1) at a density of 500,000 cells per transwell with chondrogenesis differentiation 
media for up to 14 days at 37oC in 5% (v/v) CO2/humidified air, replacing the chondrogenic 
media every 2-3 days. (Barter et al. 2015) 
 
2.2.2 Generation and use of expression vectors  
Expression vectors used in this study can be found in section 2.1.6 Plasmids. 
2.2.2.1 Bacterial Transformation 
Reagents 
 LB (EZMix (Sigma-Aldrich, Poole, UK) in dH2O, autoclaved) 
 LB-agar (LB plus 15g/L,- Bacto Agar in dH2O autoclaved) with addition of (100µg/ml) 
ampicillin 
Method 
2µl of plasmid DNA was added to 20µl Subcloning EfficiencyTM DH5αTM Competent Cells 
and incubated on ice for 30 minutes before a 20 second heat-shock at 42°C. SOC medium was 
added to the cells and incubated at 37°C with shaking for 1 hour. Next, the transformation 
mixture was spread onto LB-agar plates and incubated inverted at 37°C overnight. The 
following day individual colonies were selected and incubated in 5ml of LB supplemented 
with ampicillin (100µg/ml) at 37°C on an orbital shaker at 225rpm for 16 hours prior to 
miniprep isolation.  
2.2.2.2. Minipreps 
Minipreps were performed using the PureYieldTM plasmid miniprep system (Promega, 
Southampton, UK) following the manufacturer’s protocol. Plasmid DNA was eluted in 30µl 
nuclease-free water for minipreps. DNA concentration was determined using the NanoDrop 
ND-1000 spectrophotometer. 
 
2.2.3 Cartilage digestion of MSC-derived cartilage discs 
Reagents 
 0.1M Phosphate buffer pH 6.5 
 Papain (SIGMA Aldrich) 
 Cysteine- HCl 
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 EDTA 
 Starstedt tubes 
Method 
Two different solutions of 0.1M phosphate buffer pH 6.5 were made. Solution A contained 
9.36g/ 600ml dH2O 0.1M Na2HPO4 and solution B contained 7.1g/ 500ml dH2O 0.1M 
NaH2PO4. Next 137ml from solution A was mixed with 63ml from solution B and the pH was 
confirmed at 6.5. The phosphate buffer was stable for one week and was used to make the 
papain solution (0.25g/10ml phosphate buffer), the cysteine-HCl solution (0.078g/ 10ml 
phosphate buffer) and the EDTA (0.19g/10ml phosphate buffer). Cartilage discs produced 
after a 14-day differentiation period of MSC were put in Starstedt tubes and a mix of 
phosphate buffer, papain solution, cysteine-HCl solution and EDTA was added as shown in 
Table 2.3. The cartilage discs were then incubated at 65oC overnight. The following day 
450µl of phosphate buffer were added per tube and the samples were either kept at 4oC  and 
assayed at the same day, or stored at -20oC to be assayed at a later stage. 
 
 Per transwell = 1 disc (µl) Per cell pellet or ¼ of a disc (µl)  Per plate (10cm) (µl) 
Phosphate buffer 420 105 3500 
papain 120 30 1000 
Cysteine- HCl 60 15 500 
EDTA 60 15 500 
Table 2.3. Digestion of cartilage. 
 
2.2.4 Glycosaminoglycan (GAG)/ Dimethyl-methylene blue (DMB) assay 
GAG/DMB assay can be used to measure proteoglycan degradation by determining the 
amount of glycosaminoglycan in a sample. (Burkhardt et al. 2001) 
Reagents 
 Dimethyl-methylene blue (DMB) pH 3 (3.04g glycine, 2.37g NaCl, 95ml 0.1M HCl 
make up to 1L of dH2O, add 16mg DMB, Absorbance ~0.3 at 530nm, store at RT, 
light sensitive) 
 1mg/ml chondroitin sulphate 
Method 
In a flat bottomed 96-well plate a series of chondroitin sulphate concentrations beginning 
from 0mg/ml up to 40mg/ml were diluted in phosphate buffer and then 40µl were added to 
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each well in duplicate. 40µl of each sample prepared as described above in section 2.2.3 were 
also added in other wells in duplicate and 250µl of DMB solution were added in each well 
and the plate was immediately read in a plate reader at 530nm. 
 
2.2.5 PicoGreen DNA quantification 
Reagents 
 Quant-iT™ PicoGreen® dsDNA Assay Kit (P7589, Thermo Scientific Leicestershire, 
UK) 
Method 
The Picogreen Reagent was prepared in 1 X TE buffer provided by the kit. Then the DNA 
standard (100µg/ml) was prepared in Eppendorfs by diluting in 1 X TE buffer and the 
appropriate amount was added in triplicate in a clean black 96-well plate. The DNA stock was 
diluted 1:50 in 1 X TE to make a working solution of 2µg/ml and was then added in a series 
of concentrations starting from 0 up to 1000ng/ml. Each sample was also diluted 1:4 in 1 X 
TE Buffer and then added in duplicate. Finally PicoGreen working solution was added to each 
well, the wells were mixed and incubated for 2-5 minutes at room temperature, protected from 
light, before measuring the sample fluorescence using a Fluorostar fluorescence microplate 
reader and standard wavelengths (excitation ~480nm, emission ~520nm). The DNA 
concentration of the unknown samples was then calculated from the standard curve. The 
results obtained from the GAG assay above were subsequently normalised with reference to 
the DNA levels contained to each sample and expressed as µg GAG/ µg DNA. 
 
2.2.6 Hydroxiproline assay 
Hydroxiproline assay can be used to measure collagen content in tissue homogenates. The 
procedure is based on hydrolysis of the tissue homogenate and subsequent determination of 
the free hydroxiproline in hydrolyzates. (Reddy and Enwemeka, 1996) 
Reagents 
 Concentrated HCl (12M) 
 Chloramin T (7% w/v in water, dilute 1:5 in acetate citrate buffer, make up before use) 
 Acetate citrate buffer (57 g sodium acetate, 37.5 g trisodium citrate, 5.5 g citric acid, 
358 mL propan-2-ol per litre of distilled water) 
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 p-Dimethylaminobenzaldehyde (DAB; Sigma Aldrich) 20 g dissolved in 30 mL of 
60% per-chloric acid (VWR Int Ltd). Dilute 1:3 in propan-2-ol immediately before 
use. 
 Hydroxyproline (OHPro; Sigma. 1 mg/mL stock dissolved in water). This may be 
stored in aliquots at –20◦C 
Method 
Cartilage discs were incubated at 37°C in a humidified atmosphere of 5% v/v CO2 for 24 
hours, after which the medium was replaced with serum-free DMEM containing cytokines 
and/or HDAC inhibitors; each treatment was performed in quadruplicate. Supernatants were 
harvested on day 7, the treatments were replaced, and the explants were incubated until day 
14, when the remaining cartilage and medium were harvested. The remaining cartilage 
explants were digested in papain overnight at 65°C. Hydroxyproline release was assayed as a 
measure of collagen degradation at 560nm. (see also Hui and Cawston, 2010 for detailed 
protocol) 
 
2.2.7 RNA interference (RNAi) 
Standard ON-TARGET plus SMARTpool siRNAs were purchased from Dharmacon 
(Leicestershire, UK). The ON-TARGET plus collection takes advantage of a dual-strand 
modification pattern to decrease off-target effects by up to 90%. SMARTpool siRNAs contain 
4 siRNAs that target different regions of the target gene to maximise potency and specificity; 
the sequences of which can be found in Table 2.4. 
 
ON-TARGETplus non-
targeting Control 
siRNA 
ON-TARGETplus 
Human HDAC3 (8841) 
siRNA 
ON-TARGETplus 
Human E2F1 (1869) 
siRNA 
ON-TARGETplus 
Mouse HDAC3 (15183) 
siRNA 
UAAGGCUAUGAAGAGAUAC AACAAGAUCUGUGAUAUUG UCGGAGAACUUUCAGAUCU GGGAAUGUGUUGAAUAUGU 
AUGUAUUGGCCUGUAUUAG GGAAUGCGUUGAAUAUGUC GAGAAGUCACGCUAUGAGA CGGCAGACCUCCUGACGUA 
AUGAACGUGAAUUGCUCAA GCACCCGCAUCGAGAAUCA GAGCAGAUGGUUAUGGUGA GCACCCGCAUCGAGAAUCA 
UGGUUUACAUGUCGACUAA AAAGCGAUGUGGAGAUUUA GAACAGGGCCACUGACUCU UAUAAGAAGAUGAUCGUCU 
Table 2.4. The 4 sequences which make up the ON-TARGETplus SMARTpool siRNAs for 
HDAC3, E2F1 and the non-targeting siRNA. 
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Method 
SW1353 were seeded in a 96-well plate at a density of 1.5 x 104 cells/cm2. The following day, 
at around 50% cell confluency, cells were transfected with different concentrations of siRNA 
targeting HDAC3 (siHDAC3), E2F-1 (siE2F-1) or a non-targeting control siRNA (siCon) 
using DharmaFECT transfection reagent 1 (DF1). In separate tubes, the siRNA and DF1 were 
diluted in the appropriate volume of serum-free, antibiotic-free DMEM and incubated at room 
temperature for 5 minutes. Both tubes were then combined and incubated at room temperature 
for a further 20 minutes. Following incubation, an appropriate volume of serum-containing 
DMEM was added to the transfection mix; culture medium was aspirated from the cells in 
each well and replaced with the transfection mix. Cells were then incubated at 37°C in 5% 
(v/v) CO2 for the required time as described in each experiment independently. Alternatively, 
MSC were seeded in 10cm dishes at a density of 18,000/cm2 cells/ dish and siRNA 
transfection was performed when the cells acquired the required confluency (45-55%), as 
described above. The cells were then incubated for three days at 37oC in 5% (v/v) CO2 before 
chondrogenic differentiation was performed as described in (Barter et al. 2015). 
Different concentrations of ON-TARGET siRNAs were used starting from 5-100nM and 
knockdown efficiency was determined using quantitative real-time PCR and immunoblotting 
(see also Figure 3.7). Following optimisation, the 50nM of siRNA concentration was 
determined to be optimal, and as such was the concentration of all the siRNAs used in the 
subsequent experiments of this thesis. The optimal minimum transfection time has generally 
been found to be 24h for efficient knockdown for the SW1353 cells (thesis of Dr Heather 
Bromby, Newcastle University, Newcastle upon Tyne, UK) and 3 days for the MSC and these 
times were used in this thesis. 
 
2.2.8 Luciferase reporter assays 
NF-B, MMP1 and MMP13 reporter assays 
A pNFκB-Luc Vector (provided by Dr Matt Barter, Newcastle University, UK) gene assay 
was conducted using the Dual-Luciferase Reporter Assay System (Promega, Southampton, 
UK) according to the manufacturer’s protocol. The two MMP13 luciferase reporter constructs 
have been previously described (Schmucker et al., 2012) and both of them, and the MMP1 
luciferase construct were a kind gift of Professor David Young, (Newcastle University, 
Newcastle upon Tyne, UK). Briefly, cells were seeded into 48-well or 96-well plates at 1.5 x 
104/cm2 and the next day transfected with the appropriate concentration of Firefly luciferase 
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reporter and Renilla (pRL-TK, PROMEGA) expression vectors. Following transient 
transfection of the expression vectors for 24h, cells were serum starved overnight before IL-1 
stimulation was performed for 6h. After incubation with IL-1 the cells were washed in PBS 
and lysed in 30µl passive lysis buffer (1 X) provided by the kit. Next, cell lysate was added to 
a cross-talk-free, white walled 96-well plate (PerkinElmer, Wellesley, MA, USA), luciferase 
assay reagent was injected to initiate the firefly luciferase reaction and luminescence was 
measured using a Glomax-Multi+ Detection System (Promega, Southampton, UK). After the 
firefly initial expression reading, a second reagent was injected to stop the reaction and 
luminescence for Renilla luciferase was subsequently measured.  
For experiments in which NF-κB luciferase reporter was used, 100ng of the reporter was 
transfected together with 6ng of Renilla reporter for 24 hours before serum starvation and IL-
1 stimulation was performed. For experiments in which MMP13 or MMP1 luciferase 
reporters were used with or without over-expressing HA-E2F1 and HA-DP1 plasmids DNA, 
96-well plates were used and 25ng of each MMP reporter together with 50ng of HA-E2F1, 
50ng HA-DP1 and 1.5ng of Renilla reporter were transfected for 24 hours before serum 
starvation and IL-1 stimulation was performed. 
 
2.2.9 Protein analysis 
2.2.9.1 Whole Cell Lysis 
Reagents 
 Lysis buffer (50mM Tris-HCl, pH 7.4, 10% (v/v) glycerol, 1mM EDTA, 1mM EGTA 
pH 8.0), 1mM Na3VO4, 5mM NaF, 10mM β-glycerol phosphate, 5mM Na4P2O7, 1% 
(v/v) Triton X-100, 1μM microcystin-LF and 1 Complete protease inhibitor Mini 
tablet (Roche Diagnostics, West Sussex, UK) for 50ml of buffer  
Method 
Cells were seeded in 12-well or 6-well plates at a density of 150,000 cells/cm2.  After the 
appropriate experimental period, the plates were transferred on ice, culture medium was 
removed and cells were washed with ice-cold PBS. Ice-cold lysis buffer (containing 0.01% 
(v/v) β-mercaptoethanol) was added at 75µl/well or 100µl/well for 12- or 6-well plates, 
respectively. Cells were scraped and the cell suspension transferred to a cooled Eppendorf for 
20 minutes incubation on ice. Following incubation the lysates were centrifuged at 4°C for 3 
minutes at 10 000 x g. Supernatants were removed and immediately either stored at -80°C or 
a Bradford protein assay was performed.  
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2.2.9.2 Bradford Assay 
Method 
Bradford protein assays were used for protein quantification of the cell lysates. A range of 
standards of 0-4 mg/ml BSA (2mg/ml stock concentration) were made using increasing 
increments of 0.4 mg/ml in a flat bottomed 96 well plate, making each well volume up to 10μl 
with dH2O. Next, 3μl of each sample was added to the plate together with 3μl of lysis buffer 
as a loading control, making each volume up to 10μl with dH2O. 150μl of Bradford Ultra 
Reagent were then added to each well according to the manufacturer’s instructions. A 5 
minutes incubation at room temperature followed and the absorbance was then measured at 
595nm using a Tecan Sunrise microplate absorbance reader. A standard curve was then drawn 
using Microsoft Office Excel and the protein concentration of each sample was calculated, 
after subtracting the absorbance of the lysis buffer control. The protein content of samples 
was then equalised using 5X Laemmli sample buffer and dH2O. The samples were then boiled 
for 5 minutes and were loaded onto a SDS-PAGE gel (described in section 2.2.9.3 
Immunoblotting) or frozen at -20oC. 
2.2.9.3 Immunoblotting 
Reagents 
 Separating gel solution: dH2O, 4x lower gel buffer (LGB) (1.5M Tris-Base pH8.8, 
0.4% SDS (w/v)), 37.5:1 acrylamide/bis-acrylamide 40%, APS and TEMED  
 Stacking gel solution: 4 X upper gel buffer (UGB) (0.5M Tris- HCl pH 6.8, 0.4% 
(w/v) SDS), APS, TEMED 
 10 X Running buffer (250mM Tris Base, 2M Glycine and 10% (w/v) SDS) 
 Transfer buffer (20mM Tris Base, 0.6M glycine and 20% (v/v) methanol) & Methanol 
 Tris buffered saline (TBS)-Tween (TBS-T) (150mM NaCl, 10mM Tris Base pH7.4, 
0.1% (v/v) Tween-20) 
 5X Laemmli sample buffer (0.1 M Tris-HCl, pH 6.8, 0.35 M SDS, 20% (v/v) glycerol, 
0.01% bromophenol blue and 10% (v/v) β-mercaptoethanol) 
 Polyvinylidene difluoride membrane (PVDF) (#88518, Thermo Scientific, 
Leicestershire, UK) and blotting paper 
 Stripping buffer (for 1L): 15g Glycine, 1g SDS, 10ml Tween 20, pH 2.2, bring volume 
up to 1L with ultrapure dH2O 
Method 
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Cell lysate samples containing 5X Laemmli sample buffer were heated at 100°C for 5 minutes 
prior to loading onto a 10% SDS-polyacrylamide gels. For the separating gel, acrylamide/bis-
acrylamide 40% solution was diluted with 4X LGB and water at the correct volumes to give a 
10% gel. 10µl TEMED and 30µl APS 0.2% (w/v) were added to the gel solution for 
polymerisation and the gel poured into 1.0mm Bio-Rad separator glass plates (Bio-Rad 
Laboratories, Hemel Hempstead, UK). Stacking solution made up of 4X UGB, polymerised 
with TEMED and APS and was then added on top of the polymerised separating gel, with 
combs inserted. The SDS-PAGE gels were electrophoresed at 140V using the Bio-Rad mini-
PROTEAN gel vertical electrophoresis system (Bio-Rad Laboratories, Hemel Hempstead, 
UK) in which the gel plates are inserted into a sealed casting frame and placed into a tank 
filled with 1 X Running buffer. PageRuler™ pre-stained protein ladder (#26616, Thermo 
Scientific, Leicestershire, UK) was loaded onto the gel alongside the protein samples. 
After electrophoresis, proteins were transferred from the gel to a PVDF membrane by 
electroblotting in transfer buffer using a Scie-Plas V20-SDB 20 x 20cm semi-dry blotter at 
1mA/cm2 for 1.5 hours. Membranes were blocked for 1 hour in TBS-T containing 5% (w/v) 
non-fat dry milk powder. After thoroughly washing in TBS-T 3 times for 5 minutes each with 
gentle agitation, membranes were incubated overnight at 4°C with primary antibody (see 
Table 2.1) with gentle agitation, diluted according to manufacturer’s instructions in primary 
antibody dilution buffer (TBS-T containing 5% BSA). The membrane was then incubated 
overnight and the following day 3 washes with TBS-T (3 times for 5 minutes each with gentle 
agitation) were performed. The membrane was then incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibody (diluted 1:5000 in TBS-T, 5% milk) for one hour at 
room temperature with gentle agitation. Membranes were again washed for 3 x 5 minutes with 
TBS-T and then visualised on high-speed X-ray film using ECL detection reagents. 
To allow probing with a different antibody, membranes were incubated in stripping buffer for 
5-10 minutes. The buffer was discarded and fresh stripping buffer was added to the membrane 
and 5-10 minutes incubation followed. After washing with PBS twice for 10 minutes each 
time and with TBS-T twice for 5 minutes, membranes were then incubated with the desired 
primary antibody overnight as described above. An anti-GAPDH or anti-β catenin antibody 
was used to ensure equal loading, as indicated in each experiment. 
 
2.2.10 Immunoprecipitation (IP)  
Method 
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HEK293T cells were seeded in 10cm dishes at a density of 4 x 106 cells/dish. The following 
day cells were transfected with the appropriate tagged protein for 24 hours as outlined in 
section 2.2.2 Generation and use of expression vectors. The next day whole cell lysis was 
performed as described above (in section 2.2.9.1 Whole Cell Lysis and cell lysate protein was 
quantified using Bradford assay as in section 2.2.9.2 Bradford Assay.  
For IP experiments 300μg of protein lysate was used. First the lysate was pre-cleared by 
adding 3μg of irrelevant antibody (IgG mouse). Samples were then placed on ice for one hour 
and then incubated at 4oC with end-over-end rotation with 20μl added Protein G PLUS-
agarose conjugate suspension. After a 10 minutes centrifugation at 14,000 x g at 4oC, 
supernatants were removed for IP. 
On ice, 3μg of the IP antibody was added to the pre-cleared lysate and incubated overnight 
with end-over-end rotation at 4oC. The following day 20μl Protein G PLUS-agarose conjugate 
suspension was added to each sample. The samples were then incubated for 3 hours at 4oC 
with end-over-end rotation. The complex lysate-antibody-beads was collected by 
centrifugation at 10, 000 x g for 1 minute at 4oC and the supernatant was discarded. The bead 
pellet was then washed 3 times with washing buffer (10mM Tris-HCl pH 7.5, 1mM EDTA 
pH 8.0, 150mM NaCl, 1% (v/v) NP-40, 0.2mM Na-Orthovanadate and 1x cOmpleteTM 
Protease inhibitor cocktail). After the last wash, the washing buffer was discarded and the 
bead pellet resuspended in 2 X Laemmli buffer and heated to 100oC for 5 minutes. The 
samples were centrifuged at 4oC for 1 minute at 10, 000 x g and then left to stand for 1 minute 
at room temperature. The supernatant was collected and electrophoresis was performed as in 
section 2.2.9.3 Immunoblotting. 
 
2.2.11 RNA analysis  
2.2.11.1 Cell lysis 
The Ambion® Cells-to-cDNA™ II lysis buffer was used to yield cell lysates for reverse 
transcription from SW1353 cells in culture and MSCs differentiated into pellets. The lysis 
buffer integrates RNase inactivation into an RT-PCR compatible cell lysis buffer, eliminating 
RNA isolation altogether. 
For the transwell differentiation of MSC, RNA isolation using TriZOL and ¼ of two cartilage 
discs (technical replicates) from two independent MSC donors (biological repeats) per time-
point were performed. 
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Reagents 
 Ambion® Cells-to-cDNA™ II  Lysis Buffer (ThermoFisher Scientific) 
 Molecular grinding resin and pestles (G-Biosciences) 
 TriZOL 
 Chloroform 
 100% Isopropanol 
 75% (v/v) Ethanol 
 RNase-free H2O 
 
Method 
Cell lysis was performed using Cells-to-cDNA II lysis buffer following the manufacturer’s 
protocol. For RT-PCR, 96-well culture plates were used for the SW1353 cells and 14ml 
falcon tubes for the MSC differentiation into pellets. After siRNA transfection/HDACi 
treatment and IL-1 stimulation, cell culture medium was removed and cells were washed in 
ice-cold PBS. Next, cells were lysed in 30µl ice-cold Cells-to-cDNA II lysis buffer per 
well/falcon tube, transferred to a 96-well PCR plate and heated to 75°C for 15 minutes to 
ensure RNase inactivation. Lysates were then stored at -80°C or reverse transcription was 
performed immediately as described below.  
To homogenise the differentiated cartilage discs 20µl grinding resin together with 250µl of 
TriZOL were pipetted into the ¼ of each cartilage disc contained in an Eppendorf tube. 
Homogenisation followed by using pestles and grinding against the side of the tube. The 
pellet resin was then removed by centrifugation and the supernatant was transferred to a new 
Eppendorf tube. The lysate was incubated for 5 minutes at room temperature and then 50µl of 
chloroform per 100µl TriZOL was added and shaken vigorously for 15 seconds. Following 
two minutes incubation at room temperature, samples were centrifuged at 13,000 rpm for 15 
minutes at 4oC. After the centrifugation, the aqueous phase (~250µl) was transferred to a fresh 
tube and 50µl of isopropanol per 100µl of TriZOL was added and the samples were vortexed. 
The samples were then incubated for 10 minutes at room temperature, before 10 minutes 
centrifugation at 13,000 rpm at 4oC. The supernatant was discarded and the pellet was washed 
with 75% (v/v) ethanol, vortexed and centrifuged at 10,000 rpm for 5 minutes at 4oC. 
Following centrifugation, the ethanol was removed and the pellet was air dried for 10 minutes 
at room temperature and then resupended in 20µl of RNase-free H2O. Samples were then 
quantified to determine RNA concentration, using NanoDrop ND-1000 spectrophotometer, 
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and either stored at -80oC or reverse transcription was performed immediately as described 
below.  
2.2.11.2 Reverse transcription 
Method 
For reverse transcription of SW1353 cells or MSC differentiated into pellets, 8µl of the lysate 
produced using the Cells-to-cDNA II lysis buffer was transferred to a new 96-well PCR plate 
to which final concentrations of 0.375µM dNTPs and 10ng/µl random hexamers p(dN)6 were 
added to each well and heated to 70°C for 5 minutes. The samples were then placed on ice 
and 5 X First Strand Buffer, final concentration of 10mM DTT and 0.5µl 200U/µl M-MLV 
reverse transcriptase were added. The reaction was made up to 20µl total volume per well 
with dH2O, incubated at 37°C for 50 minutes followed by incubation at 75°C for 15 minutes. 
To this cDNA, 30µl dH2O was added for target gene quantification and diluted further 1:50 
for housekeeping gene (18S) quantification. The cDNA was stored at -20°C prior to analysis 
or quantified immediately by real-time qRT-PCR. 
If TriZOL RNA isolation was performed, 500ng of total RNA was transferred to a new 96-
well PCR plate and volume was adjusted to 8µl with H2O to which 10mM dNTPs and 1µg/µl 
random p(dN)6 were added to each well and heated to 70°C for 5 minutes. An identical 
process as above (Cells-to-cDNA) was performed, however the cDNA produced was then 
diluted 1:50 with dH2O for target gene quantification and diluted 1:10 further for 18S 
quantification.  
 
2.2.11.3 Taqman® Probe-Based Real- time qRT-PCR 
Reagents 
 Taqman Fast Universal PCR Mastermix (2 X) 
Method 
For quantification of target genes using the cDNA prepared above, a 6µl reaction mix of 2 X 
TaqMan gene expression master mix, 200nM of each forward and reverse primers, 150nM 
probe were made up with H2O and added to each well of a FAST Optical 96-well qPCR 
plate. Similarly, for quantification of the housekeeping gene a 5µl reaction mix of 2 X 
TaqMan gene expression master mix, 300nM of each forward and reverse primers and 75nM 
probe was prepared. Next, 4µl or 5µl diluted cDNA was used for target or housekeeping gene 
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quantification respectively and added to each well to give a total 10µl reaction. Real-time 
qRT-PCR was performed using the ABI 7900HT Fast Real-time PCR system (Applied 
Biosystems, Life Technologies Ltd., Paisley, UK). Oligonucleotide primers and probes were 
designed using the Roche ProbeFinder Assay Design Software (Roche, Applied Science) and 
the sequences are shown in Table 2.5. Thermocycling parameters were: 95°C for 10 minutes 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  
 
Gene Primer Primer sequence (5’-3’) Probe 
Human 
ACAN 
Forward 
Reverse 
AGACGGCTTCCACCAGTGT 
GGGAGTGTGGATGGGGTAT 
Probe library #20 
Human 
CCL2 
Forward 
Reverse 
AGTCTCTGCCGCCCTTCT 
GTGACTGGGGCATTGATTG 
Probe library #40 
Human 
COL10A1 
Forward 
Reverse 
CACCTTCTGCACTGCTCATC 
GGCAGCATATTCTCAGATGGA 
Probe library #6 
Human 
COL11A1 
Forward 
Reverse 
AGGTCCTCCTGGAAAACGAG 
TCACCTTGTCTTCCCTCTGC 
Probe library #1 
Human 
COL1A1 
Forward 
Reverse 
CCCCTGGAAAGAATGGAGATG 
TCCAAACCACTGAAACCTCTG 
5’-TTCCGGGCAATCCTCGAGCA-3’ 
Human 
COL2A1 
Forward 
Reverse 
ACCTTCATGGCGTCCAAG 
AACCAGATTGAGAGCATCCG 
5’-AGACCTGAAACTCTGCCACCCTG-3’ 
Human 
COL9A1 
Forward 
Reverse 
AGATAATCCTCAAGTTTCTGTTCCA 
GCAGCTCATGGCAAGTTTCT 
Probe library #89 
Human 
E2F-1 
Forward 
Reverse 
TCCAAGAACCACATCCAGTG 
CTGGGTCAACCCCTCAAG 
Probe library #5 
Human 
FRA1 
Forward 
Reverse 
AACCGGAGGAAGGAACTGAC 
CTGCAGCCCAGATTTCTCA 
Probe library #4 
Human 
IL6 
Forward 
Reverse 
CAGGAGCCCAGCTATGAACT 
GAAGGCAGCAGGCAACAC 
Probe library #45 
Human 
IL8 
Forward 
Reverse 
AGACAGCAGAGCACACAAGC 
AGGAAGGCTGCCAAGAGAG 
Probe library #72 
Human 
JUNB 
Forward 
Reverse 
ATACACAGCTACGGGATACGG 
GCTCGGTTTCAGGAGTTTGT 
Probe library #49 
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Human 
JUND 
Forward 
Reverse 
CAGCGAGGAGCAGGAGTT 
GAGCTGGTTCTGCTTGTGTAAAT 
Probe library #81 
Human 
MATN3 
Forward 
Reverse 
TTCCAGGAAACCTTCTGTGC 
TGTATCCTTGGCTACACTCACAGT 
Probe library #60 
Human 
MMP1 
Forward 
Reverse 
AAGATGAAAGGTGGACCAACAATT  
CCAAGAGAATGGCCGAGTTC 
5’FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-
TAMRA 3’ 
Human 
MMP13 
Forward 
Reverse 
AAATTATGGAGGAGATGCCCATT 
TCCTTGGAGTGGTCAAGACCTAA 
5’FAM-CTACAACTTGTTTCTTGTTGCTGCGCATGA-TAMRA 
3’ 
Human N-
CAD 
Forward 
Reverse 
GGTGGAGGAGAAGAAGACCAG 
GGCATCAGGCTCCACAGT 
Probe library #66 
Human N-
CAM 
Forward 
Reverse 
GCGTTGGAGAGTCCAAATTC 
GGGAGAACCAGGAGATGTCTTT 
Probe library #51 
Human 
RUNX2 
Forward 
Reverse 
GGAGTGGACGAGGCAAGAGTTT 
AGCTTCTGTCTGTGCCTTCTGG 
Probe library #29 
Human 
SERPINB2 
Forward 
Reverse 
CATGGAGCATCTCGTCCAC 
ACTGCATTGGCTCCCACTT 
Probe library #1 
Human 
SOX9 
Forward 
Reverse 
CTGGTACTTGTAATCCGGGTG 
ACTTGCACAACGCCGAG  
5’FAM-TCTGGAGACTTCTGAACGAGAGCGA- TAMRA 3’  
 
Human 
TNFAIP6 
Forward 
Reverse 
GGCCATCTCGCAACTTACA 
GCAGCACAGACATGAAATCC 
Probe library #34 
Human 
WNT7B 
Forward 
Reverse 
TGGCGTCCTGTACGTGAA 
TCTTGTTGCAGATGATGTTGG 
Probe library #49 
Human 
18S 
Forward 
Reverse 
CGAATGGCTCATTAAATCAGTTATGG 
TATTAGCTCTAGAATTACCACAGTTATCC 
5’FAM-TCCTTTGGTCGCTCGCTCCTCTCCC0-TAMRA 3’ 
 
Table 2.5. Sequences of Taqman qRT-PCR primers and corresponding Universal Probe Library 
(UPL) probe numbers/ probes. 
 
2.2.11.4 SYBR Green Real- time qRT-PCR 
Reagents 
 Platinum® SYBR® Green qPCR SuperMix-UDG with ROX (Thermo Scientific, 
Leicestershire, UK). 
Method 
For quantification of target genes using the cDNA prepared from the cartilage discs, 4.8µl of 
SYBR Green mix together with 0.2µl ROX (Reference dye), 250nM of each forward and 
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reverse primer were added in a Fast Optical 96-well qPCR plate. To this 4µl of cDNA was 
added to make up a final volume of 10µl. This was then subject to a denaturation stage at 
95oC for 2 minutes followed by 40 cycles of 95oC for 15sec and 60oC for 1 minute. All SYBR 
Green reactions included a final dissociation stage of 95oC for 15sec and 60oC for 15sec. All 
reactions were performed using the ABI 7900HT Fast Real-time PCR system. 
Oligonucleotide SYBR Green primer sequences can be found in Table 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.12  Generation of a cartilage specific HDAC3 conditional knockout mouse model. 
To determine the role of HDAC3 in endochondral ossification, HDAC3 was conditionally 
deleted in cells expressing Cre recombinase under the control of Col2α1 promoter (called 
HDAC3(Fl/Fl); Col2-Cre(+) or HDAC3CartΔEx3). The steps taken for the generation of the 
conditional knockout mouse model are summarised in Chapter 7- Figure 7.5. Briefly, three 
males and three females HDAC3tm1a(EUCOMM)Wtsi targeted; knockout first allele (reporter-
tagged insertion with conditional potential) mice, were purchased from the University of 
Veterinary Medicine, (Vienna, Austria) and detailed information as well as phenotypic data 
are available from the International Mouse Phenotypic Consortium (IMPC, at 
http://www.mousephenotype.org/data/search/gene?kw="hdac3").  
These mice accounted for the parental line (P) and carried one Wild-type (Wt) allele and a 
HDAC3 target locus allele (shown in Figure 2.2), containing a lacZ-neomycin reporter 
Gene Primer Primer sequence (5’-3’) 
Human ATF2 
Forward 
Reverse 
TCCAGCTGCAGTCCCACT 
TTTTTGCTTCTGACTGTACTGGTT 
Human c-FOS 
Forward 
Reverse 
AGAATCCGAAGGGCCTTGAC 
TCCGCTTGGAGTGTATCAGTC 
Human HDAC3 
Forward 
Reverse 
GGGTGGTGGTGGTTATACTGTC 
ATGAAACGGGGTCTGAAGTGTGGAGTAGGT 
Human FOSB 
Forward 
Reverse 
CAGGCGGAGACAGATCAGTTG 
CCAGCACAAACTCCAGACGTT 
Human FRA1 
Forward 
Reverse 
ACAGATCAGCCCGGAGGAAG 
CTTCCAGTTTGTCAGTCTCCGC 
Human FRA2 
Forward 
Reverse 
CAGCAGAAATTCCGGGTAGATATG 
TATGGGTTGGACATGGAGGTG 
Table 2.6. Sequences of SYBR Green qRT-PCR primers.  
All primers were purchased from SIGMA Aldrich (Poole,UK). 
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cassette flanked by two 48bp FRT sites and a floxed exon 3 (one loxP site either side of exon 
3). Presence of the HDAC3 target locus allele was confirmed using primer pairs 1 and 2 (see 
Table 2.7 and Figure 2.2). These mice are called HDAC3(+/Fl) hereafter.  
The parental line HDAC3(+/Fl) was bred with mice expressing FLP recombinase 
ubiquitously (Rodriguez et al., 2000; Dymecki 1996), to promote site-specific DNA 
recombination in the presence of an FRT site and remove the lacZ-neomycin cassette. These 
breedings resulted in the F1 generation of mice, which were called HDAC3(+/Fl); FLP(+) 
and carried one Wt allele and a Post-FLP HDAC3 locus allele. For genotyping, primer pairs 3 
and 4 (Table 2.7) were used to confirm FLP recombination and absence of the lacZ-neomycin 
reporter. Presence of FLP was also confirmed using a PCR reaction which will specifically 
amplify FLP gene and one example is shown in Figure 2.3.  
 
 
Figure 2.2. HDAC3 transgene and primer pairs used for genotyping mice. 
Numbers in red indicate the primer pairs as shown in Table 2.7. Double arrows indicate the size of the 
PCR amplicon. 
 
F1 heterozygous mice were then bred with Col2-Cre mice to generate (F2) heterozygous 
HDAC3(+/Fl); FLP(+); Col2-Cre(+) mice. In F3 generation HDAC3(+/Fl); FLP(+); Col2-
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Cre(+) heterozygous mice were used for the final breeding step that would generate the 
conditional knockout mouse model. Genotyping results were obtained using primer pairs 3 
and 6 to confirm Cre recombination and HDAC3 exon 3 deletion. Real-time PCR was also 
used to quantify Col2α1-Cre expression of the F5 mice and normalised to type X collagen 
expression levels (Figure 2.4). 
 
Figure 2.3. FLP presence was confirmed with PCR which would give a band at 234bp. 
Animals 4, 5, 8 and 9 were FLP positive, while all the other animals (1, 2, 3, 6 and 7) did not inherit 
the FLP recombinase gene. bp: base pairs 
 
Pair Primer Name Primer sequence (5’-3’) Annealing Tm 
Pair 1 
Forward- Upstream of 5’-FRT TGAGTCTGATGATGGCTCAAG  65 
Reverse- 5’-LAR3 CACAACGGGTTCTTCTGTTAGTCC  
Pair 2 
Forward- 3’-RAF5 CACACCTCCCCCTGAACCTGAAAC 65 
Reverse- Downstream of 3’-LoxP CAGTCATGGGCCTCCTCACAG  
Pair 3 
Forward- Upstream of 5’-FRT TGAGTCTGATGATGGCTCAAG 65 
Reverse- Downstream of 3’-LoxP CAGTCATGGGCCTCCTCACAG  
Pair 4 
Forward- Downstream of 5’- LoxP GCCGTGGTATTGGGAATGTCT 65 
Reverse- Downstream of 3’- LoxP CAGTCATGGGCCTCCTCACAG  
Pair 5 
Forward- Exon 4 GTGATGTAACCCTGAGTCTTG 65 
Reverse- Exon 7 AGTCATGACCCGGTCAGTGAG  
Pair 6 
Forward- Start of exon 3 CAGGTCTTCAAGCCTTACC 65 
Reverse- Downstream of 3’-LoxP CAGTCATGGGCCTCCTCACAG  
FLP 
Forward- FLP 
Reverse- FLP 
GGACCGGCAATTCTTCAAGCA 
 
CCACGGCAGAAGCACGCTTAT 
65 
Table 2.7. Sequences of primers used for genotyping mice. 
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Figure 2.4. Primer pairs 3 and 6 were used to confirm Post-FLP and Post-Cre recombination of 
the HDAC3 target locus. 
A. Primer pair 3 was used to confirm Cre recombination of the Post-FLP allele. The Wt allele 
amplicon is 1118bp long, whilst the HDAC3 target locus allele recombined by Cre is 326bp 
long. There is still a band for the Post-FLP HDAC3 target allele amplicon at 1170bp, indicating 
Cre recombination is not 100% efficient. Primer pair 6 could also be used to demonstrate the 
presence of the floxed allele, since it amplifies a region around exon 3 (see Figure 2.2), which 
is smaller by 82bp in comparison to the Wt allele. B. Cre expression was quantified using qRT- 
PCR and normalised to type X collagen expression. C. Genotyping results from A & B show 
that animals number 1, 2, 4 and 5 are heterozygous for the HDAC3 (Fl/+) and have also 
inherited Cre recombinase (Cre positive, Cre+), while animal number 3 is Cre negative (Cre -). 
 
2.2.12.1 Housing and care of animals 
Mice were housed at the Comparative Biology Centre (CBC) in Newcastle University, in 
compliance with the Animals (Scientific Procedures) Act 1986 and its associated Codes of 
Practice. Mice were ear/notched at postnatal day 21 and separated into males/females after the 
weaning period. Up to 6 mice were housed together in special containers (300cm2, 12cm 
height) to allow enough space for physical activities/ exercise. In cases where single housing 
had to be performed, close visual monitoring of the activity of the animals was maintained. In 
the case of breeding, one male was introduced to one or two females and re-introduction of 
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the breeders to already established groups was avoided in order to avoid problems of 
incompatibility and disrupted social relationships. Cleaning of the containers was performed 
by the technical staff in the CBC twice a week. All animals always had access to food and 
drinking water. Detailed record keeping of each animal used in this study was performed 
using the AniBio software system and returns of procedures (for Home Office) including 
severity limits and protocols performed annually.  
2.2.12.2 Genotyping mice 
Genotypes of the HDAC3 mice used in this study were determined using the Phire Tissue 
Direct PCR Master Mix (F170S, Thermo Scientific, Leicestershire, UK). 
Method 
DNA extraction was performed following the manufacturer’s protocol.  Briefly, an ear notch 
was obtained from each mouse and incubated in a 20µl mix of Dilution buffer and 0.5µl DNA 
release additive. Next tissue extracts were incubated at room temperature for 5 minutes, 
vortexed, centrifuged for 1 minute at 13,000 rpm and incubated at 95°C for 5 minutes. 
Samples were next vortexed and centrifuged as above and then stored at 4°C or PCR was 
performed immediately.  
All PCR preparations were performed at room temperature as the Phire Hot Start II DNA 
Polymerase is specific for hot start amplification. To a 0.2ml PCR tube 10µl Phire Hot Start II 
DNA PCR reaction mix was added together with 0.25µM of each forward and reverse primers 
(see Table 2.7) and 1µl tissue extract and dH2O to give a 20µl total reaction. Thermocycling 
stages included: 94°C for 5 minutes followed by 35 cycles of 94°C for 30 seconds, 65°C for 
30 seconds, 72°C for 1 minute and a final step of 72°C for 10 minutes. The produced 
amplicons were then loaded onto a 1.5% (w/v) agarose TAE (Tris-Acetate-EDTA) gel and 
determination of mouse genotype followed. Mice were not born at expected Mendelian ratios 
since no conditional knockout animals were found during this study (see Chapter 7, Tables 
7.1 & 7.2). COL2-Cre expression was quantified using real-time RT-PCR and the primers 
sequences can be found at Table 2.8. Figure 2.2 shows where the primers are located, the 
size of the amplicons produced depending on the genotype and if they were used following 
FLP or Cre recombination. 
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Gene Primer Primer sequence (5’-3’) 
Mouse COL2 
Forward 
Reverse 
TCGATGCAACGAGTGATGAGG 
GAAACCATTTCCGGTTATTCAACTTGC 
Mouse COL10 
Forward 
Reverse 
CTTCCTGTCAAGCTCATCC  
TAGGATTGCTGAGTGCTCC 
Table 2.8. Sequences of primers used for COL2-Cre quantification using real-time RT-PCR 
(SYBR Green). 
 
2.2.12.3 Agarose gel electrophoresis 
Reagents 
 TAE buffer (0.04M Tris (pH 8), 5.7% (v/v) glacial acetic acid and 0.001M 
ethylenediaminetetraacetic acid (EDTA) 
 Loading buffer (Tris 0.125M (pH 6.8), 10% (v/v) glycerol and 0.001% (w/v) 
bromophenol blue)  
Method 
Gels were prepared at 1.5% (w/v) agarose in TAE with the addition of final 0.2µg/ml 
ethidium bromide (EtBr) solution. The DNA was electrophoresed on the gel in loading buffer 
and bands visualised on a ChemiGenius II BioImager (Syngene, Cambridge, UK) using a 
GeneRulerTM 100bp or 1kb DNA ladder to determine DNA band size.  
2.2.12.4 Cloning 
Cloning reactions using the TOPO® TA Cloning® Kit (Life technologies) and bacterial 
transformation were performed according to manufacturer’s instructions to check the 
sequence of the amplicons produced. Briefly reactions were prepared using 2μl of the PCR 
product produced as described above, 1μl of TOPO® vector and made up to 6μl with H2O. 
The reaction was gently mixed and incubated for 5 minutes at room temperature. After 
performing the TOPO cloning reaction, One Shot® Mach1™-T1R E. coli competent cells 
were transformed. For each transformation one LB plate containing 100μg/ml Ampicillin and 
40mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) diluted in 
Dimethyleformamide (DMF) were placed at 37oC until ready for use. S.O.C medium was also 
warmed up at room temperature and one vial of One Shot cells was thawed on ice. (see also 
section 2.2.2 Generation and use of expression vectors). 2μl of each TOPO cloning reaction was 
added into a vial of One Shot cells, mixed gently and incubated on ice for 30 minutes. The 
cells were then heat-shocked at 42oC for 30 seconds and then immediately transferred on ice. 
250μl of S.O.C medium was then added to the tube and the samples were then incubated at 
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37oC for 1 hour at 225rpm. Following incubation 50μl from each transformation were spread 
onto a pre-warmed LB-agar ampicillin + x-gal selective plate and incubated at 37oC for 16 
hours. The next day individual white (or light blue) colonies were selected and incubated in 
5ml of LB supplemented with ampicillin (100µg/ml) at 37°C with shaking at 225rpm. 
Plasmid DNA was then isolated and analysed as described in section 2.2.2 Generation and use 
of expression vectorsand the samples were sequenced by Sanger sequencing (Source 
BioScience Life Sciences, Nottingham, UK) using the M13 Forward (−20) and M13 Reverse 
primers, the sequence of which can be found on Table 2.9. 
 
Primer Sequence (5’-3’) 
M13 Forward  GTAAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC 
Table 2.9. Primers used for sequencing. 
 
2.2.13 Destabilisation of the medial meniscus (DMM) surgery 
Pre-operation: Male mice at 10 weeks of age were used for the DMM surgery. Each mouse 
was anaesthetised separately using isoflurane (2.5-3.5%) 1L/min O2 and then placed in a 
recumbent position with their head in the mask. The left knee was shaved and the area 
disinfected with chlorohexidine solution (ECOLAB, MN, USA). An ear notch was taken at 
this stage if not earlier for genetic identification; the animal was weighed and checked for any 
possible infection. Subcutaneous injection of buprenorphine (0.15ml, 3µg/ml solution) was 
then performed. 
Operation: A scalpel was used to make a small vertical incision in the skin just left of the knee 
joint avoiding the patella ligament region. The incision was then increased using curved 
scissors and any blood vessels present were cauterised to avoid bleeding. The fat tissue was 
then removed with scalpel/ scissors pealing back and avoiding blood vessels. If necessary, 
blood vessels, coming from the fat pad, were cauterised to avoid excess bleeding. 
Identification of the medial collateral ligament and the patella ligament was then necessary 
and a small vertical incision was made (large scalpel) down the side of the patella ligament 
and extended to the left. The fat pad was cleared with two fine forceps to expose the medial 
meniscus with the white medial meniscotibial ligament (MMTL) lying horizontal extending 
towards and behind the patella region. Throughout the surgery, any veins were cauterized to 
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avoid bleeding. Using a small scalpel blade an incision of the medial meniscus was made. The 
skin was then hold together with forceps and clipped. The clips were checked later that day 
and every day post-surgery before removal seven days post-surgery.  
Post-operation: The animals were located in clean cages and the cages placed at 27oC until the 
animals reach consciousness. Another dose of pain relief (buprenorphine, 0.15ml, 3µg/ml 
solution) was subcutaneously injected to all mice the following day and the animals were 
closely watched thereafter to ensure successful recovery.  
End of experiment: Eight weeks post-surgery the animals were euthanized using CO2 or by 
dislocation of the neck and both knee joints harvested and fixed in formalin solution, neutral 
buffered 10% (contains formaldeyde 4% (w/v), SIGMA-Aldrich, Poole, UK) overnight at 
room temperature with rotation, before decalcification in Formica 2000 (Formic acid, EDTA, 
Decalcifier, #1340, Decal Chemical Corp, NY) for 16 hours at room temperature was 
performed. 
 
2.2.14 Intra-articular injections 
For intra-articular delivery of RNAi for HDAC3 in vivo, the AteloGene™ in vivo siRNA 
Transfection Kit (KKN-1395, Reprocell-Europe) was used according to manufacturer’s 
instructions and diluted in 0.01% (w/v) of Evan’s blue dye (SIGMA Aldrich, Poole UK) 
which was used to ensure accuracy of the injection. Animals were anesthetised using 
isoflurane (2.5-3.5%) 1L/min O2 and prepared as described for the DMM surgery in section 
2.2.13 Destabilisation of the medial meniscus (DMM) surgery Using a 0.5ml syringe and 27G 
needles, 10μl of the prepared solution was gently inserted in the joint space. The skin was 
then held together and clipped. The clips were checked later on the same day and removed at 
the end of the experiment either three or six days after the injections.  
 
2.2.15 Histological Staining  
2.2.15.1 Embedding and microtome sectioning 
After fixation of mouse knee joints or cartilage discs/pellets produced by differentiated MSC 
in Formalin solution for 24 hours at room temperature with rotation, tissue was sent in 
Newcastle Biomedicine Biobank (Newcastle University, UK) for dehydration in an ethanol 
series. Following tissue processing the samples were placed in wax moulds and heated 
forceps used to position the limb/tissue for longitudinal sectioning. Wax embedded 
 63 
 
joints/cartilage discs/pellets were sectioned at a thickness of 5μm using a rotary microtome. 
Coronal sectioning was performed for the DMM joints stained for Safranin-O (see Figure 7.1 
and Figures 7.2-7.3), while sagittal sectioning was performed for analyzing growth plate 
development (as shown in Figure 7.10). Sections were taken and placed on warm water 
(37°C), allowed to expand and then transferred to slides (placed as sister sections, 100 slides/ 
joint and 20 slides/ disc or pellet). Slides were then left to dry and then placed in an oven 
overnight at 37°C. The slides were then stored at room temperature until staining was to be 
performed. Prior to any staining procedure, slides were placed in an oven at 60oC for 
approximately 30min-1h to allow excess wax to melt. For the DMM experiment, 20 sections 
from each mouse were scored by two independent scorers blinded to drug treatments and the 
scores were combined and averaged. For analyzing the development of the growth plate of the 
three-week old wild-type and heterozygotes HDAC3(Fl/+), at least 3 mice from different 
litters with the same genotype were used and in total 27 sections were stained and analysed. 
2.2.15.2 Haematoxylin and Eosin staining 
Haematoxylin and Eosin staining (H&E) is one of the principal stainings in histology. In 
H&E staining, nuclei are stained black due to the binding of the haematoxylin-dye-complex to 
the DNA and cytoplasm is stained pink/red. Slides were dewaxed in xylene (2 times, for 5 
minutes each) and then rehydrated through a series of ethanol concentrations (100%, 95%, 
75% and 50%) and ddH2O for 2 minutes each. Slides were then placed in Mayers 
haematoxylin solution (SIGMA Aldrich, Poole, UK) for 1.5min and then placed under 
running tap water for 2-3 minutes until tissue sections turned a purple- blue colour. Slides 
were then placed in 1% aqueous eosin (SIGMA Aldrich, Poole UK) for 2 minutes and then 
quickly rinsed in running tap water for 30sec. The slides were then dehydrated through a 
series of ethanol concentrations (50%, 75%, 95%, 100% and 100%) for 1min each. Finally 
slides were placed in xylene (2 times for 10 minutes each), before mounting in DPX mountant 
(SIGMA-Aldrich, Poole, UK) and left overnight in a dehumidifier chamber to dry. 
2.2.15.3 Safranin-O staining 
This method is used for the detection of cartilage, mucin and mast cell granules on formalin- 
fixed; paraffin- embedded tissue sections and may be used for frozen sections as well. The 
cartilage and mucin will be stained orange to red and the nuclei will be stained black. The 
cytoplasm is stained green. This method is recommended as a semi-quantitative scoring 
system following DMM surgery (see Table 2.10 and Figure 2.5). Two independent and blind 
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scorers assessed cartilage damage following eight weeks of the DMM surgery. Briefly, slides 
were de-waxed and rehydrated as described in section 2.2.15.2 Haematoxylin and Eosin 
staining. Slides were then placed in Weigert’s iron haematoxylin working solution (SIGMA-
Aldrich, Poole, UK) for 10min and then briefly washed under running distilled water. Slides 
were then dipped briefly in acid alcohol (70% (v/v) EtOH, 1% (v/v) HCl) to remove excess 
haematoxylin and then rinsed in running tap water to stop the reaction. Slides were then 
placed in 0.06% (w/v) Fast Green solution (SIGMA-Aldrich, Poole, UK) for 5 minutes and 
then quickly rinsed in 1% (v/v) acetic acid solution (SIGMA-Aldrich, Poole, UK) for no more 
than 10-15 seconds. Finally, slides were stained in 0.1% Safranin O solution for 5 minutes 
before they dried to absorb excess staining and then transferred to 95% of ethanol for 1 
minute and then to two 100% ethanols for 2 minutes each. Finally slides were placed in 
xylene (2 times for 10 minutes each), before mounting in DPX mountant (SIGMA-Aldrich, 
Poole, UK) and left overnight in a dehumidifier chamber to dry. 
 
Figure 2.5. Safranin-O photomicrographs showing the medial femoral chondyle (MFC- above) 
and medial tibial plateu (MTP- below) and the medial meniscus (left), displaying a variety OA 
severity and semi-quantitive scores. 
First score represents MFC, second score is MTP; A. 0, 0.5; B. 0, 1; C. 0.5, 2; D. 3, 3; E. 0, 4; F. 5, 6 
[taken from (Glasson et al. 2010)]. 
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Grade Osteoarthritic damage 
0 Normal 
0.5 Loss of Safranin-O without structural changes 
1 Small fibrillations without loss of cartilage 
2 
Vertical clefts down to the layer immediately below the superficial layer and some loss of 
surface lamina 
3 Vertical clefts/erosion to the calcified cartilage extending to <25% of the articular surface 
4 
Vertical clefts/erosion to the calcified cartilage extending to 25- 50% of the articular 
surface 
5 
Vertical clefts/erosion to the calcified cartilage extending to 50- 75% of the articular 
surface 
6 Vertical clefts/erosion to the calcified cartilage extending >75% of the articular surface 
Table 2.10. The recommended semi-quantitative scoring system for assessing cartilage damage 
on DMM mouse joints [taken from (Glasson et al. 2010)]. 
 
2.2.15.4 Masson’s trichrome staining 
This method is used for the detection of collagen fibres in tissues such as skin, heart, knee, 
etc. on formalin-fixed, paraffin-embedded sections and may be used for frozen sections as 
well. The collagen fibres will be stained blue and the nuclei will be stained black and the 
background is stained red. De-waxing and rehydration of slides was performed as described 
above (in 2.2.15.2 Haematoxylin and Eosin staining). Slides were stained in Weigert’s iron 
haematoxylin working solution (SIGMA-Aldrich, Poole, UK) for 10min and then rinsed in 
running tap water for 10min and washed in distilled H2O. Sections were subsequently 
differentiated in phosphomolybdic-phosphotungstic acid solution (SIGMA Aldrich, Poole, 
UK) for 10-15min until collagen was not red. Slides were then transferred directly to aniline 
blue solution and stained for 5-10min before rinsed briefly in dH2O and differentiated in 1% 
acetic acid solution for 2-5min. Finally slides were washed in dH2O, dehydrated very quickly 
in 95% ethanol, 100% ethanol for 1-2 minutes and cleared in xylene before mounting in DPX 
mountant (SIGMA-Aldrich, Poole, UK) and left overnight to dry. 
2.2.15.5 Alcian Blue staining 
This method was used to stain sulphated proteoglycans in cartilage. At pH 0.75 Alcian Blue 
specifically stains sulphated proteoglycans and this pH is recommended for staining 
cartilage. At pH 2.5 it stains most acid mucins (except some of the strongly sulphated groups), 
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at pH 1.0 it will stain only weakly and strongly sulphated acid mucins, and at pH 0.2 it will 
only stain strongly sulphated acid mucins. De-waxing and rehydration of slides was 
performed as described above (in 2.2.15.2 Haematoxylin and Eosin staining). Slides were 
stained in alcian blue solution (SIGMA Aldrich, Poole, UK) for 10 minutes, washed twice 
with distilled H2O for 5 minutes each time and then placed in fast red solution for 3-5 minutes 
(SIGMA Aldrich, Poole, UK). Finally slides were washed in dH2O, dehydrated very quickly 
in 95% ethanol, 100% ethanol for 1-2 minutes and cleared in xylene before mounting in DPX 
mountant (SIGMA-Aldrich, Poole, UK) and left overnight to dry. 
2.2.15.6 Toluidine Blue staining 
This method is used to stain polysaccharides in cartilage (purple), since it is a basic dye with 
affinity for acidic tissue components. De-waxing and rehydration of slides was performed as 
described above (in 2.2.15.2 Haematoxylin and Eosin staining). Slides were then placed in 
toluidine blue O solution (0.04g toluidine blue in 0.1M acetate buffer) (SIGMA Aldrich, 
Poole, UK) for 10 minutes, washed twice with distilled H2O for 5 minutes each time and then 
placed in fast red solution for 3-5 minutes (SIGMA Aldrich, Poole, UK). Finally slides were 
washed in dH2O, dehydrated very quickly in 95% ethanol, 100% ethanol for 1-2 minutes and 
cleared in xylene before mounting in DPX mountant (SIGMA-Aldrich, Poole, UK) and left 
overnight to dry. 
2.2.15.7 Alizarin red/Alcian blue staining of one day old mouse skeletons 
One-day old pups were sacrificed, and the skin and intestines were removed. The skeletons 
were then fixed in 95% EtOH for three days and then placed in alcian blue solution (15mg + 
80ml 95% EtOH + 20ml HAc, pH 0.75) for 24 hours to stain cartilaginous tissues. The 
skeletons were then rinsed twice using 95% ethanol and placed in 95% ethanol for 48 hours 
before clearing with 1% (w/v) KOH for 6 hours was performed. Alizarin red solution (50mg/l 
2% (w/v) KOH) was subsequently used to stain bone and the skeletons were then placed in 
2% (w/v) KOH for 24 hours following by incubation in 80:20 2% KOH: glycerol, 60:40 2% 
KOH: glycerol, 40:60 2% KOH: glycerol and 20:80 2% KOH: glycerol for 24 hours each. 
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2.2.16 Immunohistochemistry (IHC) 
Method 
Sections were de-paraffinised and rehydration was performed as described above (in 2.2.15.1 
Embedding and microtome sectioning). For heat-induced epitope retrieval the sections were 
placed in sodium citrate buffer pH 6.0 and microwaved for 2 x 5 minutes. The endogenous 
peroxidase activity was quenched by incubating the slides in 0.3% (v/v) H2O2 in dH2O for 30 
minutes. Sections were then blocked in 2% (v/v) normal horse blocking serum for 30 minutes 
before 1 hour incubation with a 1:100 dilution of primary antibody for anti-acetyl Lysine, 
1:1000 dilution for anti-HDAC3, 1:50 dilution for anti-acetyl α-tubulin and 1:100 dilution for 
Ki67 antibody (diluted in PBS with 2% (v/v) normal horse blocking serum) (dilutions 
optimised by Sharon Watson, Newcastle University). Slides were then incubated with Biotin-
conjugated secondary antibody for 30 minutes followed by further 30 minutes incubation with 
Avidin/Biotin Complex (ABC). Peroxidase substrate 3,3’-diaminobenzidine (DAB) 
demonstrated peroxidase activity. Sections were washed in running tap water for 5 minutes 
and were counterstained with haematoxylin followed by dehydration through graded 
concentrations of ethanol for 5 minutes each: 50%, 70%, 95% (x2) and 100% (x2) with a final 
5 minutes in xylene (x2). All incubation steps were carried out at room temperature and 
sections were washed thoroughly in between each step; all washing steps used PBS for 2 x 5 
minutes unless otherwise stated. Slides were mounted with D.P.X. mounting medium and 
covered with glass coverslips for visualisation under a Leica DM4000B microscope (Leica, 
Milton Keynes, UK). IHC experiments were carried out by Sharon Watson, Musculoskeletal 
Research Group (Institute of Cellular Medicine, Newcastle University, Newcastle, UK). 
 
2.2.17 Image analysis 
All images were taken using a Leica SCN 400 slide scanner and viewed with the Slide Path 
software (Leica, Milton Keynes, UK). A scale bar was automatically included in each image 
at scanning and is given in µm. Quantification of the immunoblotting (IB) bands and 
immunohistochemistry (IHC) staining was performed using ImageJ software and compared to 
the positive loading control used in each experiment (either GAPDH or β-catenin for IB).  
Briefly, the images were saved as .jpeg or .tiff files and opened with ImageJ software. Then 
for IB quantification the brightness/contrast was adjusted by the Image -> Adjust -> 
Brightness/Contrast menu. The rectangular selection tool was then selected and a rectangular 
drawn around the first band to be quantified. Then Analyse -> Gels-> Select first lane was 
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selected. The first rectangular was then dragged to the second gel band to be quantified and 
then Analyse-> Gels-> Select next lane. The second lane box was dragged to the third gel 
band and then Analyse-> Gels-> Select next lane and this process was repeated for all the 
bands present in the gel. To finish this step go back to Analyse-> Gels-> Plot lanes. This will 
bring up a graphical depiction of band intensity for each band selected in the image. Then the 
straight line tool was selected from the tool menu and a straight line was marked under the 
peak for the first lane and the same process was repeated for all the lanes. Then the wang tool 
was selected from the tool menu and each band peak was selected. The areas under the peaks 
were then measured and the results copied to Microsoft Office Excel for further normalisation 
with reference to the loading control used.  
For IHC quantification, the area of interest was determined using an area cut off. The image 
was calibrated based on a colour threshold by selecting Image-> Adjust -> Colour threshold. 
Thresholding method was set to ‘Default’, Threshold colour to ‘Red’, and the colour space 
was set to HSB (Hue, Saturation, Brightness). The risk area was then selected and background 
excluded from the analysis by adjusting the brightness and saturation of the image and 
clicking on select to apply the filter. Two filters were applied, one to define the area of 
interest, and a second filter to select the positive (brown) stained cells present in the already 
defined by the first filter area. Both filtered areas were then measured and a percentage of the 
positive stained cells was calculated with reference to the whole area. 
 
2.2.18 Flow cytometry 
To study the effect of HDAC3 and/or E2F1 knockdown in cell cycle progression of the 
SW1353 cells DNA quantitation and flow cytometry analysis was performed. Propidium 
Iodide (PI) binds the DNA present in the cell. Cells that are in S phase will have more DNA 
than cells in G1 phase and will take up proportionally more dye and will fluoresce more 
brightly. Once the G1 cells have doubled their DNA content and in G2 phase they will be 
approximately twice as bright as the ones in G1.  
Reagents 
 70% (v/v) Ethanol 
 50µg/ml Propidium Iodide diluted in PBS (P4170, SIGMA Aldrich, Poole, UK) 
 100μg/ml Ribonuclease I diluted in H2O (R6513, SIGMA Aldrich, Poole UK) 
Method 
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One million SW1353 cells were plated in 10cm culture dishes and the following day 
transfected with siRNA as described in section 2.2.7 RNA interference (RNAi). Next, serum 
starvation followed to achieve cell cycle synchronisation, growth restriction in the G0/G1 
phase and induce quiescence (Rosner et al. 2013). The following day, cells were harvested by 
trypsinisation, washed twice in PBS and fixed in cold 70% ethanol to allow entry of the dye 
which is otherwise actively pumped out by living cells. The ethanol was added dropwise 
while vortexing to avoid cell clumping. Samples were then stored at 4oC for at least 30 
minutes, pelleted by brief centrifugation at 2,000 rpm to discard the ethanol, washed twice 
with PBS and centrifuged each time at 2,000rpm for 5 minutes. To ensure that only DNA is 
stained, cells were treated with Ribonuclease I (100µg/ml), and PI at a final concentration 
50μg/ml was added to each sample.  
For analysis the FACSCanto II analyser (Flow cytometry unit, Newcastle university, UK), 
was used and at least 10,000 single cell-reads were taken for each sample. Two biological 
repeats were performed to ensure statistical significance and reproducibility. First forward and 
side scatter were measured to identify single cells and pulse processing was used to exclude 
cell doublets from the analysis, this was achieved by using pulse area versus pulse width. PI 
has a maximum emission at 605nm so can be measured in either FL2 (585/42 filter) or FL3 
(650LP filter) and 400 voltage. While running the cytometer the following plots were 
displayed; forward and side scatter to identify the cells, pulse area versus pulse width to 
identify clumps and doublets, forward scatter versus PI signal and PI histogram as shown in 
Figure 2.6 A.  
For analysis, first a gate was set on the single cell population using pulse width versus pulse 
area, then this gate was applied to the scatter plot and obvious debris was gated out. The gates 
were then combined and applied to the PI histogram plot, as shown in Figure 2.6 B. By using 
markers set within the analysis program, the number of cells in each cell cycle phase was 
quantified (Figure 2.6 C). Next, using FlowJo, an algorithm which attempts to fit Gaussian 
curves to each phase was used and a more objective quantitation of the percentage of cells in 
each cell cycle phase was acquired (Figure 2.6 D). 
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Figure 2.6. Flow cytometry analysis and cell gating following DNA staining using Propidium 
Iodide.  
A. From the left to the right the following plots are displayed: Forward and side scatter to identify 
the cells, Pulse area versus pulse width to identify clumps and doublets, Forward scatter 
versus PI and finally the PI histogram plotting cell counts relative to PI emission. B. Gating 
was first performed to set on the single cell population using pulse width versus pulse area, 
then this gate was applied to the scatter plot and obvious debris was gated out. The gates were 
then combined and applied to the PI histogram plot. C. Next, markers set within the analysis 
program were used to quantify the number of cells in each cell cycle phase. D. Using FlowJo, 
the Watson pragmatic algorithm was used to fit in Gaussian curves to each phase of the cell 
cycle. 
 
 
 
 
 
 
  
A 
B 
C D 
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2.2.19 RNA microarray analysis 
A gene expression array experiment was performed to identify differentially expressed genes 
following HDAC3 gene silencing or inhibition after Apicidin treatment in SW1353 cells (as 
described in sections 2.2.7 RNA interference (RNAi) and 2.1.7 Histone Deacetylase Inhibitors 
respectively). Two independent IL-1 stimulation time-points were performed including IL-1 
stimulation for 1 hour and for 6 hours and compared with the basal-no IL-1 stimulation time-
point. Three biological replicates were included per time-point and treatment. Following RNA 
extraction using the RNeasy mini kit (Qiagen, West Sussex, UK) according to manufacturer’s 
instructions, RNA quality was checked using real-time RT-PCR and the samples analysed by 
the Central Biotechnology Services (Cardiff University) for analysis using the Illumina 
platform. For total RNA assays using an Agilent 2100 bioanalyzer, the ribosomal ratio of 28S 
and 18S were determined, giving an indication on the integrity of the RNA sample. In 
humans, 28S rRNA has ~5070 nucleotides, and 18S has 1869 nucleotides, which gives a 
28S/18S ratio of ~2.7. A high 28S/18S ratio is an indication that the purified RNA is intact 
and has not degraded. Usually, a 28S/18S ratio of >2 is taken to mean that the purified total 
RNA is of high quality. Additionally, the RNA integrity number (RIN) was utilized to 
estimate the integrity of total RNA samples based on the entire electrophoretic trace of the 
RNA sample, including the presence or absence of degradation products. The data obtained 
were also displayed as a densitometry plot, creating a gel-like image. Numbers from ’1’ to 
’10’ were used as labels. ’10’ stands for a perfect RNA sample without any degradation 
products, whereas ’1’ marks a completely degraded sample. The labels in-between are used to 
indicate progressing degradation states of the RNA sample. Figure 2.7 shows typical 
representatives of the rRNA ratio and RIN number for one out of the 36 samples included in 
this microarray experiment. RNA integrity and quality of all samples presented similar 
ratios/RIN. 
Following RNA quality and degradation assessment, RNA was fluorescent labelled and 
hybridisation followed. Briefly, the samples were allowed to hybridize onto the same 
microarray glass slide containing millions of copies of identical oligonucleotides that 
correspond to a gene. At this point any RNA sequence in the sample will hybridize to specific 
copies on the glass slide based on complementarity. The amount of bound RNA to a copy will 
be directly proportional to the initial number of RNA molecules present for that gene in a 
sample. Following the hybridisation step, the hybridized microarray is excited by a laser and 
scanned at suitable wavelengths to detect the fluorescent dyes. The amount of fluorescence 
emitted upon excitation corresponds to the amount of bound nucleic acid. 
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The Illumina BeadChip HT12-v4 array was used, which is based on the GRCh37 human 
assembly. Raw data (IDAT files) from the Illumina scanner were summarised into a sample 
probe profile and control probe profile using Illumina’s Genome Studio. In this process, 
replicate bead measurements are collapsed to ascertain average signal intensity and bead 
standard error, which allows for a more reliable measure of signal intensity. The raw data was 
normalised in R using robust spline normalisation (RSN), and variance stability 
transformation (VST), which is a more sophisticated method to quantile. Normalisation 
functions were used from the Lumi library (Lu et al. 2008). A bead level filtering step is 
implemented to remove any probes that fail detection p value in more than 50% of samples. 
Differentially expressed gene lists were finally obtained and a final cut off of ± 1.5-fold 
change and a p-value ≤ 0.05 were applied. Differential expression was performed using a 
linear model framework and Bayesian adjustments from the Limma package (Ritchie et al. 
2015). Additional analysis were performed using GATHER (A Gene Annotation Tool to Help 
Explain Relationships) (Chang and Nevins, 2006), a bioinformatic tool that has the capacity 
to discover novel functions and predict transcription factor binding sites and pathways 
affected by a specific gene group.  
Other bioinformatic tools used in this study include STRING (a functional protein association 
network) (Szklarczyk et al. 2015) that predicts protein-protein interactions, PROMO 
(Messeguer et al. 2002; Farre et al. 2003) was used to predict transcription factor binding sites 
to the MMP promoters and Ingenuity Pathway Analysis (IPA) was used to identify upstream 
regulators, mechanistic networks, pathways and microRNA that might have caused the results 
observed in the microarray. VENNY was used to create all the venn diagrams in this thesis 
(Oliveros, 2007-2015) and the Open Targets platform (Koscielny et al. 2017) was used to 
identify OA and cartilage disease related genes.  
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Figure 2.7. Representatives of the rRNA ratio [28S/18S] and RNA Integrity Number (RIN) (red 
box) for sample 13. The densitometry plot on the right shows the integrity of 28S (top band) and 
18S (bottom band) in a gel-like image. 
 
Two differential expression tests were carried out using a cut off of ± 2 fold change and a p-
value ≤ 0.01. 
(i) Knockout comparisons: siHDAC3 versus siCON and Apicidin versus DMSO for 
each time point and 
(ii) Time point comparisons: no IL1 versus IL1- 1 hour or IL1- 6 hours of stimulation 
for each treatment. 
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2.2.20 Chromatin Immunoprecipitation (ChIP) 
Reagents 
 ChIP Lysis buffer: 50mM HEPES-NaOH pH 7.5, 140mM NaCl, 1mM EDTA pH 8.0, 
0.1g SDS, 0.1g Sodium Deoxycholate, 1ml Triton X-100, 2 tablets protease inhibitors 
(cOmpleteTM Protease inhibitor cocktail ), add up to 100ml with ddH2O 
 RIPA Buffer: 50mM Tris-HCl pH 8.0, 150mM NaCl, 2mM EDTA pH 8.0,  1ml NP-
40, 0.1g SDS, 0.5g Sodium Deoxycholate, 2 tablets protease inhibitors, add up to 
100ml with ddH2O 
 Low Salt Buffer: 0.1g SDS, 2mM EDTA pH 8.0,  20mM Tris-HCl pH 8.0, 150mM 
NaCl, 1ml Triton X-100, add up to 100ml with ddH2O 
 High Salt Buffer: 0.1g SDS, 2mM EDTA pH 8.0,  20mM Tris-HCl pH 8.0, 500mM 
NaCl, 1ml Triton X-100, add up to 100ml with ddH2O 
 LiCl Salt Buffer: 0.25M LiCl (SIGMA-Aldrich, L4408), 1mM EDTA pH 8.0,  10mM 
Tris-HCl pH 8.0, 1ml NP-40, 1g Sodium Deoxycholate, add up to 100ml with ddH2O 
 Elution Buffer: 1g SDS, 100mM NaHCO3, add up to 100ml with ddH2O 
 TE Buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA pH 8.0, add up to 100ml with ddH2O 
 TBS Buffer: 50mM Tris-HCl pH 7.5, 150mM NaCl, add up to 100ml with ddH2O 
 Proteinase K (P6556, SIGMA-Aldrich) 
 Glycogen (AM9516, Invitrogen) 
Method 
Cross- linking and cell harvesting: First 2-3 x 106 SW1353 cells were plated in T75 flasks or 
150cm2 tissue culture dishes and incubated for 5 days at 37oC in 5% (v/v) CO2. Cross-linking 
was performed in confluent flasks (107 -5 x 107 cells) by adding formaldehyde dropwise to a 
final concentration of 0.75% with rotation for 10 minutes. Then 125mM glycine was added to 
the flask and rotation for 5 minutes at room temperature followed. The cells were then rinsed 
twice using ice- cold PBS, harvested by trypsinisation and immediately transferred to a 50ml 
cold tube. Centrifugation then followed at 4oC for 5 minutes at 1,000 x g to pellet the cells 
and remove supernatant. The cell pellets were then suspended in ChIP Lysis buffer (750µl per 
107 cells) and incubated on ice for 10 minutes. The chromatin was then either stored at -80oC 
or sonication and IP followed immediately. 
Sonication: Sonication was performed using Bioruptor (Diagenode) and optimised as different 
cells require different sonication times. 12 cycles (30 seconds ON: 20 seconds OFF each 
cycle) were chosen for SW1353 cells (see also Chapter 5, Figure 5.11), since after 12 cycles 
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of DNA sonication, there was the highest amount of 200-500bp sonicated chromatin which is 
considered to be ideal for real-time PCR analysis.  The samples were then centrifuged for 10 
minutes at 4oC at 800 x g to pellet cell debris. Supernatant was transferred to a new tube and 
used for immunoprecipitation. 
Immunoprecipitation:  First the amount of chromatin to be used for IP was determined and 1- 
10% input was also included for each antibody used. Pre-clearing of the sonicated chromatin 
was performed as previously described (section 2.2.10 Immunoprecipitation (IP)). 106 cells 
were used for 1µg of E2F-1 antibody and 3 x 106 cells for 4µg of HDAC3 antibody (see also 
Table 2.1) and incubated at 4oC for 1 hour with rotation. An equal volume of Protein A and G 
beads were prepared and washed three times with 1ml RIPA Buffer, centrifuged each time at 
10,000 x g, at 4oC for 1 minute. Then 20µl of beads in RIPA buffer were added per 0.2-2µg of 
primary antibody used and incubated overnight at 4oC with rotation. The following day the 
complex of sonicated chromatin- primary antibody-beads was collected by centrifugation at 
2,000 x g for 1 minute at 4oC and the supernatant was discarded. The bead pellet was then 
washed 3 times once with low salt buffer, second with high salt buffer and finally with LiCl 
buffer and centrifuged each time at 2,000 x g for 1 minute at 4oC.  
Elution and reverse cross-linking: After the last wash, the DNA was eluted from the beads by 
washing with elution buffer and rotating at room temperature for 30 minutes. The samples 
were centrifuged at 4oC for 1 minute at 2, 000 x g and then supernatant was transferred to a 
new tube. The input was included at this stage. 400µl TBS and 5µl 20mg/ml Proteinase K 
were added to each sample and heat at 65oC overnight with rotation. 
DNA extraction using phenol-chloroform: An equal volume of organic phase of phenol-
chloroform was added to each sample and then vortexed for 30 seconds. Centrifugation for 5 
minutes at 13, 000 rpm followed and the upper phase transferred to a new tube. To this twice 
the volume of 100% ethanol was added together with 10µl of 5mg/ml glycogen, vortexed for 
20 seconds and incubated at -20oC for 30 minutes. Centrifugation for 30 minutes at 4oC, at 
13,000 rpm followed to remove the ethanol and then 200µl of 70% ethanol was added to each 
sample. The samples were centrifuged again for 5 minutes at 13,000 rpm to remove the 
ethanol and let to evaporate for 15 minutes at room temperature. DNA was diluted in 20-50µl 
of dH2O and NanoDrop ND-1000 spectrophotometer was used to define the exact amount of 
DNA present in each sample. At least 10ng of each sample were used for each real-time RT-
PCR and the primers used can be found in Table 2.11. Reactions were performed as 
described in section 2.2.11.3 Taqman® Probe-Based Real- time qRT-PCR. 
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Primers used in ChIP 
experiments 
Sequence (5’-3’) Size of amplicon (bp) Probe 
P1M13 
GCCATTACAGTTGTTCCGTTCC 
TGGCATGACCTCTCGACAAA 
98 SYBR Green 
P2M13 
TCTGCGGAAAGACAACAGTC 
GCCCGACAATGAGTCCAG 
96 #35 
P3M13 
TTGAGCTGGACTCATTGTCG 
GGAGGTCTTCCTCAGACAAATC 
76 #9 
P4M13 
CAAGATGCGGGGTTCCTGAT 
TGAGGTATTCTCGGCAACCAT 
220 SYBR Green 
P5M13 
GAAAAAGTCGCCACGTAAGC 
CGACAATGAGTCCAGCTCAA 
198 SYBR Green 
P1M1 
GAAGAGCCCCTTTCACTATTTTC 
GGTGCGGCAGAGACCAAAGAACA 
74 #59 
P2M1 
ACGCTCAGTCTCTTTCCAGC 
GATAACTCCCCACCCCTTGC 
108 SYBR Green 
P3M1 
CAGGGTCCCTCTCTGTTGC 
AAGAGGTGGGAGGATCACTTGG 
94 #19 
Table 2.11. Primers used for real-time RT-PCR in ChIP experiments. 
 
 
2.2.21 Statistical analysis 
Luminescence values were normalised against Renilla values and combined technical 
replicates values from each experiment were given as mean ± standard error of the mean 
(SEM).  
The statistical test used in the microarray experiment is a moderated t-test, implemented in the 
Limma package, with an additional empirical Bayes moderation. P values were adjusted for 
multiple testing using a Benjamini Hochberg correction, and thresholded at 0.01 for 
significance filtering. An additional significance filter was applied for magnitude of change, 
by only keeping observations with a fold change > 2.   
 
2.2.22.1 Real-time RT-PCR analysis  
The 18S ribosomal RNA (rRNA) gene was used as the housekeeping gene, as an endogenous 
control for normalisation and to allow analysis of the relative expression of the target gene. 
Real-time RT-PCR results were analysed using the relative quantification method (2-ΔCΤ). CΤ 
values of controls and different treatments were averaged. Normalised values were obtained 
using 18S rRNA CΤ values as a reference, and then the ΔCΤ values were calculated (ΔCΤ: 
Difference of the CT values = CT of sample – CT of 18S). Relative expression levels of 
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controls and treated samples were then compared and formulated into a bar graph. Data from 
at least 2 experimental repeats were combined and values given as mean + standard deviation 
of the mean (SD). A One-way analysis of variance (one way ANOVA) with a Bonferroni 
multiple comparison test was performed using Graph Pad PRISM to compare the means of 
more than two groups of samples, to determine the statistical significance of the different data 
sets and a p-value of ≤ of 0.05 was considered significant. Alternatively, an unpaired 
Student’s t-test was performed to compare the means and determine any statistical 
significance between two independent sample groups. Statistical significance is shown as: 
* p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. 
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Chapter 3. HDAC3 regulates collagenases expression and NF-κB in 
chondrocytes. 
 
3.1 Introduction 
Besides their role in collectively being able to degrade every component of the extracellular 
matrix (ECM), the matrix metalloproteinases (MMPs) also play an important role in tissue 
repair after injury and in pathological disorders such as in arthritis and cancer metastasis 
(Clark et al. 2008). Many MMPs are regulated at the level of transcription by a variety of 
chemokines, growth factors and cytokines, including Interleukin-1 (IL-1) and oncostatin M 
(OSM). (Rowan & Young 2007) Modulation of the acetylation state of chromatin by histone 
deacetylases (HDACs ) has also been suggested to affect the expression of inducible MMPs  
(Clark et al. 2008). However, specific inhibition of these enzymes has not proven notably 
useful for the treatment of various diseases and therefore an alternative therapeutic approach 
is to try to understand and control the expression of these genes. 
Interestingly, histone deacetylase inhibitors (HDACi), trichostatin A (TSA) and sodium 
butyrate (NaBy) have been shown to inhibit collagen breakdown from cartilage explants and 
in vitro these compounds inhibit cytokine induced (IL-1) MMP expression. The induction of 
aggrecan degrading enzymes such as the ‘a disintegrin and metalloproteinase with 
thrombospondin motif 4’ (ADAMTS4), 5 (ADAMTS5), and 9 (ADAMTS9) was also abrogated 
in chondrocytes following cytokine stimulation and HDACi treatment, making these 
molecules potential therapeutic agents for patients with arthritis. Some of these HDACi, such 
as TSA, act on specific regions, altering the acetylation state of the adjacent chromatin and 
allowing or not specific protein binding. For instance, the identification of an Sp1 binding 
motif in Timp-1 promoter constructs shed some light on the differential regulation of TSA 
upon Timp-1 expression. (Young et al. 2005) A role for class I HDACs and in particular for 
HDAC3 in activating TGF-β-dependent signalling pathways and subsequent gene expression 
regulation of the disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) 
and the tissue inhibitor of metalloproteinases-1 (TIMP1) in mouse C3H10T1/2 fibroblasts has 
also been proposed. (Barter et al. 2010) 
Of particular relevance to MMP transcription, the c-Jun N-terminal kinases (JNKs) and the 
extracellular signal regulated kinases (ERKs) phosphorylate and activate the activating 
protein-1 (AP-1) transcription factors to drive transcription of numerous genes. One AP-1 
family member in particular, c-Jun, which dimerizes with c-Fos, drives transcription of 
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multiple MMPs. It has also been shown that the ERK pathway regulates the activity of 
erythroblastosis-26 (Ets) transcription factor, which co-operate with AP-1 proteins on many 
MMP promoters. Another major cytokine-induced signalling pathway includes the 
translocation of the nuclear factor B (NF-B) family members from the cytoplasm to the 
nucleus. Upon phosphorylation and subsequent ubiquitination of the inhibitor of B (IB), 
p50/p65 NF-B dimers are free to translocate to the nucleus and transactivate several genes 
including selected MMPs. When NF-B is maintained in the cytoplasm due to constitutive 
levels of IB, reduced expression of MMP1, MMP3 and MMP13 is observed in cytokine- 
stimulated cells. (Vincenti & Brinckerhoff 2002) 
Reports about the chondroprotective role of HDACi also comes from the destabilisation of the 
medial meniscus (DMM) mouse model, where osteoarthritis was surgically induced in nine 
weeks old male mice and cartilage erosion assessed eight weeks post- surgery. In vivo 
efficacy of TSA in blocking cartilage erosion was observed in the mice undergoing either 
DMM surgery, in comparison to the mice that underwent sham surgery and were used as 
vehicle control. In addition to, TSA, valproic acid and MS-275 (two class I HDACi) 
significantly repressed the IL-1 induced levels of MMP1 and MMP13 expression in human 
articular chondrocytes (HACs) and RNA interference (RNAi) studies for class I HDACs 
confirmed these findings in the SW1353 cells. The use of TSA and MS-275 also inhibited 
cartilage degradation of a bovine nasal cartilage (BNC) explant assay. As such a class I 
HDAC- mediated mechanism of collagenase gene expression regulation has been proposed 
following these findings.  (Culley et al. 2013) 
When this project started, the role of the class I HDACs and in particular of Histone 
Deacetylase 3 (HDAC3) in gene regulation was only poorly understood. Therefore, the first 
step to be taken was to confirm the aforementioned findings by using the TSA and MS-275 
HDACi in SW1353 chondrocyte-like cells and determine the effect on collagenase 
expression. To decide whether HDAC3 is important for MMP expression, a selective HDAC3 
inhibitor, Apicidin, and RNA interference (RNAi) against HDAC3 were used and MMP 
expression determined using the SW1353 cell-line. As the effect of HDAC3 on MMP 
expression may be indirect and might involve other intermediate signalling molecules, 
transcription factors and/or pathways, the wider effect of TSA, MS-275, Apicidin and 
HDAC3 RNAi on the Immediate Early Genes (IEG) expression, essentially AP-1 factors, and 
on a NF-B luciferase reporter construct was also examined. 
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3.2 Aims 
 To determine the effect of HDAC inhibition or HDAC3 gene depletion or specific 
inhibition in gene expression programmes associated with cartilage degeneration using 
a chondrocyte-like cell line 
 Determine whether HDAC3 is involved in cell signalling pathways associated with 
osteoarthritis. 
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3.3 Results 
3.3.1 MMP13 and MMP1 are responsive to IL-1 cytokine stimulation. 
To explore whether MMP13 and MMP1 genes are responsive to IL-1 cytokine stimulation an 
initial experiment, where the levels of MMP13 and MMP1 gene expression following IL-1α 
cytokine stimulation for 1, 3, 6 and 24 hours were quantified, was performed. Human 
chondrosarcoma SW1353 cells were used for this experiment as these cells have been shown 
to have a similar gene expression profile as primary human articular chondrocytes (HACs) 
following IL1-β treatment and can be used to study protease expression, a phenomenon also 
seen in chondrocytes (Gebauer et al. 2005). Cells were seeded onto 96- well culture plates and 
following overnight serum starvation, IL-1 stimulation over a time-course was performed. 
MMP13 and MMP1 gene expression was quantified by qRT-PCR. Both MMPs are responsive 
to IL-1α with a significant increase in expression observed after 6 and 24 hours of stimulation 
(Figure 3.1). Therefore, and for the needs of this study 6h of IL-1α stimulation was chosen 
and used for subsequent experiments. 
 
3.3.2 Histone deacetylase inhibition affects collagenase expression. 
3.3.2.1 The effect of HDAC inhibition on acetylation of histones and α-tubulin. 
HDAC inhibitors induce histone acetylation predominantly through the inhibition of HDACs. 
In the current study the activities of three different HDACi on gene expression were 
compared. TSA, a broad-spectrum HDACi, which inhibits all HDACs in the nM range, the 
benzamide MS-275, which exhibits EC50 values in the nM range against HDAC1 and is less 
potent (in the µM range) for HDAC2, 3 and 9 and the selective HDAC3 inhibitor Apicidin 
(Table 2.2) were used. The concentrations of the HDACi used here were not toxic, as shown 
in Figure 2.1, and were carefully selected based on the HDAC inhibitory IC50 (see section 
2.1.7 Histone Deacetylase Inhibitors) and previous literature (Culley et al. 2013). The effect 
upon acetylation of total histone H3 and α- tubulin in SW1353 cells was then assessed by 
immunoblotting. HDAC5 and HDAC6 are reported to deacetylate α-tubulin and therefore an 
increase in its acetylation is likely to indicate inhibition of these two HDACs.  Treatment of 
SW1353 cells with all three HDACi resulted in a significant increase of the acetylation of 
histone H3. In particular, TSA increased acetylation by 90% in comparison to the ethanol 
control; while treatment with MS-275 and Apicidin resulted in 20% and 15% increase in 
acetylation respectively compared with the DMSO control (Figure 3.2 top lane). Acetylation 
of α- tubulin on the other hand, was only increased following HDAC inhibition by TSA 
 82 
 
(Figure 3.2 second lane). This observation indicated that TSA alone inhibits the catalytic 
activity of HDAC5 and/or HDAC6, supporting in this way its status as an HDAC “pan-
inhibitor”. 
 
 
 
Figure 3.1. MMP13 and MMP1 gene expression after a time-course of IL-1α cytokine 
stimulation. 
SW1353 cells were stimulated with IL-1α (0.5ng/ml) for 1, 3, 6 or 24 hours, or left unstimulated 
following an overnight serum starvation. Total RNA was extracted, reverse transcribed to cDNA and 
MMP expression measured by quantitative Real-time PCR (qRT- PCR). Results are shown relative to 
18S ribosomal RNA expression. Significance was compared with respect to non-stimulated cells (-) 
for each time point. Figure shows two independent experiments (n=4 per experiment) and bars show 
the mean of eight biological replicates +SD. For statistical analysis, one-way ANOVA with a 
Bonferroni multiple comparison test was performed. *** p<0.001 
 
 
Figure 3.2. Inhibition of HDACs increased the acetylation of histone H3 and α-tubulin.  
SW1353 cells were treated with TSA (330nM) or EtOH control (0.1%), MS-275 (10μM), Apicidin 
(160nM) or DMSO control (0.2%) for 6.5h before cells were harvested, lysed and total protein 
extraction was performed. Immunoblotting was performed with an anti-acetylated Histone H3 
antibody, an anti-acetylated alpha tubulin antibody and GAPDH served as a loading control. EtOH 
was the control for the TSA-treated samples, while DMSO was the control for the MS-275 and 
Apicidin- treated samples. Quantification of immunoblotting was performed using ImageJ software 
and with reference to the GAPDH loading control. 
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3.3.2.2 The effect of TSA, MS-275 and Apicidin on the induction of gene expression 
by IL-1. 
As IL-1α stimulation induced MMP13 and MMP1 expression, the effect of HDAC inhibition 
on collagenase expression was then examined. SW1353 serum-starved cells were incubated 
for 30 minutes with the indicated concentrations of TSA (20ng/ml=66nM, 50ng/ml=165nM, 
100ng/ml=330nM and 250ng/ml=756nM), MS-275 (1μΜ, 2μΜ, 5μΜ and 10μΜ) or Apicidin 
(20ng/ml=32nM, 50ng/ml=80nM, 100ng/ml=160nM and 250ng/ml=401nM) or treated with 
DMSO (0.25%), before IL-1α stimulation (0.5ng/ml) was performed.  IL-1 induces the 
expression of synergistic cytokines such as IL-6, IL-8 and IL-17, which augments the 
catabolic effects of IL-1β and TNF-α in cartilage (Mueller & Tuan 2011). Therefore, gene 
expressions of IL-6 and IL-8 were also measured, following IL-1 induction and histone 
deacetylase inhibition using TSA, MS-275 or Apicidin inhibitors.  
TSA treatment of SW1353 cells showed similar pattern of repression of the induced 
expression of both MMPs and IL-6 (Figure 3.3 A-C), but significantly increased IL-8 induced 
expression at 250ng/ml concentration (Figure 3.3 D). Maximum repression of MMP1, 
MMP13 and IL-6 was observed following treatment with 100ng/ml of TSA, with significant 
inhibition also at 250ng/ml, suggesting this is an HDAC-mediated event. The levels of MMP1 
and MMP13 expression remained low in the basal (no stimulation) condition and no 
significant effect of TSA was found, while IL-6 and IL-8 expression were not detected in 
unstimulated cells, confirming the induction following IL-1 stimulation. 
HDAC inhibition using the class I HDACi MS-275 also decreased the IL-1 - induced levels of 
MMP13, MMP1 and IL-6 (Figure 3.4 A-C), strongly indicating that class I HDACs, 
including HDAC1, HDAC2 and HDAC3 are important for regulating the expression of these 
genes. However, MS-275 did not significantly change IL-8 induced expression (Figure 3.4 
D). MS-275 blocked the induction of MMP13 and IL-6 expression at concentrations of 5μM 
and above, although inhibition at the higher concentration (10μM) was more pronounced for 
MMP1. Basal expression of all genes remained low and was not significantly changed 
following MS-275 treatment.  
Apicidin inhibited the IL-1 induced expression of MMP13, MMP1 and IL-6 in a 
concentration-dependent manner (Figure 3.5 A-C). On the contrary, apicidin did not alter the 
induced expression of IL-8 (Figure 3.5 D). In the absence of IL-1 stimulation, apicidin had no 
significant effect on the expression of any of the aforementioned genes.   
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Figure 3.3. Regulation of gene expression by TSA HDACi 
SW1353 cells were incubated for 30min with increasing concentrations of TSA (20- 250ng/ml) or DMSO 
(0.25%), before IL-1 (0.5ng/ml) stimulation for 6h was performed, following an overnight serum 
starvation. Total RNA was extracted using the cells-to cDNA lysis buffer, reverse transcribed to cDNA 
and MMPs, IL-6 and IL-8 expression quantified by qRT-PCR. Results are shown relative to 18S ribosomal 
RNA expression. Significance was compared with respect to the DMSO control treated cells in the basal 
and IL-1 induced level. Figure shows two independent experiments and bars represent the mean of eight 
biological replicates +SD. For statistical analysis, one-way ANOVA with a Bonferroni multiple 
comparison test was performed. ***p<0.001, **p<0.01, *p<0.05 
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Figure 3.4. Regulation of gene expression by the class I HDACi MS-275. 
SW1353 cells were incubated for 30min with increasing concentrations of MS-275 (1-10µM) or DMSO 
(0.25%), before IL-1 (0.5ng/ml) stimulation for 6h was performed, following an overnight serum 
starvation. Total RNA was extracted using the cells-to cDNA lysis buffer, reverse transcribed to cDNA 
and MMPs, IL-6 and IL-8 expression quantified by qRT-PCR. Results are shown relative to 18S 
ribosomal RNA expression. Significance was compared with respect to the DMSO control treated cells in 
the basal and IL-1 induced level. Figure shows two independent experiments and bars represent the mean 
of eight biological replicates +SD. For statistical analysis, one-way ANOVA with a Bonferroni multiple 
comparison test was performed. ***p<0.001, **p<0.01, *p<0.05 
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Figure 3.5. Regulation of gene expression by the selective HDAC3 inhibitor Apicidin. 
SW1353 cells were incubated for 30min with increasing concentrations of Apicidin (20-250ng/ml) 
or DMSO (0.25%), before IL-1 (0.5ng/ml) stimulation for 6h was performed, following an overnight 
serum starvation. Total RNA was extracted using the cells-to cDNA lysis buffer, reverse transcribed 
to cDNA and MMPs, IL-6 and IL-8 expression quantified by qRT-PCR. Results are shown relative 
to 18S ribosomal RNA expression. Significance was compared with respect to the DMSO control 
treated cells in the basal and IL-1 induced level. Figure shows two independent experiments and bars 
represent the mean of eight biological replicates +SD. For statistical analysis, one-way ANOVA 
with a Bonferroni multiple comparison test was performed. ***p<0.001 
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3.3.2.3 Collagen release after addition of HDACi to IL-1α/OSM treated bovine nasal 
cartilage.  
It is known that bovine and human cartilage in explant culture respond to pro-inflammatory 
cytokines stimulation with both an increase in the expression activation of collagenases (eg. 
MMP1, MMP8, MMP13). More particularly, in bovine nasal cartilage (BNC) explants, more 
than 90% of collagen release is observed after 14 days of culture, with little, if any, collagen 
release seen before 7 days of culture. (Barksby et al., 2006; Cawston et al., 2003) Herein, 
BNC explants were cultured with/without IL-1α and/or oncostatin M (OSM). Cartilage was 
treated with different HDAC inhibitors including the pan-HDACi TSA and the selective 
HDAC3 inhibitor Apicidin. Collagen levels were determined by assay of hydroxyproline 
following 14 days of culture. Figure 3.6 A shows the levels of collagen release remain 
unchanged when no cytokine stimulation occurs, in the presence of all the different HDACi. 
This suggests that no extra cartilage breakdown happens in the presence of each HDACi when 
compared to the control and cytokine stimulation is required for the increased expression and 
activation of procollagenases and subsequent collagen release. The addition of TSA to the IL-
1α stimulated cartilage, significantly decreased collagen breakdown (Figure 3.6 B). In Figure 
3.6 C not only TSA but also apicidin partially blocked the breakdown of collagen from IL-1α 
+ OSM treated bovine cartilage. Taken together, these results suggest that pro-inflammatory 
cytokine stimulation is required for cartilage collagen breakdown and HDACi including TSA 
and apicidin can protect, at least in part, collagen breakdown. It also predicts a novel- specific 
role for the class I HDAC3, in mediating cartilage degradation and in particular collagen 
breakdown. 
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Figure 3.6. Addition of HDAC inhibitors (HDACi) to Interleukin-1α ± Oncostatin M (IL-1α ± 
OSM) treated bovine nasal cartilage (BNC). 
BNC was cultured in medium with or without HDACi: TSA (250ng/ml), Apicidin (100ng/ml) or 
DMSO-Control at Day 0, and either stimulated with IL-1α (10ng/ml) and/or IL-1α (4ng/ml) plus OSM 
(20ng/ml), or left unstimulated (Basal). Combined media from Day 7 and Day 14 as well as papain 
digested day 14 cartilage were collected and collagen release was quantified by measuring the levels 
of hydroxyproline. For statistical analysis, one-way ANOVA with a Bonferroni multiple comparison 
test was performed. *** p<0.001, ** p<0.01 
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3.3.3 The effect of HDAC3 RNAi on the induction of collagenase expression by IL-1. 
3.3.3.1. The effect of RNAi on HDAC3 mRNA and protein levels. 
The inhibition of IL-1- induced collagenase expression by the selective HDAC3 inhibitor 
apicidin and the blockage of collagen breakdown following apicidin treatment and IL-1 + 
OSM stimulation in a BNC assay suggested a specific role for the class I HDAC3. Therefore, 
RNAi-mediated gene depletion of HDAC3 was used to study the effect of HDAC3 in the 
induction of MMP1 and MMP13 expression by IL-1. The optimal transfection procedure and 
duration of siRNA incubation is described in section 2.2.7 RNA interference (RNAi). 
Transfection of SW1353 cells with different concentrations of siRNA targeting HDAC3 were 
used starting from 5-100nM and knockdown efficiency was determined using quantitative 
real-time PCR and immunoblotting. Transfection with 50nM and 20nM concentration of 
siHDAC3 reduced HDAC3 mRNA levels by >80% in the basal (Figure 3.7 A) and by >60% 
in the IL-1 induced level (Figure 3.7 B) and 5nM of siHDAC3 concentration halved HDAC3 
mRNA levels in the basal level (Figure 3.7 A). Protein levels of HDAC3 (quantified using 
ImageJ software) were decreased following siRNA transfection at 100nM by 68%, at 50nm 
by 52% and at 20nM by 46% (Figure 3.7 C). 
 
3.3.3.2 The effect of HDAC3 RNAi on the induction of collagenase expression by 
IL-1. 
Initially the effect of depleting HDAC3 on gene expression using 5-50nM concentration of 
siRNA was examined. HDAC3 gene depletion significantly decreased the induction of 
MMP13, MMP1, IL-6 and IL-8 expression by IL-1 at 50nM compared to the non-targeting 
control siRNA levels (Figure 3.8 A-D). MMP1 induced expression was also blocked at 20nM 
of siRNA concentration. RNAi-mediated depletion of HDAC3 had no effect on the basal 
levels of MMP1, MMP13, IL-6 and IL-8 expression. 
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Figure 3.7. Gene silencing of HDAC3 expression using a HDAC3-specific siRNA.  
SW1353 cells were transfected with decreasing concentrations (nM) of a non-targeting siRNA control 
(siCON) or a HDAC3-specific siRNA (siHDAC3) for 24h. The following day, the cells were serum 
starved for 16h and then stimulated with IL-1α (0.5ng/ml) (B) or left unstimulated (A). A- B. Total 
RNA was extracted, reverse transcribed to cDNA and HDAC3 expression measured by qRT- PCR. 
Results are shown relative to 18S ribosomal RNA expression. Significance was determined with 
respect to siCON treated cells in comparison to the siHDAC3 treated cells, both in the basal and IL-1 
induced level. Figure shows the mean of two independent experiments each with four biological 
replicates +SD. For statistical analysis, one-way ANOVA with a Bonferroni multiple comparison test 
was performed. C. HDAC3 protein levels were quantified following a 24h transfection with 
decreasing concentrations of siRNA. Cell lysate was harvested the next day, proteins were quantified 
and immunoblotting for an anti-HDAC3 specific antibody was performed. GAPDH served as a 
loading control. ** p<0.01, * p<0.05 
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Figure 3.8. Gene expression regulation following HDAC3 gene silencing.  
SW1353 cells were transfected with decreasing concentrations (nM) of a non-targeting siRNA control 
(siCON) or a HDAC3-specific siRNA (siHDAC3) for 24h. The following day, the cells were 
stimulated with IL-1α (0.5ng/ml) following an overnight serum starvation. Total RNA was extracted, 
reverse transcribed to cDNA and MMPs, IL-6 and IL-8 expressions measured by quantitative Real-
time PCR. Results are shown relative to 18S ribosomal RNA expression. Significance was determined 
by comparing the siCON with the siHDAC3 treated cells, both in the basal and IL-1 induced level. 
Figure shows two independent experiments and bars represent the mean of eight biological replicates 
+SD. For statistical analysis, one-way ANOVA with a Bonferroni’s multiple comparison test was 
performed. *** p<0.001, ** p<0.01 
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3.3.4 The effect of HDAC inhibition or RNAi for HDAC3 on the induction of Immediate 
Early Genes expression. 
3.3.4.1 Immediate Early gene expression following IL-1 stimulation. 
Immediate Early Genes (IEG) encode for transcription factors that control cell proliferation, 
differentiation and survival by controlling specific transcriptional programs (Hargreaves et al. 
2009). Two of the most well characterised IEG include the FOS and JUN family of 
transcription factors, binding sites of which have been found in both MMP1 and MMP13 
promoters, suggesting these are potential regulators of MMP1 and MMP13 expression 
(Vincenti & Brinckerhoff 2002). Initially an experiment to test whether IEG expression is 
induced following IL-1 stimulation for 30, 60 and 120 minutes was performed and compared 
to non-stimulated cells. IL-6 and IL-8 gene induction were included in the analysis as their 
expression has been shown to be induced following IL-1 stimulation (Figure 3.9 A-B). From 
the genes studied (Figure 3.9) only FRA1 (Figure 3.9 C), cFOS (Figure 3.9 E), FOSB 
(Figure 3.9 G) and JUND (Figure 3.9 J) were significantly induced after 60 and 120 minutes 
of IL-1 stimulation, suggesting a potential role for these genes on the induced collagenase 
expression regulation in chondrocytes. Other genes studied include ATF2, JUNB, FRA2, 
cJUN but no significant induction of their expression was found in the SW1353 cells, hence 
the effect of HDACi on the induction of these genes was not studied. 
 
3.3.4.2 The effect of HDAC inhibitors on selected IL-1- regulated IEG. 
To determine the effect of TSA, MS-275 and Apicidin on the IL-1 induced expression of IEG, 
SW1353 serum starved cells were treated with the indicated HDACi before IL-1 stimulation 
was performed. mRNA quantification followed, and only FRA1 induced expression was 
significantly decreased by HDACi; after 60 and 120 minutes of IL-1 stimulation when treated 
with TSA (Figure 3.10 A) and after 30 and 120 minutes of IL-1 stimulation when treated 
with Apicidin (Figure 3.10 C). A modest but not significant decrease was also found at 30 
minutes of the TSA and MS-275 treated cells (Figure 3.10 B), yet no effect of MS-275 was 
observed following further IL-1 stimulation. The induced expression of no other IEG was 
significantly changed following HDACi treatment (Figure 3.10 D-I).  
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Figure 3.9. Immediate early genes (IEG) expression following IL-1 cytokine stimulation.  
SW1353 cells were stimulated with IL-1α (0.5ng/ml) for different times (30, 60 and 120 minutes), 
following an overnight serum starvation. Total RNA was extracted, reverse transcribed to cDNA and 
IEG expressions measured by qRT- PCR. Results are shown relative to 18S ribosomal RNA 
expression. Significance was determined by comparing the unstimulated with the IL-1 treated cells. 
Figure shows one independent experiment and bars represent the mean of four biological replicates 
+SD. For statistical analysis, one-way ANOVA with a Bonferroni multiple comparison test was 
performed. *** p<0.001, ** p<0.01, * p<0.05 
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Figure 3.10. Regulation of IEG gene expression by HDAC inhibitors. 
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SW1353 cells were incubated for 30min with HDAC inhibitors: TSA (100ng/ml) (A, D, G), MS-275 (10μM) (B, E, H) and Apicidin (100ng/ml) (C, F, I), 
before IL-1α (0.5ng/ml) stimulation for different times (30, 60 and 120 minutes) was performed, following an overnight serum starvation. Total RNA 
was extracted, reverse transcribed to cDNA and IEG expression measured by qRT- PCR. Results are shown relative to 18S ribosomal RNA expression. 
Significance was compared with respect to the DMSO control treated cells in the basal and IL-1 induced levels. Figure shows one independent 
experiment and bars represent the mean of four biological replicates +SD. For statistical analysis, two-way ANOVA with a Bonferroni post- test to 
compare replicate means by row was performed. ** p<0.01, * p<0.05 
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3.3.4.3 The effect of HDAC3 RNAi on selected IL-1-regulated Immediate Early Genes. 
HDAC inhibitory treatment with TSA and apicidin suggested FRA1 IEG had a similar expression 
pattern with MMP1 and MMP13 following IL-1 stimulation. Knowing that binding sites for these 
genes have been found in the promoters of both MMPs (Weiss et al. 2003), FRA1 renders a good 
candidate for regulating expression of collagenases in cartilage. To examine the specific effect of 
HDAC3 on FRA1 induced expression, RNAi targeting HDAC3 was used, HDAC3 was 
subsequently depleted and FRA1 induction was measured following IL-1 stimulation. HDAC3 
expression was significantly blocked following siRNA treatment (Figure 3.11 A.). FRA1 
induction was prevented following HDAC3 depletion and IL-1 stimulation at 60 minutes (Figure 
3.11 B), but did not change at earlier or later time-points of IL-1 induction. 
 
 
 
Figure 3.11. Regulation of FRA1 gene expression following HDAC3 gene silencing.  
SW1353 cells were transfected with a non-targeting siRNA control (siCON) or the HDAC3-specific 
siRNA (siHDAC3) for 24h. The following day the cells were stimulated with IL-1α (0.5ng/ml) for 
different times (30, 60 and 120 minutes), following an overnight serum starvation. Total RNA was 
extracted, reverse transcribed to cDNA and HDAC3 (A) and FRA1 (B) expression measured by qRT- 
PCR. Results are shown relative to 18S ribosomal RNA expression. Significance was compared with 
respect to the siCON control treated cells in the basal and IL-1 induced levels. Figure shows one 
independent experiment and bars represent the mean of four biological replicates +SD. For statistical 
analysis, two-way ANOVA with a Bonferroni post- test to compare replicate means by row was 
performed. *** p<0.001 
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3.3.5 Effect of HDAC inhibition on the activation of NF-B signalling pathway. 
Most of the immune and inflammatory genes induced by IL-1 are NF-B regulated, making it 
a key regulator of IL-1 effects in cells. (O’Neill & Greene 1998) To clarify the impact of 
HDACs in the activation of NF-B signaling pathway, a luciferase reporter assay was 
performed. SW1353 cells were transfected with a NF-κB responsive firefly luciferase reporter 
and a control Renilla expression vector before HDACi treatment with 100ng/ml TSA or 
10μM MS-275 or 100ng/ml Apicidin was performed (as described in section 2.2.7). After 
stimulation with interleukin-1 (IL-1), luciferase activity was measured and normalised to 
Renilla. Optimal stimulation conditions were previously described in section 2.2.7. The 
reporter assay determined that HDAC inhibition using TSA or class I HDAC inhibition using 
MS-275 significantly reduced both basal and IL-1-induced NF-κB activity compared to the 
control. (Figure 3.12) Interestingly, the selective HDAC3 inhibitor apicidin also blocked 
luciferase transactivation of NF-κB activity, indicating HDAC3 as a potential mediator of the 
NF-κB regulated gene expression. 
 
Figure 3.12. NFB luciferase reporter activity is repressed following HDACi treatment.  
SW1353 serum-starved cells were incubated with TSA (100ng/ml), MS-275 (10μΜ) or Apicidin 
(100ng/ml) for 30min before IL-1 (0.5ng/ml) stimulation for 6h was performed. Luciferase expression 
was quantified using the Dual-Glo® Luciferase Assay system (Promega) and normalised to Renilla on 
a GloMax®- Multi Luminescene Module (Promega). Significance was compared with respect to the 
DMSO control treated cells in the basal and IL-1 induced levels. Assays were performed at least 3 
times, containing six repeats per treatment per biological repeat. Bars show the average ± SD of two 
experiments. *** p ≤ 0.001 
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3.4 Discussion 
The nucleosomal histones can be modified by reversible acetylation by histone 
acetyltransferases (HAT) and deacetylases (HDACs). The general model supports that HATs 
induce hyperacetylation causing nucleosomal relaxation which is associated with 
transcriptional activation. HDACs on the other hand, form co-repressor complexes which 
negatively regulate gene transcription. (Dangond et al. 1998) Histone deacetylase inhibitors 
(HDACi) enhance acetylation by preventing removal of acetyl groups by HDACs inducing 
gene transcription. (Clayton et al., 2006) It has been shown that treatment of chondrocytes 
with TSA, MS-275 or valproic acid was able to dose-dependently induce the acetylation of 
H3 histone and H4 histone and demonstrated similar efficacy across the tested doses. (Culley 
et al. 2013) In the current study, treatment of SW1353 cells with HDAC inhibitors TSA, MS-
275 and Apicidin resulted in an increase in the acetylation of total histone H3 (Figure 3.2). 
TSA, but not MS-275 or Apicidin induced acetylation of α-tubulin, confirming that only the 
former could inhibit the activity of HDAC5 and/or HDAC6. (Cho & Cavalli 2012; Hubbert et 
al. 2002) 
Although diminished histone acetylation generally correlates with gene silencing, there is also 
evidence that HDACs can activate some genes. (Kim & Bae 2011) HDAC inhibition for 
example using TSA was found to cause both the induction and repression of a large number 
of genes in pancreatic cancer cell lines, although the number of genes whose expression was 
up-regulated was greater than the number of genes that were down-regulated. When 
categorised into cellular functions, the differentially expressed genes were found to be 
involved in a variety of cellular processes including cell proliferation, signalling, regulation of 
transcription and apoptosis. (Moore et al. 2004) Similarly, many differentially regulated genes 
following TSA treatment were identified in hepatoma cells, with decreased expression to be 
linked to the development of hepatomas. (Chiba et al. 2004) Other studies demonstrated that 
apoptosis of human multiple myeloma cells was induced following treatment with 
suberoylanilide hydroxamic acid (SAHA), due to down-regulation of members of the insulin 
growth factor (IGF)/ IGF-1 receptor and IL-6 receptor (IL-6R) signalling cascade, anti-
apoptotic molecules, oncogenic kinases, DNA repair enzymes and transcription factors 
including E2F-1 and XBP-1. (Mitsiades et al. 2004) Interestingly, histone deacetylase 
inhibitors TSA and sodium butyrate (NaBy) have been also shown to block MMP and 
aggrecan degrading enzymes expression in vitro and reduced collagen breakdown from 
cartilage explants. (Young et al. 2005) A role for class I HDACs and in particular for HDAC3 
in activating TGF-β-dependent signalling pathways and subsequent gene expression 
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regulation of ADAM12 and TIMP1 in mouse C3H10T1/2 fibroblasts has also been proposed. 
(Barter et al. 2010) 
The main aim of this chapter was to investigate the role of HDACs and in particular of 
HDAC3 in regulating gene expression in chondrocytes. Parallel experiments were designed 
and gene expression of collagenases, IEG and NF-κB signaling pathway activation was 
determined following HDAC inhibition or HDAC3 specific depletion and IL-1 stimulation. A 
BNC assay also determined how HDACi affect collagen release in the presence or absence of 
stimulus. The results presented in this chapter imply a role for HDACs and particularly 
HDAC3 in regulating collagenase and FRA1 IEG expression in chondrocytes as well as in 
positively regulating the activation of NF-κB signalling and collagen release in a cartilage 
assay. 
 
3.4.1 HDACi and RNAi for HDAC3 abrogate IL-1-induced collagenase expression. 
TSA, MS-275 and Apicidin could all abrogate the IL-1 induced expression of MMP1 and 
MMP13, both of which are key collagenases involved in cartilage degradation in human 
articular chondrocytes (Figure 3.3 and Figure 3.4 and Figure 3.5). IL-1-induced IL-6 
expression was also blocked using all three HDAC inhibitors, supporting a role for class I 
HDACs and HDAC3 in particular in regulating its expression. RNA interference targeting 
HDAC3 mRNA also significantly decreased MMPs and IL-6 expression (Figure 3.8). Similar 
findings using TSA, valproic acid and MS-275 have previously shown a down-regulation in 
the expression of both MMPs and knockdown of each class I HDAC blocked the IL-1 induced 
expression of MMP1 and MMP13, while knockdown of HDAC2 showed statistically 
significant repression of MMP13 expression in the basal level. (Culley et al. 2013) A number 
of mechanisms might have accounted for these results. Some of these HDACi may act on 
specific genomic regions altering the acetylation state of the adjacent chromatin and allowing 
or preventing specific transcription factor binding or protein-DNA interactions. For instance, 
the identification of an Sp1 binding motif in Timp-1 promoter constructs shed some light on 
the differential regulation by TSA on Timp-1 expression. (Young et al. 2005) Moreover, 
transcription factor half-life, stability, subcellular localisation or transcriptional potential may 
be impaired. HDACi mediated increase in acetylation in critical DNA regions, including the 
promoters of the above genes, might block the tissue-specific interaction of transcription 
factors necessary for inducing gene transcription.  
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Other reports supported that HDACi could affect intermediate negative regulators such as 
MCPIP1, which is a negative regulator of IL-6 expression and is expressed at low levels in 
human osteoarthritis cartilage. Treatment of OA chondrocytes with SAHA robustly induced 
the expression of MCPIP1 and inhibited the expression of IL-6 and secretion of IL-6 
following IL-1β stimulation. This effect was mediated by recruitment of the CEBPα 
transcription factor to the hyperacetylated MCPIP1 promoter following SAHA treatment. 
(Makki & Haqqi 2015) Therefore, HDAC inhibition or HDAC3 specific depletion could 
prevent the induction of selected genes by activating their negative regulators. 
Normal signal transduction or protein-protein interactions could also be impaired following 
HDAC inhibition. It is known that IL-1 activates numerous pathways involved in cartilage 
destruction and dedifferentiation of chondrocytes. p38MAPK and/or PI3K/JNK signalling 
pathways have been identified as being crucial for IL-1 induced IL-6 secretion by 
chondrocytes and the down-regulation of aggrecan mediated by p38MAPK and/or ERK1/2. 
(Radons et al. 2006) HDACi treatment could impinge upon IL-1 mediated induction of IL-6 
expression by inhibiting signal transduction or protein-protein interaction of intermediate 
molecules of the aforementioned pathways. Involvement of ERK-, p38- and JNK- MAPK as 
well as AP-1, ATF2 and NF-κB transcription factors have been suggested to be involved in 
aggrecanase expression in chondrocytes. (Sylvester et al. 2012) And MS-275 and TSA 
treatment suppressed MAPK- mediated activation of RUNX2, ADAMTS5 and MMP3 in 
human articular chondrocytes. (Saito et al. 2013) Therefore, histone deacetylation may be 
necessary for facilitating normal signal transduction and HDAC inhibitors may render novel 
therapeutic agents against degenerative joint diseases such as osteoarthritis. 
Additionally, RNAi of HDAC3 would impact on the large multi-component subunit that 
contains HDAC3, the NCoR and SMRT co-repressors, which are necessary for HDAC3 
activity, modulating in this way its repressive effect. Interestingly, through interactions with 
these co-repressors, HDAC3 can associate with other class II HDACs including HDAC4, 
HDAC5 and HDAC7 and due to the presence of nuclear import and export signals it can 
translocate to the cytoplasm, where it is phosphorylated by Src. (Longworth & Laimins 2006) 
Therefore, HDAC3 depletion could not only affect its repressor- deacetylase activity, but also 
its subcellular localisation and interaction with other HDACs. 
Other evidence indicated that inhibition of class I, II HDACs or class III sirtuin HDACs 
potently block the production of IL-6 and TNF-α by macrophages from healthy donors and 
patients with rheumatoid arthritis (RA). Importantly, inflammatory and angiogenic cytokine 
production in intact RA synovial biopsy explants was also suppressed by HDACi treatments. 
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Two HDACi, TSA and nicotinamide, selectively induced macrophage apoptosis by 
downregulating the anti-apoptotic protein Bfl-1/A1, and inflammatory stimuli enhanced this 
HDACi-induced apoptosis. (Grabiec et al. 2010) It is therefore possible that TSA and the 
other HDACi used in this study have a similar effect in inducing apoptosis and hence 
downregulating cytokine production and an inflammatory response. 
Regarding IL-8 expression, this was not affected by MS-275 or Apicidin HDAC inhibition, 
but was significantly increased by TSA in the IL-1-induced level and instead decreased 
following siRNA-mediated HDAC3 depletion and IL-1 stimulation. Strong up-regulation of 
IL-8 was previously found in MCF-7 breast cancer cells following TSA treatment and this up-
regulation was dose- and time- dependent. This transcriptional activation involved mainly the 
NF-κB site of the IL-8 promoter and blocking NF-κB abolished IL-8 induction. (Chavey et al. 
2008) In concordance with our findings TSA but not any other HDACi such as apicidin, MS-
275, valproic acid, butyrate, and depudecin increased the IL-1 induced expression of IL-8 in 
A549 human lung epithelia cells. (Kallsen et al. 2012)  
One of the most remarkable properties of IL-8 expression is the variation of its expression 
levels. In healthy tissues it is barely detectable, but it is rapidly induced in response to pro-
inflammatory cytokines such as tumor necrosis factor or IL-1, bacterial or viral products and 
stress. For IL-8 to be generated, a combination of de-repression of its gene promoter, 
transcriptional activation by the NF-κB and JNK pathways and finally stabilization of IL-8 
mRNA by the p38-MAPK pathway need to take place. As a result cells fine-tune the amounts 
of secreted IL-8. (Hoffmann et al. 2002) Hence, the effect upon IL-8 expression following 
HDAC3 depletion is probably independent of the regulatory effects of the broad-spectrum 
HDACi TSA, and suggests IL-1 specific functions for HDAC3. The stimulatory function of 
HDAC3 for inflammatory gene expression involves a mechanism that uses binding to NF-κB 
p65 and its deacetylation at various lysines. NF-κB p65-deficient cells stably reconstituted to 
express acetylation mimicking forms of p65 (p65 K/Q) had largely lost their potential to 
stimulate IL-1-triggered gene expression, implying that the co-activating property of HDAC3 
involves the removal of inhibitory NF-κB p65 acetyl groups from K122, 123, 314 and 315. 
(Ziesché et al. 2013; Sun et al. 2013) These data describe a novel function for HDAC3 as a 
co-activator in inflammatory signaling pathways and especially in the regulation of IL-8 
expression.  
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 3.4.2 Effect of HDAC inhibitors on cytokine induced collagen release in vitro using 
cartilage explants. 
The ability of different HDACi to abrogate collagen degradation in vitro was assessed in a 
BNC assay. Although, collagen breakdown remained unchanged in the basal level after the 
addition of the different HDACi, TSA significantly rescued collagen release following IL-1 
and IL-1 + OSM stimulation. Apicidin also showed inhibition of collagen breakdown in the 
IL-1 + OSM stimulated cartilage explants (Figure 3.6). These results suggest that pro-
inflammatory cytokine stimulation is required for cartilage collagen breakdown and HDACi 
including TSA and apicidin can protect, at least in part, collagen breakdown. It also predicts a 
novel- specific role for the class I HDAC3, in mediating cartilage degradation and in 
particular collagen breakdown. Previous reports confirm these findings at least as far as the 
TSA HDACi is concerned (Young et al. 2005) and also measurement of gene expression in a 
BNC assay following MS-275 inhibition showed repressed levels of MMP1, MMP13, 
ADAMTS4 and ADAMTS5. (Culley et al. 2013) In the same study proteoglycans (GAG) loss 
was also studied as a marker of cartilage degradation and following MS-275 HDAC 
inhibition, GAG loss was prevented. Taken these data together, we have shown that class I 
HDAC3 selective inhibitor apicidin can in part reduce cartilage destruction in a manner 
similar to that of the broad-spectrum TSA and the class I HDACi MS-275. 
 
3.4.3 HDACi and RNAi for HDAC3 inhibit IL-1-induced IEG-FRA1 expression. 
The transcriptional program induced following growth factor or cytokine stimulation is 
classically described in two stages as follows: the rapid protein synthesis and independent 
induction of immediate early genes (IEG) followed by the subsequent protein synthesis- 
dependent induction of secondary response genes. In this study, the effect of HDACi and 
HDAC3 RNAi upon the activating protein-1 (AP-1) family of IEG expression was 
determined, since the promoters of MMP1 and MMP13 (and most other MMPs) contain 
multiple AP-1 binding sites that may contribute to gene expression. (Tullai et al. 2007; 
Vincenti & Brinckerhoff 2002) 
From the genes studied, it was demonstrated that only FRA1, cFOS, JUND and FOSB were 
significantly up-regulated following early IL-1 stimulation (Figure 3.9) and out of these four 
genes only FRA1 expression was responsive to HDACi or RNAi for HDAC3 (Figure 3.10 & 
Figure 3.11). Induction of FRA1 expression was determined following IL-1 stimulation and 
down-regulation of its expression followed after TSA and Apicidin treatment. Further one-
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way ANOVA analysis for the MS-275 treated cells concluded in a modest but not significant 
reduction of the 30 minutes IL-1 induced FRA1 expression, but no further effect was 
demonstrated. siRNA-mediated depletion of HDAC3 also prohibited FRA1 expression 
following 60 minutes of IL-1 stimulation. It has been reported that FRA1 expression requires 
dynamic changes in histone acetylation which is catalysed by lysine acetyltransferases and 
HDACs. Moreover, FRA1 is induced by several signal transduction pathways, resulting in the 
activation of MSK protein kinase and phosphorylation of histone H3 at Ser10 of the upstream 
promoter and regulatory region of the target gene. (Khan & Davie 2013) Interestingly, HDAC 
inhibition using TSA or Apicidin prevented FRA1 induction and the association of HDAC1, 
HDAC2 or HDAC3 with the gene body. The mechanism of HDAC recruitment to the gene 
body is thought to be via RNAPII which is required to transfer HDAC to the coding region of 
the gene. As the HDAC inhibitors prevented the initiation of transcription, RNAPII is not 
present to do this task. However, HDACi did not prevent the nucleosomal response but 
enhanced acetylation of histones at the upstream FRA1 promoter. (Khan & Davie 2013) 
Consistent with our results, others have shown that HDAC inhibitors can attenuate 
transcriptional initiation possibly by abrogating the binding of RNAPII and other transcription 
factors to promoter regions. (Yamaguchi et al. 2005; Rascle et al. 2003; Wolter et al. 2008) 
Furthermore, acute short term depletion of all or some specific HDACs differs significantly to 
the depletion of one HDAC for over 48 hours. Therefore, dynamic acetylation required for 
transcriptional initiation of IEG FRA1 would be opposed by HDAC inhibition. These reported 
findings support our data and suggest that FRA1 is among the genes that are down-regulated 
by HDACi or RNAi for specific HDACs. These results demonstrate that inhibition of all 
HDACs or specific depletion of HDAC3 can hinder transcription possibly via dynamic 
protein acetylation on the upstream promoter region.  
However, the effect of FRA1 gene on either MMP1 or MMP13 expression was not studied 
here, (for limitations of the study and future work, see Chapter 8: General Discussion). 
Nevertheless, there are reports supporting a role for FRA1 on regulating many MMPs, 
including MMP1, MMP2, MMP9 (Henckels & Prywes, 2013; Adiseshaiah et al. 2008; 
Belguise et al. 2005; Ho et al. 2008; Singh et al. 2010; Kimura et al. 2011). In particular, 
Kimura et al (2011) demonstrated that phosphorylated c-Jun and FRA1 bind to the AP-1 
element in the proximal promoter of MMP1 and are essential for its expression in 143B 
osteosarcoma cells. Differential expression of MMP1 has repeatedly correlated with 
tumorigenesis and metastasis. Henckels &Prywels (2013) showed that MMP1 expression is 
regulated by an AP1 element and FRA1 can differentially bind this element to regulate MMP1 
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expression in the MDA-MB-231 breast cancer cells. FRA1 expression and protein levels were 
higher in the metastatic cells, which in turn resulted in an induction of MMP1 and MMP9 
expression. (Henckels & Prywes, 2013; Belguise et al. 2005) Knockdown of FRA1 in 
lipopolysaccharide (LPS)-induced primary monocytes resulted in diminished MMP1 
expression, while over-expression of FRA1 increased MMP1 expression.  (Ho et al. 2008) 
Adiseshaiah et al. also showed that ectopic expression of FRA1 stimulated MMP9 and MMP2 
expression, which induced lung epithelial cell growth and invasion (Adiseshaiah et al. 2008).  
 
3.4.4 HDAC inhibition abrogates NF-κB signalling pathway activation. 
Transactivation by NF-κB in the presence/absence of HDACi and IL-1 stimulation was 
assessed by luciferase assay (Figure 3.12). The reporter assay determined that HDAC 
inhibition using TSA, or class I HDAC inhibition using MS-275 significantly reduced both 
basal and IL-1-induced NF-κB activity in the SW1353 cells. Interestingly, the selective 
HDAC3 inhibitor apicidin also blocked luciferase transactivation of NF-κB activity.  
The relation of HDACs to NF-κB pathway is complicated and evidence has recently 
accumulated supporting that acetylation and deacetylation events are implicated in the 
regulation of NF-κB transcriptional activity. First, acetylation of histones regulates the NF-
κB-dependent transcription factor gene accessibility. Second, acetylation events modulate 
temporally the IKK activity and subsequently the duration of NF-κB presence, translocation 
and transcriptional activation in the nucleus. Third, direct acetylation of the NF-κB subunits 
p65 and p50 regulates different NF-κB functions, including transcriptional activation, DNA-
binding affinity and IκBα assembly. It has been suggested that HDAC3 can deacetylate 
lysines 122, 123, 314 and 315 of NF-κB p65 to induce inflammatory gene expression. 
(Ziesché et al. 2013) In particular, it was shown that de-acetylation of K122 and K123 by 
HDAC3 is required for stable association of p65 with chromatin and subsequent p65-
dependent gene activation, yet does not affect nuclear translocation of p65. Elsharkawy et al. 
(2010) also showed that the p50 subunit of NF-κB can associate with HDAC1 is specific 
inflammatory gene promoters including CCL2, CXCL10, GM-CSF and MMP13 to inhibit 
transcription. Interestingly these genes were over-expressed in nfκb1 (p50) deficient mice 
suffering from chronic hepatitis and in inflammatory hepatic stellate cells isolated from nfκb1-
/- liver. The same study indicated that p50 was required for HDAC1 recruitment to the κB 
sites in the MMP13 promoter, and ChIP assays identified binding sites for HDAC1 in the 
promoters of the other inflammatory genes. (Elsharkawy et al. 2010)   
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In addition, acetyltransferases and deacetylases interact directly with several proteins involved 
in the NF-κB signaling pathway, including NF-κB itself, IκBα, IKKα and IKKγ. These 
interactions probably allow acetylation of NF-κB itself, of other transcription factors and of 
histones associated with NF-kB regulated genes. (Quivy & Van Lint 2004) It has been 
reported that MS-275 and SAHA suppressed lipopolysaccharide (LPS)- induced NF-κB p65 
nuclear accumulation, IL-6, IL-18 and TNFα secretion in THP-1 monocytic cells. The same 
study showed that Nitric Oxide (NO) secretion was inhibited and cell cycle arrest at the 
G0/G1 phase was induced. (Choo et al. 2010) These results taken together with the findings 
of this study imply a possible role for HDACi in suppressing NF-κB nuclear accumulation 
that would possibly impact upon reduced MMP expression in chondrocytes.  
While some studies support a synergistic role between HDACs and NF-κB to suppress gene 
expression, (Zhou et al. 2013), others propose an HDACi- mediated NF-κB activation of 
p65/RelA (Rosato et al. 2010). It is becoming therefore clear that further experiments are 
needed to additionally validate the role of HDACs and in particular HDAC3 in relation to NF-
κB activity in chondrocytes. RNAi for different HDACs should be used and NF-κB 
transcriptional activation or DNA binding potential should be tested.  
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3.5 Conclusions 
In SW1353 cells:  
 HDAC inhibition using TSA, MS-275 or Apicidin blocked IL-1-induced collagenase 
expression in vitro. 
 HDACi decreased collagen release following cytokine stimulation in BNC assay. 
 RNAi for HDAC3 abrogated MMP1 and MMP13 IL-1-induced expression. 
 HDACi and HDAC3 RNAi suppressed the induction of the IEG FRA1 by IL-1. 
 NF-κB transactivation was reduced following HDAC inhibition both in the basal and 
IL-1 induced level.
 107 
 
Chapter 4. Identification of differentially regulated genes by HDAC3 using 
RNA microarray analysis. 
 
4.1 Introduction 
A previous microarray analysis identified the molecular changes taking place after HDAC3 
depletion in osteoblast progenitor cells (using Osterix-Cre mediated knockout of Hdac3 in 
mice). Of the genes identified, 43 genes were significantly upregulated and 21 genes were 
down-regulated, with the most upregulated gene being a cyclin dependent kinase inhibitor 
(Cdkn1a), a known HDAC regulated gene. (Sambucetti et al. 1999; Richon et al. 2000; Han et 
al. 2000) Gene ontogeny analysis of the 64 differentially regulated genes identified 11 
pathways as being affected by Hdac3 depletion. These pathways include signal transduction 
pathways such as Wnt, Akt, G-proteins, cell cycle and DNA damage pathways and 
cytoskeletal/ cell adhesion. Thus, it became apparent that HDAC3 modulates pathways crucial 
for the development and function of the osteoblast pathways. (Razidlo et al. 2010) Very 
recently, Hdac3- deficient chondrocytes exhibited increased expression of cytokine and 
matrix-degrading genes and a decrease in expression of genes related to ECM production, 
bone development and ossification. Histone acetylation was increased at the near genes that 
had increased expression, including Il-6, Mmp3, Mmp13 and Saa3, and increased cytokine 
signalling promoted activation of NF-κB and JAK-STAT pathways. (Carpio et al. 2016) 
In addition cardiac-specific deletion of Hdac3 results in cardiac hypertrophy due to the 
upregulation of genes associated with fatty acid uptake, fatty acid oxidation, myocardial lipid 
accumulation and elevated triglyceride levels. These abnormalities were attributed to 
excessive activity of the nuclear receptor PPARα. (Montgomery et al. 2008) Sun and 
colleagues have also demonstrated that Hdac3 conditional knockout in the mouse liver, 
upregulated many lipogenic genes and resulted in severe hepatosteatosis. An increase in 
histone acetylation was profound as indicated by increased H3K9ac and H3K27ac, although 
HDAC3 target genes were not upregulated, indicating that hyperacetylation is insufficient to 
induce gene transcription. However, it was shown that while HDAC3 is the primary HDAC 
enzyme present in NCoR/SMRT complexes, other HDACs can be also recruited in a 
transcription factor- dependent or context- dependent manner, altering in this way gene 
expression programmes. (Sun et al. 2013) 
Gene profiling studies have demonstrated only a relatively small number of genes (2-10%) 
modulated by HDAC inhibitors and data obtained from the previous chapter indicated that 
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HDAC3 may mediate IL-1 induced collagenase and FRA1 IEG gene expression and NF-κB 
pathway activation in a chondrocyte-like cell line. However, one question became 
immediately obvious: How does HDAC3 work at the molecular level to regulate specific gene 
expression programmes in chondrocytes? To determine the gene expression changes that 
result from HDAC3 gene depletion or selective inhibition, the gene expression patterns in 
SW1353 cells were determined by microarray analysis and confirmed by qPCR.  
Data in the previous chapter indicated that HDAC3 selective inhibition or gene depletion 
mediates IL-1 induced collagenase and FRA1 immediate early gene expression. It was also 
proposed that HDACs in general and HDAC3 in particular may positively activate NF-κB. A 
number of possible mechanisms were introduced, yet herein a whole genome expression array 
was utilized to identify specific pathways, transcription factor binding sites and biological 
functions affected by HDAC3 knockdown or inhibition prior to and following IL-1 cytokine 
stimulation in the SW1353 cells.   
 
4.2 Aims 
 To reveal mechanistic information regarding the types of genes, pathways and 
transcription factor binding sites that are altered following HDAC3 selective inhibition 
or gene depletion in chondrocytes. 
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4.3 Results 
4.3.1. Cell treatments, RNA quantification and differential expression tests performed for 
the gene expression array experiment. 
The different treatments performed in the microarray experiment are shown in Table 4.1 and 
have been previously described (in section 2.2.19 RNA microarray analysis). Briefly, SW1353 
cells were transfected with siRNA targeting HDAC3 mRNA or a non-targeting siRNA was 
used as control.  Following 24 hours of transfection and an overnight serum starvation, cells 
were induced with IL-1α for 1 or 6 hours. Independent of HDAC3 gene depletion, HDAC3 
was also selectively inhibited using the HDACi Apicidin, with DMSO used as vehicle 
control. In this case, serum starved cells were incubated with the inhibitor for 30 minutes 
before an IL-1α stimulation for 1 or 6 hours was performed. Unstimulated cells having been 
transfected with siRNA/ HDACi were also included in this study. 
The principal component analysis to assess gene expression variation between different 
samples, leveraging all probes was constructed by Andrew Skelton, (Bioinformatics Support 
Unit, Newcastle University, Newcastle, UK) and can be found in Figure 4.1.The first 
principal component identified in my microarray experiment which explains the largest driver 
of variation is between the HDACi and siRNA treated samples and is plotted on the x axis. 
The second principal component (second biggest driver of variation) is plotted on the y axis 
and is explained based on if the samples had IL-1 stimulation or not. 
By profiling, the global gene expression changes of 23,739 genes and transcript variants were 
identified, but a subset of the significantly gene expression changes (p<0.01 and fold change 
±2) were taken into account as shown in Figure 4.2- heatmap. K-mean clustering was used to 
identify subsets of genes that present similar gene expression across the IL-1 stimulation and 
siHDAC3/siCON or Apicidin/DMSO treatments (Figure 4.3), because it was hypothesized 
that there might be a common mechanism of their gene expression regulation. The number of 
K-clusters was set to 24 and among the groups of co-regulated genes, there were clusters of 
genes that were induced at 1 hour of IL-1 stimulation but no further induced at 6 hours and 
RNAi for HDAC3 (Figure 4.3 A); clusters of genes that were induced across IL-1 stimulation 
and further induced following siHDAC3 (Figure 4.3 B) and genes which expression 
remained stable, independent of the treatment and/or IL-1 induction (Figure 4.3 C-siHDAC3 
& D-Apicidin treatment). The list of genes in each cluster is given in Appendix A. 
. 
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Two differential gene expression tests were carried out including: i) ‘knockout’ comparisons, 
by comparing the siHDAC3-treated to the siCON-treated samples or the Apicidin-treated to 
the DMSO-treated samples for each IL-1 stimulation time-point independently (Figure 4.4 A 
& C) and ii) time-point comparisons, by comparing the differentially IL-1 treated samples 
which had the same RNAi or HDACi treatment (Figure 4.4 B & D).  
 
IL-1α stimulation (0.5 ng/ml) 
No- IL-1 IL-1 for 1 hour IL-1 for 6 hours 
Vehicle 
control 
Treatment 
c 
(nM) 
Vehicle 
control 
Treatment 
c 
(nM) 
Vehicle 
control 
Treatment 
c 
(nM) 
siCON siHDAC3 50 siCON siHDAC3 50 siCON siHDAC3 50 
DMSO 
(0.25%) 
Apicidin 160 
DMSO 
(0.25%) 
Apicidin 160 
DMSO 
(0.25%) 
Apicidin 160 
Table 4.1. Treatments performed for gene expression array experiment and IL-1 stimulation 
time-points.  
 
 
 
Figure 4.1. Principal component analysis of technical replicates for microarray experiment. 
siRNA HDACi 
Basal 
IL-1 1h 
IL-1 6h 
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Figure 4.2. Heat-map showing the expression profile of IL-1 induced- HDAC3 regulated genes at 
1 hour, 6 hours after IL-1 stimulation and basally (no IL-1). 
Blue or red represents increase or decrease in gene expression relative to vehicle (either DMSO or 
siCON) treated cells respectively. Only genes that display significant changes in expression levels 
(fold change> 1.5, p<0.01) as compared to vehicle treated controls of three technical replicates are 
shown. 
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Figure 4.3. K-mean clustering was used to identify subset of genes with similar expression 
patterns across the IL-1 stimulation and Apicidin or siHDAC3 treatment. 
A. Genes induced at 1 hour of IL-1 stimulation but no further induced at 6 hours and 
siHDAC3, B. Genes that were induced across IL-1 stimulation and further induced 
following siHDAC3, C. Genes whose expression remained stable across the IL-1 
stimulation and siHDAC3 and D. Genes whose expression remained stable across the 
IL-1 stimulation and Apicidin treatment. 
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Figure 4.4. Volcano plots of two differential expression tests performed in the microarray 
experiment.  
A- C. Knockout comparison: siHDAC3 versus siCON and Apicidin versus DMSO treated samples 
following 6 hours of IL-1 stimulation and  
B- D. Time-point comparison: siCON/DMSO treated cells at 6 hours of IL-1 stimulation versus no IL-
1.  
Red dots: significantly changed gene expression, Black dots: Non- significant changed gene 
expression. HDAC3 gene is shown in all different comparisons. 
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After validating the quality and degradation of the RNA samples (see section 2.2.19 RNA 
microarray analysis), quantitative real-time RT-PCR was used and gene expression measured 
to confirm the previous effect of siRNA depletion or Apicidin inhibition and IL-1 induction. 
In particular, HDAC3 depletion was confirmed with qRT-PCR as shown in Figure 4.5. 
MMP1 and MMP13 expression were significantly induced following IL-1 stimulation and as 
expected downregulated following siHDAC3 depletion or Apicidin treatment (Figure 4.6), 
confirming the results presented in Chapter 3. 
The logFC values (log fold change = logFC) obtained from the microarray were as below: for 
MMP1 (= -0.864) and for MMP13 (= -0.487) in the Apicidin treated samples after 6 hours of 
IL-1, and for MMP1 (= -0.571) and for MMP13 (= -0.412) in the siHDAC3 treated samples 
after 6 hours of IL-1.  Additionally, FRA1 (= -1.5967), IL-6 (= -1.14965) and IL-8 (= -
1.15432) gene expressions were measured by qRT-PCR (results not shown here) and the 
effect of HDAC3 depletion/inhibition upon their expression was confirmed as previously 
described in Chapter 3. 
 
 
Figure 4.5. HDAC3 gene expression following RNAi for HDAC3 and IL-1α cytokine stimulation. 
SW1353 cells were transfected with 50nM of non-targeting siRNA control (siCON) or a HDAC3-
specific siRNA (siHDAC3) for 24h. Following an overnight serum starvation, the cells were 
stimulated with IL-1α (0.5ng/ml) for 1 hour, 6 hours or left unstimulated. Total RNA was extracted, 
reverse transcribed to cDNA and HDAC3 expression measured by qRT- PCR. Results are shown 
relative to 18S ribosomal RNA expression. Significance was determined by comparing the siCON 
with the siHDAC3 treated cells in the basal and IL-1 induced level. Bars represent the mean of three 
biological replicates +SD. For statistical analysis, an unpaired two-tailed student’s t-test was 
performed. *** p< 0.001 
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Figure 4.6. MMP13 and MMP1 gene expression following RNAi or HDACi and IL-1α cytokine 
stimulation. 
SW1353 cells were transfected with 50nM of non-targeting siRNA control (siCON) or a HDAC3-
specific siRNA (siHDAC3) for 24h. Following an overnight serum starvation, the cells were 
stimulated with IL-1α (0.5ng/ml) for 1 hour, 6 hours or left unstimulated. Alternatively, serum starved 
cells were incubated for 30min with Apicidin (100ng/ml= 160nM) or DMSO (0.25%), before IL-1α 
(0.5ng/ml) stimulation was performed. Total RNA was extracted, reverse transcribed to cDNA and 
MMP1/13 expression measured by qRT- PCR. Results are shown relative to 18S ribosomal RNA 
expression. Significance was determined by comparing the siCON with the siHDAC3 treated cells, or 
the Apicidin with the DMSO treated cells both in the basal and IL-1 induced level. Bars represent the 
mean of three technical repeats ±SD. For statistical analysis, a two-way ANOVA with a Bonferroni 
post-test was performed. *** p< 0.001 
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4.3.2 Genes and pathways induced by IL-1 following 1 or 6 hours of stimulation. 
The gene lists produced from the gene expression array and with final cut off of ±1.5 fold 
change (logFC = 0.58) and a p-value ≤ 0.05were analysed for gene ontology, KEGG pathways 
and transcription factor binding sites using GATHER (Chang & Nevins 2006). In the first 
instance, the genes significantly up-regulated by IL-1 stimulation were identified. A total of 
62 genes were significantly upregulated following IL-1 stimulation for 1 hour, while 290 
genes were induced following IL-1 stimulation for 6 hours in the DMSO-treated control 
samples. In the siCON-treated samples 78 genes were induced by IL-1 after 1 hour of 
stimulation, while 268 were induced after 6 hours.  Out of these genes, 45 and 190 were 
common between the DMSO and siCON treated samples following 1 or 6 hours of IL-1 
stimulation respectively (see Figure 4.7 A, IL-1 for 1 hour timepoint; and Figure 4.8 A, IL-1 
for 6 hours timepoint). 
As expected the most inducible gene was an immediate early gene, FOS (logFC = 0.99) which 
has been reported as being induced by IL-1 stimulation and previously linked to MMP 
expression and OA. (Cawston et al. 2003; Vincenti & Brinckerhoff 2002) The list of the 45 
common genes between the DMSO and siCON- treated samples was found to be significantly 
associated with three pathways including apoptosis, focal adhesion and the Toll-like receptor 
signaling pathway. The top ten biological functions and transcription factor binding sites are 
also shown in Figure 4.7 B and C. Among these, AP-1 binding sites come in the top of the 
list and NF-κB transcription factor was present twice. The latter could be associated with the 
IκΒ kinase/NF-κB cascade gene ontology annotation that was predicted. Interferon regulatory 
factors that are known mediators of the JAK-STAT signaling pathway and the FOXP3 
transcription factor which has been linked to immunodeficiency syndromes were also 
determined. The above predicted transcription factor binding sites, in combination with the 
prediction of the serum response factor (SRF), which can bind to the promoter regions of 
target genes could regulate important cellular physiological processes. For instance, the SRF 
can bind to the serum response element to regulate the activity of many IEG such as c-FOS 
and therefore participates in cell cycle regulation, apoptosis, cell growth and cell 
differentiation. (Johansen & Prywes 1994) This gene is the downstream target of MAPK 
signaling pathway, suggesting that other biological functions for example transcription factor 
–nucleus import, protein transportation or signal transduction may be altered following IL-1 
stimulation. 
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Figure 4.7. Differentially induced genes following 1 hour of IL-1α (0.5ng/ml) stimulation.  
A. Venn diagram of genes induced after 1 hour of IL-1 stimulation in the siCON-treated or DMSO treated samples. Only 45 genes were identified as up-regulated 
in common between the two treatments. B. Top 10 transcription factor binding sites (TRANSFAC) analysis, C. Top 10 gene ontology (GO) analysis and D. 
KEGG pathway analysis of up-regulated genes (45) were performed using GATHER. 
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The most upregulated gene following 6 hours of IL-1 stimulation in both the DMSO and 
siCON-treated samples was CXCL8 (C-X-C Motif Chemokine Ligand 8, also known as IL-8) 
with logFC = 6.17, a member of the CXC chemokine family and a major mediator of the 
inflammatory response. A more comprehensive examination (Figure 4.8) suggests that most 
of the genes induced are related to an immune response or response to stimulus as would be 
anticipated following IL-1 stimulation. However, gene ontology analysis (Figure 4.8 C) 
predicts many other biological processes including cell cycle regulation, cell death and 
proliferation, cell signalling, signal transduction, lipid metabolism and cell migration are also 
affected by the IL-1 stimulation. NF-κB transcription factor binding sites are the predominant 
binding motifs identified in the 190 common up-regulated genes (Figure 4.8 B) confirming 
NF-κB factor as the key mediator of IL-1 cytokine response. Furthermore, four pathways 
(Figure 4.8 D) were significantly associated with the IL-1 induced genes including cytokine-
cytokine receptor interaction, Toll-like receptor signalling pathway, apoptosis and JAK-STAT 
signalling pathway. 
The Open Targets platform (https://targetvalidation.org/) (Koscienly et al. 2017) was used to 
identify OA and/or cartilage related genes among the IL-1 induced genes and the results can 
be found in Table 4.2. 
 
IL-1 for 1 hour (9 out of 45 from 
Figure 4.7 A) 
IL-1 for 6 hours (54 out of 190 from Figure 4.8 A) 
BMP4 CCL2 CXCL8 IL6ST MMP7 SERPINA1 TNIP1 
CDKN1A CCL20 EGFR IRF1 MT2A SERPINB2 TRIB1 
F3 CCL8 FBXO32 KRT75 NAMPT SERPINE1 VEGFC 
IL1B CD44 IFIH1 LIF NFKBIA SERPINE2 XBP1 
IL24 CD82 IFIT1 LOX OLR1 SMAD3  
LDLR CDK6 IL11 LTB PI3 SOD2  
NLRP3 CEBPB IL1B MAP2K3 PIK3CD TNC  
RHOB CEMIP IL24 MMP1 RIPK2 TNFAIP3  
TNFRSF10B CSF2 IL32 MMP12 SAT1 TNFAIP6  
 CXCL10 IL6 MMP3 SDC4 TNFRSF1B  
Table 4.2. OA and cartilage related genes were identified among the IL-1-induced genes 
following 1 or 6 hours of stimulation.
 119 
 
 
Figure 4.8. Differentially induced genes following 6 hours of IL-1α (0.5ng/ml) stimulation.  
A. Venn diagram of genes induced after 6 hours of IL-1 stimulation in the siCON-treated or DMSO treated samples. 190 genes were up-regulated in both 
treatments. B. Top 10 transcription factor binding sites (TRANSFAC) analysis, C. Top 10 gene ontology (GO) analysis and D. KEGG pathway analysis of up-
regulated genes (45) were performed using GATHER. 
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4.3.3 Differentially expressed genes following HDAC3 selective inhibition and IL-1 
stimulation. 
Next, an identification of the differentially expressed genes following IL-1 induction and 
Apicidin treatment followed. At the basal level, 43 genes were repressed by Apicidin, while 
51 genes were induced. Most of the repressed genes were associated with having a role in 
regulation of transcription and metabolism, organogenesis and mesoderm development and 
linked to two pathways important for normal growth and development, the TGF-β (p-value = 
0.0006) and Wnt (p-value = 0.003) signalling pathways. Regarding the 51 induced genes, 
these were associated with protein-nucleus import (p-value= 0.01), negative regulation of 
cyclin dependent phosphorylation, negative regulation of transcription and KEGG pathway 
analysis identified methionine metabolism (p-value= 0.002) and Notch signaling pathway (p-
value= 0.007). Transcription factor binding sites predicted for the induced gene list included 
X-box binding protein RFX1, ATF3, PAX5 and KROX transcription factors. 
However, and because ECM modifying enzymes are regulated at the level of transcription by 
cytokines, and inducible MMPs were repressed following Apicidin treatment, a need for 
understanding how the IL-1 induced and further repressed by Apicidin genes are regulated 
became apparent. Therefore, the focal point of this study was to identify pathways and 
transcription factors of the inducible repressed genes that could clarify the molecular basis of 
the HDAC3-mediated gene regulation. 
The results obtained from the gene expression array regarding the selective HDAC3 inhibitor 
Apicidin are summarised in Figure 4.9. In total, we identified 121 genes significantly induced 
by IL-1 after 1 hour of stimulation, and 290 genes significantly induced after 6 hours of 
stimulation. A heatmap (Figure 4.9 A) shows the top 20 induced and most repressed by 
Apicidin genes at 6 hours of IL-1 stimulation and their expression in the basal level and 1 
hour of IL-1 is also shown as a comparison. Pie charts in Figure 4.9 B & D show almost half 
of the genes induced by IL-1 are no longer induced in the presence of the HDACi Apicidin, 
whereas the other half is further induced. Among them, OA/ cartilage related genes were 
identified and the results can be found in Table 4.3. The molecular network analysis of the no 
longer induced genes (Figure 4.9 C & E) identified three pathways in common, following 1 
or 6 hours of IL-1 stimulation, and these involved cytokine-cytokine receptor interaction, 
JAK-STAT signalling pathway and apoptosis, whilst MAPK and Toll-like receptor signalling 
pathways appeared only in the 1 hour list, suggesting a role for these pathways and their 
downstream targets early after a cytokine induction. The molecular functions of the down-
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regulated genes were also assessed and the results indicate a great diversity of biological 
processes such as immune response and response to stimulus, cell-cell signalling, regulation 
of cell proliferation and negative regulation of cellular physiological processes (Figure 4.9 G 
& I). With regards to the TRANSFAC analysis, NF-κB binding sites appeared multiple times 
in the list of down-regulated genes, together with AP-1 and ICSBP (Interferon Consensus 
Sequence Binding Protein, also known and IRF-8) sites (Figure 4.9 F &H). Other 
transcription factors identified in the analysis include the Ikaros 3, Maz related factor, CP2, 
TAL1 and MRF2, yet none of these have been linked to directly binding or regulating matrix 
modifying enzymes. MTF1 transcription factor was also predicted; MTF1 has been previously 
associated with zinc dependent-regulation of catabolic transcription in osteoarthritis. In 
particular, it was shown that the zinc importer ZIP8 was upregulated in osteoarthritic cartilage 
from humans and mice, and Zn+2 influx increased transcriptional activity and promoted 
nuclear localization of MTF1 transcription factor, which in turn resulted in an increased 
expression of many MMPs including, MMP3, MMP9, MMP12, MMP13 and ADAMTS5. 
(Kim et al. 2014) 
 
 
IL-1 (for 1 hour) -induced and repressed 
by Apicidin genes (20 out of 63 from 
Figure 4.9 B) 
IL-1 (for 6 hours) -induced and repressed by Apicidin (41 out 
of 137 from Figure 4.9 D) 
CCL2 LDLR CCL2 IL11 MMP1 SERPINB2 XBP1 
CCL20 LIF CCL8 IL1B MMP12 SMAD3  
CSF2 NLRP3 CDK6 IL24 MMP3 SOCS1  
CXCL8 OLR1 CEBPB IL32 MMP7 SOD2  
EDN1 SOD2 CEMIP IL6 NAMPT TNFAIP6  
IL11 SPRY2 CSF2 IL6ST NFKBIA TNIP1  
IL1B TNF DDIT4 IRF1 OLR1 TRIB1  
IL24 TNFAIP3 EGFR LIF PLAUR TUBB6  
IL32 TRIB1 FBXO32 LOX PTPRK UCN2  
KLF6 LDLR IFIH1 LTB SERPINA1 VEGFC  
Table 4.3. OA and cartilage related genes were identified following IL-1 stimulation and HDAC3 
selective inhibition using Apicidin. 
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Figure 4.9. Gene expression profiling following IL-1α (0.5ng/ml) stimulation and Apicidin (160nM) treatment in SW1353 cells. 
A.   Top 20 genes induced by IL-1 after 6 hours and repressed by Apicidin. B, D. Size-dependent pie charts of genes induced by IL-1 (B) after 1 hour or (D) 6 hours 
and repressed by Apicidin. C. KEGG pathway analysis of the IL-1 induced (1 hour) and Apicidin- repressed genes. E. KEGG pathway analysis of the IL-1 
induced (6 hours) and Apicidin- repressed genes. F, G. TRANSFAC and GO analysis of the IL-1 induced (1 hour) and Apicidin- repressed genes. H, I. 
TRANSFAC and GO analysis of the IL-1 induced (6 hours) and Apicidin- repressed genes. 
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4.3.4 Differentially expressed genes following HDAC inhibition and IL-1 stimulation. 
In the current study, data obtained from another gene expression array analysis performed by 
Dr Matthew Barter (Newcastle University, Newcastle, UK) was taken into account. In this 
microarray SW1353 cells were treated with 756nM (250ng/ml) of the pan-HDACi TSA for 
30 minutes before IL-1 stimulation for 6 hours followed. RNA extraction and microarray 
analysis were then performed as previously described (see section 2.2.19). The results 
obtained from this microarray were compared to the data obtained from the Apicidin treated 
cells basally (no IL-1) (Figure 4.10) and following 6 hours of IL-1 stimulation (Figure 4.11). 
The lists of induced and repressed by both HDACi genes with/without IL-1 stimulation were 
subjected to GO, KEGG pathway and TRANSFAC analysis using the same cut off of ± 1.5 
fold change as before. 
In the basal level (no IL-1), 231genes were induced only by TSA-mediated HDAC inhibition 
and 35 genes were induced only by Apicidin (Figure 4.10 A). Between the two treatments 13 
genes were induced in common and these were associated significantly with three pathways, 
including methionine metabolism (p-value= 0.0002), aminoacyl-tRNA biosynthesis (p-value= 
0.0003) and selenoamino acid metabolism (p-value= 0.0003). The most significant identified 
GOs included methionyl-tRNA aminoacetylation (p-value= 0.0003), negative regulation of 
cyclin dependent protein kinase activity (p-value= 0.0009), odontogenesis (p-value= 0.002), 
bone mineralization/ remodelling (p-value= 0.003) and ossification (p-value= 0.008). 
TRANSFAC analysis indicated enrichment for E2F, Pax3, Nuclear factor Y-binding box, 
ELF1, SMAD4 and Ras-responsive binding element transcription factors. 
Furthermore, 141 genes were repressed only by TSA and 27 genes only by Apicidin when no 
IL-1 stimulation was performed. Seven genes were decreased by both HDACi and these were 
also subjected to GO (Figure 4.10 C), TRANSFAC (Figure 4.10 D) and KEGG pathway 
analysis (Figure 4.10 E). GO analysis predicted B-cell differentiation and activation, 
lymphocyte differentiation/ activation, haemopoiesis, immune cell activation and cell growth, 
while Wnt signalling and focal adhesion pathways are predicted following KEGG analysis. 
Both of these pathways have been previously associated with osteoarthritis and rheumatoid 
arthritis. (Corr 2008; Shahrara et al. 2007; Prasadam et al. 2013; Luyten et al. 2009) 
Following IL-1 stimulation, 23 genes were further induced by TSA and 141 by Apicidin, 
while 12 genes were in common between the two treatments (Figure 4.11 A). The top 4 GO 
terms predicted were linked to mating/reproductive behaviour (p-value< 0.001) and the next 
terms were associated with regulation of viral genome replication, immune response and 
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regulation of apoptosis (all had p-value< 0.01). Cytokine- cytokine receptor interaction (p-
value= 0.001), Toll-like receptor signalling pathway (p-value= 0.005) and tight junction (p-
value= 0.006) were among the pathways affected by these 12 genes, whereas the most 
prevalent transcription factor identified was NF-κB (p-value <0.0001). 
Interestingly, of the 85 repressed by TSA and the 110 by Apicidin, 27 genes were no further 
induced in the presence of both HDACi. Except for the GO terms immune response, response 
to biotic stimulus and response to wounding and inflammatory response, which were 
previously described in the Apicidin section, collagen catabolism is a newly predicted 
biological function in the GO analysis (Figure 4.11 C), fortifying the involvement of HDACs 
in regulating critical for this process enzymes. With reference to the pathway analysis (Figure 
4.11 E), the results were similar to the inducible genes that were no longer induced by 
Apicidin (Figure 4.9 E) and contained cytokine-cytokine interaction, apoptosis, Toll-like 
receptor and JAK-STAT signalling pathways. These results suggest that HDAC3 may act 
through specific signalling pathways and by associating with specific transcription factors 
controls important gene expression programs in chondrocytes.  As far as the TRANSFAC 
analysis is concerned interferon regulatory transcription factors come at the top of the list with 
ICSBP first and IRF second (Figure 4.11 D). NF-κB and AP-1 binding motifs are also 
predicted, but for the first time the no longer induced by both HDACi genes are predicted to 
be enriched for E2F and E2F-1 transcription factor binding sites. 
The Open Targets platform predicts the OA/cartilage related genes among the lists of 
repressed genes in the basal and IL-1 induced level as shown in Table 4.4. 
 
TSA and Apicidin repressed genes (no IL-1, 1 
out of 7 from Figure 4.10 A) 
IL-1 (for 6 hours) -induced and repressed by TSA & 
Apicidin (10 out of 27 from Figure 4.11 A) 
KLF6 CCL8 
 CSF2 
 IFIH1 
 IL1B 
 IL24 
 IL6 
 LTB 
 MMP1 
 MMP12 
 MMP3 
Table 4.4. OA and cartilage related genes were identified following HDAC inhibition with TSA 
or Apicidin in the presence or absence of IL-1 stimulation.
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Figure 4.10. Differentially expressed genes following TSA (756nM) or Apicidin (160nM) treatment in SW1353 cells.  
A. Venn diagrams of genes induced or repressed by the HDACi. B. X-Y scatter plot of the total number of induced or repressed by the HDACi genes. C. Top 10 
gene ontology (GO) analysis of the repressed genes. D. Top 10 TRANSFAC analysis of the repressed genes and E. KEGG pathway analysis of the repressed 
genes were performed using GATHER. 
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Figure 4.11. Differentially expressed genes following IL-1α (0.5ng/ml) stimulation for 6 hours and TSA (756nM) or Apicidin (160nM) treatment in SW1353 
cells.  
A. Venn diagrams of IL-1 induced genes and further induced or repressed by the HDACi genes. B. X-Y scatter plot of the total number of induced or repressed by 
the HDACi genes. C. Top 10 gene ontology (GO) analysis of the IL-1 induced and further repressed genes. D. Top 10 TRANSFAC analysis of the IL-1 induced 
and further repressed genes and E. KEGG pathway analysis of the IL-1 induced and further repressed genes were performed using GATHER. 
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4.3.5 Differentially expressed genes following RNA interference for HDAC3 and IL-1 
stimulation. 
To further improve our understanding of the role that HDAC3 plays in chondrocytes we 
specifically depleted HDAC3 using RNA interference in the SW1353 chondrosarcoma cells. 
At the basal level, 118 genes were down-regulated following gene depletion, with HDAC3 
being at the top of this list (logFC = - 2.0667, p-value<0.0001). Regulation of the cell cycle, 
UDP- glucose metabolism, isoprenoid biosynthesis and metabolism, mitosis checkpoint, co-
enzyme metabolism and nucleotide-sugar metabolism are some of the predicted gene 
ontology annotations of the repressed by the siHDAC3 genes. Interestingly, these genes are 
enriched mainly for E2F-1 transcription factor binding sites; the same factor came up four 
times in the list of the top ten predicted factors (see Appendix B for list of transcription 
factors predicted). Moreover, cell cycle, isoprenoid biosynthesis and nucleotide sugars 
metabolism are the pathways associated with the repressed gene list. However, 28 genes were 
significantly induced following HDAC3 depletion. These genes were mainly associated with 
muscle development and maintenance, myelination, ionic insulation of neurons, nerve 
maturation and organ development. In terms of pathways, coagulation cascades and focal 
adhesion were predicted.  
However, following IL-1 stimulation and HDAC3 gene depletion only a small number of 
genes are no longer induced, with most of them being significantly up-regulated. In particular, 
after 1 hour of IL-1 stimulation only 2 inducible genes are suppressed by the siHDAC3 
(Figure 4.12 B). These genes included the CSF2 and HMGCS1. CSF2 is a cytokine which 
controls production and differentiation of granulocytes and macrophages, while HMGCS1 is 
involved in the regulation of cholesterol biosynthesis. HMGCS1 gene expression has been 
shown to depend on HDAC3 to regulate cholesterol or fatty acid biosynthesis (Bhaskara et al. 
2011). Both CSF2 and HMGCS1 were recently found to be upregulated in a different 
microarray analysis performed in two prostate cancer cell lines, after HDAC inhibition (Lin et 
al. 2016). Interestingly, 151 genes were repressed by the siHDAC3, but not induced by IL-1 
stimulation. When these genes were analysed for TRANSFAC, E2F-1 came up four times in 
the top 10 list of transcription factors predicted by GATHER with a p-value <0.0001 (see 
Appendix B). 
Following 6 hours of IL-1 induction 29 IL-1-induced genes are no longer induced by the 
siHDAC3 (Figure 4.12 C). A heatmap (Figure 4.12 A) shows the top 20 induced and most 
repressed by siHDAC3 genes after 6 hours of IL-1 stimulation and their expression in the 
basal level at 1 hour of IL-1 is also shown as a comparison. Cytokine-cytokine receptor 
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interaction and JAK-STAT signalling pathway were predicted following analysis of the no 
longer induced genes at the IL-1- 6 hours timepoint. Moreover, Toll-like signalling pathway, 
C21 steroid hormone metabolism and nucleotide sugars metabolism are associated with the 
IL-1-6 hours induced and siHDAC3 repressed genes (Figure 4.12 E), while HDAC3 role in 
inflammatory response and cell-cell signalling is also manifested after 6 hours of cytokine 
stimulation. The no longer induced by siHDAC3 genes appear to negatively regulate cellular 
physiological processes and are enriched for ISRE (Interferon Stimulated Response Element) 
and E2F-1 binding sites (Figure 4.12 D). Interestingly, previous reports support a role of the 
ISRE in immune-regulation by Toll-like receptors and other pattern recognition receptors 
(Honda & Taniguchi 2006). Additionally, 239 genes were repressed by the siHDAC3, but not 
induced by IL-1 stimulation and TRANSFAC analysis suggests these genes are enriched for 
E2F-1 transcription factor binding sites, similarly to the genes repressed by siHDAC3 at 1 
hour of IL-1 and  at the basal (no IL-1) level (see Appendix B). The OA/ cartilage related 
genes are shown in Table 4.5. 
Nevertheless, 71 genes were further significantly upregulated following IL-1 induction (6 
hours) and siHDAC3 treatment. Organogenesis, phosphate transport, fatty-acid beta 
oxidation, muscle contraction and development are among the GO predicted terms with p-
values <0.01.  KEGG pathway analysis identified TGF-β signaling pathway (p-value= 0.003), 
ECM receptor interaction (p-value= 0.003), focal adhesion (p-value= 0.003) and cell cycle (p-
value= 0.004) to be accompanied with the induced gene list. Finally, the most common 
transcription factor identified was serum response factor (p-value= 0.007). 
 
IL-1 (for 1 hour) -induced and repressed by 
siHDAC3 genes (1 out of 2 from Figure 4.12 B) 
IL-1 (for 6 hours) -induced and repressed by 
siHDAC3 (14 out of 29 from Figure 4.12 C) 
CSF2 CCL2 SERPINB2 
 CCL8 STAT1 
 CSF2 TNFAIP6 
 CXCL10 UGDH 
 CXCL8  
 IFIT1  
 IL11  
 IL1B  
 IL6  
 MMP12  
Table 4.5. OA and cartilage related genes were identified following IL-1 stimulation and HDAC3 
gene depletion.
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Figure 4.12. Gene expression profiling following IL-1α (0.5ng/ml) stimulation and RNAi (50nM) 
for HDAC3 in SW1353 cells. 
A.   Top 20 genes induced by IL-1 after 6 hours and further repressed by the siHDAC3. B, C. Size-
dependent pie charts of the genes induced by IL-1 after 1 hour (B) or 6 hours (C) and further 
repressed by the siHDAC3. D. TRANSFAC analysis of the IL-1-induced and further repressed by 
siHDAC3 genes at 6 hours of IL-1 stimulation. E. KEGG pathway analysis IL-1-induced and 
further repressed by siHDAC3 genes at 6 hours of IL-1 stimulation. F. GO analysis of the IL-1-
induced and further repressed by siHDAC3 genes at 6 hours of IL-1 stimulation.  
 
4.3.6 Genes repressed by HDAC3 selective inhibition and gene depletion following 1 hour 
of IL-1 stimulation. 
By comparing the genes repressed by the selective HDAC3 inhibitor Apicidin or the siRNA 
after 1 hour of cytokine IL-1 induction only one gene was identified to be suppressed by both. 
This gene was CSF2 (Colony stimulating factor 2), a cytokine that stimulates the growth and 
differentiation of haematopoietic precursor cells from various lineages, including 
granulocytes, macrophages, eosinophils and erythrocytes. The active form of this gene is 
found extracellularly as a homodimer. It has been localised to a cluster of related genes at 
chromosome region 5q31 which is known to be associated with interstitial deletions in the 5q 
syndrome and acute myelogenous leukaemia. Other genes in the cluster include those 
encoding for interleukins 4, 5 and 13 and thus pathway analysis predicts a role for JAK-STAT 
signalling pathway and for cytokine-cytokine receptor interaction. (Hamilton 2008)  Active 
repression of this gene is linked to cellular defence response, response to wounding, immune 
response and response to biotic stimulus, as well as cell surface receptor linked signal 
transduction and development. (https://www.ncbi.nlm.nih.gov/gene/1437) 
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4.3.7 Genes repressed by HDAC3 selective inhibition and gene depletion following 6 hours 
of IL-1 stimulation. 
Next, the genes repressed by the siHDAC3 depletion and the Apicidin inhibition, following 
IL-1 stimulation for 6 hours were examined (Figure 4.13). 13 genes were identified to no 
longer be induced by both treatments (Figure 4.13 A). KEGG pathway analysis showed three 
pathways were significantly associated with the repressed genes including cytokine-cytokine 
receptor interaction, JAK-STAT signalling pathway and Toll-like receptor signalling pathway 
(Figure 4.13 B). Most of the GO annotations have been predicted before and these include 
response to stimulus, immune/inflammatory response and cell-cell signalling (Figure 4.13 D).  
Using TRANSFAC the 13 IL-1 repressed genes were enriched for E2F-1 transcription factor 
binding site as shown in Figure 4.13 C (in red boxes). By using a less stringent cut off (fold 
change < 0), all the genes that were significantly downregulated by both treatments were 
taken into account and analysed for transcriptional regulators using Ingenuity Pathway 
Analysis (IPA) software. In total 200 genes showed induction after IL-1 and decreased 
expression following siHDAC3 or Apicidin treatment and upstream transcriptional regulators 
analysis by IPA supports there is role for E2F-1 transcription factor (p-value =7.37 x 10-10) for 
the observed expression changes. The E2F-1 network with predicted transcription factors can 
be seen in Figure 4.13 E. The OA/cartilage related genes were identified as before and are 
presented in Table 4.6.  
These findings suggest a possible common mechanism regulating the IL-1 induced and 
siHDAC3/ Apicidin repressed genes and E2F-1 transcription factor may play a key role in this 
process. 
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IL-1 (for 1 hour) -
induced and 
repressed by 
Apicidin and 
siHDAC3 genes 
IL-1 (for 6 hours) -
induced and repressed by 
Apicidin and siHDAC3 (9 
out of 13 from Figure 
4.13 A) 
All significantly induced by IL-1 and repressed by 
Apicidin and siHDAC3 genes (36 out of 200 that were 
subjected to IPA) 
CSF2 CCL2 CCL2 IFIH1 LIF SERPINB2 
 CCL8 CCL8 IFIT1 LMNB1 SERPINE1 
 CSF2 CCNA2 IL11 MGLL TNFAIP6 
 IL11 CDK4 IL1B MMP1 TTK 
 IL1B CSF2 IL24 MMP12 TUBA1A 
 IL6 DIO2 IL6 MMP13 TUBB4B 
 MMP12 FAM46A IRF1 OLR1 XBP1 
 SERPINB2 FGF2 KLF6 RPL29 ZC3HAV1 
 TNFAIP6 HMGB2 KRT75 RRM2 SERPINB2 
Table 4.6. OA and cartilage related genes were identified following IL-1 stimulation and HDAC3 
inhibtion or gene depletion.
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Figure 4.13. Genes induced by IL-1α (0.5ng/ml) after 6 hours of stimulation and repressed by 
Apicidin (160nM) treatment or siHDAC3 (50nM) gene knockdown. 
A.   Venn diagrams of the genes induced by IL-1 after 6 hours and repressed by the siHDAC3 or by 
Apicidin (13). B. KEGG pathway analysis, C. TRANSFAC analysis and D. GO analysis of the 13 
repressed genes E. IPA upstream transcription regulator analysis of the genes induced by IL-1 and 
repressed by siHDAC3 or Apicidin (200 genes) identified E2F-1 as one of the potential transcription 
factors important for regulating expression of the repressed genes. 
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4.4 Discussion 
Several studies have used HDAC3- deficient cells to compare gene expression changes 
targeting a specific gene set in the heart (Montgomery et al. 2008), liver (Sun et al. 2013) or 
skeleton (Razidlo et al. 2010). More recent reports suggest that embryonic deletion of 
HDAC3 in type II collagen alpha 1 (Col2α1) expressing chondrocytes is lethal, while 
postnatal deletion impaired endochondral bone formation, delayed secondary ossification 
centre formation and altered maturation of the growth plate (Carpio et al. 2016). In the 
previous chapter, the effect of HDAC3 on IL-1 induced matrix metalloproteinases and IEG 
genes expression was determined by qRT- PCR. This chapter aimed to comprehensively 
analyse gene expression changes following HDAC3 gene depletion or inhibition in the 
SW1353 chondrosarcoma cell line. First, validation of the RNA used for microarray analysis 
was performed using qRT- PCR and the data obtained confirmed the results presented in 
Chapter 3, since both MMP1 and MMP13 followed identical expression patterns with 
significant induction by IL-1 and down-regulation following HDAC3 knockdown or 
inhibition. Validation of the expression changes of other genes including IL-6, IL-8 and FRA1 
using qRT- PCR was also performed and then our microarray data confirmed these expression 
changes.  
 
4.4.1 Genes and pathways induced by IL-1 stimulation. 
In total, 45 and 190 genes were up-regulated with a fold change ≥1.5, following IL-1 
stimulation for 1 hour or 6 hours in both the DMSO and siCON treatments respectively. The 
datasets obtained by the 1 and 6 hours induced gene lists indicated the different gene ontology 
enrichment, networks and transcription factor binding sites predicted (Figure 4.7 & Figure 
4.8). Using GO analysis, cellular physiological processes, transcription factor nuclear import 
and protein transport appeared to be negatively regulated in the 1 and 6 hour list. Dynamic 
expression changes of the up-regulated genes showed gene ontology enrichment for NF-κB 
signaling, in accordance with previous reports (Ohne et al. 2016). As expected upon IL-1 
stimulation an immune/ defense response is also predicted as well as a role in the cell cycle.  
With regards to the network analysis, apoptosis and Toll-like receptor (TLR) signaling 
pathways were among the common pathways predicted in both the 1 hour and the 6 hours IL-
1-induced genes list. Interestingly, the ability of IL-1β to induce apoptosis has been 
previously linked to nitric oxide generation (Dunger et al. 1996; Hoorens et al. 2001). 
However in human articular chondrocytes IL-1β has been shown to have an anti-apoptotic 
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activity, though NF-κB inhibition partially reversed the anti-apoptotic activity of IL-1, 
suggesting NF-κB may be part of the protective mechanism (Kuhn et al. 2000). Furthermore, 
TLRs can be classified into two subfamilies: the cell surface TLRs which recognize microbial 
cell membrane components and the intracellular TLRs which recognize nucleic acids from 
bacteria, viruses or self-nucleic acids in the case of auto-immunity. Toll- like receptors signals 
through the recruitment of specific ligands leading to the activation of NF-κB and MAPKs for 
the induction of inflammatory cytokine genes and IRFs which dictates innate immune 
responses. (Kawasaki & Kawai 2014) Cytokine-cytokine receptor interactions and JAK-
STAT signaling pathways were only predicted in the 6 hour gene list while focal adhesion 
appeared in the 1 hour list. 
In terms of the TRANSFAC analysis of the IL-1 induced genes, as expected NF-κΒ (p50/ 
p65) appear to be the main binding motifs together with AP-1 sites. NF-κB p50/ p65 can 
induce the expression of target genes including Interferon regulatory factor 1 (IRF1), heme 
oxygenase 1, nitric oxide synthase 2A (iNOS), coagulation factor III (F3), and 
proinflammatory cytokines such as TNF-α, IL-6 and IL-8 (Oeckinghaus & Ghosh 2009). 
Interestingly, AP-1 comes at the top of the list after only 1 hour of cytokine stimulation, 
confirming the immediate induction of these genes (Tullai et al. 2007). This is particularly 
interesting since MMP1 and MMP13 (and most other MMPs) gene promoters contain 
multiple AP-1 binding sites that may contribute to gene expression (Tullai et al. 2007; 
Vincenti & Brinckerhoff 2002) and a recent study has implied a role of ATF3 IEG on 
regulating MMP13 expression in HACs (Chan et al. 2017). 
 
4.4.2 Correlation of genes induced by IL-1 and repressed by HDACi. 
An identification of the induced and repressed by Apicidin genes with/ without IL-1 followed. 
At the basal level, 43 genes were repressed by Apicidin, while 52 genes were induced. Most 
of the repressed genes were associated with having a role in regulation of transcription and 
metabolism, organogenesis and mesoderm development and two pathways important for 
normal growth and development were predicted following KEGG pathway analysis. The 
TGF-β and Wnt signalling pathways. With reference to the 52 induced genes, these were 
associated with protein-nucleus import, negative regulation of cyclin dependent 
phosphorylation, negative regulation of transcription. KEGG pathway analysis identified 
methionine metabolism and Notch signalling pathway. Transcription factor binding sites 
predicted for the induced gene list included X-box binding protein RFX1, ATF3, PAX5 and 
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KROX transcription factors. Of particular interest here is ATF3 transcription factor, which 
was shown to be necessary for activating transcription of MMP13 in human articular 
chondrocytes. ATF3 expression is AP-1 (cFOS/cJUN) dependent and can bind to the AP-1 
binding motif of the proximal MMP13 promoter of cytokine-induced (IL-1 +OSM) 
chondrocytes at time points that no longer support cFOS binding, indicating its importance in 
regulating MMP13 expression (Chun et al. 2017). Also increased expression of ATF3 was 
found in synovial membranes from OA patients. (Zhang et al. 2016) Conditional deletion of 
Atf3 did not impair normal skeletogenesis or affect chondrogenesis, but alleviated the OA 
generated by surgically induced knee joint instability in mice. Moreover, IL-1 cytokine 
induction was found to induce expression of ATF3 through NF-κB pathway in Atf3- deleted 
mice and human chondrocytes. (Iezaki et al. 2016) 
In total, 121 genes were significantly induced after 1 hour and 290 after 6 hours of cytokine 
induction with around 50% of these genes being significantly down-regulated in each time-
point. Interestingly, MMP3 and MMP12 are present in the top 20 IL-1 induced and Apicidin 
repressed gene list (Figure 4.9). In accordance to these results, it has been previously reported 
that in SW1353 chondrosarcoma cells, the majority of metalloproteinase genes that were 
robustly induced by IL-1+ OSM combination, were then repressed by HDACi including: 
MMP1, MMP3, MMP7, MMP8, MMP10, MMP12, MMP13 and ADAMTS9 (Young et al. 
2005). MMPs were evolved from a single-domain protein which underwent successive rounds 
of duplication, gene fusion and exon shuffling events to generate the current functional 
diversity exhibited by MMPs and hence share the same regulatory elements. (Fanzul-
Fernadez et al. 2010) The most obvious shared motif among inducible MMPs is an AP-1 site 
in the proximal promoter (Rowan and Young, 2007). However, it is probable that the effect of 
HDACi is on signalling pathways induced by these pro-inflammatory cytokines rather than on 
the MMP gene promoters themselves. 
The molecular network analysis identified three pathways in common following 1 or 6 hours 
of IL-1 stimulation and these involved cytokine-cytokine receptor interaction, the JAK-STAT 
signaling pathway and cell apoptosis. These pathways were expected to be induced by 
cytokine stimulation and these results have been partly confirmed (Zhang et al. 2016). MAPK 
and Toll-like receptor signaling pathways appeared only in the 1 hour list, suggesting a role 
for these pathways and their downstream targets early after a cytokine induction.  
Of particular relevance, the ERK MAPK pathways have been extensively studied in terms of 
its relevance in regulating matrix metalloproteinase gene expression (Q. Zhang et al. 2008). 
Also, the involvement of the ERK1/2 MAPK signalling pathway was demonstrated in 
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regulating the hypertrophic changes of normal articular cartilage chondrocytes induced by 
osteoarthritic subchondral osteoblasts. It was shown that osteoarthritic subchondral 
osteoblasts inhibited p38 phosphorylation and induced ERK1/2 signal phosphorylation in 
cultured articular cartilage chondrocytes. The ERK1/2 pathway inhibitor PD98059 
significantly attenuated the hypertrophic changes induced by conditioned medium from 
osteoarthritic subchondral osteoblasts, while the p38 inhibitor SB203580 resulted in up-
regulation of hypertrophic genes in articular cartilage chondrocytes. (Prasadam et al. 2010) 
Wang et al. showed that ERK1/2 activation is involved in IL-1 mediated MMP3, MMP13, 
type II collagen and aggrecan expression in chondrocytes (Wang et al. 2011). Other studies 
reported that upregulation of ADAMTS4, ADAMTS5 and many MMPs (including MMP1, 
MMP3 and MMP13) in co-cultures of human articular chondrocytes with osteoarthritic 
subchondral bone osteoblasts correlated with activation of MAPK-ERK1/2 pathway. 
(Prasadam et al. 2012) Importantly, Barter et al. (Barter et al. 2010) showed that HDAC3 is 
required for activation of ERK and PI3K pathways by TGF-β and for subsequent gene target 
activation, such as Timp1 and Adam12, dependent on ERK signalling. In addition another 
HDACi, vorinostat was shown to inhibit IL-1 induced ERK1/2 and p38 activation and 
blocked MMP1 and MMP13 expression as well as IL-1 induced NF-κB nuclear translocation. 
(Zhong et al. 2013) 
Toll-like receptor ligands (TLR) have also been implicated in differentially regulating gene 
expression in chondrocytes. Ligands for TLR6/2 and TLR3 showed the greatest upregulation 
of MMP1 and MMP13 respectively, although all TLR ligands upregulated these MMPs. 
These inductions were dependent upon the NF-κB pathway, but were differentially inhibited 
by various MAPK inhibitors, with MMP13 induction most reliant on the extracellular signal-
regulated kinase pathway. (Zhang et al. 2008)  
Herein, the molecular functions of the Apicidin repressed genes were also analysed. Gene 
expression changes following HDAC3 inhibition resulted in a great diversity of biological 
functions to be affected including immune response and response to stimulus, cell-cell 
signalling, regulation of cell proliferation and negative regulation of cellular physiological 
processes. In accordance with these results, gene expression profiling was conducted to 
identify differential expressed genes in inflamed OA samples and up- and down-regulated 
genes were identified. Up-regulated genes were involved in inflammatory response, while 
down-regulated genes were involved in cell cycle. (Dong et al. 2015) 
With reference to the TRANSFAC analysis NF-κB binding sites appeared multiple times in 
the list of down-regulated by Apicidin genes, together with AP-1 sites. ICSBP was also 
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identified and this constitutes an important regulator of macrophages differentiation and 
function. IRF-8 together with IRF-1 are involved in the onset of an innate immune response 
and MMP9 promoter has been found to be responsive to exogenous IRF-8 expression. (Dror 
et al. 2007) Other transcription factors identified in the analysis include Ikaros 3 (IKZF1), 
Maz related factor, CP2, TAL1 and MRF2, yet none of these have been linked to directly 
binding or regulating matrix modifying enzymes. MTF1 transcription factor was also 
predicted and has been previously associated with zinc dependent-regulation of catabolic 
transcription in osteoarthritis (Kim et al. 2014). 
In this study, a previous microarray study performed by Dr Matt Barter at Newcastle 
University was taken into account. This array compared gene expression changes following 
HDAC inhibition using the TSA HDAC pan-inhibitor with/ without IL-1 stimulation.  
In the basal level (no IL-1), 231genes were induced only by TSA-mediated HDAC inhibition 
and 35 genes were induced only by Apicidin (Figure 4.10). Between the two treatments 13 
genes were induced by both TSA and Apicidin. These were associated significantly with three 
pathways, including methionine metabolism, aminoacyl-tRNA biosynthesis and selenoamino 
acid metabolism. Accordingly, the most significant GO terms identified were methionyl-
tRNA aminoacetylation, negative regulation of cyclin dependent protein kinase activity, 
odontogenesis, bone mineralization/ remodelling and ossification. TRANSFAC analysis 
indicated enrichment for Pax3, Nuclear factor Y-binding box, ELF1, SMAD4 and Ras-
responsive binding element transcription factors. 
Furthermore, 141 genes were repressed only by TSA and 27 genes only by Apicidin when no 
IL-1 stimulation was performed. Seven genes were decreased by both HDACi and these were 
also subjected to GO (Figure 4.10 C), TRANSFAC (Figure 4.10 D) and KEGG pathway 
analysis (Figure 4.10 E). Our hypothesis here was that the genes repressed by both TSA pan-
HDACi and the selective HDAC3i will be regulated by a common mechanism. GO analysis 
predicted B-cell differentiation and activation, lymphocyte differentiation/ activation, 
haemopoiesis, immune cell activation and cell growth, while Wnt signalling and focal 
adhesion pathways are predicted following KEGG analysis.  
Both of these pathways have been previously associated with osteoarthritis and rheumatoid 
arthritis. (Corr 2008; Shahrara et al. 2007; Prasadam et al. 2013; Luyten et al. 2009) Products 
of the Wnt- signalling pathway, Frizzled, secreted Frizzled related protein (sFRP), Dickkopf 
and LDL- receptor related protein gene families have been implicated in the development and 
maintenance of bone, cartilage and joints. In addition, increased levels of β-catenin have been 
found in degenerative cartilage, suggesting Wnt signalling might contribute to cartilage loss. 
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Polymorphisms in sFRP have been associated with an increased susceptibility to the 
development of OA and higher levels of the Wnt inhibitor Dickkopf-1 was linked to slowed 
progression of OA. (Corr 2008) Loughlin et al. also found that non-synonymous SNPs in the 
FRZB gene, a Wnt antagonist are associated with hip OA in females. (Loughlin et al. 2004) 
The association of FRZB with susceptibility for OA was confirmed in a number of other 
cohorts (Lane et al. 2006; Valdes et al. 2007) including a differential association between hip 
OA and osteoporosis (Lories et al. 2006). Deactivated focal adhesion kinase pathway was 
implicated in morphological abnormalities of cytoskeletal structure, focal adhesions, 
increased apoptosis, altered osteocyte specific gene expression and increased MMP2 and 
MMP9 expression of osteocytes cultured in normal or OA-derived ECMs. (Prasadam et al. 
2013) 
Comparison between the IL-1 induced and TSA or Apicidin treated samples identified 27 
genes were no longer induced in the presence of both HDACis and novel GO annotations 
were predicted including collagen catabolism (Figure 4.11). Indeed, the role of HDACs in 
regulating the expression of matrix degrading enzymes was indicated when using HDAC 
inhibitors including TSA and sodium butyrate. Both HDACi reduced cytokine-induced 
metalloproteinase expression at the mRNA and protein level, in the chondrosarcoma cell line 
SW1353 and also in primary human articular chondrocytes (HACs). In addition to that, in a 
bovine nasal cartilage (BNC) explants assay, the same compounds were shown to inhibit 
cytokine-induced cartilage degradation via the reduction of MMP expression (Young et al., 
2005). Moreover, the chondroprotective role of HDAC inhibitors is also supported in in vivo 
models of osteoarthritis (Culley et al., 2013; Chen et al., 2010). With the use of selective 
HDAC inhibitors, class I HDACs were implicated in the regulation of MMP expression, and 
RNAi studies introduced HDAC3 as a potentially key regulator of their expression (Culley et 
al., 2013). 
Moreover, the identification of the JAK-STAT signalling pathway in all the IL-1 induced and 
then HDACi and siHDAC3 repressed gene lists analysed here, was one of the main pathways 
predicted. While originally it was thought that STAT proteins only translocate to the nucleus 
upon JAK-mediated phosphorylation and dimerization following cytokine-mediated induction 
of JAK kinases, other studies have revealed that STATs can exist in the cytoplasm as stable 
non-phosphorylated dimers without cytokine stimulation (Mitchell & John 2005). However, 
upon cytokine induction, phosphorylated STATs translocate to the nucleus and together with 
other transcription factors regulate specific transcriptional programs. It has been proposed that 
for maximal transcription activation by STATs, chromatin remodelling by histone 
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acetylases/deacetylases is required. Although the role of HDAC3 is still not clear, cytokine 
induction of STAT1, STAT2 and STAT5 signalling requires chromatin recruitment of histone 
deacetylases and HDAC inhibition by TSA, SAHA or butyrate inhibits transcriptional 
activation by these STAT, IFN-γ induced JAK1 activation, STAT1 phosphorylation, its 
nuclear translocation and STAT1 dependent gene activation (Klampfer et al. 2004; Rascle et 
al. 2003). HDACs may also negatively regulate the duration and magnitude of STAT 
transcriptional activation by the recruitment to the STAT transcriptional complex via the 
nuclear co-repressor protein, SMRT, which directly associates with the coiled-coil domain of 
STAT5 (Nakajima et al. 2001). 
It has been also shown that HDAC1 is essential for the transcription of interferon-responsive 
genes, via association with STAT1 and STAT2 activators of transcription and antiviral 
response is inhibited in the absence of HDAC1 (Nusinzon & Horvath 2003). Gene silencing 
experiments of HDAC1, HDAC2 and HDAC3 decreased IFN-γ driven gene activation, while 
over-expression of each one of them enhanced STAT1-dependent transcriptional activity and 
downstream signalling (Klampfer et al. 2004). Therefore previous findings and our data imply 
a role for HDAC3 in mediating JAK-STAT signalling, although more experiments are needed 
to better clarify the role of each HDAC in JAK-STAT signalling pathway and downstream 
target gene transcription. 
Furthermore STAT3 was shown to be acetylated at a specific Lysine in the carboxyl-terminal, 
Lys685, and HDAC1 could reverse the p300-mediated STAT3 acetylation at this site. Yuan et 
al. demonstrated that acetylation at Lys685 is critical for STAT3 ability to form stable dimers 
required for cytokine induced-DNA binding and transcriptional regulation, to enhance 
transcription of cell-growth related genes and to promote cell cycle progression in response to 
treatment with oncostatin M. (Yuan et al. 2005) STAT3 can be modified by acetylation both 
in vitro and in vivo and HDACi results in increased STAT3 nuclear localization. (Wang et al. 
2005) 
Regarding the TRANSFAC analysis of the IL-1 induced and further HDACi repressed genes, 
an enrichment for interferon-related transcription factor binding sites such as IRF-8, IRF-1 
and ISRE as well as NF-κB and AP-1 were found. The use of HDACi have revealed an 
essential role for HDACs in the transcription of interferon- responsive genes, since such 
inhibitors have been shown to repress IFN- stimulated gene expression (Chang et al. 2004; 
Genin et al. 2003; Sakamoto et al. 2004).  In addition to these factors enrichment for E2F 
family factors and in particular for E2F-1 is also predicted, and this prediction becomes more 
dominant when comparing the genes repressed by both siHDAC3 and Apicidin. 
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4.4.3 Correlation of genes induced by IL-1 and repressed by the HDAC3 RNAi. 
To further define the molecular pathways and genes of HDAC3- mediated gene expression 
regulation, RNAi-mediated gene depletion was performed and gene expression changes were 
identified. Although only a small number of genes were induced by IL-1 at 1 hour and 
repressed by the siHDAC3, after 6 hours of stimulation approximately 12% of genes were no 
longer induced in the presence of the siHDAC3 when compared to the control siCON. Many 
of these genes are immune response-related genes: CCL2, IL-6, CXCL10, CXCL8, CSF2, IL-
11, CCL7, IFIT2, IFIT1 and IL-1β.  Interestingly, MMP12 is present in the top 20 repressed 
gene list, reinforcing the notion of an HDAC3-mediated mechanism of its gene expression. 
Based on the KEGG pathway analysis, cytokine-cytokine receptor interaction and JAK-STAT 
signalling pathway were predicted following analysis of the siHDAC3 down-regulated genes. 
Acetylation and deacetylation of the above signalling pathway components makes studying 
gene expression regulation a complex process. A typical example of this complexity can be 
given with many inducible MMP genes such as MMP1, MMP3, MMP7, MMP9, MMP10, 
MMP12 and MMP13 which contain promoter proximal AP1 sites that are key features of their 
inducibility. In order for c-Jun to activate gene transcription, it requires phosphorylation by 
the Jun-N-terminal kinase (JNK) at serines 63/73 and threonines 91/93. A model whereby c-
Jun phosphorylation mediates dissociation of an inhibitory complex containing HDAC3 has 
been proposed. Subsequent to this dissociation, c-Jun can then go on to activate target genes. 
This example made it clear that c-Jun can itself be the target of acetylation, which in turn may 
lead to altered transcription factor binding to MMP promoters. (Weiss et al. 2003) 
Accordingly, TRANSFAC analysis of the siHDAC3 down-regulated genes appeared to be 
enriched for ISRE and E2F-1 binding sites. Interestingly, previous reports support a role of 
the ISRE in immune-regulation by Toll-like receptors and other pattern recognition receptors 
(Honda & Taniguchi 2006). Also, repression of E2F-regulated promoters was shown to be 
mediated by the Retinoblastoma protein (Rb), which often recruits a histone deacetylase 
complex (often relying on HDAC1 and HDAC2) (Nicolas et al. 2001). 
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4.4.4 Comparison of genes induced by IL-1 and repressed by Apicidin and the HDAC3 
RNAi. 
Finally, a comparison of the induced by IL-1 and repressed by both the HDAC3 selective 
inhibitor Apicidin and the siRNA for HDAC3 was performed (Figure 4.13). Following 6 
hours of IL-1 stimulation, 13 previously IL-1 induced genes were identified as being 
significantly repressed by both treatments. TRANSFAC analysis predicts there are E2F-1 
binding motifs on these genes, suggesting that HDAC3-regulated gene expression is 
potentially mediated through E2F-1 transcription factor. Adding to this hypothesis, an 
analysis for transcription regulators of all the genes that were significantly down-regulated by 
both treatments was performed. In total 200 genes were subjected to IPA and E2F-1 regulator 
was predicted again with a p-value = 7.37 x 10-10. These results support that there is a 
common mechanism regulating the IL-1 induced and siHDAC3 or Apicidin repressed genes 
involving E2F-1 transcription factor. 
Brehm et al. (Brehm et al. 1998) and Magnaghi et al. (Magnaghi-Jaulin et al. 1998) were the 
first to establish that hypophosphorylated Rb binds to the cell cycle regulator E2F and either 
blocks activation of E2F target genes or actively represses transcription by recruitment of a 
histone deacetylase. Auwerx’s lab showed that Rb can directly interact with HDAC3 to 
suppress PPARγ (Peroxisome Proliferator-Activated Receptor γ) expression, a nuclear 
receptor pivotal for adipogenesis. Phosphorylation of Rb or inhibition of HDACs stimulated 
adipocyte differentiation. (Fajas et al. 2002) Moreover, histone deacetylase inhibition has 
been investigated on neuronal fate. Boutillier et al. (Boutillier et al. 2003) showed that 
HDACi TSA induces apoptosis in neurones, partly by activating the pro-apoptotic factor E2F-
1. In the same paper, histone acetylation of the E2F-1 promoter was investigated, but this 
modification was neither required, nor by itself sufficient, to induce transcription. Activation 
of transcription might thus occur through acetylation of non-histone proteins binding E2F-1 
regulatory element. Nonetheless, others have shown that E2F-1 transcription factor can be 
acetylated at Lys117, Lys120 and Lys125, as well as deacetylated by the Rb-associated HDACs. 
Acetylation of E2F-1 occurs when it is not bound by Rb. In this Rb-free state acetylated E2F-
1 may have three functional consequences: increased DNA binding activity, transactivation 
potential and protein half-life. It is also possible that acetylated E2F-1 can recognize a subset 
of promoters distinct from those normally bound by the repressor E2F-1- Rb complex. 
(Balbas et al. 2000) 
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A typical example whereby gene transcription is regulated in a complex fashion by a HDAC-
Rb-E2F dependent pathway is given by Kimura et al. (Kimura et al. 2003). Herein, they 
showed that DNMT1 (DNA Methyltransferase 1) promoter activity was decreased by 
expression of E2F-1 and Rb and this suppression was reversed in the presence of TSA. 
Another example is reported by Zhang et al. (Zhang et al. 2003), who showed that EBP1-
mediated transcriptional repression depends on the presence of an E2F-1 consensus motif to 
the target core promoter and recruitment of HDAC activity, probably HDAC2. In vitro an 
EBP1 mutant lacking the HDAC binding domain in the C-terminal region failed to inhibit 
transcription. Most importantly, Johnson et al. (Johnson et al. 2012) suggest E2F transcription 
factors may play a role in promoting metastasis via regulating matrix metalloproteinase 
expression and targeting the Rb- E2F pathway is a promising approach for treating metastatic 
disease. 
These reports in conjunction with our microarray data support a novel mechanism by which 
HDAC3 may co-operate with E2F-1 transcription factor to regulate specific gene expression 
programmes in chondrocytes. The possible relationship between HDAC3 and E2F-1 was 
further investigated and the results are presented in the next chapter.  
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4.5 Conclusions 
 In total, 45 and 190 genes were induced following IL-1 stimulation for 1 hour or 6 
hours in the control samples. Various GO terms and KEGG pathways were predicted, 
but most importantly the up-regulated genes were enriched for NF-κB and AP-1 
binding sites, as would be anticipated. 
 At the basal level (no IL-1), the genes repressed by both TSA and Apicidin were 
related to B-cell differentiation and activation, lymphocyte differentiation/ activation, 
haemopoiesis, immune cell activation and cell growth, while Wnt and focal adhesion 
signalling pathways are predicted following KEGG analysis, both of which have been 
previously associated with osteoarthritis. 
 13 genes were induced by both TSA and Apicidin treatments (no IL-1).  
 Following IL-1 stimulation and HDACi, using either TSA or Apicidin, 27 genes were 
no longer induced. These were related to immune response and collagen catabolism. 
Network analysis also predicted cytokine-cytokine receptor interaction, apoptosis, 
Toll-like receptor signalling pathway and JAK-STAT signalling pathway were 
affected.  
 All the genes repressed by siHDAC3 with/without IL-1 stimulation were enriched for 
E2F-1 transcription factor binding sites. 
 Comparison of the IL-1 induced and siHDAC3 or Apicidin repressed genes are 
enriched for E2F-1 transcription factor, implying a role for this regulator on HDAC3-
mediated gene regulation in chondrocytes. 
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Chapter 5. Regulation of MMP1 and MMP13 expression by HDAC3 
involves the E2F-1 transcription factor. 
 
5.1 Introduction 
The retinoblastoma tumour suppressor protein, Rb, together with the E2F transcription factors 
are the main regulators of the mammalian cell cycle (Chen et al. 2009). Rb physically 
interacts with E2Fs 1-3 to repress their transcriptional activity, via binding to the activation 
domain and inhibiting nearby enhancer elements (Magnaghi-Jaulin et al. 1998; Brehm et al. 
1998). Transcriptional repression by Rb is mediated partly through the recruitment of histone 
deacetylases and the Rb-associated histone deacetylase complex contains the RbAp48 protein, 
which directly interacts with HDAC1 and HDAC2 (Nicolas et al. 2001). However, Rb is 
inactivated in the G1 phase of the cell cycle leading to its dissociation from E2Fs 1-3. Hence, 
E2Fs 1-3 binding to DNA facilitates the expression of various genes that are necessary for 
DNA synthesis and cell cycle progression, including cyclin E, dihydrofolate reductase and 
DNA polymerase α. Not surprisingly mutations of the Rb-E2F pathway have been identified 
in human cancers, such as small cell lung carcinoma and osteosarcoma, indicating a major 
role for this pathway in cell cycle progression and oncogenesis. (Classon & Harlow 2002) 
E2Fs are also important for proper execution of development, differentiation, apoptosis and 
DNA damage repair programmes (Attwooll et al. 2004; Singh et al. 2010). Interestingly, the 
different E2F family members show overlapping functions especially in the control of cell 
cycle progression, but also unique functions during development, tissue homeostasis and 
tumour formation. Earlier studies had shown that all 23 human MMP genes have potential 
E2F binding sites in their promoters and some, such as MMP9, MMP14 and MMP15 have 
multiple E2F binding sites and are regulated by the Rb-E2F pathway. In addition, ChIP assays 
and RNAi experiments supported that E2F-1 can associate with MMP9, MMP14 and MMP15 
promoters and the genes are E2F responsive. (Johnson et al. 2012) 
Moreover, gene expression arrays suggest that E2F-1 may also regulate cellular functions in 
addition to cell cycle, such as pathways involved in apoptosis, signal transduction, 
transcriptional control and membrane biology. Most surprisingly, E2F-1 expression repressed 
a number of genes, including MMP5, MMP14 and ADAMTS1, suggesting that E2F-1 may 
have the potential to repress transcription (Ma et al. 2002). E2F-1 importance in regulating 
MMP expression has been also shown in a small cell lung cancer (SCLC) metastasis study of 
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a Chinese Han population. Knockdown of E2F-1 reduced MMP9 and MMP16 expression, 
which resulted in the down-regulation of migration and invasion in SCLC. Further study 
demonstrated that E2F-1 transcriptionally controlled the expression of other transcription 
factors such as Sp1 and p65, which in turn enhanced MMP9 promoter activity. (Li et al. 2014) 
Gene expression array data presented in the previous chapter revealed genes induced by IL-1 
and repressed by HDAC3 inhibition or RNAi are enriched for E2F-1 transcription factor 
binding sites, implying a role for this transcription factor in mediating HDAC3 gene 
expression regulation. Herein, the relationship between HDAC3 and E2F-1 was further 
investigated and the effect on MMP1 and MMP13 expression and cell cycle progression 
determined.  
 
5.2 Aims 
 To investigate a possible interaction between HDAC3 and E2F-1 transcription factor. 
 To determine the mechanism by which E2F-1 and by interaction with HDAC3 
controls MMP1 and MMP13 expression in chondrocytes. 
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5.3 Results 
 
5.3.1 MMP1 and MMP13 promoters have E2F-1 binding sites. 
Microarray studies have suggested that MMP genes may be E2F responsive (Ma et al. 2002; 
Stanelle et al. 2002) and the data obtained from our gene expression array showed enrichment 
for the E2F-1 regulator on genes repressed by the siHDAC3 or Apicidin following IL-1 
induction. To examine the possibility of MMP1 and MMP13 being regulated by E2F-1, the 
promoter region 2Kb upstream of the transcription start site (TSS) of both MMPs was 
analysed using PROMO (Messeguer et al. 2002; Farre et al. 2003). Putative E2F-1 binding 
sites were observed in both MMP1 and MMP13 gene promoters as shown in Table 5.1. 
MMP1 has three and MMP13 has five E2F-1 putative binding sites, upstream of the TSS 
within the 2Kb region, or downstream of the TSS within 600bp. Because MMP1 and MMP13 
are the major collagenases in cartilage and one of the main aims of this study is to identify 
how HDAC3 regulates gene expression of these and other genes in cartilage, the relation 
between HDAC3/E2F-1 and the effect on MMP gene expression regulation were further 
studied. 
 
Table 5.1. PROMO analysis of E2F-1 putative binding sites on MMP1 and MMP13 promoters 
 (-2Kb upstream of the Transcription Start Site (TSS) to 600bp downstream of the TSS). 
Promoter Number of E2F-1 binding sites E2F-1 Binding sites relative to TSS Sequence 
MMP1 3 
-1666 to -1659 
-869 to -862 
-751 to -744 
TCTGCCGC 
TACTCCGC 
GCGGCACA 
MMP13 5 
-539 to -532 
-8 to -1 
176 to 183 
277 to 284 
407 to 414 
GCGGTTGT 
GCGGAAAG 
GCGGTTGG 
GCGGGAAT 
GCGGGGTT 
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5.3.2 In silico analysis predicts a direct protein-protein interaction between HDAC3 and 
E2F-1. 
Based on the predictions that E2F-1 can bind to the MMP promoters, a possible association 
between E2F-1 and HDAC3 was examined using STRING, a protein-protein interaction tool 
(Franceschini et al. 2013). A novel interaction between HDAC3, E2F-1 and its coactivator 
DP1 is predicted and the Retinoblastoma protein 1 (Rb1) takes part in this predicted complex 
(p-value= 1.41 x 10-5) (Figure 5.1). Using STRING, an extended view of the predicted 
network could be viewed with novel association molecules, which were predicted to be part of 
the HDAC3/ E2F-1/DP1/Rb network (Figure 5.1 B). STRING also predicts gene ontology, 
molecular functions and biological processes, and KEGG pathways for the protein association 
network and among the most significant biological processes predicted were negative 
regulation of transcription involved in G1/S transition of mitotic cell cycle, regulation of 
cellular protein localisation and negative regulation of fat cell proliferation. Transcription 
factor binding is the main molecular function associated with the predicted association 
network and cell cycle regulation as well as many cancer-related pathways arose from the 
KEGG pathway analysis. The complete list accompanied by the p-values can be found in 
Table 5.2.   
 
 
 
Figure 5.1. A. STRING analysis predicts a novel protein- protein interaction between HDAC3 and 
E2F-1/DP1 transcription factors which is possibly mediated through the Rb1 protein. B. Extended 
view of the predicted network shown in A predicts novel association molecules of the 
HDAC3/Rb/E2F-1/DP1 network. Stronger predicted associations are represented by thicker blue lines. 
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Biological process p-value 
negative regulation of transcription involved in G1/S transition of mitotic cell cycle 0.0011 
regulation of cellular protein localization 0.0019 
negative regulation of fat cell proliferation 0.0019 
Notch signaling pathway 0.0028 
G1/S transition of mitotic cell cycle 0.0043 
positive regulation of transcription from RNA polymerase II promoter 0.0063 
cell cycle process 0.0066 
positive regulation of protein insertion into mitochondrial membrane involved in 
apoptotic signaling pathway 
0.0085 
epithelial cell apoptotic process 0.0085 
cell cycle 0.0095 
Molecular function p-value 
transcription factor binding 0.0005 
KEGG pathway p-value 
Cell cycle 0.0002 
Bladder cancer 0.0027 
Pancreatic cancer 0.0027 
Glioma 0.0027 
Melanoma 0.0027 
Chronic myeloid leukemia 0.0027 
Non-small cell lung cancer 0.0027 
Prostate cancer 0.0032 
Small cell lung cancer 0.0032 
Hepatitis B 0.0078 
Table 5.2. Functional analysis of the predicted by STRING association network between 
HDAC3/ E2F-1/DP1 and Rb.  
Gene ontologies involved two categories (Biological processes and molecular function) and KEGG 
pathway analysis was also performed. 
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5.3.3 In vitro co- immunoprecipitation analysis predicts a direct interaction between 
HDAC3 and E2F-1. 
Given the STRING data prediction, co-Immunoprecipitation (co-IP) experiments were 
conducted in HEK293T cells to assess whether HDAC3 associates with E2F-1 and DP1 
transcription factors in vitro (as described in section 2.2.9). Over-expression of E2F-1 (Figure 
5.2) was necessary, since endogenous levels could not be detected by immunoblotting. 
Endogenous IP’s are often difficult with low expressed proteins such as transcription factors. 
Over-expression of the factors overcame this issue allowing for the addition of immunogenic 
tags for easier/better IP. After expressing each tagged protein, immunoprecipitation (IP) for 
FLAG (the tag of HDAC3 vector) was performed. The levels of the endogenous (lane 1) and 
over-expressed HDAC3, E2F-1 (lane 2) and HA tags (red arrows in lane 2- representing E2F-
1 and DP1) were detected after immunoblotting (Figure 5.3). HDAC3 protein was 
immunoprecipitated as anticipated (lane 6, Figure 5.3 A). Immunoblotting for E2F-1 
transcription factor confirmed its co- immunoprecipitated (lane 6) (Figure 5.3 A), supporting 
a direct interaction between HDAC3 and E2F-1. Similarly, the HA tag present on both DP1 
and the E2F-1 were also detected in the FLAG co-immunoprecipitates (red square and arrows 
in lane 6), but not in the pcDNA3.1 control (compare lanes 5 versus 6 in Figure 5.3 A). There 
was no HDAC3, E2F-1 or HA present on the irrelevant IgG immunoprecipitates (lanes 3 and 
4), which acted as the negative control, further establishing the specificity of this assay. 
Immunoprecipitation for HA (tag of E2F-1 and DP1 vectors) was also performed and 
confirmed the association between HDAC3 and E2F-1/DP1 as shown in Figure 5.3 B (lane 
6).  
 
 
Figure 5.2. Expression of HA-E2F1 in HEK293 cells. 
HEK293 cells were transfected with HA-E2F-1 (2µg). At 24 hours post-transfection cells were lysed, 
total proteins were extracted, and immunoblotting was performed with an anti-E2F-1 and an anti-HA 
antibodies. β-catenin served as a loading control. Molecular weights (MW) (kDa) are indicated. 
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Figure 5.3. Co-Immunoprecipitation experiments suggest there is a direct association between 
HDAC3 and E2F-1. 
A. HEK293 cells were transfected with FLAG-HDAC3 (2µg), HA-E2F-1 (2µg), and HA-DP1 (2µg) 
or pcDNA3.1 (6µg). At 24 hours post-transfection cells were lysed. Total proteins were extracted, 
pre-cleared, immunoprecipitated for FLAG or an irrelevant IgG antibody, resolved by SDS-
PAGE and immunoblotted with an anti-HDAC3, an anti-E2F-1 and an anti-HA antibodies. 
Representative blots out of three independent experiments are shown. B. A reciprocal experiment 
was performed and IP for HA or an irrelevant IgG antibody was performed this time. 
Immunoblotting followed with an anti-HDAC3 and an anti-E2F-1 antibody. 
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5.3.4 The effect of E2F-1 RNAi on IL-1 induced gene expression. 
Since MMP1 and MMP13 have putative E2F-1 binding sites in their promoters [see Table 5.1 
and (Johnson et al. 2012)], their expression was further studied following E2F-1 gene 
depletion. 
 
5.3.4.1 The effect of RNAi on E2F-1 mRNA and protein levels. 
The gene expression array data (Chapter 4) support that the IL-1 induced and repressed 
(siHDAC3 or Apicidin) genes are enriched for E2F-1 transcription factor binding sites. 
STRING analysis and co-IP experiments also showed that HDAC3 and E2F-1 can directly 
associate in vitro, predicting a novel interaction network between the two molecules. The 
optimal transfection procedure and duration of siRNA incubation is described in section 2.2.6. 
Transfection of SW1353 cells with 50nM of siRNA targeting E2F-1 was used and depletion 
efficiency was determined using quantitative real-time RT-PCR and immunoblotting. As 
shown in Figure 5.4, E2F-1 expression was significantly reduced at the mRNA (Figure 5.4 
A) and protein levels (Figure 5.4 B). E2F-1 expression was very low in the SW1353 cells and 
although mRNA levels were detected with real-time PCR, endogenous protein levels could 
not be detected with immunoblotting; therefore over-expression of the protein and then RNAi 
confirmed the efficacy of the siRNA used in this study to silence E2F-1 gene expression 
(Figure 5.4 B). 
 
5.3.4.2 The effect of E2F-1 RNAi on the induction of MMP, IL-6 and IL-8 gene 
expression by IL-1. 
siE2F-1 significantly increased the induction by IL-1 of MMP1 and MMP13 genes (Figure 5.5 
A and 5.5 B respectively), yet had no effect on IL-6 (Figure 5.5 C) and IL-8 (Figure 5.5 D) 
expression. These results suggest the two major collagenases in cartilage, MMP1 and MMP13 
may in fact be E2F-1 regulated. Nonetheless, RNAi-mediated depletion of E2F-1 did not alter 
MMP13, MMP1, IL-6 and IL-8 basal gene expression.  
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Figure 5.4. Gene silencing of E2F-1 expression using an E2F-1-specific siRNA 
A. SW1353 cells were transfected with 50nM of a non-targeting siRNA control pool (siCON) or 
an E2F-1-specific siRNA pool (siE2F-1) for 24h. The following day, the cells were serum starved for 
16h and then stimulated with IL-1α (0.5ng/ml) for 6 hours or left unstimulated. Total RNA was 
extracted, reverse transcribed to cDNA and E2F-1 expression measured by qRT-PCR. Results are 
shown relative to 18S ribosomal RNA expression. Significance was determined with respect to siCON 
treated cells in comparison to the siE2F-1 treated cells, both in the basal and IL-1 induced level. 
Figure shows two biological experiments and bars represent the mean of eight technical repeats +SD. 
For statistical analysis, one-way ANOVA with a Bonferroni multiple comparison test was performed. 
B. SW1353 cells were transfected with HA-E2F-1 (2µg) before a 24 hour siRNA (50nM) transfection 
was performed. Cell lysate was harvested the next day and protein levels quantified by SDS-PAGE 
and immunoblotting for an anti-E2F-1 antibody. β-catenin served as a loading control. ** p<0.01 
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Figure 5.5. Gene expression regulation of MMP1, MMP13,  IL-6 and IL-8 following E2F-1 gene 
silencing.  
SW1353 cells were transfected with 50nM of a non-targeting siRNA control (siCON) or an E2F-1-
specific siRNA (siE2F-1) for 24h. Following an overnight serum starvation, the cells were stimulated 
for 6 hours with IL-1α (0.5ng/ml). Total RNA was extracted, reverse transcribed to cDNA and MMP1 
(A), MMP13 (B), IL-6 (C) and IL-8 (D) expression measured by qRT- PCR. Results are shown 
relative to 18S ribosomal RNA expression. Significance was determined by comparing the siCON 
with the siE2F-1 treated cells, both in the basal and IL-1 induced level. Figure shows two biological 
experiment and bars represent the mean of eight technical repeats +SD. For statistical analysis, one-
way ANOVA with a Bonferroni’s multiple comparison test was performed. * p<0.05, ** p<0.01, *** 
p<0.001 
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5.3.4.3 The effect of E2F-1 RNAi on the induction of genes identified in the 
microarray analysis. 
So far, our results support a role for HDAC3 and E2F-1 on regulating gene expression in the 
SW1353 chondrosarcoma cells. A novel protein-protein interaction was also determined 
between E2F-1/HDAC3 and direct binding sites for E2F-1 transcription factor were predicted 
on both MMP promoters. Four other genes (out of the 13 showed in Figure 4.11 A), that had 
similar gene expression patterns with MMP1 and MMP13, were identified in the gene 
expression array and further analysed. These genes included: the WNT7B, CCL2, SERPINB2 
and TNFIP6. E2F-1 binding sites were also predicted to be present in their promoters (data 
not shown), and HDAC3 expression was also quantified following E2F-1 depletion. All the 
genes analysed here (Figure 5.6), except for HDAC3, were significantly induced following 
IL-1 cytokine stimulation and a further significant increase was found only for SERPINB2 
(Figure 5.6 C) in the siE2F-1 treated samples when compared to the siCON samples. A trend 
towards increased expression was found for WNT7B (Figure 5.6 A), CCL2 (Figure 5.6 B) and 
TNFAIP6 (Figure 5.6 D), but these findings were not statistically significant. HDAC3 
expression (Figure 5.6 E) was not altered with or without IL-1 and/or in the presence of the 
siE2F-1. Interestingly, our microarray data showed that E2F-1 expression also remained 
stable following HDAC3 depletion and cytokine stimulation. These results indicate that E2F-1 
and/or HDAC3 expression do not change when either is depleted, and therefore HDAC3 
might impact upon E2F-1 binding affinity, cellular localisation or transactivation activity, 
which in turn may alter specific gene expression programmes in cartilage. 
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Figure 5.6. Gene expression regulation following E2F-1 gene silencing.  
SW1353 cells were transfected with 50nM of a non-targeting siRNA control (siCON) or an E2F-1-
specific siRNA pool (siE2F-1) for 24h. Following an overnight serum starvation, the cells were 
stimulated for 6 hours with IL-1α (0.5ng/ml). Total RNA was extracted, reverse transcribed to cDNA 
and WNT7B (A), CCL2 (B), SERPINB2 (C), TNFAIP6 (D) and HDAC3 (E) expression measured by 
qRT- PCR. Results are shown relative to 18S ribosomal RNA expression. Significance was 
determined by comparing the siCON with the siE2F-1 treated cells, both in the basal and IL-1 induced 
level. Figure shows two biological experiment and bars represent the mean of eight technical repeats 
+SD. For statistical analysis, one-way ANOVA with a Bonferroni’s multiple comparison test was 
performed. * p<0.05, ** p<0.01, *** p<0.001 
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5.3.5. MMP promoters are responsive to E2F-1 expression and HDAC inhibition or RNAi. 
 
5.3.5.1 The effect of E2F-1 over-expression on CDC6, MMP1 and MMP13 
promoter activity. 
Previous studies had demonstrated that MMP promoters including MMP9, MMP14, MMP15 
and MMP16 are regulated by E2F family members such as E2Fs 1-3 and E2F-4, suggesting 
the MMPs may be a new class of E2F target genes. (Johnson et al. 2012; Li et al. 2014) Since 
E2F-1 putative binding sites were predicted on MMP1 and MMP13 promoters (Table 5.1), 
we next wanted to assess whether E2F-1 can regulate their promoters via luciferase reporter 
activation, using vectors containing part of the proximal promoters of each MMP, as 
previously described in section 2.2.8 Luciferase reporter assays. SW1353 cells were transiently 
transfected with luciferase constructs with or without over-expression of HA- E2F-1 and its 
heterodimer HA- DP1 (Figure 5.7). Initially, the effect on an E2F-1- responsive promoter, 
namely CDC6 reporter was examined. E2F-1 and DP1 over-expression activated the CDC6 
luciferase reporter (Figure 5.7 A), confirming previous reports (Ingram et al. 2011). On the 
other hand, over-expressing E2F-1 reduced the activation of all the MMP reporter vectors 
analysed here (Figure 5.7 B), suggesting that (overexpressed) E2F-1 binding to MMP1 and 
MMP13 promoters might suppress their transcriptional activation. Since E2F-1 decreased 
luciferase activation of both MMP13 constructs, only the 3.2 kb reporter, which contains the 
1.6 kb (from the TSS) proximal promoter region plus an (1.5 kb) enhancer element (inserted 
immediately 5’ to the promoter) was used in subsequent experiments. 
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Figure 5.7. CDC6, MMP1, MMP13 luciferase reporter activity following E2F-1/DP1 over-
expression. 
SW1353 cells were transfected with the indicated expression vectors (HA-E2F-1= 50ng, HA-DP1= 
50ng) or an empty vector pcDNA3.1 (100ng) together with 1.5ng of Renilla reporter and the effect on 
(A) CDC6 (25ng) and (B) MMP1 (25ng), 1.6 kb (fromTSS) MMP13 (25ng), 3.2 kb (1.6 kb form TSS 
plus 1.5 kb enhancer) MMP13 (25ng) luciferase expression was measured. The luciferase activity was 
quantified using the Dual-Glo® Luciferase Assay system (Promega) and normalised to Renilla on a 
GloMax®- Multi Luminescene Module (Promega). Assays were performed once, containing six 
repeats per treatment per biological repeat. Bars show the average +SD of six samples. For statistical 
analysis an unpaired two-tailed student’s t-test was performed. RLU: Relative Light Unit, * p<0.05, ** 
p<0.01, *** p<0.001 
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5.3.5.2 The effect of E2F-1 over-expression and HDAC inhibition or HDAC3 gene 
depletion on CDC6, MMP1 and MMP13 promoter activity. 
Next, the effect of HDAC inhibition, using the TSA HDAC pan-inhibitor and E2F-1/ DP1 
over-expression was determined on the same luciferase reporters as previously (section 
5.3.5.1 The effect of E2F-1 over-expression on CDC6, MMP1 and MMP13 promoter 
activity.). HDAC inhibition, using TSA, decreased the activation of the CDC6 reporter, even 
though E2F-1 and DP1 were over-expressed (Figure 5.8 A), but was still higher than the 
basal level. Activation of MMP1 and 3.2Kb MMP13 luciferase reporters was decreased 
following E2F-1/ DP1 exogenous expression and TSA treatment (Figure 5.8 B), suggesting 
there might be a direct interaction between E2F-1 and some HDACs on the promoters of both 
collagenases. Histone H4 de-acetylation of lysines 5 and 12 for instance has been linked to 
gene expression regulation by HDAC-1, which is stably bound to classical E2F target 
promoters during the G0 and G1 phase of the cell cycle. (Ferreira et al. 2001)  
The MMP13 luciferase reporter activation was also decreased following Apicidin treatment 
and E2F-1/DP1 expression, as shown in Figure 5.9 A.  MMP1 reporter presented a small but 
not significant decrease following HDAC3 inhibition with Apicidin (Figure 5.9 A). Also 
RNAi-mediated HDAC3 depletion significantly reduced MMP1 and MMP13 reporter 
activation (Figure 5.9 B). These results introduce a novel mechanism by which MMP1 and 
MMP13 promoters may be regulated by a direct interaction/ binding of HDAC3 and E2F-1 
transcription factor. 
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Figure 5.8. CDC6, MMP1 and MMP13 luciferase reporter activity following E2F-1/DP1 over-
expression and HDAC inhibition using TSA. 
SW1353 cells were transfected with the indicated expression vectors (HA-E2F-1= 50ng, HA-DP1= 
50ng) or an empty vector pcDNA3.1 (100ng) together with 1.5ng of Renilla reporter. The following 
day the cells were incubated with 330nM TSA for 6.5 hours and the effect on (A) CDC6 (25ng), (B) 
MMP1 (25ng) and MMP13 (25ng) luciferase expression was measured. The luciferase activity was 
quantified using the Dual-Glo® Luciferase Assay system (Promega) and normalised to Renilla on a 
GloMax®- Multi Luminescene Module (Promega). Assays were performed once, containing six 
repeats per treatment per biological repeat. Bars show the average +SD of six samples. For statistical 
analysis an unpaired two-tailed student’s t-test was performed. RLU: Relative Light Unit, * p<0.05, ** 
p<0.01, *** p<0.001 
 
 
Figure 5.9. MMP1 and MMP13 luciferase reporter activity following E2F-1/DP1 over-expression 
and HDAC3 inhibition/ depletion by Apicidin or RNAi. 
SW1353 cells were transfected with the indicated expression vectors (HA-E2F-1= 50ng, HA-DP1= 
50ng) or an empty vector pcDNA3.1 (100ng) together with 1.5ng of Renilla reporter. The following 
day the cells were incubated with 160nM Apicidin in (A) or 50nM siRNA targeting HDAC3 in (B) 
and the effect on MMP1 (25ng) and MMP13 (25ng) luciferase expression was measured. The 
luciferase activity was quantified using the Dual-Glo® Luciferase Assay system (Promega) and 
normalised to Renilla on a GloMax®- Multi Luminescene Module (Promega). Assays were performed 
once, containing six repeats per treatment per biological repeat. Bars show the average +SD of six 
samples. For statistical analysis an unpaired two-tailed student’s t-test was performed. RLU: Relative 
Light Unit, * p<0.05, *** p<0.001 
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5.3.6 E2F-1 and HDAC3 are necessary for normal cell cycle progression. 
To understand the relationship between E2F-1 and HDAC3 in the cell cycle control, SW1353 
cells were synchronised in the G0/ G1 phase by a 24- hour serum starvation and HDAC3 
and/or E2F-1 were depleted by RNAi. The cells were then released to re-enter into the cell 
cycle (by stimulation with growth media containing 10% FBS). To test whether HDAC3 has a 
cell cycle related function, flow cytometry was used to determine whether HDAC3 depletion 
can impair cell cycle progression. The cell cycle phase distribution was then analysed (Figure 
5.10). As expected, E2F-1 depletion led to a significant increase in the proportion of cells by 
12.6% in the G1 phase when compared to the control treated cells. This increase was most 
likely due to the lack of the E2F-1 transcriptional induction of its G1– S transition target 
genes. As a consequence, the number of cells in the S and G2/M phase decreased by 4.8% and 
by 7.3% respectively. Interestingly, HDAC3 depletion also significantly increased the number 
of cells in the G1 phase by 15.7% in comparison to the control. An increase of 3.1% of the 
proportion of cells in the G1 phase of the HDAC3 depleted cells in comparison to the E2F-1 
depleted cells was also observed, though this increase was not statistically significant. 
Consequently, the percentage of cells in the S phase was reduced by 8.3%, as was the 
percentage of cells in the G2/M phase by 8.6%. The effect of HDAC3 and E2F-1 double 
depletion on cell cycle phase distribution was also analysed. No additive effect was observed 
following double gene depletion. The proportion of G1 cells increased by 14.4%, leading to a 
decrease in cells in the S phase by 7.6% and in the G2/M phase by 7.3% compared to control 
cells. The FACs gating data from one experiment can be found in Appendix C. 
These results revealed that HDAC3 is necessary for normal cell cycle progression at the G1- S 
transition phase. As no cumulative effect was found when using both HDAC3 and E2F-1 
siRNAs, it suggests HDAC3 could positively control the cell cycle through the E2F-1 
regulatory pathway. 
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Figure 5.10. HDAC3 depletion induces cell accumulation in G1 phase. 
SW1353 cells were synchronised by a 24-hour serum starvation, released and collected. Endogenous 
HDAC3, E2F-1 or both were depleted and cell cycle analysis was performed using FlowJo. Assays 
were performed twice, containing four replicates per treatment per biological repeat. Bars show the 
average +SD of eight samples. For statistical analysis an unpaired two-tailed student’s t-test for each 
cell cycle phase was performed. ** p<0.01, * p<0.05 
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5.3.7 HDAC3 recruitment of E2F-1 to MMP promoters. 
Given the above results, a speculation on whether HDAC3 could act directly or indirectly on 
E2F-1 DNA binding ability in association with the chromatin within the E2F-1 binding region 
was tested. To answer this question, chromatin immunoprecipitation (ChIP) assays and real-
time PCR were performed on SW1353 cells. Primers were designed based on the PROMO 
predicted E2F-1 binding sites (Table 5.1) and are depicted as arrows in Figure 5.11 A. An 
extra primer set (P6M13), which has been previously used in the literature (Bui et al. 2012) 
and amplifies a 198bp genomic region around the Transcription Start Site (TSS) of MMP13 
was also utilised in this experiment. Sonication times were optimised for the SW1353 cell line 
(as described in section 2.2.19) and 12 cycles were chosen as the optimum time (Figure 5.11 
B). The sonicated samples were then de- cross-linked, DNA was extracted and all the primer 
assays tested with PCR to confirm correct size amplification as shown in Figure 5.11 C. All 
primer sets gave the correct size amplicons, while HBB (human haemoglobin) served as a 
positive control. 
ChIP assays were conducted on asynchronously dividing SW1353 cells to assess whether 
HDAC3 and E2F-1 can directly associate with the MMP1 and MMP13 promoters. The cells 
were transfected with the HA-E2F-1/ HA-DP1 and FLAG-HDAC3 vectors and stimulated for 
6 hours with IL-1α. Unstimulated cells were also used for comparison. ChIP was performed 
using an E2F-1 or HDAC3 antibody. 10% input of the sonicated chromatin was used in each 
ChIP assay for normalization of the adjusted Ct values obtained from the qRT- PCR. CDC2 
and p21 genes were the positive controls for E2F-1 and HDAC3 respectively and were 
provided with the ChIP kits (see section 2.1.10). However, no significant enrichment of either 
CDC2 or p21 promoters could be detected following IP for E2F-1 and HDAC3 with or 
without IL-1 stimulation (Figure 5.12). Hence the representative results (obtained using the 
indicative primer sets) presented in Figure 5.13 should be viewed with caution. Non-specific 
binding to the irrelevant IgG antibodies was detected, generating doubtful results. Also the 
small fold enrichment found for CDC2 (+ IL-1) (Figure 5.12 B) and p21 (± IL-1) (Figure 
5.12 C-D) is not in accordance with the fold enrichment suggested by the company, where 
86.80 increase was reported for CDC2 and 14.45 increase for p21. 
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Figure 5.11. MMP promoters are responsive to E2F-1 transcription factor. 
A. Schematic representation of MMP1 and MMP13 promoters showing potential E2F-1 binding 
sites as black circle symbols. The arrows represent the primers designed -2Kb to +600bp around the 
TSS, spanning E2F-1 binding sites, used in ChIP assays. B. SW1353 cell chromatin was used for ChIP 
assays (see Figure 5.12) and sonication time optimised following reverse-cross-linking and DNA 
extraction. C. The primer sets designed in A were tested using PCR. nt: nucleotides 
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Figure 5.12. Chromatin immunoprecipitation (ChIP) assays failed to show enrichment of 
HDAC3 and/or E2F-1 on p21 and CDC2 promoters respectively with or without IL-1 
stimulation. 
SW1353 cells were transfected with FLAG-HDAC3 (2µg), HA-E2F-1 (2µg), and HA-DP1 (2µg). 24 
hours post-transfection cells were stimulated with IL-1α (0.5ng/ml) for 6 hours or left unstimulated. 
Proteins were then cross-linked to DNA using formaldehyde for 10 minutes and cells harvested. 
Sonicated chromatin was pre-cleared and immunoprecipitation followed using an anti-E2F-1 or an 
anti-HDAC3 or an irrelevant IgG antibody. The following day the DNA was eluted from the beads 
and the cross-linking reversed by incubation at 65oC including proteinase K. DNA was then extracted 
using phenol-chloroform and used for qRT-PCR. 10% input of the sonicated chromatin was used in 
each assay for normalization of the adjusted Ct values obtained from the qRT- PCR. A-B. CDC2 
served as the positive control for E2F-1 immunoprecipitates, while C-D. p21 was the positive control 
for HDAC3. 
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Figure 5.13. Chromatin immunoprecipitation (ChIP) assays failed to show a direct interaction of 
HDAC3 and/or E2F-1 on MMP1/13 promoters in the absence of IL-1 stimuli. 
SW1353 cells were transfected with FLAG-HDAC3 (2µg), HA-E2F-1 (2µg), and HA-DP1 (2µg). 
ChIP assays were performed as previously described and 10% input of the sonicated chromatin was 
used in each assay for normalization of the adjusted Ct values obtained from the qRT- PCR. Indicative 
examples (no IL-1 stimulation) for primer sets (A) P1M13, (B) P2M13, (C) P5M13, (D) P6M13, (E) 
P2M1 and (F) P4M1 are shown.  
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5.4 Discussion 
The E2F family of transcription factors have been implicated in a plethora of cellular and 
organismal functions, including cell cycle progression, DNA repair, apoptosis, development 
and tumorigenesis. (New et al. 2012) The ability of E2F family members to regulate these 
processes has been linked to their ability to regulate transcription of target promoters. A 
considerable amount of work has been dedicated to identifying novel E2F- regulated genes by 
gene expression arrays and chromatin immunoprecipitation arrays. (Lavrrar & Farnham 2004; 
Wells et al. 2002; Weinmann et al. 2001) Most of these studies aimed to identify proteins or 
enzymes involved in the metastatic spread of tumor cells which physically requires the 
degradation of the ECM. It is therefore intriguing that at least in cell lung cancer cell lines, 
E2Fs act as transcriptional activators of MMP9, MMP14 and MMP15. (Johnson et al. 2012) 
In addition, many MMP promoters can be bound by Sp1, and E2Fs are well known to work 
co-operatively with Sp1 to regulate gene expression. (Clark et al. 2008; Li et al. 2014) 
The gene expression array data presented in the previous chapter supports an important role 
for E2F-1 transcription factor in mediating the expression of the IL-1 induced and repressed 
by HDAC3 loss genes. Therefore, the purpose of this chapter was to investigate the 
relationship between HDAC3 and E2F-1 in regulating MMP expression and shed light on the 
regulatory mechanism.  
 
5.4.1 E2F-1 binding sites are present on MMP1 and MMP13 promoters. 
To identify whether MMP1 and MMP13 are potentially E2F-1 target genes, an analysis of the 
promoters within 2 Kb of the transcription start site (TSS) was performed using PROMO, 
since it has been suggested that most E2F-1, E2F-4 and E2F-6 binding sites are frequently 
located within 2Kb of the TSS in both normal and tumor cells. (Xu et al. 2007) We found that 
both MMP1 and MMP13 carry potential binding sites within their promoters (Table 5.1), 
confirming in this way previous reports which support that matrix metalloproteinase genes 
have E2F-1 binding motifs (Johnson et al. 2012). Interestingly, it has been demonstrated that 
the majority of E2F-1 binding sites (>80%) are located in core promoters and that >50% of 
these sites overlap with TSS. (Bieda et al. 2006) Only a small fraction of these sites possessed 
the E2F-1 consensus binding sequence (TTTSSCGC, where S is either a G or a C), suggesting 
that E2F-1 is recruited to promoters via a method distinct from recognition of the own 
consensus motif. (Bieda et al. 2006)  These findings point toward a new understanding of 
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E2F-1 as a factor that potentially contributes to the regulation of a large fraction of human 
genes including MMPs. 
ChIP-chip assays were used to demonstrate that the majority of active promoters (as defined 
by TAF1 or POLR2A binding) in both normal (GM06990 B lymphocyte cell line) and 
carcinoma (Ntera2) cells were also bound by an E2F member. (Xu et al. 2007) This very close 
relationship between E2F binding sites and binding sites for general transcription factors in 
both normal and carcinoma cells, suggests that a chromatin-bound E2F could indicate an 
active transcription region. Moreover, Xu and colleagues suggest that there is only modest 
cell type specificity of the E2F family and as a result it is difficult to assess the role of any 
E2F in transcriptional regulation, due to redundancy to target promoters. As a consequence, 
Rabinovich et al. (Rabinovich et al. 2008) propose three models of E2F recruitment to a core 
promoter lacking a consensus binding motif in vivo: i) indirect recruitment through another 
transcription factor, ii) looping to the core promoter mediated by an E2F bound to a distal 
motif and iii) assisted binding of E2F to a site that only weakly resembles an E2F binding site. 
These studies implied that examination of the binding and subsequent transcriptional 
regulation of any of the E2F family members is not as straightforward as it might have been 
anticipated. 
 
5.4.2 HDAC3 directly interacts with E2F-1 transcription factor in vitro. 
Next, a direct association between HDAC3 and E2F-1 was examined using both in silico and 
in vitro analysis. First, STRING protein-protein interaction prediction tool suggested that 
HDAC3 interacts directly with E2F-1 and its co-activator heterodimer the DP1 transcription 
factor, and Rb protein also takes part in this predicted complex (Figure 5.1). Second, co-IP 
experiments in HEK293 cells confirmed the above predicted association between HDAC3 and 
E2F-1, since IP for FLAG (a tag added to HDAC3 vector) resulted in both HDAC3 and E2F-
1 to be immunoprecipitated. In addition to, IP for FLAG also resulted in the HA tagged E2F-1 
and DP1 being co-immunoprecipitated (Figure 5.3 A). When an IP for HA (the tag of E2F-1 
vector) was performed both HDAC3 and E2F-1 proteins were co-immunoprecipitated (Figure 
5.3 B). Also, GO analysis of the predicted network supports a role in determining protein 
localisation and transcription factor binding (Table 5.2). These results suggest HDAC3 may 
bind directly to E2F-1 to alter its DNA binding potential or cellular localisation. It is also 
possible that HDAC3 is responsible for de-acetylating E2F-1 factor and therefore changing its 
transactivation capability. Rb may facilitate deacetylation of E2F-1 either by stimulating 
HDAC3 enzymatic activity or by facilitating the interaction between HDAC3 and E2F-1. As a 
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consequence, regulation of gene expression programmes may be altered or intermediate 
transcription factor binding/ localisation affected, which in turn impact on MMP1 and 
MMP13 expression.   
To our knowledge this is the first time that a protein- protein interaction between HDAC3 and 
E2F-1 has been shown. Previous reports have concentrated on whether Rb can bind any 
HDAC during cell cycle progression. Indeed, it has been shown that Rb can associate with 
HDAC1 to repress E2F- regulated promoters, such as the gene encoding for the cell cycle 
protein cyclin E. Inhibition of HDAC activity by TSA only partly inhibited the Rb-mediated 
repression of E2F-regulated promoters, supporting there are possibly other HDACs taking 
part in this complex. (Magnaghi-Jaulin et al. 1998; Brehm et al. 1998) Nicolas and colleagues 
(Nicolas et al. 2001) have subsequently demonstrated that the Rb-associated histone 
deacetylase contain the RbAp48 protein which directly interacts with HDAC1 and HDAC2 
and could favour the deacetylation of histones since it binds directly to histone H4. The same 
study has also indicated that transcriptional repression of the E2F activity requires the 
presence of RbAp48. HDAC3 was suggested to act as a bridge between RbAp48 and Rb and 
it is considered that it favours the recruitment of RbAp48 to Rb.  
 
5.4.3 E2F-1 gene silencing up-regulates MMP1 and MMP13 expression following IL-1 
induction. 
Based on the above results which suggest the presence of multiple E2F-1 binding sites on 
MMP1 and MMP13 promoters, and a direct interaction between HDAC3 and E2F-1, 
depletion and over-expression experiments were conducted and the effect of E2F-1 on MMP1 
and MMP13 expression was determined. First, the efficacy of E2F-1 siRNA was confirmed at 
the mRNA and protein level, as shown in Figure 5.4. Endogenous E2F-1 protein levels could 
not be detected with immunoblotting in the SW1353 cells, and thus an over-expression had to 
be performed for subsequent experiments. This could be due to very low transcription factor 
expression and hence low protein levels and perhaps loading more protein on a SDS-PAGE or 
exposing the membrane for longer could have proven beneficial. Another reason could be that 
the endogenous protein is folded in such a way that the antibody used here can no longer 
recognise the epitope. SDS-denaturing conditions were used here and this could have also 
impacted on E2F-1 structure and therefore detection by immunoblotting. 
E2F-1 gene depletion significantly increased the IL-1 induced levels of MMP13 and MMP1 
genes (Figure 5.5) yet had no effect on IL-6 and IL-8 expression or the basal levels of either 
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MMP. These results suggested the two major collagenases of cartilage degradation, MMP1 
and MMP13 may in fact be E2F-1 regulated. Other genes identified by the microarray aspect 
of this study and predicted to be regulated by E2F-1 also showed a similar expression pattern 
with MMP1 and MMP13 following E2F-1 depletion (Figure 5.6). HDAC3 expression was 
also analysed and no change was identified, indicating that E2F-1 and/or HDAC3 do not 
impact on the expression of each other. Therefore, E2F-1 and HDAC3 must affect gene 
regulator networks via a mechanism which does not alter each regulator’s expression.  
 
5.4.4 E2F-1 over-expression decreases MMP1 and MMP13 luciferase activity. 
At the molecular level, ChIP experiments failed to show a direct binding of HDAC3 or E2F-1 
to the positive controls used, p21 and CDC2 genes respectively (Figure 5.12). Therefore, 
examination of HDAC3 or E2F-1 binding to MMP1 and MMP13 promoters did not generate 
trustworthy results, although several sets of primers were used in the ChIP assays (Figure 
5.13). [For the ChIP experiments, ChIP assay kits containing the positive controls primers and 
antibodies for immunoprecipitation were purchased from Millipore (Watford, UK). However, 
for future experiments, it is worth including more than one positive control and also a 
negative control in the assays. Alternatively, an antibody that has been previously optimised 
for IP experiments could also be used to decrease the possibility of non-specific binding.]  
Nonetheless, the effect of over-expressing E2F-1 and its heterodimer the DP-1 transcription 
factor on MMP promoters was determined using luciferase constructs. Transient transfections 
of SW1353 cells with luciferase constructs driven by MMP1 or MMP13 promoters revealed 
that over-expressing E2F-1 abrogates the activation of each promoter (Figure 5.7). The effect 
on an E2F-1- responsive promoter, the CDC6 reporter was also examined and a significant 
induction of this promoter was found following E2F-1/DP1 over-expression, consistent with 
previous reports (Ingram et al. 2011). In the first place, these data imply that the E2F-1 
predicted binding sites to MMP1 and MMP13 promoters are functional and secondly, E2F-1 
binding to the promoters of these genes might suppress their transcriptional activation in 
chondrocytes.  
Furthermore, HDAC inhibition by TSA decreased the E2F-1-mediated activation of the 
CDC6 reporter and further reduced MMP1 and MMP13 luciferase transactivation (Figure 
5.8). In addition, when HDAC3 was selectively inhibited using Apicidin or depleted by RNA 
interference, MMP13 reporter activation was decreased (Figure 5.9). These results suggest a 
novel mechanism by which MMP1 and MMP13 promoters may be regulated by a direct 
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interaction/ binding of some HDACs, possibly including HDAC3 and E2F-1 transcription 
factor. 
Previous studies support that E2F-1-mediated transcription is repressed partly by the Rb 
protein which recruits members from the HDAC family, but also by direct regulation by 
HDACs of two E2F-responsive elements in the E2F-1 gene promoter. (Boutillier et al. 2003; 
Panteleeva et al. 2004). Interestingly, HDAC inhibition by TSA induced E2F-1 dependent 
apoptosis in neurons by caspase-dependent mechanisms. (Boutillier et al. 2003) Others have 
shown that the E2F-7 can interact with the co-repressor CtBP (C-terminal Binding Protein) 
and recruit HDAC1 to the E2F-1 and CDC6 promoters to repress transcription. Nevertheless, 
E2F-7 repression on E2F-1 and CDC6 was not rescued by siRNA-mediated depletion of 
HDAC1, suggesting that E2F7-mediated repression might include other HDACs. (Liu et al. 
2013) HDAC1 has been suggested to be responsible for E2F-1 de-acetylation, which in turn 
affects DNA- binding activity and downstream target activation, and depletion of HDAC1 
only partially rescued transcription factor activity. (Xiong & Xu 2014)   
One hypothesis here is that HDAC3, as a chromatin associated factor, could localise to the 
E2F-1 target promoters and participate in their transcriptional regulation with or without any 
physical contact with E2F-1. Direct interaction between HDAC3 and E2F-1 may allow 
recognition of different sites from those normally bound and repressed by the typical Rb/E2F-
1. Also there is evidence that certain E2F-1 regulated promoter elements act positively 
whereas other act negatively to regulate transcription. (Dyson 1998; Johnson et al. 2012) This 
could be an indicator of different E2F-1 binding specificity depending on the cell type or 
binding motif recognised, or whether or not E2F-1 is bound by other proteins such as 
HDAC3. 
Another hypothesis that could explain an indirect effect of HDAC3 on E2F-1 binding to DNA 
is modulation of its post-translational modifications. Among them, acetylation of lysine 
residues 117, 120 and 125 by p300/CBP and/or the associated factor P/CAF has been shown 
to strongly enhance E2F-1 binding to its target genes and further enhance transcription factor 
stability and half-life. (Bauer et al. 2000) Acetylation of E2F-1 by P/CAF leads to an 
increased transcriptional activity, but whether this is due to increased binding activity or 
increased stability due to acetylation remains unclear. However, until now, acetylation of 
E2F-1 has only been observed in conditions of DNA damage where it has been shown that 
acetylated E2F-1 is recruited to specific target genes like p73 (Pediconi et al. 2003), APAF-1 
(Wallace & Cotter 2009) or Bim (Zhao et al. 2005) to induce apoptosis. Additionally, the 
acetylated residues of E2F-1 do not directly take part in DNA binding (Bauer et al. 2000), yet 
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the close proximity of the acetylated residues to the N-terminal of the E2F-1 DNA binding 
domain makes it likely that a conformational change mediated by acetylation allows better 
access to DNA. De-acetylation of E2F-1 by HDAC3 is therefore a novel mechanism by which 
E2F-1 could be regulated.  
Finally, another possibility is that HDAC3 by de-acetylating E2F-1 could decrease the 
proteins half-life or reduce stability, and hence alter transcription of E2F-1 target genes like 
MMP1 and MMP13. It is possible that de-acetylation of E2F-1 by HDAC3 leads to E2F-1’s 
degradation through a yet unknown mechanism and blocks binding to DNA or activation of 
other transcription factors. For example, E2F-1 protein levels are regulated by the ubiquitin-
proteasome-dependent degradation pathway and tight control of E2F-1 levels is a prerequisite 
to allow for particular cell cycle transition (Campanero & Flemington 1997; Harper & Elledge 
1999). Therefore, upon HDAC3 de- acetylation ubiquitin- proteasome -mediated degradation 
of E2F-1 could be triggered. Moreover, the effect of HDAC3 loss on FRA1 immediate early 
gene expression was discussed in sections 3.3.4.2 and 3.3.4.3, though whether E2F-1 affects 
FRA1 expression, which in turn might regulate MMPs was not studied and is yet to be 
determined.  
  
5.4.5 HDAC3 and E2F-1 are required for normal cell cycle progression. 
In the present study, we extended the characterization of HDAC3 function and its existing 
relationship with E2F-1 transcription factor during the cell cycle. This is partly because of the 
KEGG Pathway and GO terms predicted in my microarray experiment which included 
apoptosis and regulation of cell proliferation annotations in addition to the well known role of 
E2F-1 in controlling cell cycle progression. Interestingly, we showed by flow cytometry that 
HDAC3 siRNA can mimic the effect of an E2F-1 siRNA on cell cycle progression, by 
blocking the G1/S phase transition of the cell cycle similar to E2F-1 interference (Figure 
5.10). This could lead to a delay of cell growth, cell differentiation or chondrocyte maturation 
during endochondral ossification. Moreover, the lack of an additive effect of the double 
HDAC3/ E2F-1 depletion on cell cycle proliferation, suggests that these two proteins can be 
found in the same regulatory pathway. Altogether, HDAC3 participates in a positive 
regulation of the E2F-1- mediated G1/S transition. HDAC3 may be required for the 
recruitment of E2F-1 to its target gene promoters or modulate E2F-1 deacetylation status that 
could modify its binding properties to DNA. Another prospect is that HDAC3 depletion could 
abrogate the expression of a gene whose expression is required for E2F-1 binding to specific 
targets during the G1/S transition.  
 176 
 
Cytokine or growth factor stimulation has been generally linked to activating CDK (Cyclin 
dependent kinases) which phosphorylate Rb, which in turn is released from E2F-1 or E2F-
1/DP complexes. Free E2F-1 can induce transcription of several genes involved in cell cycle 
entry, induction or inhibition of apoptosis. (Ertosun et al. 2016) Furthermore, E2F-1 regulates 
expression of various cytokines and growth factor receptors, establishing positive or negative 
feedback mechanisms. (Ertosun et al. 2016) In particular, IL-1β has been suggested to cause 
growth arrest in human melanoma cell line A375-C6 by increasing phosphorylation of Rb 
protein, while over-expressing E2F-1 reverted growth inhibition. (Muthukkumar et al. 1996) 
While IL-1β obstruct E2F-1 function, E2F-1 seems to induce IL-1α release. In keratinocytes 
transformed with E7 protein or HPV-16, E2F-1 over-expression induced IL-1α release and 
apoptosis (Iglesias et al. 1998). E2F-1 was shown to be required for NF-κB- mediated IL-1β 
expression, and binding sites of both have been found on IL-1β. In particular, following E2F-
1 siRNA depletion, the expression of four pro-inflammatory cytokines was impaired 
including CCL3, IL23A, IL-1β and TNF-α, indicating an adverse relationship between E2F-1 
and IL-1β. (Lim et al. 2007) 
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5.5 Conclusions 
 HDAC3 can interact with E2F-1 transcription factor in vitro. These findings imply a 
role for HDAC3 on modifying E2F-1 function.  
 E2F-1 binding sites have been predicted on both MMP1 and MMP13 promoters and 
transient transfections of luciferase constructs support these sites are functional.  
 Over-expressing E2F-1 reduced the transactivation of all MMP luciferase reporters, 
while HDAC3 inhibition or gene depletion also decreased luciferase activation. 
 Gene silencing of E2F-1 up-regulated MMP1 and MMP13 expression. 
 Finally, HDAC3 and E2F-1 are required for normal cell cycle progression, since loss 
of either or both induced cell cycle arrest at the G1 phase. Moreover, the lack of an 
additive effect of the double HDAC3/ E2F-1 knockdown on cell cycle proliferation, 
suggests that these two proteins can be found in the same regulatory pathway.  
 
 
5.6 Hypothetic model of HDAC3 and E2F-1 in the SW1353 cells. 
Our hypothesis is that HDAC3 could be responsible for de-acetylating E2F-1 
transcription factor and HDAC3 inhibition or depletion leads to an increase in acetylated E2F-
1. So far, acetylated E2F-1 has only been linked to an induction of apoptosis, though it is 
likely that a conformational change mediated by increased acetylation allows better E2F-1 
access to DNA. Acetylated E2F-1 could bind either directly to MMP1/13 promoters and block 
transcription or abrogate transcription of intermediate molecules required for MMP 
expression. 
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Chapter 6. The role of HDAC3 in chondrogenesis in a human mesenchymal 
stem cell model system. 
 
6.1 Introduction  
In vivo, human mesenchymal stem cells (MSC) are multipotent cells that can proliferate as 
undifferentiated cells but have the potential to differentiate into mesenchymal lineages 
including bone, cartilage, fat, tendon, muscle, and marrow stroma. (Ferrari et al. 1998; Jiang 
et al. 2002; Pittenger et al. 1999) This differentiation is regulated by specific intrinsic and 
extrinsic determinants that affect gene expression profiles, signal transduction pathways and 
epigenetic modifications. (Smith 2001) Thus specific growth factors that are contained in the 
respective media of MSCs in culture will induce the expression of genes, which will cause 
differentiation for a particular lineage. (Barry et al. 2001; Darfoul et al. 2006) 
Briefly, for the initiation of the chondrogenic process, mesenchymal stem cells from the bone 
marrow aggregate to form high density condensations (Onyekwelu et al. 2009). Essential for 
this process are many transcription factors, especially SOX9 which will promote the 
expression of ECM genes including type II collagen and aggrecan (Akiyama 2008). In vitro, 
chondrocyte differentiation of MSCs can be achieved in a similar process driven by TGF-β 
stimulation over a 14-day differentiation period (Murdoch et al. 2007). However, in different 
cell models, for example the mouse embryonic carcinoma ATDC5 cells, induction of 
chondrogenesis is achieved by insulin and the cells require 14-21 days to differentiate into 
chondrocytes and 42 days for the maturation into hypertrophich chondrocytes. (Chen et al. 
2005; Tare et al. 2005) Therefore, there is increasing interest for MSCs as a source to repair 
diseased or damaged tissues for new therapeutic strategies in regenerative medicine. In 
particular, osteoarthritis (OA) patients who experience severe cartilage damage may benefit 
from autologous MSC-derived in vitro preparations of cartilage. (Roelofs et al. 2013) 
OA has a strong genetic component; however numerous studies have failed to identify genes 
that provide the full genetic susceptibility to the disease. This could be a result of low 
penetrance polymorphisms in the general population, but it is also suggested that in part, this 
could be accounted for by epigenetic modifications such as DNA methylation, histone 
modifications and microRNAs (miRNAs) (Barter et al. 2012). Regulation of histone 
acetylation/ deacetylation for example by HAT/ HDAC complexes holds promise in the field 
of OA. In addition to the HDACi studies in chondrocytes,(Young et al. 2005) (see also 
 180 
 
Chapter 3),the role of HDACi was studied in MSC differentiation and chondrogenesis. 
HDACi have pleiotropic effects on cell homeostasis, and under distinct developmental 
conditions can promote either self-renewal or differentiation of embryonic stem cells. 
(Kretsovali et al. 2012) 
Previous studies suggested that histone deacetylases regulate the expression of many ECM 
components produced by chondrocytes. In particular, it has been shown that short-term 
treatment of human bone-marrow derived MSCs with TSA, an HDAC pan-inhibitor, induced 
anabolic gene expression of COL2α1, COL9α1, and ACAN and enhanced cartilage matrix 
formation (El-Serafi et al. 2011). In contrast, extended treatment of primary articular 
chondrocytes with the same HDACi repressed many of these transcripts (Huh et al. 2007). 
However, others have suggested that treatment of human MSCs with TSA suppressed the 
TGF-β1- induced chondrogenic differentiation partly through inhibition of the TGF-β1- 
induced transcription factor Sp1 (Wang et al. 2011). More recently, Carpio et al. supported 
that HDAC3 is important for normal endochondral ossification and HDAC3 deficient 
chondrocytes exhibited reduced abundance of chondrogenic genes such as COL2α1, Ihh, 
ACAN and COL10α1. (Carpio et al. 2016) 
This chapter aims to further establish the contribution of HDACs and particularly of HDAC3 
in MSC-derived chondrogenesis over 7 or 14 days of differentiation. Herein, RNAi targeting 
HDAC3 and drug-inhibitory treatments including TSA and Apicidin will be used to define the 
role of inhibiting deacetylation early in cartilage development. Matrix deposition and cartilage 
disc composition will also be determined. 
 
6.2 Aim 
 To determine how HDAC inhibition, and particularly HDAC3 depletion or selective 
inhibition, affects chondrogenic differentiation in vitro, using human bone marrow-
derived mesenchymal stem cells.  
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6.3 Results 
6.3.1 Differential expression of HDACs in mesenchymal stem cells (MSCs) and MSC-
differentiated chondrocytes. 
MSCs were cultured in chondrogenic differentiation media either in transwell hanging cell 
culture inserts or V-bottomed cell culture plates/ tubes (Figure 6.1 A). RNA interference for 
HDAC3 or HDACi treatments were performed before the induction of chondrogenesis as 
described in sections 2.2.7 RNA interference (RNAi)and 2.1.7 Histone Deacetylase Inhibitors 
respectively. A flexible, translucent cartilage disc or cell pellet was formed in each case.  
Gene expression data for cartilage ECM components and transcription factors in conjunction 
with proteoglycan quantification, histology and immunohistochemistry were used to assess 
chondrogenic differentiation, as previously described. (Murdoch et al. 2007; Barter et al. 
2015)  
RNA-seq analysis revealed all HDACs are differentially expressed in MSCs (Day 0 MSCs- 
before inducing chondrogenic differentiation) (Figure 6.1 B) (data provided by Kathleen 
Cheung, PhD student, Newcastle University). HDAC1 and HDAC2 are expressed at the 
highest level in MSCs (FPKM: fragments per kilobase of exon per million fragments mapped 
~20-25), while HDAC3, HDAC5, HDAC6, HDAC7 and HDAC8 exhibited medium expression 
(FPKM ~ 15). HDAC4, HDAC10 and HDAC11 are present at lower levels (FPKM ~ 5), 
whilst HDAC9 is barely detectable in MSCs (FPKM < 2). During chondrogenesis, class I 
HDACs including HDAC1, HDAC2, HDAC3 and HDAC8 are also expressed, with maximum 
HDAC3 expression observed after 6 days of differentiation (Figure 6.1 C), after which it 
declined to its initial levels. HDAC2 and HDAC8 showed similar expression patterns with 
increased expression values during the first 3 days of the chondrogenic period and decrease of 
their expression thereafter. Finally, HDAC1 was the most highly expressed class I HDAC at 
Day 0, yet showed decreased expression after the addition of TGF-β3 and the induction of 
chondrogenic differentiation. These results were also confirmed by microarray analysis for 
Day 0 and Day 14 (data provided by Dr Matt Barter, Newcastle University) (Figure 6.1 D). 
 
 
 
 
 182 
 
 
Figure 6.1. Differential expression of HDACs in human bone marrow- derived mesenchymal stem cells (MSCs). 
MSCs were pre-treated with HDAC3 siRNA (1) or HDACi (2) before they were cultured in chondrogenic differentiation media over 14 or 7 days in hanging 
transwell inserts or cell culture tubes/ plates to form a cartilaginous disc or cell pellet respectively and analysed as indicated above. Bar= 500µm, B. MSCs were 
cultured in maintenance medium and RNA was isolated from confluent cells. RNA-seq was used to measure expression levels of HDACs. For each bar the gene 
counts (fragments per kilobase of exon per million fragments mapped, FPKM) and normalised expression are shown from one MSC donor. C. Class I HDAC 
expression at indicated time-points during MSC chondrogenesis. D.  Relative expression values (log2) of class I HDAC expression at Day 0 and Day 14 during MSC 
chondrogenesis based on microarray data (n=3 per timepoint). * p<0.05, *** p<0.001 
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6.3.2 HDAC inhibition affects chondrogenic differentiation of human bone marrow- 
derived mesenchymal stem cells. 
6.3.2.1 The effect of HDAC inhibition on the acetylation of lysine residues and α-
tubulin. 
Considering the fact that HDAC4 null mice have severe skeletal defects (Vega et al., 2004), 
while HDAC3 global knockout mice are embryonic lethal (Bhaskara et al., 2010) and bone-
specific HDAC3 conditional knockout mice had impaired ossification, an investigation of 
whether MSCs respond to HDAC inhibitors (HDACi) such as TSA, a pan-HDACi, and 
Apicidin, a selective HDAC3 inhibitor was performed. First, immunohistochemistry was used 
to test whether HDAC inhibitors induce acetylation by using a total acetyl-α-tubulin antibody 
and a pan acetyl-lysine antibody. As anticipated, treatment of MSCs with 165nM TSA one 
day before inducing chondrogenesis (Day -1 treated MSCs) (Figure 6.2 A-B) or at the day of 
the induction of differentiation (Day 0 treated MSCs) (Figure 6.2 C-D) resulted in hyper-
acetylation of α-tubulin and protein lysine residues. In particular, MSC treatment with TSA 
increased the percentage of acetylated lysines by 10% when treated at Day -1 (Figure 6.2 B, 
top) and by 11% when treated at Day 0 (Figure 6.2 D, top), while acetylation of α-tubulin 
was increased by 19% when treated at Day -1 (Figure 6.2 A, top) and by 6% when treated at 
Day 0 (Figure 6.2 C, top). In contrast, treatment of MSCs with 80nM Apicidin did not have 
any effect on the acetylation status of α-tubulin or changed the acetylation of protein lysine 
residues, as identified by immunohistochemistry for the indicated antibodies (Figure 6.2 A-
B-C-D, bottom). Quantification of the DAB staining was measured using ImageJ software as 
previously described in section 2.2.17 Image analysis. 
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Figure 6.2. Effect of HDACi treatments on acetylation of MSCs. 
MSCs were cultured in maintenance media and treated either with 160nM TSA or 80nM Apicidin, 24h 
before the addition of chondrogenic media (Day -1) (A and B), or at the day of inducing 
chondrogenesis (Day 0) (C and D). Chondrogenic differentiation was induced over 7 days in cell 
culture tubes and media was replaced after one day (Day -1 treated cells) or three days (Day 0 treated 
cells) and differentiation followed in the absence of HDACi. TSA was dissolved in ethanol (EtOH, 
0.1%) and Apicidin was diluted in DMSO (0.2%), which served as vehicle controls. A-C. 
Immunohistochemistry was performed using an anti- acetylated α- tubulin antibody and, B-D. An anti-
acetylated lysine antibody. Bar = 200μm 
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6.3.2.2 The effect of HDAC inhibition on cartilage gene expression and matrix 
deposition during MSC-derived chondrogenesis. 
Next, the effect of the HDACi on ECM deposition and cartilage gene expression was 
determined. Three methods of chondrogenesis were performed: (i) cell pellets were formed in 
V-bottomed 96 well plates and used for RNA quantification, (ii) cell pellets were formed in 
14ml falcon tubes and used for histology and (iii) micromass cell cultures were performed in 
24-well plates and used for alcian blue staining. 
MSCs from three different donors were cultured in V-bottomed 96-well plates to form smaller 
cell pellets (50,000 cells per pellet) and three pellets per treatment were formed (i). HDACi 
treatments were performed as described in section 6.3.2.1 The effect of HDAC inhibition on 
the acetylation of lysine residues and α-tubulin.. Chondrogenic differentiation was then 
performed over seven days. The media was replaced after one day (for the Day -1 treated 
cells) or after three days (for the Day 0 treated cells) and differentiation followed with the 
absence of HDACi. The smaller cell pellets were used for gene expression analysis using 
qRT-PCR. The expression of chondrogenic markers measured included type II collagen, 
aggrecan and the transcription factor SOX9. Alternatively, cells from the same MSC donors 
were cultured in V-bottomed tubes (14ml falcon tubes) in order to form cell pellets (500,000 
cells per pellet) and used for histological scoring (ii). As above, cells were differentiated for 
seven days after HDACi treatments had been previously performed. In order to establish if 
there were any morphological differences among the HDACi treated cell pellets formed, H&E 
histologic staining was performed. Additionally, safranin-O staining for determining 
proteoglycan deposition and Masson’s trichrome staining for the detection of collagen fibres 
were used to assess matrix composition of the newly differentiated/synthesized cartilage. 
Finally, micromasses of MSCs from one donor (250,000 cells/ micromass) were assessed with 
alcian blue staining as a marker of mucopolysaccharides formation (iii). MSCs were treated 
with HDACi one day prior to inducing chondrogenesis and allowed to differentiate for five 
days in the absence of HDACi. 
No difference in the gross morphology of all the cell pellets was observed for the Day -1 
treated or Day 0 treated controls; EtOH versus DMSO (Figure 6.3 A-C). Also there was no 
difference between the TSA and EtOH treated cell pellets or the Apicidin and DMSO treated 
pellets following seven days of chondrogenic differentiation, regardless as to whether the 
MSCs were treated one day prior to the induction of chondrogenesis or on the day of 
induction. The expression of selected chondogenic markers including SOX9 gene were 
quantified at the end of the differentiation period. Results from three different donors were 
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combined and showed a trend towards decreased, but non- significant, SOX9 expression 
(Figure 6.3 B-D). It is worth noting that SOX9 expression has been shown to reach its 
maximum level as early as day one of this MSC- chondrogenesis model, and remains at the 
same levels, or lower, thereafter up to day fourteen. (Barter et al. 2015) 
 
 
 
Figure 6.3. Effect of HDACi treatments on cell pellet morphology and gene expression of 
differentiated- MSCs. 
MSCs were cultured in maintenance media before treatments either with 160nM TSA or 80nM 
Apicidin, 24h before the addition of chondrogenic media (Day -1 treated MSCs) (A-B), or on the day 
of inducing chondrogenesis (Day 0 treated MSCs) (C-D) were performed. Chondrogenic 
differentiation was induced over 7 days in cell culture plates/tubes and media was replaced after one 
day (for the Day -1 treated cells) or three days (for the Day 0 treated cells) and differentiation followed 
in the absence of HDACi. TSA was diluted in ethanol (EtOH, 0.1%) and Apicidin was diluted in 
DMSO (0.2%), which served as vehicle controls. A-C. Cell pellets were harvested at day 7, fixed, 
sectioned and stained for H&E. Bar= 200μm B-D. RNA was extracted from MSCs undergoing 
chondrogenic differentiation at day 7 and SOX9 expression was assessed by qRT- PCR and 
normalized to 18S. Results are representative of the gene expression data pooled from three separate 
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MSC donors and bars show the mean +SD. For statistical analysis, an unpaired two-tailed student’s t-
test was performed. 
However, histological staining for Safranin-O, that stains for cartilage proteoglycans 
(Goldring & Marcu 2009; Martel-Pelletier et al. 2008), revealed a difference in the Day 7 
stained cell pellets. In particular, red staining (which corresponds to the amount of 
proteoglycans present in cartilage), was present in the EtOH and DMSO control cartilage 
formed after seven days of differentiation. HDAC inhibition reduced the amount of red 
staining at the indicated time-points (Figure 6.4 A-C). Furthermore, the TSA treated cell 
pellets were consistently smaller than the controls, indicating TSA may have impaired 
chondrogenesis (Figure 6.4 A, top). Because of the importance of aggrecan for cartilage 
(Martel-Pelletier et al. 2008), more emphasis was given to the expression of this gene. ACAN 
expression was significantly decreased at the Day -1 TSA treated MSCs (p= 0.02) when 
compared to the ethanol control, confirming the observations of the Safranin-O stained cell 
pellets (Figure 6.4 B). Apicidin treatment also showed decreased ACAN expression of the 
Day -1 treated MSCs, but these results were not statistically significant (Figure 6.4 B). The 
same observation towards reduced ACAN expression was found for the Day 0 TSA treated 
MSCs following seven days of differentiation (Figure 6.4 D). However, Apicidin had no 
significant effect in the expression of aggrecan. There is therefore very little evidence that 
inhibiting HDAC3 selectively before or after the initiation of the chondrogenic process alters 
chondrogenic gene expression. 
Chondrogenesis can also be indicated by alcian blue staining, which stains 
mucopolysaccharides (mainly glycosaminoglycans (GAG)), and can be quantified by 
extracting alcian blue using guanidine hydrochloride (GuHCl) (see also 2.2.15.5 Alcian Blue 
staining). MSCs were pre-treated with HDACi, as previously described, one day prior to 
inducing chondrogenesis. The cells were then seeded in micromasses in 24-well plates and 
differentiation was induced for five days in the absence of HDAci. As expected from the 
previous results, TSA treatment showed a decrease of alcian blue staining, while Apicidin 
treatment caused an increase, but neither significantly (Figure 6.5 A-B). These results were 
only validated using cells from one MSC donor.   
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Figure 6.4. Effect of HDACi treatments on aggrecan gene expression and proteoglycan 
deposition of differentiated- MSCs. 
MSCs were cultured in maintenance media before treatments either with 160nM TSA or 80nM 
Apicidin, 24h before the addition of chondrogenic media (Day -1 treated MSCs) (A-B), or at the day 
of inducing chondrogenesis (Day 0 treated MSCs) (C-D) were performed. Chondrogenic 
differentiation was induced over 7 days in cell culture plates/tubes and media was replaced after one 
day (for the Day -1 treated cells) or three days (for the Day 0 treated cells) and differentiation followed 
in the absence of HDACi. TSA was diluted in ethanol (EtOH, 0.1%) and Apicidin was diluted in 
DMSO (0.2%), which served as vehicle controls. A-C. Cell pellets were harvested at day 7, fixed, 
sectioned and stained for Safranin-O. Bar= 200μm E. A cell pellet that had no treatment was included 
in the experiment (Bar= 200μm) and a wild-type mouse knee joint section served as a positive control 
(Bar= 500μm) B-D. RNA was extracted from MSCs undergoing chondrogenic differentiation at day 7 
and ACAN expression was assessed by qRT- PCR and normalized to 18S. Results are representative of 
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the gene expression data pooled from three separate MSC donors and bars show the mean +SD. For 
statistical analysis, an unpaired two-tailed student’s t-test was performed. * p<0.05 
 
 
 
Figure 6.5. Alcian Blue staining was used as a marker of cartilage formation. 
A. MSCs were cultured in maintenance media before treatments either with 160nM TSA or 
80nM Apicidin or EtOH (0.1%) or DMSO (0.2%) were performed one day prior to inducing 
chondrogenesis. Chondrogenic differentiation was then induced over 5 days in tissue culture plates, 
the cells were seeded in micromasses and media was replaced every 2-3 days without any HDACi and 
up to day 5. Bar= 0.5cm B. Alcian blue was extracted using guanidine hydrochloride (GuHCl) and 
absorbance measured at 610nm.  Data are representative of three biological replicates using cells from 
one MSC donor. For statistical analysis, an unpaired two-tailed student’s t-test was performed. 
 
 
Finally, Masson’s trichrome staining was used to reveal collagen fibres present in the matrix 
of differentiated MSCs, following HDACi treatment. Type II collagen expression was also 
quantified with qRT- PCR. My results indicate there was no difference in collagen fibre 
presence in the Day -1 or Day 0- treated MSCs between the control and HDACi treated 
samples (Figure 6.6 A-C). Also, although there was a trend of decreased COL2A1 expression 
in the TSA samples of the Day-1 treated MSCs these results were not significant. Moreover, 
no significant difference was found when comparing the DMSO to the Apicidin samples in 
both time points as well as in the TSA treated samples of the Day 0 MSCs (Figure 6.6 B-D). 
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Figure 6.6. Effect of HDACi treatments on collagen fibres deposition and type II collagen gene 
expression of differentiated- MSCs. 
MSCs were cultured in maintenance media before treatments either with 160nM TSA or 80nM 
Apicidin, 24h before the addition of chondrogenic media (Day -1 treated MSCs) (A-B), or at the day 
of inducing chondrogenesis (Day 0 treated MSCs) (C-D) were performed. Chondrogenic 
differentiation was induced over 7 days in cell culture plates/tubes and media was replaced after one 
day (for the Day -1 treated cells) or three days (for the Day 0 treated cells) and differentiation followed 
in the absence of HDACi. TSA was diluted in ethanol (EtOH, 0.1%) and Apicidin was diluted in 
DMSO (0.2%), which served as vehicle controls. A-C. Cell pellets were harvested at day 7, fixed, 
sectioned and stained for Masson’s trichrome. Bar= 200μm E. A cell pellet that had no treatment was 
included in the experiment (Bar= 200μm) and a wild-type mouse liver section served as a positive 
control (Bar= 1mm) B-D. RNA was extracted from MSCs undergoing chondrogenic differentiation at 
day 7 and COL2A1 expression was assessed by qRT- PCR and normalized to 18S. Results are 
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representative of the gene expression data pooled from three separate MSC donors and bars show the 
mean +SD. For statistical analysis, an unpaired two-tailed student’s t-test was performed.  
 
 
6.3.3 HDAC3 gene silencing increases anabolic gene expression in MSC chondrogenesis. 
To further establish the role of HDAC3 in MSC chondrogenesis, a siRNA against HDAC3 
mRNA was used to specifically deplete HDAC3 from MSCs before the induction of 
chondrogenesis. MSCs from two independent donors were cultured in maintenance media in 
tissue culture plates and transfected at 40-50% confluency with 100nM of siHDAC3 or a non-
targeting control siRNA (siCON) three days before the induction of chondrogenesis, as 
described in section 2.2.6. Chondrogenic differentiation was then performed in hanging 
transwell filters (500.000 cells per transwell) over fourteen days and the media was replaced 
at day 3, 7, 10, 12 up to day 14 as described in (Barter et al. 2015). Two cartilage discs were 
formed for each time-point per MSC donor, and cells frozen at Day 0 were also included in all 
experiments. For each time-point transwell discs were harvested and either frozen for RNA 
extraction and gene expression quantification by qRT- PCR or fixed in 4% paraformaldehyde 
and processed into paraffin wax. Sections cut at 4 µm were either stained with H&E, Safranin 
O, or Masson’s trichrome. A quarter of each disc was also used for glycosaminoglycans 
(GAG) quantification (GAG assay) and normalised to the disc’s DNA content. 
Immunoblotting was also performed using a disc from each donor to establish HDAC3 
protein levels following siRNA transfection during the differentiation period.   
All discs formed had a normal morphology and no weight difference was detected between 
the siHDAC3 and siCON treated samples at Day 14 (Figure 6.7 A). HDAC3 knockdown 
efficiency was confirmed with immunoblotting (Figure 6.7 B) and qRT- PCR (Figure 6.7 D) 
at Day 3, Day 7 and 14 during the differentiation period as well as with 
immunohistochemistry (Figure 6.7 C) at Day 14. Quantification of the 
immunohistochemistry with ImageJ software (as described in section 2.2.17 Image analysis) 
showed there was 52% less HDAC3 staining in the siHDAC3 Day 14 cartilage discs when 
compared to the siCON discs.  
 
 192 
 
 
Figure 6.7. Effect of HDAC3 gene silencing on cartilage disc formation of differentiated-MSCs. 
MSCs were transfected for 3 days with a HDAC3-targeting or a non-targeting control siRNA (100nM) 
prior to inducing chondrogenic differentiation for 14 days in hanging transwell inserts. A. Day 14 
cartilage discs showed normal morphology and similar weight (average of 4 discs per treatment/ time-
point from 2 independent MSC donors). B. Day 3, 7 and 14 cartilage discs were harvested, lysed and 
total protein extraction was performed. Immunoblotting was performed with an anti- HDAC3 antibody 
and GAPDH served as a loading control. C. Day 14 cartilage discs were harvested, fixed, sectioned 
and stained for an anti-HDAC3 antibody. Bar (top)= 200μm and Bar (bottom)= 50μm D. RNA was 
extracted from MSCs undergoing chondrogenic differentiation at the indicated time-points between 
Day 0 and Day 14 and HDAC3 expression quantified by qRT- PCR. Results are shown relative to 18S 
ribosomal RNA expression. Significance was determined with respect to siCON treated cells in 
comparison to the siHDAC3 treated cells. Results are representative of the gene expression data 
pooled from two separate MSC donors and bars show the mean +SD. For statistical analysis, an 
unpaired two-tailed student’s t-test was performed. ** p<0.01, * p<0.05 
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The cells in both the siCON and siHDAC3-treated discs had similar morphology as detected 
by H&E staining at the end of the differentiation period (Day 14) (Figure 6.8 A). However, 
HDAC3-depleted differentiated chondrocytes exhibited increased expression of genes related 
to extracellular matrix production including ACAN [Figure 6.8 B (iii)] at Day 14 and 
COL2A1 [Figure 6.8 B (ii)] at Day 3 and Day 14. The chondrogenic marker SOX9 was also 
significantly increased at Day 14 [Figure 6.8 B (i)]. In accordance with the ACAN expression, 
proteoglycan deposition detected by Safranin-O staining showed higher deposition of 
proteoglycans of the Day 14 HDAC3-depleted cartilage discs in comparison to the siCON 
discs (Figure 6.8 A).  Additionally, a significantly increased GAG content was found in the 
siHDAC3 treated discs when compared to the siCON discs at Day 7, while no significant 
difference was observed at Day 3 or Day 14 (Figure 6.8 C), indicating that HDAC3 might 
play an important role in the regulation of genes such as aggrecan earlier rather than later in 
chondrogenesis. Nonetheless, Masson’s trichrome staining for the detection of collagen fibres, 
shows a decrease of collagens, as the real-time results for COL2A1 suggested. Increased 
expression for matrix-remodelling enzymes such as MMP13 (Figure 6.9 H) was also detected 
in the siHDAC3 treated discs, following 14 days of differentiation.  
Notably, none of the other genes analysed showed any significant difference in their 
expression as a result of HDAC3 depletion, including the osteoblast markers COL1A1 and 
RUNX2, hypertrophic and differentiation/maturation chondrocyte markers such as COL10A1, 
COL11A1, COL9A1, MATN3 and the MSC-condensation marker N-Cadherin (Figure 6.9 A-
G). Although these data did not show a significant statistical difference, all genes showed a 
trend towards increased expression up to Day 3 followed by a decrease at Day 14, suggesting 
that HDAC3 knockdown increases the expression of matrix genes and cytokine-induced 
remodelling enzymes early in chondrocyte development and differentiation. Also the 
reduction of COL1A1, COL11A1, COL9A1 and COL10A1 expressions could explain the 
decreased trichrome staining found on the Day 14 siHDAC3 discs (Figure 6.8 A).
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Figure 6.8. Effect of HDAC3 gene silencing on matrix components deposition and cartilage gene expression of differentiated-MSCs.  
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MSCs were transfected for 3 days with a HDAC3-targeting or a non-targeting control siRNA (100nM) prior to inducing chondrogenic differentiation for 14 
days in hanging transwell inserts. A. Day 14 cartilage discs were harvested, fixed, sectioned and stained for H&E, Safranin-O and Masson’s trichrome. Bar= 
100μm B. RNA was extracted from MSCs undergoing chondrogenic differentiation at the indicated time-points between Day 0 and Day 14 and gene 
expression quantified by qRT- PCR and normalised to 18S ribosomal RNA expression. Significance was determined with respect to siCON treated cells in 
comparison to the siHDAC3 treated cells. Results are representative of the gene expression data pooled from two separate MSC donors and bars show the 
mean +SD. For statistical analysis, an unpaired two-tailed student’s t-test was performed. C. Quantification of cartilage GAG-bearing proteoglycans after 
performing papain digestion at 60oC overnight to solubilize cartilage components. Dimethyl-methylene blue (DMB) was added and the results were read at 
530nm. The results obtained from the GAG assay above were subsequently normalised with reference to the DNA levels contained to each 
sample and expressed as µg GAG/ ng DNA. **p<0.01, * p<0.05 
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Figure 6.9. Effect of HDAC3 gene silencing on cartilage gene expression during MSC-
chondrogenic differentiation. 
MSCs were transfected for 3 days with a HDAC3-targeting or a non-targeting control siRNA (100nM) 
prior to inducing chondrogenic differentiation for 14 days in hanging transwell inserts. RNA was 
extracted from MSCs undergoing chondrogenic differentiation at the indicated time-points between 
Day 0 and Day 14 and gene expression quantified by qRT- PCR. Results are shown relative to 18S 
ribosomal RNA expression. Significance was determined with respect to siCON treated cells in 
comparison to the siHDAC3 treated cells. Results are representative of the gene expression data 
pooled from two separate MSC donors and bars show the mean +SD. For statistical analysis, an 
unpaired two-tailed student’s t-test was performed. *p<0.05 
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6.4 Discussion 
Histone deacetylases (HDACs) play a major role in chromatin remodelling, gene regulation 
and cellular signaling. While the role of each class of HDACs during normal development and 
chondrocyte differentiation is unclear, recent reports suggest HDAC inhibitors are embryo-
toxic and can impair normal chondrogenesis and osteogenesis (Paradis & Hales 2015). More 
specifically, treatment of E12 embryonic forelimbs from COL2A1-ECFP, COL10A1-
mCherry, and COL1A1-YFP CD1 reporter mice with the class I HDAC inhibitor MS-275 
reduced the expression of COL2A1, COL10A1 and COL1A1, suggesting gene expression 
regulatory effects of class I HDACs on both chondrogenesis and osteogenesis (Paradis & 
Hales 2015). Moreover, the bone-specific HDAC3 conditional knockout mouse model 
(Razidlo et al. 2010) and cartilage-specific HDAC3 inducible conditional knockout mouse 
model (Carpio et al. 2016) supported HDAC3 depletion interfere both with normal bone and 
cartilage formation.  
Herein, an established chondrogenesis model (Barter et al. 2015) was used to determine how 
HDAC inhibition and HDAC3 depletion or selective inhibition affects chondrogenic 
differentiation in vitro, using human bone marrow-derived mesenchymal stem cells. MSCs 
were transfected with a siRNA targeting HDAC3 for three days, before the induction of 
chondrogenesis with medium containing TGF-β3, and then cultured in hanging transwell 
inserts for up to 14 days. In this way the cells receive media from the top and bottom surface 
when a cartilage disc is starting to form, having more optimal nutrient access (Murdoch et al. 
2007). Alternatively, MSCs were pre-treated with TSA or Apicidin one day before the 
induction of chondrogenesis or at the day of the induction. The cells were cultured in V-
bottomed cell culture tubes/plates for up to 7 days for the formation of cell pellets which were 
then used for cartilage gene expression and matrix deposition analysis (Figure 6.1 A).  
RNA-seq analysis revealed HDAC1-11 are differentially expressed in MSCs (Figure 6.1 B). 
In particular, HDAC1 and HDAC2 were expressed at highest expression in MSCs, while 
HDAC3, HDAC5, HDAC6, HDAC7 and HDAC8 exhibited medium expression. HDAC4, 
HDAC10 and HDAC11 are present in lower levels, whilst HDAC9 is barely detectable in 
MSCs. The differential expression of HDACs and sirtuins have also been reported in adipose-
derived MSCs by (Dudakovic et al. 2015). During chondrogenesis, class I HDACs including 
HDAC1, HDAC2, HDAC3 and HDAC8 are also expressed, with HDAC3 maximum 
expression observed after 6 days of differentiation (Figure 6.1 C) and microarray analysis 
showed no class I HDAC exhibited significant differences in their expression between Day 0 
and Day 14 in chondrogenesis (Figure 6.1 D). 
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6.4.1 HDACi agents including TSA and Apicidin negatively regulate the ability of MSCs to 
differentiate into cartilage. 
My analysis revealed that HDACi treatment with TSA 24 hours prior to inducing 
chondrogenesis or at the day of the induction resulted in hyperacetylation of acetyl-α tubulin 
and acetyl-lysine residues (Figure 6.2) of the Day 7 cell pellets. As expected, Apicidin did 
not result in hyper-acetylation of α-tubulin, since it is a HDAC3 selective inhibitor (Khan & 
Davie 2013) and de-acetylation of α-tubulin is largely regulated by the catalytic activity of 
HDAC5 and HDAC6 (Cho & Cavalli 2012; Hubbert et al. 2002). Apicidin did not increase 
acetylation of lysine residues. In this study, histone acetylation at and near the genes analysed, 
such as aggrecan or type II collagen was not studied. However, data provided by Kathleen 
Cheung (PhD student, Newcastle University) for the H3K27Ac active enhancer marker 
showed an increase during chondrogenesis approximately 20Kb away from the COL2A1 
promoter and 10Kb from the ACAN promoter, which correlated to an increase in their gene 
expression during chondrogenesis (unpublished data). Similar experiments using MSCs-
treated with vorinostat, another broad-spectrum HDACi revealed hyper-acetylation of 
histone-H3 (Xu et al. 2013), while human adipose derived MSCs-treated with SAHA, a class 
I HDAC inhibitor resulted in hyper-acetylation of both histone H3 and histone H4 
(Dudakovic et al. 2015).  
MSCs pre-treated with HDACi prior to inducing chondrogenesis showed decreased ACAN 
expression and proteoglycan deposition (Figure 6.4 and Figure 6.5). In particular, Safranin-O 
staining revealed there was less peptidoglycans present at the TSA- and Apicidin- treated Day 
7 cell pellets in comparison to the EtOH- and DMSO- treated control cells. Accordingly, 
aggrecan expression was significantly reduced in the TSA-treated cells, whilst the pellets 
formed were much smaller in size than those of the controls, suggesting HDAC pan-inhibition 
in MSCs might impair differentiation into the chondrogenic lineage. Apicidin treatment also 
showed decreased ACAN expression of the Day -1 treated MSCs and a slight increase when 
treated at Day 0, but these results were not statistically significant. As expected from the 
previous results, TSA treatment also decreased alcian blue staining, while Apicidin treatment 
had no effect (Figure 6.5). Moreover, no difference was found in cell morphology or the 
expression of the chondrogenic marker SOX9 with neither HDACi at the end of the 
differentiation period (Figure 6.3). In accordance with these results, MSCs which were 
induced to undergo osteogenic or chondrogenic differentiation and treated with TSA, showed 
a slight but not significant increase in RUNX2 and SOX9 expression respectively. (Hye Joung 
et al. 2016) Furthermore, TGF-β1 induced chondrogenesis of MSCs was inhibited when cells 
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were exposed to TSA. Decreased chondrogenic gene expression of genes such as aggrecan, 
type II collagen and SOX9 and chondrogenic proteins were found in the TSA-treated samples. 
(Wang et al. 2011) Also TGF-β1- mediated activation of Sp1 was suppressed in the presence 
of TSA, whereas when Sp1 was over-expressed the TSA-mediated inhibition of TGF-β1 
induced chondrogenesis was abolished. (Wang et al. 2011) 
Along with the aforementioned genes (aggrecan and SOX9), the expression of type II 
collagen was quantified using qRT- PCR and collagen content determined using Masson’s 
trichrome staining. No significant effect on type II collagen expression was observed 
following pan-HDACi. Hye Joung et al., showed that TSA treatment alone failed to alter 
COL2A1 expression, yet when TSA was combined with a hypo-methylating agent (HMA), 5-
azacytidine (5-azaC), MSC chondrogenic and osteogenic differentiation were enhanced, as 
evidenced by increased type II collagen protein levels and increased calcium deposition and 
osterix expression respectively (Hye Joung et al. 2016). Based on these observations, the 
ability of the 5-azaC agent to induce chondro and osteo- differentiation was studied alone and 
it was shown that hypo-methylation plays a dominant role in enhancing MSC differentiation. 
(Hye Joung et al. 2016) 
On the contrary, El-Serafi et al., showed that pre-treatment of MSCs for 3 days with TSA, 
followed by culture in the absence of TSA enhanced cartilage matrix formation and 
chondrogenic structure, as indicated by increased SOX9 and aggrecan expression 4 weeks 
after the induction of chondrogenesis (El-Serafi et al. 2011). In contrast, TSA decreased 
adipogenesis of bone-marrow derived MSCs when treated with 50 or 500nM for 2 days 
before the initiation of the differentiation. However the 500nM dose has proven to be cyto-
toxic for the cells as it decreased cell proliferation. (Zych et al. 2013) Vorinostat an HDACi 
which is currently in a clinical phase III trial for multiple myeloma patients has been 
previously reported to cause bone loss. When the effect of vorinostat was tested on MSC-
derived osteogenic differentiation, it was found that it inhibited the viability of MSCs in a 
dose-dependent manner, but it was also demonstrated that at lower concentrations it promotes 
osteogenic differentiation. (Xu et al. 2013) Also, administration of 100mg/kg vorinostat in 
vivo in mice for three weeks did not result in any bone loss. (Xu et al. 2013) Another study 
which utilized SAHA HDACi on adipose-derive MSCs showed that SAHA interfered with 
osteogenesis, adipogenesis and chondrogenesis. It also induced loss of differentiation 
potential of MSCs, by changing the expression of principal transcription factors that control 
mesenchymal or pluripotent states including NANOG, OCT4/POU5F1, and SOX2. In 
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addition, induction of the chondrogenic gene SOX6 was not detected when SAHA was 
present, but clearly induced when the agent was removed. (Dudakovic et al. 2015) 
Huh and colleagues found that HDAC activity in primary articular chondrocytes decreases 
during de-differentiation induced by monolayer culture and that HDAC activity recovered 
during re-differentiation induced by three-dimensional culture in a cell pellet. Inhibition of 
HDACs with TSA or PXD101, a class I HDAC selective inhibitor, was sufficient to block 
type II collagen expression in primary culture chondrocytes. HDAC inhibition also blocked 
the re-differentiation of de-differentiated chondrocytes by suppressing the synthesis and 
accumulation of type II collagen. HDAC inhibition promoted the expression of Wnt-5a, 
which is known to inhibit type II collagen expression, and knockdown of Wnt-5a blocked the 
ability of HDAC inhibitors to suppress type II collagen expression. In addition, the induction 
of Wnt-5a expression by HDAC inhibitors was associated with acetylation of the Wnt-5a 
promoter. Taken together, these results suggest that HDACs promote type II collagen 
expression in part by suppressing the transcription of Wnt-5a. (Huh et al. 2007) 
To achieve better therapeutic strategies with the use of MSCs, it is a prerequisite to retain 
their pluripotency properties during ex vivo expansion. Although some studies have indicated 
that ageing of MSC in culture cause gradual loss of their differentiation potential (Lee et al. 
2004; Li et al. 2011), more recently Han and colleagues demonstrated that an effective 
supplement for MSC pluripotency and differentiation potential is the TSA HDACi. In 
particular, it has been shown that in the presence of low concentrations of TSA (6.25nM), the 
acetylation of histone H3 at K9 and K14, particularly near pluripotent genes including OCT4, 
SOX2 and TERT in passage 6 MSCs showed no significant difference compared to passage 1 
MSC, which allowed them to retain their primitive pluripotency properties. Low doses of this 
HDACi markedly prevented the de-acetylation of histone H3 K9 and 14 and the appearance 
of ageing signs, whilst higher doses (200-300nM) were cyto-toxic. (Han et al. 2013) 
My results indicate that the expression of chondrogenic genes ACAN, COL2A1 and SOX9 
involves HDAC-dependent mechanisms, yet further studies are required to fully understand 
the molecular mechanisms of MSC differentiation. It is obvious that data regarding the effect 
of different epigenetic agents on MSC differentiation remains controversial. All of the 
discrepancies among the studies, including ours, may be associated with variations in 
experimental designs, with heterogeneity in the cells originating from various species such as 
humans, rats and mice or from different MSC sources including bone marrow, fat and cord 
blood could provide further explanation. Furthermore, variations in the type or dose of the 
HDACi used among the studies could also provide an explanation. In our study, cells were 
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exposed to the HDACi either 24h prior to inducing chondrogenesis or for 3 days after the 
induction. Other studies have included the epigenetic regulators throughout the differentiation 
period, therefore for slightly longer duration (Hye Joung et al. 2016). These influences of the 
individual epigenetic modifiers and for optimal doses and dose schedules could be researched 
and further optimized to achieve better differentiation for future studies. Another factor that 
we need to take into account is the half-life of each HDACi and hence its impermanent effect, 
which for example is 6.3 min for TSA it is upon peritoneal administration (Elaut et al. 2007), 
while for Apicidin is 0.8-1.1h upon intravenous injection (Shin et al. 2014).  
Additionally, other epigenetic modifications may contribute differently in MSC 
chondrogenesis and/or progression of osteoarthritis. For example, one study showed that 
inhibition of lysine-specific demethylase 6A (UTX) and Jumonji domain- containing 3 
(JMJD3) by GSK-J4 inhibitor abrogated expression of chondrogenic genes, such as SOX9 and 
COL2A1 in chondrogenic MSCs, and disrupted glycosaminoglycan and collagen synthesis. 
GSK-J4 also prevented cartilage destruction and expression of the OA-related genes MMP13 
and PTGS2 in HACs. (Yapp et al. 2016) It is therefore important to understand how different 
epigenetic modifications modulate chondrogenesis and progression of OA. Additionally, 
whole genome ChIP revealed a large number of genes linked to MSC-properties are 
epigenetically pre-patterned by changes in H3K4me3 and H3K9ac near transcription start 
sites, but remained transcriptionally unaltered during chondrogenesis. Transcriptionally 
upregulated genes, more closely associated with chondrogenesis, are marked by H3K36me3 
in gene bodies, increased H3K36me3 and H3K9ac on promoters and 5’ end and increased 
H3K27ac and H3K4me1 marking in at least one enhancer region per upregulated gene. 
Within the 7-day differentiation period changes in promoter DNA methylation do not 
correlate significantly with gene expression changes. (Herlofsen et al. 2013). Histone 
modifications rather than DNA methylation may therefore provide the primary epigenetic 
control of early MSC chondrogenesis. 
 
6.4.2 HDAC3 depletion enhances anabolic gene expression and proteoglycan deposition of 
MSC-derived cartilage. 
Most of the research to date has focused on the effect of broad-spectrum HDACi in 
combination with de-methylating agents on MSC-derived chondrogenesis. However, the 
current study takes into account that independent HDACs may contribute differently to the 
induction of chondrogenic differentiation. To further determine the role of HDAC3 in human 
MSC-derived chondrogenesis, the RNA interference approach was taken to deplete MSCs of 
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HDAC3 prior to inducing chondrogenesis as described in (Barter et al. 2015). All cartilage 
discs formed presented normal morphology (Figure 6.8 A- H&E staining), and no weight 
difference was detected between the siHDAC3 and siCON discs at Day 14 (Figure 6.7 A). 
HDAC3 knockdown efficiency was confirmed with immunoblotting, qRT- PCR and 
immunohistochemistry (Figure 6.7 B-D).  
Interestingly, HDAC3 knockdown resulted in increased chondrogenic gene expression, 
including genes such as aggrecan [Figure 6.8 B (iii)] at Day 14 and type II collagen [Figure 
6.8 B (ii)] at Day 3 and Day 14. Besides these genes, the chondrogenic marker SOX9 also 
presented a significant increase at Day 14 [Figure 6.8 B (i)]. In concordance with the 
aggrecan expression, proteoglycan deposition detected by Safranin-O staining showed higher 
content of proteoglycans at the Day 14 siHDAC3 discs when compared to the siCON discs 
(Figure 6.8 A).  Additionally, a significantly increased amount of GAGs were found in the 
siHDAC3 treated discs at Day 7, yet no significant difference was observed at Day 3 or Day 
14 (Figure 6.8 C). Nevertheless, trichrome staining for the detection of collagens, failed to 
show an increased abundance of collagens, as the real-time PCR data suggested for type II 
collagen. Notably none of the other genes studied (COL1A1, RUNX2, COL10A1, COL11A1, 
COL9A1, MATN3, N-Cadherin) showed any difference in their expression, except for 
MMP13 (Figure 6.9 H) which was significantly induced in the siHDAC3 treated discs, 
following 14 days of differentiation. Finally, the reduction of COL1A1, COL11A1, COL9A1 
and COL10A1 expressions could be an explanation of the decreased trichrome staining found 
on the Day 14 siHDAC3 discs (Figure 6.8 A). 
Embryonic deletion of HDAC3 in type II collagen α1 expressing tissues is lethal as shown in 
the next chapter and also by (Carpio et al. 2016). However, postnatal deletion of HDAC3 in 
articular chondrocytes showed increased expression of cytokine and matrix-degrading genes 
such as IL-6, MMP3, MMP13 and Saa3 and activation of signalling pathways, classically 
related to inflammation. Reduced abundance of genes related to extracellular matrix 
production, bone development and ossification has also been observed in the same study, 
where ACAN, COL2A1, Ihh and COL10A1 were reduced in contrast to our gene expression 
data, suggesting a role for HDAC3 in the final stages of chondrocyte maturation. (Carpio et 
al. 2016) Our results could be explained by the fact that when HDAC3 is lost, inhibition of 
deacetylation may result in altered affinity of transcription factors for DNA binding sites on 
target gene regulatory regions. It could also be a direct effect on signaling molecules 
responsible for the chondrogenic process and induction of chondrogenic genes, an altered 
interaction with other transcription factors or an altered protein half-life.  
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In a similar way, when Hdac3 was conditionally deleted from osteo-/chondro- progenitor 
mouse cells with Osx1-Cre, severe osteopenia was caused due to abnormal maturation of 
osteoblasts and decreased long bone length. (Bradley et al. 2013) To address this abnormal 
phenotypes the role of HDAC3 was evaluated in chondrocyte differentiation. This study 
demonstrated that HDAC3 was highly expressed in the resting and pre-hypertrophic zone of 
the growth plate chondrocytes as well as in articular chondrocytes. HDAC3-deficient 
chondrocytes entered hypertrophy sooner and were smaller than normal chondrocytes. ECM 
production was suppressed, evidenced by GAG secretion and production of aggrecan, 
osteoponin and matrix extracellular phosphoglycoprotein. These findings led to the 
hypothesis that Akt/mTOR pathway was repressed in Hdac3-deficient chondrocytes, because 
Akt promotes hypertrophy and matrix production in many tissues. Indeed, phosphorylation 
and activation of Akt, its substrate mTOR and the mTOR substrate, p70 S6 kinase were 
reduced in Hdac3-deficient chondrocytes. Constitutive expression of Akt restored 
phosphorylation of mTOR and p70 S6 kinase as well as matrix gene expression levels. 
Reduced expression of Akt in Hdac3-deficient chondrocytes and chondrocytes treated with 
HDACi correlated with increased expression of the phosphatase Phlpp1 gene. It was found 
that HDAC3 associates with a Phlpp1 promoter region containing Smad binding elements and 
was released after the addition of TGF-β in culture. These results demonstrated that HDAC3 
plays an important role in chondrocyte hypertrophy and extracellular matrix production by 
repressing Phlpp1 expression and facilitating Akt activity. (Bradley et al. 2013) 
Injuries or age-related cartilage degeneration that occurs in osteoarthritic patients demands 
effective repair strategies. Thus the discovery and use of mesenchymal stem cells (MSCs) that 
can differentiate into specialised cartilaginous tissue could prove valuable for regenerative 
medicine purposes. My results suggest that HDAC3 loss prior to the induction of 
chondrogenesis could prove beneficial for autologous tissue regeneration and repair, since it 
promotes ECM production/ anabolic gene expression. After obtaining the tissue, cells could 
be treated in a similar way presented in this chapter and expanded in culture for 14 days for 
the formation of differentiated-functional chondrocytes. These chondrocytes can then be 
seeded onto a previously tested scaffold before transplantation back to the patient-donor can 
take place. Ideally these structures should be made of biocompatible and biodegradable 
materials capable to provide mechanical strength and to promote implant integration, uniform 
cell spreading and preserve phenotypes and functional characteristics of the transplanted cells. 
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6.5 Conclusions 
 HDACs are differentially expressed in MSCs. 
 HDAC inhibition using TSA, but not Apicidin, induced hyper-acetylation of α-tubulin 
and total lysines in MSCs. 
 MSCs pre-treated with HDACi prior to the induction of chondrogenesis showed 
decreased anabolic gene expression and proteoglycan deposition as evidenced by 
safranin-O and alcian blue staining as well as gene expression data for aggrecan.  
 No significant difference was found at the type II collagen levels or collagens 
deposition of the HDACi treated cells. 
 HDAC3 knockdown promoted anabolic gene expression of SOX9, ACAN and COL2A1 
and increased proteoglycan and GAG content after 14 days of differentiation. 
 HDAC3 knockdown also induced the expression of matrix remodelling enzymes such 
as MMP13.  
 My results indicate that the expression of chondrogenic genes involves HDAC-
dependent mechanisms, yet further studies are required to fully understand the 
molecular mechanisms of MSC-derived chondrogenic differentiation. 
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Chapter 7. The effect of Hdac3 loss in cartilage murine development. 
 
7.1 Introduction 
Osteoarthritis is a degenerative joint disease epitomised by articular cartilage loss and has yet 
no modifying therapies. HDAC inhibitors including TSA have been assessed in vivo in 
surgically induced- and drug induced- osteoarthritis mouse models and showed a 
chondroprotective role. (Culley et al. 2013; Cai et al. 2015) Cartilage damage was blocked in 
the presence of TSA and expression of OA-associated enzymes such as MMP1, MMP3 and 
MMP13 were reduced. (Culley et al. 2013; Cai et al. 2015) The role of TSA has also been 
assessed in vivo in rats, whereby knee joints were intra-articularly injected with mono-
iodoacetate (MIA) to induce osteoarthritis. Reduced gene expression and protein levels of 
MMP1, MMP3, MMP13 and increased expression of TIMP1 were observed in the TSA-
treated group and safranin-O staining indicated cartilage retention, although not to the level of 
the sham-treated rats. (Qu et al. 2016) However, the exact mechanisms underlying this 
protective effect remain to be elucidated.  
Mutant mice lacking individual HDACs are a powerful tool for defining the functions of 
individual HDACs in vivo and the molecular targets of HDACs inhibitors in disease. Several 
HDACs have been found to contribute to skeletal development. Deletion of Hdac1 in 
zebrafish for example causes a variety of skeletal defects. The specific target genes 
responsible for these phenotypes have not been defined, but it has been proposed that they are 
downstream of canonical and non-canonical Wnt signalling. (Cunliffe 2004; Cunliffe & 
Casaccia-Bonnefil 2006; M. Yamaguchi et al. 2005). While global Hdac1 knockout is 
embryonic lethal (Lagger et al. 2002), Hdac1 deletion in tissues such as the heart, brain, 
skeletal muscle and smooth muscle is well tolerated in mice, possibly due to functional 
redundancy with Hdac2 later in development and in post-natal life. (Montgomery et al. 2007) 
However, there is disagreement regarding the role of Hdac2 in vivo, with studies showing null 
mice are either viable (Trivedi et al. 2007)or show post-natal lethality (Montgomery et al. 
2007). Global Hdac3 null mice die before E9.5 due to gastrulation defects and defective 
DNA- double stranded break repair. (Bhaskara et al. 2011) Deletion of Hdac3 in 
osteo/chondro- progenitor cells resulted in decreased bone density and severely impaired 
intramembranous and endochondral bone formation. (Razidlo et al. 2010) 
Regarding the role of class II HDACs, Hdac4 deletion has been shown to cause premature 
ossification of the developing bones accompanied with ectopic hypertrophy of chondrocytes, 
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resulting in the conversion of cartilaginous skeletal elements to ossified bone, while its 
overexpression prevents chondrocyte hypertrophy and endochondral ossification. (Vega et al. 
2004) Global Hdac6 deficiency modestly enhances trabecular bone formation (Y. Zhang et al. 
2008), whereas global Hdac8 loss negatively affects intramembranous ossification (Haberland 
et al. 2009). Global Hdac7 deletion also leads to embryonic lethality, owing to a loss of 
integrity and endothelial-cell interactions and consequent rupture of blood vessels and 
heamorhaging. Furthermore, Hdac7 deletion caused increased expression of MMP10 and 
subsequent down-regulation of TIMP1 in endothelial cells. (Chang et al. 2006) 
When this project was about to start the role of Hdac3 conditional deletion and/or selective 
inhibition in cartilage development in vivo had not been studied. Although previous studies 
have supported a role for the broad-spectrum inhibitor TSA in protecting cartilage damage in 
OA (Culley et al. 2013; Cai et al. 2015), Hdac3 selective inhibitors have never been tested for 
efficacy in preclinical OA models before. The first step to be taken here was to confirm the 
aforementioned findings by using TSA, but also try the selective Hdac3 inhibitor Apicidin in 
the destabilized of the medial meniscus (DMM) - surgically induced mouse model. Then, 
intra-articular delivery of a small interfering RNA for Hdac3 was also attempted in wild-type 
mice. Finally, the role of Hdac3 in type II collagen expressing tissues was assessed by 
developing a conditional knockout mouse model through selective breeding. 
 
7.2 Aims 
 Determine the consequence of Hdac3 inhibition on DMM-induced osteoarthritis, 
through the delivery of HDACi (TSA and Apicidin) via intra-articular injections. 
 In vivo delivery of a siRNA targeting Hdac3 in the joint via intra-articular injections, 
and determine if there is any effect on cartilage morphology soon after the delivery. 
 To establish a chondrocyte-specific Hdac3 conditional knockout mouse model that 
will be used to study cartilage development in vivo. 
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7.3 Results 
7.3.1 The effect of Hdac3 inhibition on a DMM-induced osteoarthritis mouse model. 
To define the role of HDAC inhibitors in OA in vivo, experiments were performed in wild-
type C57BL-6J mice in accordance with the UK Home Office regulations. OA was induced in 
10-week old mice, following surgical destabilization of the medial meniscus as described in 
section 2.2.12. In this model, cartilage erosion develops primarily in the center of the load-
bearing region of the medial tibial plateau and to a lesser extent to the medial femoral 
condyles, 8 weeks postoperatively (Glasson et al., 2010). To test our hypothesis that HDAC 
inhibitors have a chondroprotective role in vivo, three groups of 6 mice underwent DMM 
surgery. The first group of mice received DMSO (control), the second one the non-selective 
HDACi TSA and the third the specific HDAC3i Apicidin. Both HDACi were diluted in 
DMSO at c= 10mg/ml and delivered immediately following the DMM surgery and via an 
intra-articular injection two weeks post-surgery. No sham surgeries were performed in this 
experiment. Four weeks post-DMM the mice were sacrificed and both knee joints were 
harvested for histologic examination and scoring as previously described (Glasson et al., 
2010) (see also Table 2.10). Scoring was carried out by two experienced independent scorers 
blinded to drug treatments and scores were combined and averaged. 
Cartilage degeneration was not rescued by TSA or Apicidin treatment (Figure 7.1). On the 
contrary, there were no significant effects of both HDACi in the cartilage of the medial tibial 
plateau and the femoral condyle in the HDACi treated samples when compared to control-
DMSO knee joints (Figure 7.1 A-B). However, due to obvious inflammation in three of the 
TSA treated mice, almost certainly due to an infection, the number of mice taken into account 
and averaged was reduced to three.  
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Figure 7.1. In vivo effects of TSA and Apicidin on blocking cartilage destruction in a destabilised 
of the medial meniscus (DMM) OA mouse model. 
Osteoarthritis-like (OA) was induced in C57BL/6J mice following surgical DMM. TSA/Apicidin 
(10mg/ml) or vehicle control (DMSO) were injected during the surgery and two weeks after the 
surgery. A. Left: Representative coronal sections of the knee joint, stained for Saffranin O-Fast Green. 
B. Histologic scoring of OA (Glasson et al. 2010). Twenty sections from each mouse were scored in a 
blinded manner by 2 scorers, using a validated scoring system from 0 (normal knee) to 6 (vertical 
clefts, erosion to the calcified cartilage extending to 75% of the articular surface). Results at 4 weeks 
post-DMM are shown. Values are the mean +/- range of the maximum scores per 10 sections scored 
per mouse for the medial femoral chondyle (F), the medial tibial plateau (T) and the sum of the medial 
femoral chondyle and the tibial plateau (F+T) for each drug treatment (n=6 mice/group) and for TSA 
(n=3). 
 
 
 
 
 
 
 
 210 
 
7.3.2 Intra-articular delivery of a siRNA targeting HDAC3 in C57Bl/6 mice joints 
Next, AteloGene was combined with a siRNA suitable for in vivo transfections targeting 
Hdac3 as described in section 2.2.16. Two groups of three mice were established, and three 
different treatments were performed in each group. The first mouse from each group received 
AteloGene combined with siHDAC3, the second mouse received siHDAC3 in PBS and 
finally the third mouse received siRNA buffer (siBuffer) plus PBS. All treatments were 
delivered through intra-articular injections on the left knee joint capsule of each mouse with 
0.01% (w/v) Evans blue dye to confirm precision of the injection. The two groups of mice 
were sacrificed three or six days post- injections and knee joints were harvested, fixed, 
sectioned and stained with an anti-Hdac3 antibody. If siHdac3 was efficiently transfected to 
articular cartilage chondrocytes; reduced Hdac3 protein levels would be detected following 
immunohistochemistry. However, quantification of the staining did not reveal any significant 
difference among the three treatments neither at Day 3 (Figure 7.2) nor at day 6 (Figure 7.3), 
indicating siHdac3 intra-articular delivery was not efficient or it did not penetrate the joint 
tissue. In particular, 41% of positive staining was found in the siHdac3 + AteloGene treated 
mouse at day 3 (Figure 7.2 A), while 34% of positive stained cells were counted in the 
second siHdac3 + PBS mouse (Figure 7.2 B) and 30% in the third animal which had only 
siBuffer + PBS (Figure 7.2 C). In a similar manner, 48% of staining were observed in the 
siHdac3 + AteloGene treated mouse at day 6 (Figure 7.3 A), while 46% of Hdac3 staining 
was observed in the siHdac3 + PBS mouse (Figure 7.3 B) and 39% in the third siBuffer + 
PBS treated mouse (Figure 7.3 C).  
siRNA delivery to the joint is only poorly established and AteloGene has not been widely 
used for local siRNA administrations and in particular intra-articular injections. This was a 
very preliminary experiment to decide whether or not AteloGene could be used to deliver 
siHdac3 in vivo in mice. 
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Figure 7.2. In vivo efficacy of the intra-articular delivery of a siRNA targeting Hdac3 on the 
mouse knee joint.  
Adult C57BL/6J mice were anaesthetized and intra-articular injections performed in the left knee joint. 
Treatments included: A. siHdac3 (20µM) prepared in siRNA buffer (1.6x, provided in the AteloGene 
kit) and diluted in AteloGene containing 0.01% Evans blue dye (SIGMA Aldrich). B. siHdac3 (20µM)  
were prepared in siRNA buffer and diluted in PBS including 0.01% Evans blue dye C. siBuffer and 
PBS with 0.01% Evans blue dye were injected into the knee joint. For all treatments 15µl were 
injected into the joint capsule. Representative coronal sections of the knee joint, stained with an anti-
Hdac3 antibody are shown in A-C. Three sections from each mouse were used for quantification.  
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Figure 7.3.  In vivo efficacy of the intra-articular delivery of a siRNA targeting Hdac3 on the 
mouse knee joint. 
Adult C57BL/6J mice were anaesthetized and intra-articular injections performed in the left knee joint. 
Treatments included: A. siHdac3 (20μM) were prepared in siRNA buffer (1.6x, provided in the 
AteloGene kit) and diluted in AteloGene containing 0.01% Evans blue dye (SIGMA Aldrich). B. 
siHdac3 (20μM) were prepared in siRNA buffer and diluted in PBS including 0.01% Evans blue dye. 
C. siBuffer and PBS with 0.01% Evans blue dye were injected into the knee joint. For all treatments 
15µl were injected into the joint capsule. Representative coronal sections of the knee joint, stained 
with an anti-Hdac3 antibody are shown in A-C. Three sections from each mouse were used for 
quantification.  
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7.3.3 Generation of a cartilage- specific Hdac3 conditional knockout (cKO) mouse model. 
Previous studies showed that Hdac3 is expressed in proliferating and hypertrophic growth 
plate chondrocytes of one-month old mice. (Bradley et al., 2013) Further analysis also 
revealed that Hdac3 is detectable in these zones as early as E14.5. To further determine the 
role of Hdac3 in endochondral ossification, Hdac3 was conditionally deleted in cells 
expressing Cre recombinase under the control of type II collagen alpha 1 promoter [called 
Hdac3(Fl/Fl); Col2-Cre(+) or Hdac3CartΔEx3]. The steps taken for the generation of the 
conditional knockout mouse model are summarised in Figure 7.5 and also described in detail 
in section 2.2.11.  
Briefly, three males and three females Hdac3tm1a(EUCOMM)Wtsi targeted; knockout first allele 
(reporter-tagged insertion with conditional potential) mice, were obtained from the University 
of Veterinary Medicine, (Vienna, Austria). Detailed generation as well as phenotypic data are 
available from the International Mouse Phenotypic Consortium (IMPC, at 
http://www.mousephenotype.org/data/search/gene?kw="Hdac3"). In general no significant 
phenotype associations were found following x-rays, eye morphology and skin histopathology 
analysis and no association with a human disease found. These mice accounted for the 
parental line (P) and carried one Wild-type (Wt) allele and a Hdac3 target locus allele as 
shown in Figure 7.4 A, containing a lacZ-neomycin reporter cassette flanked by two 48bp 
FRT sites (5’-GAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC-3’) and a floxed 
exon 3 (one loxP site either side of exon 3). These mice are called Hdac3(+/Fl) hereafter. An 
initial experiment to compare endochondral ossification using Alizarin red/ Alcian blue 
staining of one day old (P1) mice was performed after breeding the parental line and results 
revealed endochondral ossification was normal and no significant difference of the length of 
femurs or tibias was found between the Hdac3(+/Fl) mice (n=3) and the Wt Hdac3(+/+) 
littermates (n=2) (Figure 7.6). Genotypes at this stage were confirmed using primer pairs 1, 2 
and 5 as indicated in Figure 7.4 B & C (lanes 1-7). 
The parental line Hdac3(+/Fl) was bred with mice expressing FLP recombinase (which 
recognises and cleaves at this site TCTAGAAA) (Rodriguez et al., 2000; Dymecki 1996), to 
promote site-specific DNA recombination and remove the lacZ-neomycin cassette. The mice 
generated formed the F1 generation of mice, were called Hdac3(+/Fl); FLP(+) and carried 
one Wt allele and a Post-FLP Hdac3 locus allele (Figure 7.4 A). For genotyping, primer pairs 
3 and 4 were used to confirm FLP recombination and absence of the lacZ-neomycin reporter 
(Figure 7.4 D & E). Presence of FLP was also confirmed using PCR as described in section 
2.2.11 and shown in Figure 2.3. Lane 8 for example (Figure 7.4 D) shows that when primer 
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pair 3 was used the Wt allele amplicon was 1118bp long, whereas the Hdac3 target locus 
allele recombined by FLP had 1170bp size. Therefore the Post-FLP allele amplicon was 
bigger by an FRT and two loxP sites in comparison to the Wt allele. Similarly, when primer 
pair 4 was used (lanes 10-13, Figure 7.4 E), the Post-FLP allele amplicon was 692bp long, 
while the Wt allele was 782bp long. In this case the Wt allele amplicon is slightly longer, 
because in order to introduce the Hdac3 target locus cassette into the mouse genome part of 
the wild-type sequence was removed, and although there is an extra loxP site in the Post-FLP 
allele, this is still smaller than the Wt amplification product. 
F1 heterozygous mice were then bred with Col2-Cre mice (F2 generation in Figure 7.5) to 
generate heterozygous Hdac3(+/Fl); FLP(+); Col2-Cre(+) and promote recombination and 
exon 3 deletion via recognition of the loxP sites (5’-
ATAACTTCGTATAGCATACATTATACGAAGTTAT-3’) by Cre recombinase (which recognises and 
cleaves at this site GCATACAT). Col2α1 is expressed in embryonic cartilaginous tissues as early 
as E10.5 and in developing skeletal structures at E13.5. (Chen et al. 2007; Nakamura et al. 
2006) Hdac3(+/Fl); FLP(+); Col2-Cre(+) heterozygous mice were born at expected ratios 
and used for the final breeding step (F4 generation) that would generate the conditional 
knockout mouse model (F5). Genotyping results were obtained using primer pairs 3 and 6 to 
confirm Cre recombination and Hdac3 exon 3 deletion. In particular, when primer pair 3 was 
used, the Wt allele amplicon was 1118bp long, whilst the Hdac3 target locus allele 
recombined by Cre was only 326bp long (lane 9 in Figure 7.4 D). [Note here that there is still 
a band for the Post-FLP Hdac3 target allele amplicon at 1170bp, though it is not as intense as 
that in lane 8, indicating Cre recombination is not 100% efficient].  In addition, primer pair 6 
could also be used to demonstrate the presence of the floxed allele, since it amplifies a region 
around exon 3, which is smaller by 82bp in comparison to the Wt allele (lanes 14-18, Figure 
7.4 F). Real-time PCR was also used to quantify Col2α1-Cre expression of the F5 mice and 
normalised to type X collagen expression levels (see also Figure 2.4). 
Sanger Sequencing was used to confirm the sequence of the amplicons produced from all the 
different breeding steps. 
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Figure 7.4. Genotyping results from different primer pairs. 
A. Wild type (Wt) allele, Hdac3 target locus, Post-FLP Hdac3 locus and Post Cre Hdac3 locus alleles. B. Primer pairs 1 and 2 were used to confirm Hdac3 
target locus presence before any FLP or Cre recombination occurs. C. Primer pair 5 amplifies a region from Hdac3 exon 4 to exon 7 in the Wt gene. D. Primer pair 3 
was used to distinguish between the presence of a Post-FLP and/ or a Post-Cre Hdac3 allele. E & F. Primer pairs 4 & 6 were used to confirm the presence of a Post-
FLP floxed Hdac3 allele. Right Arrowheads indicate hybridization of the forward primer, while left arrowheads indicate where the reverse primer would hybridize. 
Black squares represent exons. The size of each PCR product is given in base pairs (bp). 
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Figure 7.5. Selective breeding was performed in order to generate a cartilage-specific Hdac3 
conditional knockout mouse model.  
The steps performed in each generation are summarised above. 
 
 
 
Figure 7.6. A. Whole mount Alizarin Red/ Alcian blue skeletal preparations from one day old 
Hdac3(+/+) (n=2) and Hdac3(+/Fl) (n=3) mice. B. Measurements of femoral and tibia length from 
one day old Hdac3(+/+) (n=2) and Hdac3(+/Fl) (n=3) mice. 
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Table 7.1 shows the expected genotypes at F5 after breeding Hdac3(+/Fl); FLP(+); Col2-
Cre(+) animals and Table 7.2 shows the expected and observed numbers of animals found 
from 8 independent litters at F5. Note here that FLP genotypes are not included, since all the 
animals used for the F4 breeding step were FLP (+) positive animals. For convenience, the 
heterozygous animals (Hdac3(+/Fl); FLP(+); Col2-Cre(+)) will thereafter be called 
Hdac3(+/Fl);Col2-Cre(+) or HET. Hdac3 conditional HET animals were born at higher rate 
(1/ 1.5) than the expected Mendelian ratio (1/2.7) as shown in Table 7.2 and were a normal 
size (Figure 7.7). However, no conditional knockout (cKO) Hdac3(Fl/Fl); Col2-Cre+ 
animals were born in 8 litters. [Wt and HET mice, but no cKO, were also present at E16.5 
from 3 different litters, yet earlier developmental stages were not studied here due to limited 
time]. These findings indicate that Hdac3 may be necessary for pre-natal cartilage formation 
and bone growth before E16.5. Nonetheless, a detailed comparative analysis between the Wt 
and HET animals was performed at three weeks post-natal to determine cartilage development 
of the growth plate. 
No size or weight difference was found at three weeks of age between the Wt and HET male 
or female mice (Figure 7.7). X-rays and bone measurements were performed as shown in 
Figure 7.8 A and have been previously described (Cameron et al., 2015). Femoral and tibial 
lengths were used to indicate endochondral bone growth and intercanthal distance (ICD) and 
skull length to measure intramembranous bone growth. Moreover, growth plates of three 
weeks old Wt and HET mice (Figure 7.8 B) were stained for haematoxylin and eosin (H&E), 
alcian blue and toluidine blue to compare cell morphology of the different zones and cartilage 
formation evidenced by the amount of glycosaminoglycans (GAG) and proteoglycans 
respectively.  
At three weeks of age, endochondral bones in HET mice were a similar size to their Wt 
littermates (Figure 7.9 A-B), and no difference was found in the ICD or skull length between 
HET and Wt, indicating intramembranous bone formation also remained unaffected (Figure 
7.9 C-D). H&E staining suggested growth plate zone lengths were of similar length in HET 
and Wt mice at three weeks of age (Figure 7.10, H&E staining). Cartilage formation was 
assessed by Alcian Blue staining which revealed similar content of GAGs in the Wt and HET 
growth plates at three weeks of age (Figure 7.10, Alcian Blue staining). Finally, no apparent 
difference in proteoglycan content was detected using Toluidine blue staining in Wt and HET 
mice (Figure 7.10, Toluidine Blue staining).
 219 
 
 Gametes (F4) Hdac3 (+) ; Col2-Cre (+) Hdac3 (+) ; Col2-Cre (-) Hdac3 (Fl); Col2-Cre (+) Hdac3 (Fl) ; Col2-Cre (-) 
Hdac3 (+) ; Col2-Cre (+) Hdac3 (+/+) ; Col2-Cre (+/+) Hdac3 (+/+) ; Col2-Cre (+/-) Hdac3 (+/Fl) ; Col2-Cre (+/+) Hdac3 (+/Fl) ; Col2-Cre (+/-) 
Hdac3 (+) ; Col2-Cre (-) Hdac3 (+/+) ; Col2-Cre (+/-) Hdac3 (+/+) ; Col2-Cre (-/-) Hdac3 (+/Fl) ; Col2-Cre (+/-) Hdac3 (+/Fl) ; Col2-Cre (-/-) 
Hdac3 (Fl); Col2-Cre (+) Hdac3 (+/Fl) ; Col2-Cre (+/+) Hdac3 (+/Fl) ; Col2-Cre (+/-) Hdac3 (Fl/Fl) ; Col2-Cre (+/+) Hdac3 (Fl/Fl) ; Col2-Cre (+/-) 
Hdac3 (Fl) ; Col2-Cre (-) Hdac3 (+/Fl) ; Col2-Cre (+/-) Hdac3 (+/Fl) ; Col2-Cre (-/-) Hdac3 (Fl/Fl) ; Col2-Cre (+/-) Hdac3 (Fl/Fl) ; Col2-Cre (-/-) 
Table 7.1. Punnett square of the expected genotypes at F5 generation after breeding Hdac3(+/Fl); Col2-Cre(+/-) heterozygous mice. 
 
 
Genotypes 
Expected number of animals  
(50 animals in total from 8 Litters) 
Observed number of animals 
(50 animals in total from 8 Litters) 
Hdac3 (+/+) ; Col2-Cre + 9 10 
Hdac3 (+/Fl) ; Col2-Cre + 19 32 
Hdac3 (Fl/Fl) ; Col2-Cre +  9 0 
Table 7.2. Expected ratio and observed number of animals at F5 generation. 
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Figure 7.7. Conditional HET Hdac3(+/Fl); Col2-Cre+ mice have similar size and weight to 
Wildtype Hdac3(+/+); Col2-Cre+  littermates. 
Representative image of 3-week old wildtype and HET male mice. Average weights of male (n=3) and 
female (n=7) wildtype mice and male (n=10) and female (n=10) HET mice at the time of weaning. 
Results are representative of the mean of n=10 Wt mice and n=20 HET mice +SD. For statistical 
analysis, an unpaired two-tailed student’s t-test was performed.  
 
 
 
 
Figure 7.8. A. X-rays and bone measurements were conducted as indicated above (ICD= Intercanthal 
Distance, Skull length, Length of Femurs and Tibias were measured). B. Histological analysis of the 
growth plate was performed at three weeks of age to assess development of the cartilage between 
Wildtype Hdac3(+/+);Col2-Cre/+ and HET Hdac3(+/Fl); Col2-Cre/+ mice. 
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Figure 7.9. Morphometric characterization of HET Hdac3(+/Fl); Col2-Cre/+ mice compared to 
Wildtype Hdac3(+/+); Col2-Cre/+. 
A. Length of right and left tibias, B. right and left femurs, C. intercanthal distance and D. skull 
were measured at the time of weaning. Results are representative of the mean of n=10 Wt (male 
and female) mice and n=10 HET (male and female) mice. For statistical analysis, an unpaired 
two-tailed student’s t-test was performed. Different colours represent different animals. The 
same animals were used for all measurements. 
 
 
 
 
 222 
 
 
Figure 7.10. HET Hdac3(+/Fl); Col2-Cre/+ growth plate structure and cartilage formation 
compared to Wildtype Hdac3(+/+); Col2-Cre/+ littermates. 
A. Representative images of Haematoxylin and Eosin (H&E) staining to assess chondrocyte column 
length in Wt Hdac3(+/+); Col2-Cre/+ and HET Hdac3(+/Fl);Col2-Cre/+ growth plates. 
Arrowheads indicate areas of hypo- cellularity. Ladder indicates the length of the Resting Zone 
(RZ), Proliferating Zone (PZ) and Hypertrophic Zone (HZ) in the growth plate of three-week old 
mice.  B. Representative images of Alcian Blue staining to assess cartilage formation in Wt and 
HET growth plates and C. Representative images of Toluidine Blue staining to assess 
proteoglycan deposition in Wt and HET growth plates. Bar= 100μm 
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7.4 Discussion 
The involvement of the epigenome in common complex human diseases is becoming 
increasingly clear and more feasible to study and understand due to new advances in genomic 
and computational technologies as well as the use of animal models. One of the most 
promising approaches towards drugs that can modify epigenetic traits has been seen in the 
development of Histone Deacetylase inhibitors (HDACi), some of which are already used for 
treatment of cancers and neurological conditions or are currently in clinical trials. (Richardson 
et al. 2016; Manal et al. 2016; Hull et al. 2016) Many additional uses have been proposed for 
these drugs, based on preclinical studies including in arthritis models. (Culley et al. 2013; Cai 
et al. 2015) Understanding the effects of these epigenetic-modifying drugs and the epigenome 
in general on the skeleton is of increasing interest because of its undoubtable importance in 
maintaining overall health and fitness. Therefore the main aim of this chapter was to 
understand how HDAC3 contributes to normal cartilage development in vivo and to assess its 
role in osteoarthritis (OA) using a selective HDAC3 inhibitor or the delivery of a siRNA, and 
eventually in DMM-induced OA in cKO Hdac3-null mice.  
 
7.4.1 Hdac3 inhibition failed to rescue cartilage damage in the DMM model of 
osteoarthritis. 
Previous data from our group support a chondroprotective effect of TSA in vivo in the DMM-
induced OA mouse model (Culley et al. 2013). These findings were also confirmed by  (Cai et 
al. 2015) in two different OA models, the DMM and a drug (monosodium iodoacetate, MIA) -
induced OA mouse model after using the HDACi TSA. However, my study demonstrated that 
cartilage degeneration was not rescued after using TSA or the selective HDAC3i Apicidin in 
the DMM mouse model (Figure 7.1). There were no significant effects in the cartilage of the 
tibia or femur of either HDACi treated joints when compared to the control treated joints.  
This opposing result could be due to the different administration method used in this study in 
comparison to the previous studies, and insufficient delivery of the drug to the cartilage 
chondrocytes of the knee joint. In particular, intra-articular injections were used in this study 
and performed twice in a four-week period, first at the day of the surgery and second two 
weeks post- surgery. In the two successful reports on the contrary, the compound was 
delivered subcutaneously either via daily (2.0mg/kg) injections (Cai et al. 2015) or via 
implanted osmotic pumps (1mg/kg/day) (Culley et al. 2013). Therefore these successful 
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delivery methods indicate that the drugs may need to be administered systemically and not 
locally. Furthermore, both HDACi were diluted in DMSO in this study to a final c=10mg/ml, 
while both successful studies have previously used PBS (Cai et al. 2015), ethanol or a mixture 
of 50% DMSO/ 50% polyethylene glycol 300 (Culley et al. 2013). 
Moreover, although three groups of six mice were set up initially, the number of mice in the 
TSA-treated group was reduced to three; due to a joint infection the sections from three mice 
were not included in the final analysis. The small number of mice involved in this experiment 
may explain the non-significant results obtained. Another possible reason for not seeing any 
significant effect in the cartilage damage caused by DMM is that the drugs were not sterile or 
the injections were not sterile. This would explain why three of the TSA injected mice were 
inflamed and inflammation might have compromised cartilage damage in this group. 
 
7.4.2 Intra-articular siRNA administration targeting Hdac3 in vivo in articular cartilage 
was inefficient. 
Intra-articular injectable regimens might be a suitable way for developing, testing and finding 
a cure for OA and in vivo models currently available could be used to optimize these methods. 
Hence administration of intra-articular biomolecules targeting chondrocyte activity or 
synovial inflammation is a promising strategy for therapeutic intervention in OA. To 
understand what epigenetic alterations occur in chondrocytes following Hdac3 depletion, a 
siRNA transfection was attempted to knockdown Hdac3 specifically in articular cartilage 
chondrocytes of wildtype C57Bl/6 mice. Intra-articular injections for localized administration 
of siRNA/atelogene complexes were performed at final concentration 20µM and transfection 
efficiency assessed at day three and six post-injections. Atelogene is composed of 
atelocollagen, a highly purified type I collagen isolated from calf dermis by pepsin treatment. 
Immunohistochemistry (IHC) for Hdac3 revealed no significant difference between the 
siHdac3 + Atelocollagen (Atelogene) - treated and siHdac3 + PBS or siBuffer + PBS control 
joints following three (Figure 7.2) or six days (Figure 7.3) after the injections. However, 
intra-articular injections of miR-15a with Atelogene in the knee joint of an autoantibody 
induced- arthritis mouse model has previously been successfully delivered. (Nagata et al. 
2009) In this paper, successful administration was examined one day and three days post-
injections in the synovium of the joint capsule using qRT-PCR and IHC. The expression of 
miR-15a was also measured in other tissue-organs with no significant difference identified 
apart from the liver, where increased expression of miR-15a was found. The authors propose 
this could be the result of part of the double-stranded miRNA injectable dose to have moved 
 225 
 
from the joint cavity to the systemic circulation and emphasize the importance of addressing 
this before any clinical studies can be performed. Therefore, it is possible that following 
three/six days after the injections were performed it is no longer possible to test for siRNA 
efficiency due to degradation or minimal retention in the joint capsule. Nevertheless, it is 
worth mentioning that other studies that have utilized the same transfection kit, used 
alternative administration routes including mainly intravenous and/or intraperitoneal systemic 
delivery of the siRNA or intratumor injections in the case of localized administration. 
(Mochizuki et al. 2012; Tanaka et al. 2013; Fujiwara-Okada et al. 2013; Shoji et al. 2013)  
In this chapter the main goal was to firstly efficiently transfect an siRNA in vivo in normal 
wildtype mice and secondly to try the same regimens in the DMM-surgical OA mouse model. 
However, due to inefficient transfections in the wildtype mice, the second part was not 
studied. It has previously been reported that cartilage thickness increases with animal size and 
larger animal models more closely resemble human joints (Holyoak et al. 2016). Cartilage 
thickness is also critical for intra-articular retention of drugs, since diffusion binding kinetics 
depends on the square of cartilage thickness (Bajpayee et al. 2015). Therefore, smaller animal 
models, for example mice used in this study may not be suitable for evaluating or predicting 
intra-articular drug retention in humans. Inefficiency of the Atelogene kit is also possible and 
hence alternative delivery methods could be used for future studies. 
Since OA pathology is restricted to the affected joint, intra-articular injections offer a number 
of benefits including low doses of local administration, high potency and minimal side effects 
compared to intravenous or orally administered drugs and supplements. In comparison 
intravenous administration of drugs usually results to poor localized delivery to the affected 
joints and often requires repetitive administration of large doses. Further, orally-administered 
drugs are often associated with complications to the gastrointestinal system. (Gupta & Eisen 
2009) Nevertheless, one of the main disadvantages of intra-articular injections is the lack of 
retention which leads to decreased efficacy. This could be partly due to articular cartilage 
extracellular matrix properties, for example the dense type II collagen network, the 
avascularity and the negatively charged aggrecan molecules may prevent entrance of 
therapeutic agents into the cartilage matrix. (Rothenfluh et al. 2008) Therefore, a large 
research area has emerged in creating biomaterials to improve the delivery and retention times 
of drugs in the articular cartilage. (Holyoak et al. 2016) 
The most common form of new biomaterials being tested for intra-articular delivery of drugs 
for OA treatment are nanoparticles (NP) onto which drugs can be loaded. A major benefit of 
nanoparticles is their ability to attach and bind to specific constituents of articular cartilage, 
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improve retention within the joint and hence slow the progression of the disease. To date, the 
primary categories of drugs delivered via nanoparticles are those that inhibit inflammation, 
those that can protect chondrocytes from apoptosis and promote chondrocyte differentiation 
and those that benefit from NP delivery to limit toxic systemic side effects. Hyaluronic acid is 
for example the primary candidate in the case of drug delivery via NP to inhibit inflammation, 
and it has been used in combination with salmon calcitonin. (Ryan et al. 2013) Salmon 
calcitonin has been shown to benefit cartilage metabolism and inhibits collagen breakdown by 
inhibiting MMPs. (Esenyel et al. 2013) IL-1 inhibitors are another category of drugs delivered 
by NPs to reduce inflammation. (Cunnane et al. 2001) 
Preserving chondrocyte health and homeostasis is a major objective in OA, and so anti-
apoptotic drugs may be useful in the treatment of OA. For example, brucine is an anti-
apoptotic drug that has been loaded onto NPs and used to promote cartilage regeneration and 
inhibit apoptosis, though proven to be severely toxic to the central nervous system. (Chen et 
al. 2013) Kartogenin was also used in combination with NPs and shown to selectively 
differentiate MSCs into chondrocytes and thus may benefit from local delivery to the joint. 
(Kang et al. 2014) Intra-articular delivery of a peptidic NP complexed to NF-κB siRNA 
significantly reduced chondrocyte apoptosis and reactive synovitis in a murine model of 
controlled knee joint impact injury. (Yan et al. 2016) Lentiviral vector- mediated delivery of 
Toll-like receptor 7 gene short hairpin RNA (shRNA) on collagen-induced arthritis in rats 
showed promising results in terms of reducing ankle inflammation, articular indexes and 
radiographic and histologic scores. (Chen et al. 2012) Finally, intra-articular injections of 
biodegradable polymer microparticles which release controlled levels of anti-inflammatory 
siRNA have been successfully delivered in a rat model of painful temporomandibular joint 
inflammation, showing promising results in decreasing inflammation accompanied with 
reduced IL-6 expression levels. (Mountziaris et al. 2012) 
 
7.4.3 Cartilage specific conditional knockout Hdac3 mice are embryonic lethal before 
E16.5. 
Previous research (Bradley et al., 2013) demonstrated that Hdac3 is abundant in proliferating 
and hypertrophic growth plate chondrocytes of one-month old mice and can be detected as 
early as E14.5. To further determine the role of Hdac3 in chondrocytes during endochondral 
ossification, Hdac3 gene was first conditionally deleted in cells expressing Cre recombinase 
under the control of Col2α1 promoter (here is termed Hdac3(Fl/Fl);Col2-Cre(+) or 
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Hdac3CartΔEx3). Col2α1 has been shown to be expressed in embryonic cartilaginous tissues as 
early as E10.5 and in developing skeletal structures at E13.5. (Chen et al. 2007; Nakamura et 
al. 2006) Following selective breeding with FLP positive and Cre positive transgenic mice as 
shown in Figure 7.5, HDAC3 conditional HET animals were born at higher rate than the 
expected Mendelian ratio as shown in Table 7.2 and were normal size (Figure 7.7). However, 
no conditional knockout (cKO) Hdac3(Fl/Fl); Col2-Cre+ animals were born in 8 litters. Wt 
and HET mice, but no cKO, were also present at E16.5 from 3 different litters. These findings 
indicate that HDAC3 may be necessary for pre-natal cartilage formation and bone growth 
before E16.5. This could be due to defective DNA repair mechanism as it has previously 
shown for the global Hdac3 null mice. (Bhaskara et al., 2010) Deletion of Hdac3 from 
cartilage could also impair a number of cartilage-extrinsic phenotypes including for example 
angiogenesis which is necessary for normal endochondral ossification and bone mineral 
density as it was found for the Osterix-Cre Hdac3 cKO mice. (Razidlo et al., 2010) 
Indeed, Carpio’s et al. research also showed that Col2α1 Hdac3 cKO mice are embryonic 
lethal between E10.5 and E16.5. (Carpio et al. 2016) While expected Mendelian ratios of 
heterozygous conditional mice were born, no Hdac3 cKO mice were born in their nine litters. 
However, Hdac3 cKO and conditional HET mice were detected at E10.5, but only HET were 
present at E16.5, indicating that Hdac3 expression in chondrocytes is necessary during these 
early stages of skeletal formation between E10.5 and E16.5. (Carpio et al. 2016) 
Since the Hdac3 cKO mice were embryonic lethal, the only alternative method that we could 
use to study the effect of Hdac3 loss in chondrocyte development/ proliferation would be to 
postnatally delete Hdac3 in order to overpass the embryonic lethality. This would be possible 
if using an inducible conditional transgenic line, which could induce Hdac3 knockout in 
specific developmental stages. For example, the tamoxifen-inducible Col2α1-Cre line 
(Col2α1ERT-Cre; The Jackson Laboratory- https://www.jax.org/strain/006774) (Nakamura et 
al. 2006) could have been used to generate Hdac3-cKOCol2ERT, by injecting tamoxifen (if mice 
were to be used before weaning) or including it in the food (if the mice were to be used after 
weaning). Another example is the tamoxifen inducible Acan-CreER-Ires-Luc line (Lo Cascio 
et al. 2014) which uses an aggrecan gene enhancer to induce knockout specifically in 
cartilage, expresses firefly luciferase and has a tamoxifen-activatable Cre recombinase. The 
expression of the transgene is restricted to cartilage from embryonic to adult stages and one of 
the main advantages is the presence of luciferase which allows for visualisation of transgene 
expression in live animals. However, due to unavailability of such a transgenic line in 
Newcastle University it was time-wise impossible to perform these breedings. Furthermore, it 
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became aparrent during this thesis that the group of J.J. Westendorf had come to the same 
conclusions and were already performing these experiments (Carpio et al. 2016). 
 
7.4.4 Hdac3(Fl/+);Col2-Cre/+ HET mice present normal intramembranous and 
endochondral ossification and growth plate morphology compared to wildtype 
Hdac3(+/+);Col2-Cre/+ mice.  
My study demonstrated that cartilage- specific Hdac3 knockout was embryonic lethal. 
Nonetheless, a detailed comparative analysis between the Wildtype Hdac3(+/+);Col2-Cre/+ 
and HET Hdac3(Fl/+);Col2-Cre/+ animals was performed at three weeks post-natal to 
determine cartilage development of the growth plate. 
No significant size or weight difference was observed at three weeks of age between the Wt 
and HET male or female mice (Figure 7.7), as evidenced by x-rays and bone measurements. 
Femoral and tibial lengths were used to indicate endochondral bone formation and 
intercanthal distance (ICD) and skull length to measure intramembranous bone growth. 
Endochondral bones of HET Hdac3(Fl/+);Col2-Cre/+ mice were a similar size to the Wt 
Hdac3(+/+);Col2-Cre/+ littermates at three weeks postnatally (Figure 7.9 A-B), and no 
difference was found in the ICD or skull length between HET and Wt, indicating 
intramembranous bone formation remained unaffected (Figure 7.9 C-D).  
Furthermore, an analysis of the growth plates of three weeks old Wt and HET mice was 
performed to identify possible differences in the size or shape of the proliferative zone 
chondrocytes, or any difference in cartilage formation and proteoglycan synthesis of the 
growth plate cartilage. H&E staining suggested growth plate zone lengths were of similar 
length in HET and Wt mice at three weeks of age (Figure 7.10, H&E staining). Cartilage 
formation assessed by Alcian Blue staining which revealed similar content of GAGs in the Wt 
and HET growth plates at three weeks of age (Figure 7.10, Alcian Blue staining) and finally, 
no apparent difference in proteoglycan content was detected using Toluidine blue staining in 
Wt and HET mice (Figure 7.10, Toluidine Blue staining). 
These data are in agreement with the KOMP-phenotyping results 
(https://www.mousephenotype.org/data/genes/MGI:1343091#order) comparing Hdac3(+/Fl) 
to Hdac3(+/+) mice. X-rays showed no difference in the size of tibias, shape of femur and 
femur- tibia angle, shape of pelvis, shape of ribs or the development of abnormal teeth. 
DEXA scans also revealed normal bone mineral density, bone content and bone size between 
heterozygous and wild type mice. However, some heterozygote Hdac3(+/Fl) showed 
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abnormal eye morphology and developed cataract and also some female heterozygote mice 
had significantly higher heart weight than the female Wild type mice. This observation has 
been previously linked to a high-fat diet in mice in which HDAC3 was postnatally deleted 
from the heart and skeletal muscle and induced lethality. (Sun et al. 2011) 
Interestingly, postnatal ablation of Hdac3 in chondrocytes delays endochondral ossification. 
(Carpio et al. 2016)  Hdac3(Fl/Fl) mice carrying a flanked exon 7 were bred with the 
tamoxifen-inducible Col2α1-Cre mice to generate Hdac3-cKOCol2ERT. These animals were 
given a single injection of tamoxifen at 5 days postnatally (P5) and HDAC3 expression and 
protein levels were significantly lower than normal at four and eight weeks of age. (Carpio et 
al. 2016) Although the inducible Hdac3 cKO weighed approximately 50% less than the 
control mice, these weight deficiencies were resolved by eight weeks of age. Severe delays in 
secondary ossification centre (SOC) formation were profound in tibiae of 9- and 14-day-old 
inducible Hdac3 cKO, but by four weeks of age this phenotype was also been resolved and 
SOC were fully formed in control and cKO animals. Though, growth plate defects in the 
inducible Hdac3 cKO mice were evident. In particular, the growth plates were thinner by 18% 
than those in the control animals in the interior side of the growth plate and 67% thicker on 
the medial side and 57% thicker on the lateral side. While tamoxifen did not have any effect 
on the growth plates of control animals, Hdac3 appear to be important for maintaining normal 
DNA integrity, indicated by increased phosphorylation of γH2A.X, a marker of DNA double-
strand breaks, and also vasculogenesis, evidenced by reduced abundance of the angiogenic 
marker PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1). (Carpio et al. 2016) 
It has also been proposed that Hdac3 regulates chondrocytes transcriptome and chromatin 
landscape (Carpio et al. 2016) and it is important for inflammatory gene expression 
programmes in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). (Angiolilli et al. 
2017) It was shown that Hdac3 depleted chondrocytes had increased lysine acetylation of 
histones H3 and H4. Delays in chondrocyte maturation were confirmed by real-time PCR 
with reduced Col2α1, Acan, Ihh and Col10α1 expression and decreased proteoglycan 
production observed. (Carpio et al. 2016) On the other hand, increased expression of genes 
encoding for cytokines, and are classically linked to inflammation such as IL-6, Cxcl1 and 
Saa3, as well as catabolic factors including MMP13 and MMP3, were found in Hdac3-
depleted chondrocytes. (Carpio et al. 2016) Additionally, when HDAC3 was inhibited or 
depleted in rheumatoid arthritis-derived FLS, IL-1β inducible genes were significantly 
suppressed and IFN-dependent genes like Cxcl11 and Cxcl9 expression reduced. It is 
supported that HDAC3 is important for mediating type I IFN production and subsequent 
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STAT1 Tyr phosphorylation and activation in FLS, hence establishing a new potential 
therapeutic target in RA and type I IFN- driven auto-immune diseases. (Angiolilli et al. 2017) 
The mechanism by which Hdac3 mediates catabolic gene expression in chondrocytes has also 
been studied and it is suggested that in Hdac3-depleted chondrocytes, Erk1/2, as well as its 
downstream target Runx2, are hyperphosphorylated, as a result of decreased expression and 
activity of the ERk1/2 specific phosphatase, Dusp6. Expression of Dusp6 and Erk1/2 kinase 
inhibitors reduced MMP13 expression and restored matrix production in Hdac3-depleted 
chondrocytes. Furthermore, premature production of Erk1/2 and MMP13 was found in the 
growth plates of the inducible Hdac3 cKO. (Carpio et al. 2016) However, Dusp6 expression 
was not altered in my microarray experiment following HDAC3 inhibition by Apicidin or 
gene depletion. 
It is therefore becoming apparent that HDAC3 plays an essential role in ensuring correct 
endochondral ossification during development and targeted delivery of HDAC3 selective 
inhibitors/ drugs or siRNAs should be further tested in order to fully understand its role in OA 
progression.
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7.5 Conclusions 
 HDAC pan inhibition using TSA, failed to recapitulate previous data regarding 
decreased cartilage degeneration in the OA-surgically induced DMM mouse model. 
 HDAC3 selective inhibition by Apicidin did not show any significant difference in the 
cartilage damage observed in the DMM mouse model when compared to the vehicle-
control injected mice. 
 In vivo siHDAC3 intra-articular delivery did not efficiently decreased HDAC3 protein 
levels at three and six days post-injections. 
 Hdac3 deletion from Col2α1 expressing tissues causes embryonic lethality before 
E16.5 in mice. 
 Postnatal comparison, at three weeks of age, between HET Hdac3(Fl/+);Col2-Cre/+ 
and Wildtype Hdac3(+/+);Col2-Cre/+ did not reveal any significant difference in 
neither endochondral nor intramembranous ossification and cartilage formation in the 
growth plates.  
 Taken together my data indicate that haplo-insufficiency of Hdac3 has no effect on 
cartilage development, while early post-natal complete loss is embryonic lethal. 
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Chapter 8: General Discussion 
 
8.1 Summary 
Histone deacetylases regulate the acetylation pattern of chromatin to control gene expression 
and determine cell differentiation and mammalian development. Previous studies reported 
HDACs as potential regulators of the expression of major collagenases in articular cartilage 
and gene silencing studies identified class I HDACs and specifically HDAC3 as a key 
regulator of their expression. (Culley et al. 2013) Moreover, HDAC inhibitors including TSA 
have been assessed in vivo in surgically induced- and drug induced- osteoarthritis mouse 
models and showed a chondroprotective role. (Culley et al. 2013; Cai et al. 2015) The role of 
TSA HDAC-pan inhibitor has also been assessed in vivo in rats, whereby reduced gene 
expression and protein levels of MMP1, MMP3, MMP13 and increased expression of TIMP1 
were observed in the TSA-treated group and safranin-O staining indicated cartilage retention. 
(Qu et al. 2016) Very recently, Carpio et al. (2016) showed that cartilage Hdac3 is necessary 
for normal embryonic cartilage development and regulates transcriptome and chromatin 
landscape in chondrocytes (Carpio et al. 2016) . Previous studies also demonstrated the 
importance of HDACs in regulating the expression of many anabolic genes in chondrocytes 
such as COL2α1, COL9α1, and ACAN. (El-Serafi et al. 2011; Huh et al. 2007)  
The aims of this project were to examine the effects of HDAC3 loss on gene expression using 
SW1353 chondrocytes and also on mesenchymal stem cells (MSC) – derived chondrogenesis. 
First, we sought to confirm previous studies which indicated HDAC3 as a critical mediator of 
IL-1 induced expression in chondrocytes (Chapter 3). To do this, HDAC pan- and selective 
inhibitiors were used and the expression of MMP1, MMP13, IL-6 and IL-8 were quantified 
with qRT-PCR. Then the effect of HDACi was determined in a BNC assay, where collagen 
release was significantly reduced following HDACi and IL-1 or IL-1+OSM stimulation, with 
no significant alteration in collagen breakdown at the basal level. Gene silencing of HDAC3 
confirmed the effect of the pan-HDACi and selective HDACi on collagenase and IL-6 
expression in chondrocytes and interestingly HDAC3 appears to have IL-1 specific functions 
in regulating IL-8 expression. NF-κB signaling pathway components, in particular p65, are 
potentially good candidates here, as it has been suggested that HDAC3 is required to remove 
inhibitory acetyl-groups from p65 which then drives IL-8 expression. Indeed, when a NF-κB 
luciferase reporter was assayed in the presence/absence of HDACi and IL-1 stimuli, the 
activation of the reporter was significantly decreased. Nevertheless, no downstream signaling 
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pathway component analysis was performed (see also section 8.3 Limitations of the study and 
future work).  Immediate early gene expression was also analysed and FRA-1 constitutes a 
good candidate gene in mediating the effect of HDAC3 in MMP gene expression regulation. 
However, more experiments required to define the role of FRA-1 on MMP expression in 
chondrocytes. 
Next, we defined the global gene expression changes, transcription factor binding sites 
enrichments and pathways regulated by HDAC3 in chondrocytes by RNA microarray 
analysis, following RNAi for HDAC3 or HDAC3i using Apicidin (Chapter 4). Herein, a 
previous microarray analysis, performed by Dr Matt Barter, was taken into account and the 
data arised from the HDAC pan-inhibition using TSA were compared to my data from the 
selective HDAC3i Apicidin. This was the first time that collagen catabolism was identified in 
the GO predicted terms, as well as the first time that E2F binding sites were found in the IL-1 
induced and repressed by both inhibitors gene lists. Interestingly, all the subsequent 
comparisons between the genes that are induced by IL-1 and repressed by either Apicidin, or 
siHDAC3 or both concluded in an enrichment for E2F-1 transcription factor. Most 
importantly and as indicated in the relevant tables, many of these genes were OA or cartilage 
related (see Tables 4.2-4.6).   
The molecular mechanism of the HDAC3-mediated gene regulation and in particular the E2F-
1/HDAC3 relationship was subsequently investigated in SW1353 chondrocytes and 
HEK293T cells (Chapter 5). Here, we showed that first of all HDAC3 and E2F-1 interact in 
vitro and we also predicted novel potential E2F-1 binding sites on the promoters of both 
MMP1 and MMP13. The effect of E2F-1 over-expression and gene knockdown on MMP 
expression was determined using MMP luciferase constructs and qRT-PCR. However, a 
direct association of either HDAC3 or E2F-1 on MMP promoters was now shown in this 
study and therefore should be confirmed. HDAC3 was also shown to be required for normal 
cell cycle progression and could be part of the E2F-1 pathway, positively regulating transition 
into the S phase of the cell cyle. 
Finally, I sought to understand the role of HDAC3 in chondrocyte development by using a 
human MSC in vitro model lacking HDAC3 and by generating a cartilage-specific conditional 
knockout mouse model. Bone marrow derived MSCs were utilized and anabolic gene 
expression and proteoglycan synthesis determined following HDAC inhibition or HDAC3 
gene depletion during chondrogenesis (Chapter 6). HDACi prior to inducing chondrogenesis 
resulted in decreased anabolic gene expression and proteoglycan synthesis, although the time 
and duration of MSC treatment seems to play crucial role in altering specific epigenetic 
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programs. In contrast to the HDACi data, HDAC3 gene silencing promoted anabolic gene 
expression and GAG synthesis, indicating siRNA-mediated gene depletion may be promising, 
as an alternative to drugs tissue engineering approach for the generation of healthy cartilage. 
An Hdac3 cartilage specific conditional knockout mouse model was generated in addition to 
the DMM-OA mouse model, which were used to decide the effect of Hdac3 loss in murine 
development (Chapter 7). However, embryonic lethality of the cKO prevented phenotypic 
characterisation of the mutants and intra-articular injections of the HDACi in the DMM model 
did not ameliorate cartilage erosion. 
 
8.2 Key results 
The overall scope of my thesis was to determine the role of HDAC3 in the development and 
or/progression of osteoarthritis and in chondrogenesis.  
In the context of the development and/or progression of osteoarthritis the key conclusions 
drawn from this study are: 
 HDAC inhibition using TSA, MS-275 or Apicidin and RNAi for HDAC3 blocked IL-
1-induced MMP1, MMP13 and FRA1 gene expression in SW1353 cells. 
 HDACi decreased collagen release following cytokine stimulation in a BNC assay. 
 NF-κB transactivation was decreased following HDAC inhibition both in the basal 
and IL-1 induced level. 
 Microarray analysis showed all the genes repressed by siHDAC3 with/without IL-1 
stimulation were enriched for E2F-1 transcription factor binding sites. And 
comparison of the IL-1 induced and siHDAC3 or Apicidin repressed genes are 
enriched for E2F-1 transcription factor binding sites in their promoters. 
 HDAC3 can interact with E2F-1 transcription factor in vitro and E2F-1 binding sites 
have been predicted on both MMP1 and MMP13 promoters.  
 Over-expressing E2F-1 reduced the transactivation of three MMP luciferase reporters, 
while HDAC3 inhibition or gene depletion further decreased luciferase activation. 
 Gene silencing of E2F-1 up-regulates MMP1 and MMP13 expression. 
 HDAC3 and E2F-1 are required for normal cell cycle progression and loss of either or 
both induced cell cycle arrest at the G1 phase.  
 HDAC pan inhibition using TSA, failed to recapitulate previous data regarding 
decreased cartilage degeneration in the OA-surgically induced DMM mouse model. 
HDAC3 selective inhibition by Apicidin did not show any significant difference in the 
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cartilage damage observed in the DMM mouse model when compared to the vehicle-
control mice. 
In the context of chondrocyte differentiation/development the main conclusions are: 
 HDAC inhibition using TSA, but not Apicidin, induces hyper-acetylation of α-tubulin 
and total lysines and decreases anabolic gene expression and proteoglycan deposition 
of MSC-differentiated chondrocytes. 
 HDAC3 gene depletion promotes anabolic gene expression of SOX9, ACAN and 
COL2A1 and proteoglycan synthesis of MSC-differentiated chondrocytes. 
 Hdac3 deletion from Col2α1 expressing tissues causes embryonic lethality before 
E16.5 in mice. However, postnatally Hdac3(Fl/+);Col2-Cre/+ heterozygous animals 
were phenotypically normal. 
 
8.3 Limitations of the study and future work 
By tailoring the experiments presented in this thesis, the existing data could be made more 
considerably robust. First, the experiments presented in Chapter 3 demonstrated that HDACs 
and especially HDAC3 may positively regulate the induction of collagenase expression in 
chondrocytes, since inhibition or specific HDAC3 depletion resulted in a significant 
repression of this induction. These experiments were conducted in SW1353 cells, it would 
therefore be worthwhile validating the effect of HDAC3 on MMP and FRA1 gene expression 
regulation using human articular chondrocytes (HAC). However, previous studies have 
utilised HACs and partially confirmed the data presented in Chapter 3 (Culley et al. 2013) and 
SW1353 cells are a recognised model for studying IL-1 induced MMP gene expression 
regulation (Gebauer et al. 2005).  
Another limitation of this study is that only the mRNA levels of MMPs were quantified and 
the protein levels/activity were not taken into account. The regulation of MMP activity is 
difficult to assess due to the multitude of mechanisms regulating the activity of these 
enzymes. The easiest way of analyzing total MMP levels is by analyzing mRNA transcript 
levels, rather than the protein levels or enzyme- activity due to complex protein regulation. In 
addition to the transcriptional regulation of MMPs, they are regulated at the translational level 
through trafficking and secretion by subcellular or extracellular localization, through zymogen 
activation, by binding to endogenous inhibitors, including TIMPs and α2-macroglobulin and 
finally through degradation by proteases. (Alameddine & Morgan 2016) However, Young et 
al. (2005) showed that the protein levels (by immunoblotting) of MMP1 and MMP13 as well 
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as the activity (by gelatin zymography) of MMP2 and MMP9 were reduced in the presence of 
TSA and IL-1+OSM. Alternatively, ELISA could have been used to measure MMP activity. 
Since the induction of some genes such as FRA1 requires dynamic changes in acetylation 
(Khan & Davie 2013), other post-translational modifications such as methylation or 
phosphorylation may be required for such a turnover and future studies should take this into 
account. Moreover, the effect of FRA1 gene depletion on MMP or E2F-1 expression remains 
unclear and needs to be determined. Additionally the effect of E2F-1 on FRA1 expression 
which in turn might impact upon MMPs was not studied, and these effects could be easily 
determined by siRNA mediated gene depletions. 
A previous study comparing the expression of HDACs in normal and OA cartilage concluded 
that no significant difference in the expression of HDAC1, HDAC2, HDAC3 or HDAC8, 
although a trend toward decreased expression of HDAC1, HDAC3 and HDAC8 in OA was 
found (Higashiyama et al. 2010). It would be worth validating some of the gene expression 
data presented in Chapter 3, using OA knee cartilage and comparing it to healthy control 
cartilage. 
The role of HDAC inhibition on NF-κB transactivation was determined using luciferase 
assays (Chapter 3). However, whether siHDAC3 similarly affects NF-κB activity was not 
analysed and neither were downstream targets of NF-κB signalling pathway. It is known that 
NF-κB regulates over 200 genes involved in cell cycle and inflammation and is activated by 
cytokines (IL-1 or TNF-α) or bacterial products (lipopolysaccharide, LPS). (Pereira and 
Oakley, 2008) In order to analyse the potential action of HDACs and HDAC3 on the 
activation of signaling components of the NF-κB pathway, phosphorylated antibodies for 
some NF-κB subunits such as p65 or p50 could be used to test for activation and compared 
with total protein levels with/without HDACi or siHDAC3. Nuclear translocation of NF-κB 
could also be impaired following HDACi and this could be tested by immunofluorescence 
staining. DNA binding could be assessed by ChIP experiments or EMSA (Electro-mobility 
shift assays) and inhibitory κB α (IκB α) activity monitored by immunoblotting. HDAC3 
protein association with any NF-κB transcription factors could be tested by co-
immunoprecipitation experiments. Finally NF-κB component acetylation in the presence/ 
absence of HDACi or siHDAC3 could be monitored by immunoblotting. 
Further to the results presented in Chapter 5 (section 5.3.3), yeast-two hybrid screening 
would confirm direct interaction of HDAC3 and E2F-1 transcription factor and Fluorescent 
Resonance Energy Transfer (FRET) could prove the involvement/requirement of DP1 
transcription factor in this interaction. HDAC3 or E2F-1 potential DNA binding at or near 
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MMP promoters and the responsible for activation of transcription and binding domains could 
be identified using yeast-two hybrid screening. Whether HDAC3 is responsible for de-
acetylating E2F-1 on K117, K120 and K125 should be determined, since this could be an 
alternative way of HDAC3-mediated regulation of E2F-1 transcription factor half-life and 
stability, (an antibody is available that recognizes the acetyl-K120 and K125 E2F-1). 
EMSA could be used to show if HDAC3 can directly bind to two previously identified 
regulatory elements on e2f-1 gene promoter (Panteleeva et al. 2004) or if E2F-1 transcription 
factor can associate with the chromatin upstream of MMP1/13 promoters. Herein, sequential 
mutations of the E2F-1 predicted binding sites on the MMP promoters could be used for 
generating probes to validate direct E2F-1 binding. Alternatively, a luciferase reporter 
containing the two e2f-1 regulatory elements and similar experiments with the ones presented 
in Chapter 5, section 5.3.5.2, could be performed and the effect of HDACi and/or siHDAC3 
determined. Furthermore, the ChIP experiments performed in this study should be repeated 
since non-specific binding to the irrelevant IgG antibodies was detected, generating doubtful 
results. More than one positive and negative control genes should also be included in these 
experiments and a good candidate as a positive control gene for E2F-1 would be CDC6. 
Previous studies support an adverse effect of IL-1 stimulation on E2F-1 expression and 
downstream transcription (Ertosun et al. 2016) and E2F-1 was shown to be required for NF-
κB- mediated IL-1β expression (Lim et al. 2007). However, the effect of IL-1 on E2F-1 and 
MMP expression in chondrocytes is not entirely clear and needs to be established.  
With reference to the animal work presented in Chapter 7, the acetylation levels of proteins 
within the intra-articularly injected joints (HDACi- treated, section 7.3.1 The effect of Hdac3 
inhibition on a DMM-induced osteoarthritis mouse model., and siRNA- treated, section 7.3.2 
Intra-articular delivery of a siRNA targeting HDAC3 in C57Bl/6 mice joints were not examined in 
this thesis. Should, as expected, the HDACi (TSA or Apicidin) and siHDAC3 was 
successfully administered in the HDACi- treated joints; an increase in acetylation would 
confirm successful delivery. Sections of the TSA-, Apicidin- and siHDAC3- treated joints 
could have been stained for a total acetyl-Lysine and an acetyl-α-tubulin antibody and 
compared to the contralateral knee joints that had no treatment. Alternative delivery methods 
of the HDACi/ siHDAC3 such as minipumps (Culley et al. 2013) could be used to optimise 
successful administration.   
Furthermore, cell proliferation and apoptosis assays were performed once using 
Hdac3(Fl/+);Col2-Cre/+ heterozygous knee joint sections and compared to wildtype 
littermates. However, these experiments were not successful and staining quantification could 
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not be performed and neither the experiments could be repeated due to limited time. An IHC 
for Ki67, a proliferation marker, was also performed using siHDAC3-treated cartilage disc 
sections and compared to siCON sections from Chapter 6. These data are not presented here, 
since due to tissue folding of the sections, no staining quantification could be performed. 
However and based also on my results presented in Chapter 5 indicating cell cycle arrest 
following HDAC3 and E2F1 depletion, it would be worth validating the effect of Hdac3 loss 
in vivo in cell proliferation/ apoptosis during cartilage development. Therefore different 
developmental stages of the HET mice could be used including for example one-, three-, six- 
and nine- week old animals and compared to wildtype mice. 
One vital limitation of this project was the lethality of the Hdac3 cKO model that was 
generated. In order to overpass the embryonic lethality, the only alternative method would be 
to use an inducible conditional transgenic line, which could induce HDAC3 knockout in 
cartilage at specific developmental stages. Such examples were given in Chapter 7, section 
7.4.3 and include the tamoxifen-inducible Col2α1-Cre line (Col2α1ERT-Cre; the Jackson 
Laboratory- https://www.jax.org/strain/006774) (Nakamura et al. 2006) and the tamoxifen 
inducible Acan-CreER-Ires-Luc line (Lo Cascio et al. 2014). However, due to unavailability 
of these transgenic lines in Newcastle University it was time-wise impossible to perform these 
breedings. So time-allowing it would be worthwhile performing the DMM surgery on the 
Hdac3 HET and/or establish an inducible cKO and perform the DMM on KO and wildtype 
animals to examine progression of cartilage degradation.   
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In summary, I have fulifilled the aims of my PhD, which were to dissect the role of HDAC3 
in gene expression regulation in the development/progression of osteoarthritis and in 
chondrocyte differentiation. First, we confirmed the effect of HDAC3 on the IL-1 induced 
expression in chondrocytes and HDAC3 loss indicated decreased MMP expression. However, 
during MSC-chondrogenic differentiation HDAC3 knockdown resulted in an upregulation of 
MMP13 in addition to increasing anabolic gene expression. Our results suggest a dual role for 
HDAC3, one in development and one in differentiated tissues. This dichotomic effect of 
HDAC3 in development and in inflammatory conditions could be mediated through E2F-1 
transcription factor. For example, during an inflammatory response, HDAC3 by associating 
with E2F-1 and directly/indirectly binding to gene promoters could trigger MMP expression 
in chondrocytes. Disturbing this HDAC3/E2F-1 association alters IL-1 induced gene 
expression in chondrocytes. However, a role for HDAC3 and E2F-1 in cell cycle progression 
also became apparent in this thesis. It is therefore possible that during development, 
HDAC3/E2F-1 have a key role in the diferentiation/ maturation of the GP chondrocytes by 
controlling cell proliferation. Teasing these two roles of HDAC3 apart would be necessary for 
any future therapeutic approach involving HDAC3. 
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Appendix A 
Genes in K-mean clusters shown in Figure 4.3 are given in the Table below: 
 
Figure 4.1 A- 
siHDAC3_Cluster 18 
Figure 4.1 B- 
siHDAC3_Cluster 24 
Figure 4.1 C- 
siHDAC3_Cluster 23 
Figure 4.1 D- 
Apicidin_Cluster 2 
ARL14 AJAP1 AARS ACAT2 
ATF3 AKR1C2 ABCB9 AHNAK 
CSRNP1 BCL3 ABCC3 ALDH9A1 
CCL2 BCOR ABLIM1 AP2S1 
CSF2 BIRC2 ACOT9 APCDD1L 
DUSP1 BMF ACSL3 ATP1A1 
EFNA1 BPGM ADK ATP5I 
EGR1 C1QTNF1 AFG3L2 ATP6AP2 
EGR2 CCL20 AHSA1 ATP6V0E1 
HBEGF CCL7 AIFM1 AXL 
IL8 CD83 AK2 AXL 
IRF1 CD83 AKR1C3 B2M 
JUNB CXCL10 AKT1 BAMBI 
MAFF EGFR ALCAM BASP1 
MAFF EML1 ANX2P2 BSG 
NFKBIZ ETS2 APH1A BUD31 
SLC25A24 FAM167A NAA10 C17orf45 
TNFAIP3 FAM43B ARHGEF18 C20orf24 
ZFP36 FAT1 ARID5B ROMO1 
 GBP2 ARSD CALD1 
 GINS3 ASAP1 CALM3 
 HLX ASAP2 CALU 
 AF176921 ASNSD1 CCT7 
 IFIT2 ATP2B4 CDC37 
 IFIT3 ATP6V0D1 CDH2 
 IL11 ATP6V0E2 CDKN1A 
 IL24 ATPIF1 CETN2 
 IL32 AVPI1 CKAP4 
 IRAK2 B4GALT5 CNN3 
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 KRT34 BAIAP2L1 COL1A1 
 KRT75 BCL7C COL1A2 
 C11orf96 BMP4 COL5A1 
 GATSL3 BSCL2 COL6A3 
 FP15737 C11orf1 COX6B1 
 LRIG1 C13orf15 CREB1 
 LRIG1 INF2 CST3 
 MSC C16orf58 CSTB 
 NAMPT FOPNL CTGF 
 NEDD4L C18orf10 CYB5B 
 NFIL3 C19orf22 DAD1 
 NKX3-1 C19orf50 DCBLD2 
 NMI C19orf60 DDB1 
 NOC3L C1GALT1C1 DDT 
 NRG1 C20orf111 DRAP1 
 OAS2 C21orf33 EDF1 
 PARP12 C2CD2 EIF3B 
 PARP9 C2orf29 EIF3D 
 PGM3 RRP36 EIF4G2 
 PPAP2B C9orf119 EMP3 
 PRIC285 C9orf78 EPN1 
 RGMB CALM1 ESD 
 RIPK2 CANT1 FEZ2 
 TYMP CAPZB FHL2 
 SERPINA1 CAV2 FXYD5 
 SERPINB2 CCND3 G6PD 
 SERPINB2 CD97 GHITM 
 SERPINB8 CD99L2 GNAI2 
 SERPINB8 CDC16 GNS 
 SLC25A28 CDKN3 GSPT1 
 SLC2A6 CEBPD GSTO1 
 SLCO2B1 CEBPZ H2AFY 
 SOD2 CFDP1 HCFC1R1 
 SPHK1 CGGBP1 HDAC1 
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 SPSB1 CHIC2 HIBADH 
 TCEAL1 CHMP1A HK1 
 TJP2 CLINT1 HNRNPM 
 TMEM132A CMTM3 HNRNPA2B1 
 TMPRSS3 CNIH HNRNPM 
 TNFAIP2 CNPY2 HPCAL1 
 TNFRSF1B CNRIP1 ILK 
 TNIP1 COPE ITM2B 
 TRIM21 COPS4 JTB 
 TRIM56 COPS6 KHDRBS1 
 ZSWIM4 COPS8 LCP1 
  COPZ1 LDOC1 
  COQ2 C4orf48 
  CORO1C DKFZp686L07201 
  CPNE1 NA 
  CREB3L2 MAGED1 
  CRK URGCP 
  CTNNA1 NCOA4 
  CTSA NDUFA1 
  CTSB NDUFAB1 
  CTXN1 NDUFAF3 
  CUEDC2 NDUFB2 
  CXCR7 NDUFS8 
  CYBRD1 NGFRAP1 
  CYFIP1 NME1 
  SPECC1L NOP10 
  DAG1 NPTN 
  WDR68 NQO1 
  DCTD NUCB1 
  DCTPP1 NUCKS1 
  DDX17 ODC1 
  DDX24 P4HB 
  DEGS1 PAGE5 
  DEK PALLD 
 243 
 
  DENND5A PDLIM1 
  DHCR24 PEA15 
  DHX15 PFN2 
  DIMT1L POLR1D 
  DLD PPP2CA 
  DNAJB6 PPP2R1A 
  DUSP10 PRNP 
  DUSP22 PRSS23 
  DUSP23 PSAP 
  EEF1A2 PSAP 
  EFR3A PSMA4 
  EIF2A PSMA5 
  EIF4G1 PSMB6 
  EMD PTBP1 
  ENG PTTG1IP 
  EPAS1 QARS 
  EPDR1 RAB31 
  EPRS RARS 
  ERAP2 REXO2 
  ERCC1 RHOBTB3 
  ERGIC3 RNF7 
  EXOSC1 RRAGA 
  EXOSC3 SAT1 
  FADS1 SC4MOL 
  FAM189B SEMA3E 
  FAM50A Sep-09 
  FAM98A SERF2 
  FBXL18 SERPINE1 
  FBXO11 SH3BGRL3 
  FBXO7 SH3KBP1 
  FCAR SHC1 
  FERMT2 SLC16A3 
  FGFRL1 SLC25A3 
  FIBP SNX3 
 244 
 
  FIS1 SPCS1 
  FKBP3 TCEAL4 
  FLOT2 TIMM23 
  FNDC3B TIMP1 
  FZD2 TIMP2 
  GATAD2A TM4SF1 
  GLIPR2 TMBIM6 
  GLT25D1 TMED3 
  GNL2 TMED9 
  GOT1 TMEM14C 
  GPAA1 TMEM158 
  GPS1 TMEM17 
  GRINA TMEM59 
  GTF2E2 TMEM66 
  GTF2F2 TNFRSF21 
  H1F0 TRAM1 
  HECTD1 TSPO 
  HERC4 TXNRD1 
  HIF1A UBA1 
  HIST1H2BD UBA1 
  HMGB2 UXT 
  HMGCR WBP2 
  HNRNPA0 WDR1 
  HNRNPA2B1 YWHAH 
  HNRNPU ZFAND5 
  HNRNPUL1  
  HNRNPUL1  
  HOXA10  
  HOXC13  
  IARS  
  IDS  
  IFI27L2  
  IL7R  
  IMP4  
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  IQGAP1  
  AEN  
  ITFG3  
  ITM2C  
  JMJD8  
  KDELR3  
  KIAA0196  
  KLHDC5  
  KLHL9  
  LAMP2  
  LANCL1  
  LANCL1  
  LAPTM4A  
  LARP6  
  LCMT1  
  FAM161A  
  METTL23  
  LOC151162  
  LOC375295  
  C12orf75  
  MXRA8  
  DTYMK  
  MXRA8  
  H2AFX  
  LOX  
  LPIN1  
  LSS  
  LUZP1  
  LYRM1  
  MAD2L2  
  MAN2B2  
  LAMTOR3  
  LAMTOR2  
  Mar-04  
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  Mar-07  
  MATN2  
  MED20  
  MED6  
  MEG3  
  MFSD1  
  MGAT1  
  MGAT4B  
  MLEC  
  MMS19  
  MPP1  
  MRFAP1L1  
  MRPL17  
  MRPL18  
  MRPL22  
  MRPL27  
  MRPL40  
  MRPL41  
  MTPN  
  MTX2  
  MYL9  
  NAA20  
  NDRG1  
  NDUFB6  
  NDUFS7  
  NFATC2IP  
  NGDN  
  NGFRAP1  
  NIPA2  
  NPTN  
  NR2F2  
  NRGN  
  NSDHL  
  NUDT2  
  NUP37  
  OLFML3  
  OXSR1  
  PASD1  
  PDLIM7  
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  PDPR  
  PDXDC1  
  PDXK  
  PELO  
  PFKFB3  
  PGLS  
  PHB2  
  PHLDA3  
  PICALM  
  PIGP  
  PLEKHB2  
  PMM1  
  PMPCB  
  PNMA5  
  POLR3GL  
  PPCS  
  PPIC  
  PPP2R4  
  PPP4R1  
  PPP6C  
  PQLC1  
  SGK223  
  PRC1  
  PRICKLE1  
  PRNP  
  PRPF31  
  PSMA3  
  PSME4  
  PSMG1  
  PTGFRN  
  PTPLAD1  
  PTPMT1  
  PTPRF  
  PUM1  
  PURB  
  PYGL  
  QDPR  
  RABEPK  
  RAD23A  
  RAI14  
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  RALY  
  RDH11  
  NT5C1B  
  RHBDD2  
  RIN2  
  RNF149  
  RNF34  
  RPL34  
  RPS6KB2  
  RSPRY1  
  SAR1B  
  SCOC  
  SCYL1  
  SDF2L1  
  SDHAF2  
  SEC31A  
  SELM  
  Sep-11  
  SERINC3  
  SF3A2  
  TRA2B  
  SRSF4  
  SGK1  
  SH3GLB1  
  SIAH1  
  SIGMAR1  
  SIGMAR1  
  SIVA1  
  SLC11A2  
  SLC25A4  
  SLC35A2  
  SLC35B1  
  SLC39A1  
  SMAD3  
  SMAD5  
  SMC4  
  SNAI2  
  SPANXN3  
  SPNS1  
  SPOP  
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  SRP68  
  SRRM2  
  SSR1  
  STARD7  
  STAT2  
  STAU1  
  STK4  
  STRA13  
  STUB1  
  STX3  
  SULF2  
  SYNC  
  SYNCRIP  
  TAF10  
  TARS  
  TBK1  
  TCEAL8  
  TEX11  
  TGFBI  
  TGFBR2  
  TIAF1  
  TIAL1  
  TIMM23  
  TK1  
  TLE4  
  TM2D1  
  TMCO3  
  TMED5  
  TMEM106C  
  TMEM126A  
  TMEM131  
  TMEM14A  
  TMEM179B  
  TMEM203  
  TMEM219  
  TMEM43  
  TMEM60  
  TMEM97  
  TMUB1  
  TNC  
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  TNFAIP1  
  TNPO2  
  TOP2B  
  TPST1  
  TRAPPC1  
  TRAPPC4  
  TRIAP1  
  TRIB1  
  TRIM28  
  TRIM4  
  TRIP12  
  TRNP1  
  TROVE2  
  TSPAN3  
  TSR2  
  TUBB6  
  TWSG1  
  UBE2A  
  UBE2Z  
  UBP1  
  UBTD1  
  UGCG  
  UGP2  
  ULK1  
  USP9X  
  VAMP5  
  VPS41  
  WBSCR22  
  WDR13  
  WDR6  
  WDR61  
  WRNIP1  
  XPNPEP1  
  XYLT2  
  YIF1A  
  YIPF3  
  ZAK  
  ZC3HC1  
  ZDHHC7  
  ZDHHC9  
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  ZMPSTE24  
  LOC100506144  
  RNF115  
  ZNF483  
  ZNF622  
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Appendix B 
Top 10 list of transcription factors (Tf) predicted by GATHER for siHDAC3 repressed genes. 
 
 
  
TRANSFAC analysis for siHDAC3 repressed genes 
Basal- no IL-1 IL-1 1 hour IL-1 6 hours 
Tf predicted p-value Tf predicted 
p-
value 
Tf predicted p-value 
ELK1 < 
0.0001 
E2F 0.0002 E2F < 
0.0001 
E2F < 
0.0001 
E2F1 0.0002 E2F < 
0.0001 
E2F-1 < 
0.0001 
NRF2: nuclear 
respiratory factor 2 
0.0004 E2F < 
0.0001 
E2F1 0.0002 E2F 0.0008 E2F1 < 
0.0001 
NRF2: nuclear 
respiratory factor 2 
0.0002 E2F1 0.001 Nuclear Factor Y (Y 
box binding factor) 
< 
0.0001 
E2F-1 0.0003 ELK1 0.002 E12 < 
0.0001 
E2F 0.0007 E2F-1 0.003 E2F1 < 
0.0001 
MYCMAX: c-Myc: Max 
binding sites 
0.0008 E2F 0.004 E2F1 < 
0.0001 
E2F-1 0.002 E2F-1 0.004 Nuclear Factor Y (Y 
box binding factor) 
< 
0.0001 
NFY: nuclear factor Y 
(Y-box binding factor) 
0.002 E2F 0.005 E2F < 
0.0001 
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Appendix C 
 
The FACs gating data from one experiment containing four replicates per treatment is shown 
below. Assays were performed twice and results are presented in Figure 5.10. 
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